<SEC-DOCUMENT>0001384101-20-000058.txt : 20200506
<SEC-HEADER>0001384101-20-000058.hdr.sgml : 20200506
<ACCEPTANCE-DATETIME>20200506162840
ACCESSION NUMBER:		0001384101-20-000058
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200506
DATE AS OF CHANGE:		20200506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VERACYTE, INC.
		CENTRAL INDEX KEY:			0001384101
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				205455398
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36156
		FILM NUMBER:		20853016

	BUSINESS ADDRESS:	
		STREET 1:		6000 SHORELINE COURT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 243-6300

	MAIL ADDRESS:	
		STREET 1:		6000 SHORELINE COURT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CALDEROME INC
		DATE OF NAME CHANGE:	20061219
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vcyt-20200331.htm
<DESCRIPTION>VCYT - 10Q Q1 2020
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:0005b3b4-1d3d-4b06-88c1-edf8f62a1620,g:32b86441-5460-4f29-850a-a85559dff3e5,d:de126ddc4fe34b88b9204d0512399caf--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:vcyt="http://www.veracyte.com/20200331" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vcyt-20200331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80L2ZyYWc6YzU4MjM2ODE5YTc2NDUzZTkxMmE0NmI5MjE2MTkwODMvdGFibGU6NGM0ZjhiYmFmNjc0NDBiYjk3ZTUwOGQwODdjN2I0OGIvdGFibGVyYW5nZTo0YzRmOGJiYWY2NzQ0MGJiOTdlNTA4ZDA4N2M3YjQ4Yl8zLTEtMS0xLTA_26bd59f7-3b03-4671-b438-a5799fb38181">0001384101</ix:nonNumeric><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80L2ZyYWc6YzU4MjM2ODE5YTc2NDUzZTkxMmE0NmI5MjE2MTkwODMvdGFibGU6NGM0ZjhiYmFmNjc0NDBiYjk3ZTUwOGQwODdjN2I0OGIvdGFibGVyYW5nZTo0YzRmOGJiYWY2NzQ0MGJiOTdlNTA4ZDA4N2M3YjQ4Yl82LTEtMS0xLTA_ce99ca91-c3c5-4ec3-91d9-617c95f9c6a5">false</ix:nonNumeric><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80L2ZyYWc6YzU4MjM2ODE5YTc2NDUzZTkxMmE0NmI5MjE2MTkwODMvdGFibGU6NGM0ZjhiYmFmNjc0NDBiYjk3ZTUwOGQwODdjN2I0OGIvdGFibGVyYW5nZTo0YzRmOGJiYWY2NzQ0MGJiOTdlNTA4ZDA4N2M3YjQ4Yl83LTEtMS0xLTA_b6ad5d90-1b7d-41c7-8387-730865614688">12/31</ix:nonNumeric><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80L2ZyYWc6YzU4MjM2ODE5YTc2NDUzZTkxMmE0NmI5MjE2MTkwODMvdGFibGU6NGM0ZjhiYmFmNjc0NDBiYjk3ZTUwOGQwODdjN2I0OGIvdGFibGVyYW5nZTo0YzRmOGJiYWY2NzQ0MGJiOTdlNTA4ZDA4N2M3YjQ4Yl8xNy0xLTEtMS0w_dc825926-da57-433f-a9f1-8ec2f400bfd1">2020</ix:nonNumeric><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80L2ZyYWc6YzU4MjM2ODE5YTc2NDUzZTkxMmE0NmI5MjE2MTkwODMvdGFibGU6NGM0ZjhiYmFmNjc0NDBiYjk3ZTUwOGQwODdjN2I0OGIvdGFibGVyYW5nZTo0YzRmOGJiYWY2NzQ0MGJiOTdlNTA4ZDA4N2M3YjQ4Yl8xOC0xLTEtMS0w_b8229599-78a4-48a5-8057-ff80a9954625">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i0fd47326099244f099c155ab685c07c4_D20180409-20180409" name="vcyt:TermContractAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTg5ODQ_f0a3db4d-746a-4336-8a43-6dcb1f0c687a">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i0fd47326099244f099c155ab685c07c4_D20180409-20180409" name="vcyt:AutomaticRenewalPeriodContractAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTkwMjE_98287a7d-3a7f-425c-896d-85cf973f3c3e">P1Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="vcyt-20200331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iaaae9dd411cb4154a9358fed9e4e5c6f_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib258dfe7f0534153b328114e89c2109d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i1e857cb02e9a491ea7ee7312b9dd0c9e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9213dc93b19946a2974d68344371892e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1091751f442346ebbe0c524c9e4668a1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb46ced0a2aa4ca894e4cd6484a27349_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5ffa2062f4346428273bee28aee2826_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b5349320d4849e1a4c2f0d4d126834e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i317fc6085dfa48beab4ffe2a4f5c552d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i981f82a54dc4415d882cff6161e3cb5a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba763e838dce49179b05519385163390_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5becffb3a62e4e55a321ab87745ae9c1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9509897f2a34febb9f09b1315f20c69_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia694bf82c3654815a3b8657a08ddc3ef_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic90a9436f476424289b0a0487b606770_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id501bb45d2034ad585778730b56f0ce6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1975f844a2f4c15a1f55afecb1edc91_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i548e8d90f4e34475b13b982b902e4a7d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9da111a620cd40e8a9b6096845bf1ceb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0752101df15545318f42d72d0117da0c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee6f696c673849f2860c8d67c1f52f19_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic01cb72d9395452cb15cc978c6fadf65_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826dffa13d5d46d4b8c0b9ad504c14c8_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idebd9f954da94453a9e58cb23bf8f4e9_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b328b3431ee4903a957b091a9b8b09e_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3840aca904254efdb46618bf70d393a7_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17fe79e8a15e4bc8a7597e3847bfed46_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>vcyt:segment</xbrli:measure></xbrli:unit><xbrli:unit id="diseaseareas"><xbrli:measure>vcyt:diseaseAreas</xbrli:measure></xbrli:unit><xbrli:context id="i9a4e04bee36940d1a665002bd2ac7bf3_D20190507-20190507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-07</xbrli:startDate><xbrli:endDate>2019-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd46c80ad5fa42759560c922a438635e_D20190507-20190507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-07</xbrli:startDate><xbrli:endDate>2019-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf1f7f58b4404c6486380201c36cbda8_I20190507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="financial_institution"><xbrli:measure>vcyt:financial_institution</xbrli:measure></xbrli:unit><xbrli:context id="i54a3ab19387b41df817e1692261c8fdb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68cca2f7ddd243ba921a37d340208f12_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia991e1722be24c0bb0d615c7c31e199e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i009ef9afb3274f819477849480fd2393_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ba27eaeae954e789d56c5c4c620cf40_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b93f7856b454811a810d421cd09d494_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id743ee5e5b8148bf9e58641c5f04b9d3_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id232493caa454088900109db08487758_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c7a4983f7b4866abb02d142286638c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57e55cfffebb431ebba08541e4815fbc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6c280c6cf154f7ea8dd819b86f85a73_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6c4077b693b4c71a9881ad0c593d17e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id991525e1945478d84f961bb2f9348ac_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">vcyt:RevenueRecognitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fd47326099244f099c155ab685c07c4_D20180409-20180409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-09</xbrli:startDate><xbrli:endDate>2018-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="delivery"><xbrli:measure>vcyt:delivery</xbrli:measure></xbrli:unit><xbrli:context id="if3af9fe09e1e40829129e870dc5bb8e7_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab389aee6e60456eb379dbae0cc747b5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1b5f753a4342188cbb3be12ff68b0d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i280b0e75a2e941528ad5d310116a69ab_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85aec995c7594a55b57230e1738cb84e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86e73a154d594043a095b33e4c98e484_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0926623973444c5caf73d3278c08787f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b710a4a5abe4993a9278aad2ed6ed6c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:PerceptaV2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i665bf3400edb456f9bf74af9d39ee05e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:NasaRISKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68d35cb702de4592a9e6b6b1b313c182_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:PerceptaV2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01413ef04119474ea6616ffa333f811c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:PerceptaV2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i548a24efc9604bf5b1230a9363724472_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8be7bd0c98463195fa2424ea5db120_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c3fe671598544568e5396dda599a8f9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia18208097ace4d03aa3886966d7c6b01_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f0a5d6bb3934b7eb407eca1fae3f16a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i275dbe7307a1449492e85c3747f396b1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ec834c26f14e2d905193c57ed86a8c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b2f2d36fb04fcdb8a12000d2357117_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i661cf60c28f348a588855e09824e1932_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5031ee348bd54e3eb46dbeeabe6bced0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia20f4af3d960436784dac385c143e839_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i581ad647641b4236a34ecb7f297c1e30_D20191203-20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-03</xbrli:startDate><xbrli:endDate>2019-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc713d7148f45709edd0e4def2fa275_D20191203-20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-03</xbrli:startDate><xbrli:endDate>2019-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d4f80e336944a3588df9f7c63718be8_I20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1709eba571e842b192e2031b1c4d9b08_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd2f25cb091b48ca8213a9a4df7ffbe1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d9f79d4992742aeaaa9c1d70d147220_I20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b4444e9fe9f4984a86852673528284b_I20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i366c70e66aab457da18751b8d033eb24_I20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i414932941beb4ee4b26024d1b7d17b04_I20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:LymphMarkProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95a54fa194e14f688292b523de39ca15_D20191203-20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-03</xbrli:startDate><xbrli:endDate>2019-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a158a8048db4ff2b300dcd76423ba63_D20191203-20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-03</xbrli:startDate><xbrli:endDate>2019-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7052d1e1ab243a6bd6b0fe4e6245e27_D20191203-20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-03</xbrli:startDate><xbrli:endDate>2019-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15687bf922754ae2adfc9ec81a395382_D20191203-20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:LymphMarkProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-03</xbrli:startDate><xbrli:endDate>2019-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d59ef541093494588d84ced75c2fef2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i972755a8c17f424e96cf5cd3044f60ec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i884ba2e362494397a39b4b3ac9d4454e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vcyt:OvernightRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie698dd87420e44ce95964e6db3c81371_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vcyt:OvernightRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9b90e1ed4f74cacaf0797329a68769b_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vcyt:OvernightRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a0c568ab03f4e8d8092811c74c0250c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vcyt:OvernightRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ba4c8f0affe47d8b51e983b2a35f24d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674973e8b33f469b92b9f3edb0c4eba2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i3f2a64c5183543af9a4e1523c2354584_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40fdccc0cedd4d23b306a72908b22980_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:LaboratoryFacilitiesAustinTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e241de3601549a39ba5ab3def105dc5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:LaboratoryFacilitiesAustinTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4a031c3845c42609372921e497cac2e_I20171103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f90c73b3c3144378fa37effee913e4a_I20171103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e69109f224f45f78b4f86b7853a4f9c_I20171103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65e0aac4a63e44328e46b91201a0cd91_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id07f35bf3b6d4efdb97d4f802d200950_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5e731438a1449ba3564ed90fd6f856_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85b76fac63ed4337ba3f066627f9ee21_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9151d6a99994c3d8ad8137c5404513a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife6d0673632e406b88baa85353a6ce0a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vcyt:DebtPrepaymentTrancheAxis">vcyt:DebtPrepaymentTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb52a798d3dd45b0824f09f89f25bc71_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vcyt:DebtPrepaymentTrancheAxis">vcyt:DebtPrepaymentTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45329572800d48e7b228e61199a1894c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vcyt:DebtPrepaymentTrancheAxis">vcyt:DebtPrepaymentTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62c415d1690e4049ba06ee9e1047930c_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f773b17ae664fd1bf7ca8e49fdcbe3a_D20190501-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2da177f87084aacb8ec54951c03d633_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dc6c074bbd1456a915067e4fec93c91_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i179ded5835fe44c58d0e2db0f9f7bf28_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec64d800410545c29d93cac8e2c172ed_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26afcedec6c048e392712b52100ee027_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a47e06c25734fcba6d9adaae38a2200_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27b942a33cc641c39da58598bca5025d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c5d2c55989a46b98b6de9830693a3d5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i371cedf5a91b4b2abbfb835bb66de072_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ide126ddc4fe34b88b9204d0512399caf_1"></div><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;"> UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">WASHINGTON, D.C. 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;________________________________&#160;</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">FORM&#160;<ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2Njg2_d0de2adc-c0e4-4334-8368-b3409838d940">10-Q</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;________________________________&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:0.1%;"></td><td style="width:2.728%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.072%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6ZTVkZjE4MDg0YzVhNGViYjhlMDQyNjJlOWI5N2Y4ZjcvdGFibGVyYW5nZTplNWRmMTgwODRjNWE0ZWJiOGUwNDI2MmU5Yjk3ZjhmN18wLTAtMS0xLTEyNQ_93969fd6-c8ff-405d-8336-6931a4a55238">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF82NTk3MDY5NzY5MDkz_1af73463-fa37-4198-962c-6fafdefb9ca2">March&#160;31, 2020</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:0.1%;"></td><td style="width:2.728%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.072%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6ZmU4NGIyNTg0NDUxNGEwMGI1ZjExZWY0Y2Y4Y2U3MmUvdGFibGVyYW5nZTpmZTg0YjI1ODQ0NTE0YTAwYjVmMTFlZjRjZjhjZTcyZV8wLTAtMS0xLTEyOA_7ed4dee1-14f5-4ee4-8f44-7ba426cb4e0c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission file number <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2NzAw_230d06f0-e72f-477c-93c6-a12d5f34d21e">001-36156</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;________________________________&#160;</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2NzE3_5f3cbeed-21c3-4524-ac99-8c12ef3c6a12">VERACYTE, INC.</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">________________________________&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:46.093%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.665%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.242%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6Yzk5MWM5OTZlODBiNDU5NzgyMzlkZDgyNWExMmIwNjUvdGFibGVyYW5nZTpjOTkxYzk5NmU4MGI0NTk3ODIzOWRkODI1YTEyYjA2NV8wLTAtMS0xLTE0MQ_38d43fda-2ca0-4c59-80ab-b35594c32656">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6Yzk5MWM5OTZlODBiNDU5NzgyMzlkZDgyNWExMmIwNjUvdGFibGVyYW5nZTpjOTkxYzk5NmU4MGI0NTk3ODIzOWRkODI1YTEyYjA2NV8wLTItMS0xLTE0OQ_847dd703-e05e-484b-8e73-c08df45bbe56">20-5455398</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">incorporation or organization)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Identification No.)</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2NzQ1_bf7c5376-5a61-44d9-8a38-9f2b7a2cecab">6000 Shoreline Court</ix:nonNumeric>, <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2NzU5_9419693f-2687-4533-b064-15ddbba51e66">Suite 300</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2Nzgz_b22703b8-fd16-49bc-828d-1319d31cd65f">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2Nzk4_bb9f58f3-9f3d-4d2d-82b3-09ac57760616">California</ix:nonNumeric> <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2ODA4_105f6db3-7d3d-4afa-96d8-279e086d0a4d">94080</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(Address of principal executive offices, zip code)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2ODEz_922afa8e-daa0-4533-a5b7-caf87d0f6592">650</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2ODIz_0d86c49a-420c-4ab2-a940-47f1c884d290">243-6300</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;________________________________&#160;</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-indent:13.5pt;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-left:2.25pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.684%;"><tr><td style="width:1.0%;"></td><td style="width:37.555%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.985%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.370%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.133%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:37.557%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Title of each class</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Trading Symbol(s)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6ZDNjOWY5ZmJmNWNlNDY2NWJkMzlkMDNiN2E5ZGYyMmYvdGFibGVyYW5nZTpkM2M5ZjlmYmY1Y2U0NjY1YmQzOWQwM2I3YTlkZjIyZl8xLTAtMS0xLTE5MQ_a60ea23d-fd10-4079-85ba-adb138242abd">Common Stock, par value, $0.001 per share</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6ZDNjOWY5ZmJmNWNlNDY2NWJkMzlkMDNiN2E5ZGYyMmYvdGFibGVyYW5nZTpkM2M5ZjlmYmY1Y2U0NjY1YmQzOWQwM2I3YTlkZjIyZl8xLTItMS0xLTE5NA_69a20fe2-e213-406c-9a3c-860bcf0ab565">VCYT</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6ZDNjOWY5ZmJmNWNlNDY2NWJkMzlkMDNiN2E5ZGYyMmYvdGFibGVyYW5nZTpkM2M5ZjlmYmY1Y2U0NjY1YmQzOWQwM2I3YTlkZjIyZl8xLTQtMS0xLTE5OA_7b916075-f1c4-4628-a3bc-2ceecbf766be">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:13.5pt;"><span><br/></span></div><div style="text-indent:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2ODMx_e7c99186-7714-4a46-a9be-5474ff47b057">Yes</ix:nonNumeric>&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#253;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;No&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">o</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2ODM4_3c5499aa-890a-40cb-b2c8-61ef4a3baaff">Yes</ix:nonNumeric>&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#253;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;No&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">o</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:46.093%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.665%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.242%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6MGUxYWNlZmQxYzNjNGM3NjkzYWY0OTA1Nzg4NzYzMGIvdGFibGVyYW5nZTowZTFhY2VmZDFjM2M0Yzc2OTNhZjQ5MDU3ODg3NjMwYl8wLTAtMS0xLTIzNzQvdGV4dHJlZ2lvbjo3Y2ZjYjQ3ZWU3OTg0NmRmYjA3Mzg3NzAwYWRkODVkYV83MTQ2ODI1NTgwNjI1_c4680efa-a6dd-4aec-a883-0f78fa7f10bb">Large accelerated filer</ix:nonNumeric>&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">x</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Accelerated filer </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">o</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Non-accelerated filer </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">o</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Smaller reporting company&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6MGUxYWNlZmQxYzNjNGM3NjkzYWY0OTA1Nzg4NzYzMGIvdGFibGVyYW5nZTowZTFhY2VmZDFjM2M0Yzc2OTNhZjQ5MDU3ODg3NjMwYl8yLTItMS0xLTIyNC90ZXh0cmVnaW9uOmMzM2E2NGQxNmIyYzQ3ZDE5MDI0ZjNkM2QwNTNjZTc0Xzc2OTY1ODEzOTQ0NjU_7df7bf44-db6b-4b84-92c1-c08c8b659308">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Emerging growth company&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6MGUxYWNlZmQxYzNjNGM3NjkzYWY0OTA1Nzg4NzYzMGIvdGFibGVyYW5nZTowZTFhY2VmZDFjM2M0Yzc2OTNhZjQ5MDU3ODg3NjMwYl80LTItMS0xLTIzMS90ZXh0cmVnaW9uOjA5ZTIzYWY3NWVmODRiOTViZWY1MzRiOTVlNzk2OWVlXzc2OTY1ODEzOTQ0NjM_7e2e8d32-b3f1-42bc-b874-0b6383aff596">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">o</span></div><div style="padding-left:13.5pt;"><span><br/></span></div><div style="padding-left:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).Yes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2ODQz_b18eb525-0b4d-4685-b9fe-25ad5353a862">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> No </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#253;</span></div><div style="padding-left:13.5pt;"><span><br/></span></div><div style="padding-left:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">As of April&#160;30, 2020, there were <ix:nonFraction unitRef="shares" contextRef="iaaae9dd411cb4154a9358fed9e4e5c6f_I20200430" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83MTQ2ODI1NTgyOTc4_bb88e048-9f34-46af-bc10-9ae53b93be47">50,053,437</ix:nonFraction> shares of common stock, par value $0.001 per share, outstanding.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_7"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> VERACYTE,&#160;INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INDEX </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:89.215%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.785%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page<br/>No.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_10">PART&#160;I. &#8212; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_13">Item 1. Condensed</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_13"> Consolidated</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_13"> Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_16">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_16">Consolidated </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_16">Balance Sheets as of </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_16">March 31, 2020</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_16"> and December&#160;31, 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_16">9</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_22">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_22">C</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_22">onsolidated </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_22">Statements of Operations and Comprehensive Loss for the Three </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_22">Month Periods&#160;Ended&#160;</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_22">March 31</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_22">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_22">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_22"> and 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_22">9</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_22">2</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_28">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_28">Consolidated </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_28">Statements of Stockholders' Equity for the Three </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_28">Month Periods Ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_28">March 31</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_28">,</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_28"> 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_28">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_28"> and 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_28">9</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_28">3</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_34">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_34">Consolidated </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_34">Statements of Cash Flows for the </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_34">Three</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_34"> Month Periods Ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_34">March 31</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_34">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_34">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_34"> and 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_34">9</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_34">4</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_37">Notes to Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_37">Consolidated </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_37">Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_37">6</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_76">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_76">19</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_112">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_112">35</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_115">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_115">35</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_118">PART&#160;II. &#8212; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_124">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_124">37</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_133">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_133">64</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_136">SIGNATURES</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_136">65</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">i</span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_10"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART&#160;I. &#8212; FINANCIAL INFORMATION</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="ide126ddc4fe34b88b9204d0512399caf_13"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1. Condensed Financial Statements</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="ide126ddc4fe34b88b9204d0512399caf_16"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE,&#160;INC.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Balance Sheets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share and per share amounts)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(See&#160;Note&#160;1)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNC0xLTEtMS0w_c06575bc-d453-47e7-bbe8-f15e2cdc6e58">153,132</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNC0zLTEtMS0w_8603449d-8b1b-4e32-b62f-207dab9965a8">159,317</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNS0xLTEtMS0w_17bb3144-1e47-4c6e-8481-aa67aed7f4ba">19,091</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNS0zLTEtMS0w_32e91e85-6fe2-4fa6-a8eb-157cd09e2cdc">19,329</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNi0xLTEtMS0w_111a24ca-3616-4eb6-90cc-5a2f8d332312">6,094</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNi0zLTEtMS0w_18d02262-aab6-4370-8bf9-6ab7a5ec3e15">6,806</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNy0xLTEtMS0w_90c711d9-fae1-4dc9-a655-d074cbde5e0a">3,045</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNy0zLTEtMS0w_2f781c8d-330d-4301-bbbc-f311419c6bb4">2,235</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfOC0xLTEtMS0w_b5114512-23a4-4004-b6fc-5876faefb8d4">181,362</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfOC0zLTEtMS0w_5829d0f9-eb40-4ce6-96d9-6f92fcad1ab6">187,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfOS0xLTEtMS0w_be072bd9-7556-4cd7-b493-53b3c9b503f6">8,788</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfOS0zLTEtMS0w_1303fde3-7707-413a-b82a-e7738fc6fd84">8,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets - operating lease</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTEtMS0xLTEtMA_7e761b36-f7cc-4db0-8b01-045f2c013855">8,576</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTEtMy0xLTEtMA_e73a26bd-f110-4624-ae47-6a4f9f81406b">8,808</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finite-lived intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTItMS0xLTEtMA_56e13f29-8301-4936-975b-9dc318a88cc6">63,744</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTItMy0xLTEtMA_d2c0f29d-2719-4821-b9b7-53322b07d7fc">65,019</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTMtMS0xLTEtMA_e5a357c4-bf2a-4f0b-8297-09b2991d7a61">2,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTMtMy0xLTEtMA_4d2312c1-e2da-4e69-9021-1b20ac5e9ce5">2,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTQtMS0xLTEtMA_35c3b7f0-ac9f-4117-80c3-f066d2a9879d">603</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTQtMy0xLTEtMA_9f7e815f-d80a-4857-8ff7-824bdcc8b41e">603</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTUtMS0xLTEtMA_495dbd4f-910c-4afd-acf4-efb31e258a91">1,302</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTUtMy0xLTEtMA_30b8b556-6173-4693-9362-56ff25365e41">1,437</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTYtMS0xLTEtMA_fc451bb4-0504-4666-8ef0-aa99827cc9e0">267,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTYtMy0xLTEtMA_097eafe7-322a-4b6e-b4f4-cb2976678f4f">275,212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTktMS0xLTEtMA_4cb52879-e470-4401-beb2-d5a4d6236455">7,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTktMy0xLTEtMA_0f107639-8c7c-4d3a-a1bf-1cccb0844702">2,328</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjAtMS0xLTEtMA_9694382c-efc6-4f08-aa8d-b08f1c7f6827">10,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjAtMy0xLTEtMA_560cc9fe-a0b9-488d-96d7-3e6964308d79">13,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjMtMS0xLTEtMA_a86cfd33-bd3d-4f40-ac6e-3cab213199f5">1,450</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjMtMy0xLTEtMA_bfa56782-e3b1-4a3a-9555-21f2ed65d64a">1,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjQtMS0xLTEtMA_8ce301e6-c517-41c8-be88-0778b915405b">19,194</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjQtMy0xLTEtMA_74f1b4dc-07c6-42cb-8b12-c65cc509bd45">17,469</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjUtMS0xLTEtMA_435896cf-cef7-4e1c-95dd-e82223e996b5">748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjUtMy0xLTEtMA_a1cbe25e-dce4-4685-b3d1-004410dc9867">694</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisition-related contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjYtMS0xLTEtMA_18306eef-cca1-4b95-8679-eef6b1f44d4e">5,604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjYtMy0xLTEtMA_ef1997a6-8883-4f9e-a87a-88be17c7ae35">6,088</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjctMS0xLTEtMA_06f4cdce-55cb-446e-8655-bd7bad5026ab">11,132</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjctMy0xLTEtMA_1c5ea472-df72-4ff8-a90a-e64c0cf31056">11,506</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjgtMS0xLTEtMA_6b48235f-b7cd-46a0-ae18-32f88626d5c0">36,678</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjgtMy0xLTEtMA_d135935f-cdb4-4291-a946-2ea30f77d601">35,757</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjktMS0xLTEtMA_cc71c647-6437-48e8-9367-0b3a77c4a2ef"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjktMy0xLTEtMA_4a20b5bf-b20a-4048-87ea-bf01e3a7b609"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; equity:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2MTM_7ff85ce5-a0ff-4c70-bf47-812ea73dc390"><ix:nonFraction unitRef="usdPerShare" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2MTM_87460556-d136-45db-bc87-232397bf4649">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2MjQ_2d80b335-4b35-4f53-ab67-d89766515007"><ix:nonFraction unitRef="shares" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2MjQ_428fcf45-bccf-46ac-b700-473dc35cef5e">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2Mjg_04563424-8699-4e1e-be94-24a77108234c"><ix:nonFraction unitRef="shares" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2Mjg_2c1c0048-dc8c-4488-94a9-cddb2322e7f5"><ix:nonFraction unitRef="shares" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2Mjg_40a0ae85-ec9d-4321-b2c8-e5dd09dc2790"><ix:nonFraction unitRef="shares" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2Mjg_dfd9dbb0-41c0-4e6d-808d-f183984a0606">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2020 and December&#160;31, 2019</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMS0xLTEtMA_63f918ce-43ac-4876-a10f-1926ae7bf8bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMy0xLTEtMA_5b2c7f54-41a1-47c6-8e71-921f0879841f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2MjI_91af66d8-e2b6-45a6-b8c3-5088ebe07bd5"><ix:nonFraction unitRef="usdPerShare" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2MjI_bf735d79-b5c3-4fa4-8039-76320c944ca8">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2MzY_4e4ed90c-bfc0-4216-8ff9-44c3329dedf0"><ix:nonFraction unitRef="shares" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2MzY_7e4a6a7b-c2b5-4b69-aa35-2fd1f63a8401">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2NDg_36045560-ba63-416c-a54a-3eedd403482d"><ix:nonFraction unitRef="shares" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2NDg_c7c44842-10ee-4418-a0e6-330c1f90ff87">49,999,923</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2NjA_0c83ecc3-37af-4f30-b952-f3cce3196348"><ix:nonFraction unitRef="shares" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2NjA_52358329-d01d-4641-b90f-237f6de5fc0a">49,625,341</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMS0xLTEtMA_c5328c87-dc02-425b-9cec-8c814b825208">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMy0xLTEtMA_868e143b-c346-4509-85af-4a3d30887436">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzMtMS0xLTEtMA_e8c1e3c1-f423-44e9-8d61-59a41d91c007">488,773</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzMtMy0xLTEtMA_b5bf34c8-d4b2-455d-8efc-69c578a61f52">486,090</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzQtMS0xLTEtMA_070e7991-51df-4a09-a670-a08baf3d7d40">258,401</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzQtMy0xLTEtMA_496f3bca-c9db-414b-bf0f-1fb6c6724984">246,685</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzUtMS0xLTEtMA_2055b009-7adb-4ede-8a3b-eee4497f66dc">230,422</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzUtMy0xLTEtMA_34e2fd0a-ed33-4081-9d56-9d0ae797e6dd">239,455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders&#8217; equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzYtMS0xLTEtMA_4dd1625c-64c7-4cc5-9a83-1d4a83d1228d">267,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzYtMy0xLTEtMA_18f192d9-d0c4-4c7f-b91c-6fe2e87c1a54">275,212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_22"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> VERACYTE,&#160;INC.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share and per share amounts</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:72.707%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.280%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.283%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Testing revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e857cb02e9a491ea7ee7312b9dd0c9e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMy0xLTEtMS0xMTI4_c809cdfd-b701-4578-ad0c-5904b87d718e">26,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9213dc93b19946a2974d68344371892e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMy0zLTEtMS0yMzc1_5b0dd957-009c-480a-b076-c40fed31a5e8">25,389</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1091751f442346ebbe0c524c9e4668a1_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNC0xLTEtMS0xMTI4_627a9921-18c7-41a8-bb74-35d15073e468">3,409</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb46ced0a2aa4ca894e4cd6484a27349_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNC0zLTEtMS0yMzc1_e18c0815-43e5-490f-aab4-c619d8bb1882">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biopharmaceutical revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5ffa2062f4346428273bee28aee2826_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNS0xLTEtMS0xMTI4_ab8e66b9-8d5a-41f8-8775-a926a220b9d6">722</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b5349320d4849e1a4c2f0d4d126834e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNS0zLTEtMS0yMzc1_5c9c4517-4ef6-4cfb-9582-0196667fa33f">4,140</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMi0xLTEtMS0w_b0db6563-1402-460e-a1a3-12199fd4e302">31,122</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMi0zLTEtMS0w_86bdc74b-0f2a-49f6-a2b5-d536a46e7fb2">29,529</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of testing revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e857cb02e9a491ea7ee7312b9dd0c9e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNC0xLTEtMS0w_18de23d0-4e87-4a92-8ec2-bca9742b408d">10,568</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9213dc93b19946a2974d68344371892e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNC0zLTEtMS0w_332646fb-d4aa-467d-80dd-61ecd6aeb109"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNC0zLTEtMS0w_aab82711-0351-4a39-8e5a-252e41971ed4">8,513</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of product revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1091751f442346ebbe0c524c9e4668a1_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfOS0xLTEtMS0xMTMx_171e4db2-767c-4ce6-a179-2e003c384040">1,559</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb46ced0a2aa4ca894e4cd6484a27349_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfOS0zLTEtMS0yMzc3_f98cb6ca-4ca7-4ed0-9b83-97ba15193e59">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of biopharmaceutical revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5ffa2062f4346428273bee28aee2826_D20200101-20200331" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTAtMS0xLTEtMTEzMQ_f5030ec3-56fe-4bc7-a930-a1d4b71feb0e">116</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b5349320d4849e1a4c2f0d4d126834e_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTAtMy0xLTEtMjM3Nw_f4d9ba15-ad41-4b83-8989-7403d479ba22">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNS0xLTEtMS0w_b1ad97fc-8855-44be-9900-a7d9a63a50cb">4,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNS0zLTEtMS0w_27c3c83a-4f59-44a3-ab68-a5e15031994b">3,435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNi0xLTEtMS0w_cddff50a-f364-4fed-bbf9-9353c5e2e9a3">17,584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNi0zLTEtMS0w_77ec5861-b114-4abc-95c8-a4b3239bf5f7">12,477</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNy0xLTEtMS0w_dfcbe66a-206f-4f5a-a522-85925d71ae93">7,813</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNy0zLTEtMS0w_eabebcf0-8188-4fc5-8852-3b716b3f9a8d">6,904</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible asset amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfOC0xLTEtMS0w_a0a47042-4acb-4ca7-bf44-60bcfeb22231">1,275</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfOC0zLTEtMS0w_ddce90c5-cf9d-470a-826b-06236f83c795">267</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfOS0xLTEtMS0w_7ace3ecd-8abe-4ed2-8af2-7f81271ed41e">43,322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfOS0zLTEtMS0w_01531c31-9487-4bdc-b6e8-999c80c53aa0">31,596</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTAtMS0xLTEtMA_2e74c0c3-30e8-4dd2-ad1d-5c8598813622">12,200</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTAtMy0xLTEtMA_77720ecf-f0fb-48b8-a48a-3d3b2e3d73cd">2,067</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTEtMS0xLTEtMA_90601392-836b-43e4-9389-466dd52cb007">55</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTEtMy0xLTEtMA_0abb5e07-a6df-4105-9f2b-a08719b9cfdb">303</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTItMS0xLTEtMA_010b2798-8293-4d9b-98cb-77f1c29e896c">539</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTItMy0xLTEtMA_b7ebd370-c77f-4502-9326-97497d177c9b">453</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss and comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTMtMS0xLTEtMA_1388333b-772b-401a-824f-1e02868ea24b"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTMtMS0xLTEtMA_ca8254cd-766b-4ad8-9273-caa8eb23e3b0">11,716</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTMtMy0xLTEtMA_25fd9455-95f9-4845-9dde-d22a7d0d774b"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTMtMy0xLTEtMA_87df7ae5-dabe-4b52-8936-c942e9be84ce">1,917</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per common share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTQtMS0xLTEtMA_38e5ddec-ceb7-4d31-abe8-96a8e62275a4">0.24</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTQtMy0xLTEtMA_07841c40-b705-412c-9abf-03112e6350e6">0.05</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used to compute net loss per common share, basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTUtMS0xLTEtMA_db9a145e-1e5f-49da-93c5-02765ccb0c65">49,792,631</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTUtMy0xLTEtMA_f1d09511-38cf-4a88-8b93-233e4e670edf">41,168,593</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_28"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE,&#160;INC.</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Stockholders' Equity</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:46.748%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.983%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.983%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.425%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.162%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.755%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i317fc6085dfa48beab4ffe2a4f5c552d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTMtMS0xLTEtMA_3a5f523b-b2c9-4a3d-b3ef-0fca3103efd0">49,625</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i317fc6085dfa48beab4ffe2a4f5c552d_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTMtMy0xLTEtMA_743591a4-0dc6-4385-b038-53d8041401d4">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i981f82a54dc4415d882cff6161e3cb5a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTMtNS0xLTEtMA_d603d4af-05cb-4715-98e8-b64c30198768">486,090</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iba763e838dce49179b05519385163390_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTMtNy0xLTEtMA_c0a4e9da-c796-46c5-b541-acc63263dfab">246,685</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTMtOS0xLTEtMA_12ff9e2b-0c0f-4dc9-96cf-7117d44ed8f4">239,455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock upon exercise of stock options and vesting of restricted stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5becffb3a62e4e55a321ab87745ae9c1_D20200101-20200331" decimals="-3" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTUtMS0xLTEtMA_77915219-daf2-407b-baa9-1de8756a8e18">314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9509897f2a34febb9f09b1315f20c69_D20200101-20200331" decimals="-3" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTUtNS0xLTEtMA_f1e3d4a3-72ca-4b20-bc90-d23e7f7cd3bf">981</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTUtOS0xLTEtMA_fbfbbc36-fff9-4857-879f-b8395a0b73f4">981</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock under employee stock purchase plan (ESPP)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5becffb3a62e4e55a321ab87745ae9c1_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTYtMS0xLTEtMA_e881e39d-8337-4001-8dd0-bed6d85f0ab4">61</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9509897f2a34febb9f09b1315f20c69_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTYtNS0xLTEtMA_0e88f9b6-cb41-43a9-a16e-d6fd90c103d3">1,101</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTYtOS0xLTEtMA_d6aee759-e03b-4477-ada6-3e6c798a202e">1,101</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Tax portion of vested restricted stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id9509897f2a34febb9f09b1315f20c69_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTctNS0xLTEtMA_30c2d096-f4d8-4b74-a7b3-8e1e65f5bfe4">2,304</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTctOS0xLTEtMA_23623d2a-a117-47ac-b2f0-281f32f86ce4">2,304</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Stock-based compensation expense (employee)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9509897f2a34febb9f09b1315f20c69_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTgtNS0xLTEtMA_dee4f6e2-1442-4730-8304-2056fbddcaaa">2,551</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTgtOS0xLTEtMA_3e7f2695-b140-43f8-aac8-3c32559907e9">2,551</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Stock-based compensation expense (ESPP)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9509897f2a34febb9f09b1315f20c69_D20200101-20200331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjAtNS0xLTEtMA_8e09721f-d170-4659-b9c3-5b290059b3da">354</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjAtOS0xLTEtMA_0e0c4a46-e018-44a0-ad8b-82a4cec2cad8">354</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Net loss and comprehensive loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjEtNy0xLTEtMA_6ab75879-c718-4cf5-a47b-0459da80dc70"><ix:nonFraction unitRef="usd" contextRef="ia694bf82c3654815a3b8657a08ddc3ef_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjEtNy0xLTEtMA_e851c0f9-1763-4757-8573-9826287c4e98">11,716</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjEtOS0xLTEtMA_2310e27e-166d-439f-908d-648bc085d79e"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjEtOS0xLTEtMA_5cca0510-b4a2-4331-a359-7b07c5cd276a">11,716</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Balance at March 31, 2020</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic90a9436f476424289b0a0487b606770_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjItMS0xLTEtMA_36d8a6de-a5c8-4010-92f7-2f2fbf90aa7c">50,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic90a9436f476424289b0a0487b606770_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjItMy0xLTEtMA_265a2813-bf41-4d30-892e-ff180ecf0e6e">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id501bb45d2034ad585778730b56f0ce6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjItNS0xLTEtMA_4fc2750c-7317-45e8-82b4-ddfbd0d837fc">488,773</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1975f844a2f4c15a1f55afecb1edc91_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjItNy0xLTEtMA_22b2f48f-ed61-4393-aa87-d9f58066b8e9">258,401</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjItOS0xLTEtMA_a0ade28e-3204-4ae8-9bb6-021d8a95945b">230,422</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:46.596%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.010%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.010%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.453%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.192%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.787%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December&#160;31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i548e8d90f4e34475b13b982b902e4a7d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTItMS0xLTEtMA_7589a20a-78fb-4706-b147-92a513dae049">40,863</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i548e8d90f4e34475b13b982b902e4a7d_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTItMy0xLTEtMA_7b052af7-d1bf-426f-b64f-2fde5f222541">41</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9da111a620cd40e8a9b6096845bf1ceb_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTItNS0xLTEtMA_9e934d4a-ee14-4b0b-b380-bd917e185459">313,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0752101df15545318f42d72d0117da0c_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTItNy0xLTEtMA_81644d58-f79c-4d7a-8737-d0f857e7f93a">234,086</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee6f696c673849f2860c8d67c1f52f19_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTItOS0xLTEtMA_2f951efb-981a-43a5-81a8-6b0158fd7c4d">79,755</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock upon exercise of stock options and vesting of restricted stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic01cb72d9395452cb15cc978c6fadf65_D20190101-20190331" decimals="-3" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTQtMS0xLTEtMA_44e8216d-6701-411a-b374-b4e6c0f6b15a">566</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic01cb72d9395452cb15cc978c6fadf65_D20190101-20190331" decimals="-3" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTQtMy0xLTEtMA_16e360a4-8da3-4804-8477-fa7c6a34b7f2">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTQtNS0xLTEtMA_968083ab-e2d3-4db0-ae33-b41bd323be5c">4,239</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTQtOS0xLTEtMA_2123e877-0b80-4e3f-92b7-049bf8d87653">4,240</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock under ESPP</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic01cb72d9395452cb15cc978c6fadf65_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTUtMS0xLTEtMA_3b7db1ce-393f-4b42-b9ed-cad9c0383e3a">80</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTUtNS0xLTEtMA_3aca55ea-33e0-463e-81f5-18fa3111df7c">491</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTUtOS0xLTEtMA_f0bef8d7-7ed0-42cc-be81-2e9269ea5c12">491</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Tax portion of vested restricted stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTYtNS0xLTEtMA_dcf25bca-f5d9-4b7c-89b0-3e5be728106f">556</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTYtOS0xLTEtMA_77530e9d-ac31-48c1-b38f-e0cf6bc98e7f">556</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Stock-based compensation expense (employee)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTctNS0xLTEtMA_c1b12ee7-8405-4796-a99a-3a296d6f246b">1,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTctOS0xLTEtMA_73b419d7-614c-4a73-914f-aa8c8add5a2e">1,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Stock-based compensation expense (non-employee)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTgtNS0xLTEtMA_f6a712a8-4f5b-4bb3-8a8e-2e415bb998b2">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTgtOS0xLTEtMA_0a908e72-5b34-4365-9b90-af979e61ec4b">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Stock-based compensation expense (ESPP)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTktNS0xLTEtMA_923498f2-15d2-40c7-9fba-8a866b92bb47">141</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTktOS0xLTEtMA_18b5d86c-9eba-42df-9a39-ae5ecaa58d37">141</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Net loss and comprehensive loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i826dffa13d5d46d4b8c0b9ad504c14c8_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjEtNy0xLTEtMA_230a1667-9b41-4cdc-8098-a15461b32023"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjEtNy0xLTEtMA_778028e3-61a6-4745-ac64-9b7c8e3b8331">1,917</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjEtOS0xLTEtMA_c5ffb074-63a4-44fe-b66c-7f59da2d0b88"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjEtOS0xLTEtMA_fa0a5ec2-04c0-4c9b-9109-ebf3bdaa7556">1,917</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Balance at March 31, 2019</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idebd9f954da94453a9e58cb23bf8f4e9_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjItMS0xLTEtMA_0a0e586e-bf9d-484f-9056-c0ebc7d1b2ea">41,509</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idebd9f954da94453a9e58cb23bf8f4e9_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjItMy0xLTEtMA_469ddff9-455c-4f8a-ae85-7a149b713e73">42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b328b3431ee4903a957b091a9b8b09e_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjItNS0xLTEtMA_8acef1f3-1fd8-4228-b8d3-9409336ef6cd">319,733</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3840aca904254efdb46618bf70d393a7_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjItNy0xLTEtMA_5fd15ac9-3199-4763-8c31-600dbedc71bf">236,003</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i17fe79e8a15e4bc8a7597e3847bfed46_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjItOS0xLTEtMA_4651fd50-fce0-46cf-acb6-227abb5c569d">83,772</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_34"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE,&#160;INC. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Cash Flows</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMy0xLTEtMS0w_f6ede3eb-93c5-4a28-a60c-ea133c2ec298">11,716</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMy0zLTEtMS0w_260044b9-c805-4864-9bcc-929e415c1fbb">1,917</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfNS0xLTEtMS0w_ced7c693-89d1-4443-8572-04275ab38742">1,972</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfNS0zLTEtMS0w_cf41a831-adfa-4a74-ae69-f471d1375447">945</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on disposal of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfNi0xLTEtMS0w_1fe828a7-31a5-42cd-85a0-e700092f2db8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfNi0zLTEtMS0w_0322797f-8710-4a55-8e0b-43d28ddbd716">16</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfNy0xLTEtMS0w_26c76012-4a4a-4fbc-a725-fefaac91af59">2,905</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfNy0zLTEtMS0w_bad01743-4603-4247-8582-7b13e388d947">1,759</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfOS0xLTEtMS0w_cc5fb930-0c73-4419-a419-41616ac56e51">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfOS0zLTEtMS0w_c8daa3a6-c41b-4513-8ec6-54755fa1090d">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest on end-of-term debt obligation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" name="vcyt:InterestExpenseandPrepaymentPenalty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTAtMS0xLTEtMA_adea3219-c1d9-41fc-a6f1-c373724cbd1f">54</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="vcyt:InterestExpenseandPrepaymentPenalty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTAtMy0xLTEtMA_cbd1aec7-90f5-4338-a783-d609d397d382">64</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Write-down of excess supplies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="vcyt:InventoryReserveEffectOnIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTEtMS0xLTEtMTc3NA_125c38e2-15b6-4a60-aa78-74e8524edc11">1,088</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="vcyt:InventoryReserveEffectOnIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTEtMy0xLTEtMTc3Ng_cdc2464d-6d8f-48bc-9379-0f8b7d95aeca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncash lease expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" name="vcyt:NoncashLeaseExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTItMS0xLTEtMzc2NA_65abee01-f944-44b3-b1cb-14280f91890c">232</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="vcyt:NoncashLeaseExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTItMy0xLTEtMzc2NA_f76bce8e-a6f8-424f-bd58-a487d1257e2a">212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revaluation of acquisition-related contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTEtMS0xLTEtMTAyNg_9f868e31-bfb7-4090-b971-59cca28e1321">484</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTEtMy0xLTEtMTAyNg_816ba0e2-f20e-406c-95f1-3be06b3910f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTItMS0xLTEtMA_9d00dc94-02ed-4d8d-84f7-462ef1ab4ca2">238</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTItMy0xLTEtMA_abf86172-b122-4a9d-8475-4d829736cde9">3,447</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTMtMS0xLTEtMA_fa5679d3-944f-478b-b394-b6a8fe25b22f">376</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTMtMy0xLTEtMA_9e8d19b8-c872-40a6-854e-79e7b9596b8a">366</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTQtMS0xLTEtMA_6f2a442d-767f-4b74-a3cf-d8d853645048">818</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTQtMy0xLTEtMA_e057cc50-3544-4c33-815d-cca428138aa5">11</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" name="vcyt:IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTUtMS0xLTEtMA_836bd4d4-b5e0-4d3a-946f-5f5d41af84e1">331</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="vcyt:IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTUtMy0xLTEtMA_e83887ed-d114-4f2b-b01a-2f595a5cf7e7">292</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTYtMS0xLTEtMA_972b79f2-fc62-4cc3-a8b3-615cda362a1a">135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTYtMy0xLTEtMA_aff990d2-3e41-4eea-a390-de8b68c4a038">37</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTctMS0xLTEtMA_3a2f1fda-64af-430f-8354-f1f5f3c2e879">5,450</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTctMy0xLTEtMA_8efd1395-95fa-4d73-a973-4935fd91702d">1,726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTgtMS0xLTEtMA_7f417a4b-6eba-4ad4-bb95-edc92f79aa54">3,650</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTgtMy0xLTEtMA_4e102b87-c73d-436c-ae0a-664c7a198a83">287</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTktMS0xLTEtMA_fbc15bca-bd4f-4011-a779-637dcdf71911">5,301</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTktMy0xLTEtMA_21c7ab81-def2-4141-92c2-18a59be92d89">1,011</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjEtMS0xLTEtMA_a6e5068a-b687-4618-ae5c-745d41d8ee01">665</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjEtMy0xLTEtMA_392aec7d-947a-45bd-b8b3-b16dcedbc55e">765</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from disposal of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjItMS0xLTEtMA_db537329-3785-4ed3-954d-b0d37d7f159c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjItMy0xLTEtMA_a6435313-2e43-43bc-91bb-c8b9f558e686">16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjMtMS0xLTEtMA_f27e8b50-4266-4517-b736-459a2d91ebc6">665</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjMtMy0xLTEtMA_ec7c92e4-3325-4b09-9f10-1cdf5597147a">749</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payment of long-term debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjYtMS0xLTEtMA_d1525e66-ac99-4a0f-b987-f93ba6dfa0ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjYtMy0xLTEtMA_c33477d4-b38f-4a8a-ae3e-73aa15c6f8a8">12,500</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payment of finance lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjgtMS0xLTEtMA_2275eda7-8af5-4c81-a3c3-4e2adfb238db">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjgtMy0xLTEtMA_64a6cdff-fe58-4052-bd14-917f5ece5a9e">75</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payment of taxes on vested restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjktMS0xLTEtMTYzOA_dca01048-9294-4b77-8522-a4d30e166dfb">2,304</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjktMy0xLTEtMTYzOA_b99b01d1-bc51-4c51-84be-c4f267ebe1cd">556</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from the exercise of common stock options and employee stock purchases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjktMS0xLTEtMA_e1fe8a4b-9a90-4387-9d10-283c62140313">2,085</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjktMy0xLTEtMA_cdd81e83-bace-4aa3-ad44-68d37b57e360">4,737</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzAtMS0xLTEtMA_6bf907c9-fc21-4da6-a047-eb5265b748db">219</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzAtMy0xLTEtMA_a590ef45-2190-413a-bb5d-2c1ef79b9de0">8,394</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzEtMS0xLTEtMA_7e7dc263-f23b-46cd-8863-1ba7a6426cc1">6,185</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzEtMy0xLTEtMA_896b50e3-6bd5-44e0-88f2-0113110c4cda">10,154</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzItMS0xLTEtMA_f4b7acd0-febb-4a93-9916-043eff386e80">159,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee6f696c673849f2860c8d67c1f52f19_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzItMy0xLTEtMA_7b87e3ba-23c4-43e0-b65b-de8fc14d4eed">78,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzMtMS0xLTEtMA_c74d00b4-5786-45dd-a48c-dd5ccb2c1816">153,735</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i17fe79e8a15e4bc8a7597e3847bfed46_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzMtMy0xLTEtMA_8c13331e-d695-417c-97c1-f9e6593aabfc">68,444</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplementary cash flow information:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment included in accounts payable and accrued liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" name="vcyt:CapitalExpendituresIncurredButNotYetPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzYtMS0xLTEtMA_aa3f905f-01a1-4bf3-9677-2407b05bfcfb">113</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="vcyt:CapitalExpendituresIncurredButNotYetPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzYtMy0xLTEtMA_8f0639ac-8938-4e15-9ffe-31e7c0a47dbd">95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest paid on debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzctMS0xLTEtMA_c43a46c9-190f-4a03-bdb9-71ff4df64a43">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzctMy0xLTEtMA_266859f9-bcef-4eaa-8d3a-9c2171d6695b">228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:67.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.662%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.664%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjNhOTA1NGZlOWVkMTRiM2ViOTJlODZkZTZhODE3NWFjL3RhYmxlcmFuZ2U6M2E5MDU0ZmU5ZWQxNGIzZWI5MmU4NmRlNmE4MTc1YWNfMS0xLTEtMS0w_c06575bc-d453-47e7-bbe8-f15e2cdc6e58">153,132</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjNhOTA1NGZlOWVkMTRiM2ViOTJlODZkZTZhODE3NWFjL3RhYmxlcmFuZ2U6M2E5MDU0ZmU5ZWQxNGIzZWI5MmU4NmRlNmE4MTc1YWNfMS0zLTEtMS0w_8603449d-8b1b-4e32-b62f-207dab9965a8">159,317</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjNhOTA1NGZlOWVkMTRiM2ViOTJlODZkZTZhODE3NWFjL3RhYmxlcmFuZ2U6M2E5MDU0ZmU5ZWQxNGIzZWI5MmU4NmRlNmE4MTc1YWNfMi0xLTEtMS0w_35c3b7f0-ac9f-4117-80c3-f066d2a9879d">603</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjNhOTA1NGZlOWVkMTRiM2ViOTJlODZkZTZhODE3NWFjL3RhYmxlcmFuZ2U6M2E5MDU0ZmU5ZWQxNGIzZWI5MmU4NmRlNmE4MTc1YWNfMi0zLTEtMS0w_9f7e815f-d80a-4857-8ff7-824bdcc8b41e">603</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjNhOTA1NGZlOWVkMTRiM2ViOTJlODZkZTZhODE3NWFjL3RhYmxlcmFuZ2U6M2E5MDU0ZmU5ZWQxNGIzZWI5MmU4NmRlNmE4MTc1YWNfMy0xLTEtMS0w_c59ae5b4-6c1d-402b-a2cd-717e42727a54">153,735</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjNhOTA1NGZlOWVkMTRiM2ViOTJlODZkZTZhODE3NWFjL3RhYmxlcmFuZ2U6M2E5MDU0ZmU5ZWQxNGIzZWI5MmU4NmRlNmE4MTc1YWNfMy0zLTEtMS0w_ca0883e5-9467-4940-adcc-05a1412443c4">159,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_37"></div><hr style="page-break-after:always"/><div style="height:69.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div style="text-align:center;"><span><br/></span></div><div id="ide126ddc4fe34b88b9204d0512399caf_40"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNjI_5df29954-ea2d-48c3-945a-9d903fadacba" continuedAt="id95b22cd563541e7a9a24460301052d7" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><ix:continuation id="id95b22cd563541e7a9a24460301052d7" continuedAt="ib8d45cd09b494ed7bed1f4008da40ca1"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Veracyte, Inc., or Veracyte, or the Company, is a global genomic diagnostics company that improves patient care by providing answers to clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The Company&#8217;s growing menu of genomic tests leverage advances in genomic science and technology to change care for patients, enabling them to avoid risky, costly procedures and quicken time to appropriate treatment. With Veracyte&#8217;s exclusive global access to a best-in-class diagnostics instrument platform, the Company is positioned to deliver its tests to patients worldwide through laboratories and hospitals that can perform the tests locally.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Veracyte was incorporated in the state of Delaware on August&#160;15, 2006 as Calderome,&#160;Inc. Calderome operated as an incubator until early 2008. On March&#160;4, 2008, the Company changed its name to Veracyte,&#160;Inc.  The Company&#8217;s operations are based in South San Francisco, California and Austin, Texas, and it operates in <ix:nonFraction unitRef="segment" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfOTgw_6180214b-7cee-46fc-bdbd-7141b0f8b696">one</ix:nonFraction> segment.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company performs its genomic tests for thyroid cancer, lung cancer and idiopathic pulmonary fibrosis, or IPF, in its CLIA-certified laboratory in South San Francisco, California. In December 2019, the Company announced the exclusive global diagnostics license to the NanoString nCounter FLEX Analysis System, and the acquisition of the Prosigna breast cancer prognostic gene signature assay, which is commercially available, and the LymphMark lymphoma subtyping assay, which is in development. Both tests are designed for use on the nCounter system.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company offers genomic tests in <ix:nonFraction unitRef="diseaseareas" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="vcyt:NumberOfDiseaseAreasWithGenomicTesting" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY4MTY1Mw_7a3e4ef9-35d8-412c-8f82-8d36565cd04f">four</ix:nonFraction> disease areas: thyroid cancer; lung cancer; IPF and breast cancer.</span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Thyroid Cancer - Afirma Genomic Sequencing Classifier and Xpression Atlas.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Company's Afirma offerings comprise the Afirma GSC and Xpression Atlas, which help guide next steps for patients with potentially cancerous thyroid nodules. The offerings are intended to provide physicians with clinically actionable results from a single fine needle aspiration, or FNA biopsy. The Afirma GSC was developed with RNA whole-transcriptome sequencing and machine learning, and is used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery.</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Afirma Xpression Atlas complements the Afirma GSC by providing genomic alteration content from the same FNA samples used in Afirma GSC testing to help physicians decide with greater confidence on the surgical or therapeutic pathway for their patients. The Company commercially launched the Afirma Xpression Atlas in 2018 and in April 2020 introduced an expanded version of the test, which includes significantly more genomic content.</span></div><div style="padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Lung Cancer - Percepta Genomic Sequencing Classifier.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> The Percepta classifier improves lung cancer diagnosis when diagnostic bronchoscopy results are inconclusive. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This second-generation test was developed using the Company's RNA whole-transcriptome sequencing and machine learning platform and was commercially introduced in June 2019. The Percepta classifier identifies patients with lung nodules who are at low risk of cancer and may avoid further, invasive procedures as well as patients at high risk of cancer so they may obtain faster diagnosis and treatment. The test is built upon foundational "field of injury" science - through which genomic changes associated with lung cancer in current and former smokers can be identified with a simple brushing of a person's airway - without the need to sample the often hard-to-reach nodule directly. </span></div><div style="padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">IPF - Envisia Genomic Classifier.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Envisia classifier improves diagnosis of IPF by helping physicians better differentiate IPF from other interstitial lung diseases, or ILDs, without the need for surgery. The test identifies the genomic pattern of usual interstitial pneumonia, or UIP, a hallmark of IPF, with high accuracy on patient samples that are obtained through transbronchial biopsy, a nonsurgical procedure that is commonly used in lung evaluation.</span></div><div style="padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Breast Cancer - Prosigna Breast Cancer Prognostic Gene Signature Assay.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> The Prosigna test, acquired in December 2019 through the Company's strategic transaction with NanoString, uses advanced genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease. The test uses a set of 50 genes known as the PAM50 gene signature and can provide a breast cancer patient and physician with prognostic score that indicates the probability of cancer recurrence over ten years. Physicians use Prosigna to help guide therapeutic decisions so that patients receive a therapeutic intervention, such as </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:69.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="ib8d45cd09b494ed7bed1f4008da40ca1" continuedAt="i7ae4583f415b45bf8f7d261999459dd6"><div style="padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">chemotherapy, only if clinically warranted. Patient test results outside of the United States include intrinsic breast cancer subtypes to complement the risk-of-recurrence score.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s approach also provides multiple opportunities for partnerships with biopharmaceutical companies. In developing its products, the Company has built or gained access to unique biorepositories, proprietary technology and bioinformatics that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection.</span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company's testing services are performed in its clinical reference laboratories located in South San Francisco, California and Austin, Texas. The Prosigna test kits and associated products are sold to laboratories and hospitals in global markets.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> </span></div><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNjU_b0350904-19dc-4d1a-bf84-e3c392adb982" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet as of March&#160;31, 2020, the condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2020 and 2019, the condensed consolidated statements of stockholders' equity for the three months ended March&#160;31, 2020 and 2019, and the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2020 and 2019 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results, stockholders' equity  and cash flows for the periods presented. The condensed consolidated balance sheet at December&#160;31, 2019 has been derived from audited financial statements. The results for the three months ended March&#160;31, 2020 are not necessarily indicative of the results expected for the full year or any other period. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying interim period condensed consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div></ix:nonNumeric><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Reclassifications</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Certain prior period balances have been reclassified to conform to current period presentation of the Company&#8217;s condensed consolidated financial statements and accompanying notes. Such reclassifications have no effect on previously reported results of operations, retained earnings or consolidated balance sheet totals; however, for the period ended March 31, 2019, the Company reclassified $<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PriorPeriodReclassificationAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY4NjI1MA_a3906fd7-adca-4d1e-bb49-710dcd1a0aca">212,000</ix:nonFraction> of changes in operating assets and liabilities to noncash lease expense in the statement of cash flows.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNDQ_7c48a58c-48c3-42ee-924b-eaa5d1550818" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Use of Estimates</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Items subject to such estimates include: revenue recognition; write-down of supplies; the useful lives of property and equipment; the recoverability of long-lived assets; the incremental borrowing rate for leases; the estimation of the fair value of intangible assets and contingent consideration; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></div></ix:nonNumeric><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Issuance of Common Stock in a Public Offering</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 7, 2019, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="i9a4e04bee36940d1a665002bd2ac7bf3_D20190507-20190507" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNjQ2NQ_7ee864b3-2458-4645-81a7-218c35eb149c">6,325,000</ix:nonFraction> shares of common stock in a registered public offering, including <ix:nonFraction unitRef="shares" contextRef="ibd46c80ad5fa42759560c922a438635e_D20190507-20190507" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNjUzNA_0d817f12-90ca-4d23-85a4-16513c8edc95">825,000</ix:nonFraction> shares issued and sold upon the underwriters&#8217; exercise in full of their option to purchase additional shares, at a price to the public of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="ibf1f7f58b4404c6486380201c36cbda8_I20190507" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNjY3NQ_6cdfa407-fd39-4b18-a403-f70c142d7469">23.25</ix:nonFraction>&#160;per share. The Company's net proceeds from the offering were approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i9a4e04bee36940d1a665002bd2ac7bf3_D20190507-20190507" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNjc1Mw_774a334b-8bfa-40f2-b4fb-22c7b4f11a68">137.8</ix:nonFraction> million, after deducting underwriting discounts and commissions and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i9a4e04bee36940d1a665002bd2ac7bf3_D20190507-20190507" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNjgzNw_df1221da-bdb5-413d-b662-51d66fb7c81b">9.2</ix:nonFraction> million.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:69.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div style="text-indent:31.5pt;text-align:justify;"><span><br/></span></div><ix:continuation id="i7ae4583f415b45bf8f7d261999459dd6" continuedAt="ia4b0b6cea7514faf9b723fd1d410f305"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNzM_f11c710b-2535-4df4-b98d-93cd90007104" continuedAt="ia5e26ef5cc0f403797d503f84a56f128" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash&#160;and&#160;Cash&#160;Equivalents</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers demand deposits in a bank, money market funds and highly liquid investments with an original maturity of 90 days or less to be cash equivalents.  Cash equivalents include overnight reverse repurchase agreements which are tri-party repurchase agreements and have maturities of&#160;three&#160;months or less at the time of investment and are collateralized by U.S. treasury and agency securities of at&#160;least <ix:nonFraction unitRef="number" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="INF" name="vcyt:PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzcwMQ_8f007e3f-b90d-4ab6-9f2d-0708163b185a">102</ix:nonFraction>%&#160;of the principal amount. In a tri-party repurchase agreement, a third-party custodian bank functions as an independent intermediary to facilitate transfer of cash and holding the collateral on behalf of the underlying investor for the term of the agreement thereby minimizing risk and exposure to both parties. These overnight reverse repurchase agreements are included within cash equivalents due to their high liquidity and relatively low risk.  There were no overnight reverse repurchase agreements at March 31, 2020.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="vcyt:ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNDY_a2c6965f-2dc2-4986-baea-20baa1d58237" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The worldwide spread of coronavirus, or COVID-19, has created significant uncertainty in the global economy. There have been no comparable recent events that provide guidance as to the effect the spread of COVID-19 as a global pandemic may have, and, as a result, the ultimate impact of COVID-19 and the extent to which COVID-19 impacts the Company&#8217;s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict.  If the financial markets or the overall economy are impacted for an extended period, the Company&#8217;s liquidity, revenues, supplies, goodwill and intangibles may be adversely affected</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The majority of the Company&#8217;s cash and cash equivalents are deposited with <ix:nonFraction unitRef="financial_institution" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="vcyt:NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfODI5Mw_b5caa796-c0b9-45cb-9521-b53b370a1ef8">one</ix:nonFraction> major financial institution in the United States. Deposits in this institution may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Several of the components of the Company&#8217;s sample collection kit and test reagents, and its nCounter FLEX Analysis System and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company&#8217;s requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is also subject to credit risk from its accounts receivable related to its sales. Credit risk for accounts receivable from testing revenue is incorporated in testing revenue accrual rates as the Company assesses historical collection rates and current developments to determine accrual rates and amounts the Company will ultimately collect.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company generally does not perform evaluations of customers&#8217; financial condition for testing revenue and generally does not require collateral.  The Company assesses credit risk and the amount of accounts receivable the Company will ultimately collect for product, biopharmaceutical and collaboration revenue based on collection history, current developments and credit worthiness of the customer.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The estimate of credit losses is not material at March 31, 2020.</span></div></ix:nonNumeric><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Through March&#160;31, 2020, most of the Company&#8217;s revenue has been derived from the sale of Afirma. To date, Afirma has been delivered primarily to physicians in the United States. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNTU_181aa203-67e2-4ff6-b461-3e599f2d1f3e" continuedAt="i61dd7f2db4554453a6af84b1fb866805" escape="true">The Company&#8217;s third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:</ix:nonNumeric></span></div><ix:continuation id="i61dd7f2db4554453a6af84b1fb866805" continuedAt="i13828bea44854361926a7a8cc7329d39"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"><tr><td style="width:1.0%;"></td><td style="width:71.442%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.908%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.541%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.909%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i54a3ab19387b41df817e1692261c8fdb_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfMi0xLTEtMS0w_df8bc103-ec48-4ce8-9416-b2a3aad6b798">25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i68cca2f7ddd243ba921a37d340208f12_D20190101-20190331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfMi0zLTEtMS0w_5155f115-e47a-46d4-896a-7d9ac4d7b6e7">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Johnson and Johnson Services, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ia991e1722be24c0bb0d615c7c31e199e_D20190101-20190331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfMy0zLTEtMS0w_501c135c-eb4e-49ff-97c0-5c798f322de4">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">UnitedHealthcare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i009ef9afb3274f819477849480fd2393_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfNC0xLTEtMS0w_9792603d-af5f-4bba-99d2-a48b06b65ec4">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0ba27eaeae954e789d56c5c4c620cf40_D20190101-20190331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfNC0zLTEtMS0w_6834756e-c870-4902-b57b-45146a2a7af9">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i9b93f7856b454811a810d421cd09d494_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfNS0xLTEtMS0w_41b6bead-5c14-44c9-a7f4-e20906b9bccc">36</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id743ee5e5b8148bf9e58641c5f04b9d3_D20190101-20190331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfNS0zLTEtMS0w_9854e977-df34-4379-87e3-ce325dc24124">45</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">*Less than 10%</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:continuation><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:69.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="ia4b0b6cea7514faf9b723fd1d410f305" continuedAt="ifbf835da096f4335905a92eee05fcb7e"><ix:continuation id="i13828bea44854361926a7a8cc7329d39"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s third-party payers and other customers in excess of 10% of accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows at the following dates:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.684%;"><tr><td style="width:1.0%;"></td><td style="width:71.481%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.888%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.540%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.891%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Johnson and Johnson Services, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id232493caa454088900109db08487758_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmY3YjVlOWVmMTEyMzQyMDU4OGM1ZjcyYjNmMDE4M2JkL3RhYmxlcmFuZ2U6ZjdiNWU5ZWYxMTIzNDIwNTg4YzVmNzJiM2YwMTgzYmRfMS0zLTEtMS0w_d2f56d07-303c-4b00-9a0c-ad673620ad11">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i01c7a4983f7b4866abb02d142286638c_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmY3YjVlOWVmMTEyMzQyMDU4OGM1ZjcyYjNmMDE4M2JkL3RhYmxlcmFuZ2U6ZjdiNWU5ZWYxMTIzNDIwNTg4YzVmNzJiM2YwMTgzYmRfMi0xLTEtMS0w_a763b2fb-0cbd-4238-8ba2-6b9c6e3c4391">14</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i57e55cfffebb431ebba08541e4815fbc_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmY3YjVlOWVmMTEyMzQyMDU4OGM1ZjcyYjNmMDE4M2JkL3RhYmxlcmFuZ2U6ZjdiNWU5ZWYxMTIzNDIwNTg4YzVmNzJiM2YwMTgzYmRfMi0zLTEtMS0w_ff15be84-0e0c-4b39-b168-55765ee7d8e2">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">*Less than 10%</sup></div></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr></table></div></ix:continuation><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><ix:continuation id="ia5e26ef5cc0f403797d503f84a56f128"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Cash</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had deposits of $<ix:nonFraction unitRef="usd" contextRef="ic6c280c6cf154f7ea8dd819b86f85a73_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfOTgwNw_6624bacb-b0e6-4164-a34b-d6325a76159e"><ix:nonFraction unitRef="usd" contextRef="id6c4077b693b4c71a9881ad0c593d17e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfOTgwNw_7db1cb1b-f9c5-4528-b657-244736700390">603,000</ix:nonFraction></ix:nonFraction> included in long-term assets as of March&#160;31, 2020 and December&#160;31, 2019, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the Company&#8217;s South San Francisco facility.</span></div></ix:continuation><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNDM_3697d470-4054-4c2e-9a70-abc997f679d0" continuedAt="ia7b0b1a9dddb48da9db3dfecb5c3785e" escape="true">Revenue Recognition</ix:nonNumeric></span></div><ix:continuation id="ia7b0b1a9dddb48da9db3dfecb5c3785e" continuedAt="ia2d5babe4d354011a5e1e43a3e60283b"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Testing Revenue</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes testing revenue in accordance with the provisions of ASC 606, Revenue from Contracts with Customers, or ASC 606.  Most of the Company&#8217;s revenue is generated from the provision of testing services. These services are completed upon the delivery of test results to the prescribing physician, at which time the Company bills for the services. The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized.  In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2019, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2018 or prior years and recognized additional revenue of $<ix:nonFraction unitRef="usd" contextRef="id991525e1945478d84f961bb2f9348ac_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjQ4MQ_89f3e8b8-3375-449d-a0b1-73c6337be040">0.6</ix:nonFraction>&#160;million, which resulted in a decrease in the Company's loss from operations of $<ix:nonFraction unitRef="usd" contextRef="id991525e1945478d84f961bb2f9348ac_D20190101-20190331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNDkzODY_ab39bc1e-03d6-489b-b33c-717bec69daf7">0.6</ix:nonFraction> million and a decrease in loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="id991525e1945478d84f961bb2f9348ac_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNDkzOTM_8fdeb1b4-1ad7-4117-8f5b-0022aff8fcf5">0.02</ix:nonFraction> for the three months ended March 31, 2019.  The change in testing revenue estimates for the three months ended March 31, 2020 was not material.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Product Revenue</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company began recognizing product revenue in December 2019, when the Company executed an agreement with NanoString for the exclusive global license to the nCounter platform and acquisition of products for diagnostic use.  More details on this agreement are in Note 4 - Business Combination.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenue from instruments, consumables and in vitro diagnostic kits is recognized generally upon shipment or when the instrument is ready for use by the end customer, which is when title of the product has been transferred to the customer. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a product to the customer, meaning the customer has the ability to use and obtain the benefit of the product. The Company recognizes product revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control.  Shipping and handling costs incurred for product shipments are charged to the Company's customers and included in product revenue. Revenues are presented net of the taxes that are collected from customers and remitted to governmental authorities.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Biopharmaceutical and Collaboration Revenue</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:69.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="ifbf835da096f4335905a92eee05fcb7e" continuedAt="i4a46f7b2769647a993b2e4b1b9de3433"><ix:continuation id="ia2d5babe4d354011a5e1e43a3e60283b" continuedAt="i054e541fded54fbdb21a19415eecad08"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, the Company enters into arrangements for research and development and/or laboratory services. Such arrangements may require the Company to deliver various rights, services and/or samples, including intellectual property rights/licenses, R&amp;D services, and/or laboratory services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments, and/or profit sharing.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods is transferred or services are performed. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, the Company utilizes the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><div><span><br/></span></div><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Collaborative Arrangements</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company enters into collaborative arrangements with partners that fall under the scope of ASC Topic 808, Collaborative Arrangements, or ASC 808. While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects of these arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part of its ongoing major or central operations. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of the Company&#8217;s collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales of licensed products. Each of these payments may result in collaboration revenues or an offset against research and development expense.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net sales of data or other services to our customers are classified under biopharmaceutical revenue, and all other non-customer revenue, such as milestones, are classified under collaboration revenue in our consolidated statements of operations and comprehensive loss.  There was no collaboration revenue in the three months ended March 31, 2020 and 2019.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Up-front Fees: If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</span></div></ix:continuation></ix:continuation><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:69.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i4a46f7b2769647a993b2e4b1b9de3433" continuedAt="ia163c1a2ae65479082313f4dd7fce0e5"><ix:continuation id="i054e541fded54fbdb21a19415eecad08" continuedAt="i16a7a69107b944e99b372744f7e4c352"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Milestone Payments: At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or the collaborative partner&#8217;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the collaborative partner&#8217;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Services Agreement with Loxo Oncology</span></div><div style="padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 9, 2018, the Company entered into an agreement with Loxo Oncology, Inc., or Loxo, whereby the Company agreed to provide certain tissue samples and other services in exchange for agreed-upon fees.  The agreement has a term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTg5ODQ_f0a3db4d-746a-4336-8a43-6dcb1f0c687a">one</span> year with an automatic renewal of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTkwMjE_98287a7d-3a7f-425c-896d-85cf973f3c3e">one</span> year and Loxo may terminate the agreement at any time with at least <ix:nonNumeric contextRef="i0fd47326099244f099c155ab685c07c4_D20180409-20180409" format="ixt-sec:durday" name="vcyt:TerminationPeriodContractAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTkwOTI_ff0914a3-d317-41a2-90a7-6d4e72fcfc44">90</ix:nonNumeric> days' notice.  As of March&#160;31, 2020, the agreement has not been terminated.  The Company evaluated the accounting for this agreement under ASC 606 and concluded the performance obligations thereunder are the delivery of tissue samples and performance of services, both of which are distinct.  For the three months ended March 31, 2019, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i1091751f442346ebbe0c524c9e4668a1_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk0NDg_7734e846-1207-4247-b348-04ed335b8a99">90,000</ix:nonFraction> for the delivery of tissue samples.  There were <ix:nonFraction unitRef="delivery" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="vcyt:NumberofTissueSampleDeliveries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk0OTk_c418bf6a-3239-4ac2-bac0-f58862016747">no</ix:nonFraction> deliveries of tissue samples for the three months ended March 31, 2020.  The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="if3af9fe09e1e40829129e870dc5bb8e7_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk2Mzk_1921cfa4-aa4b-4b22-bc80-8d17b21a2227"><ix:nonFraction unitRef="usd" contextRef="iab389aee6e60456eb379dbae0cc747b5_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk2Mzk_337f1fe7-f97b-42d2-9824-3b2d2fc5c972"><ix:nonFraction unitRef="usd" contextRef="i3d1b5f753a4342188cbb3be12ff68b0d_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk2Mzk_b3374183-4517-440f-b707-a36ef67a9f85">250,000</ix:nonFraction></ix:nonFraction></ix:nonFraction> for the performance of services for each of the three months ended March 31, 2020 and 2019, respectively.  The cost of revenue associated with revenue recognized under the agreement with Loxo is not significant.  There was <ix:nonFraction unitRef="usd" contextRef="i280b0e75a2e941528ad5d310116a69ab_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk4ODA_afb60b6a-276b-40c7-9bfe-7092991c4af7"><ix:nonFraction unitRef="usd" contextRef="i85aec995c7594a55b57230e1738cb84e_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk4ODA_eebc6e17-feed-4596-9508-53cf51fa634d">no</ix:nonFraction></ix:nonFraction> deferred revenue related to this agreement at either March&#160;31, 2020 or December&#160;31, 2019.</span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Diagnostic Development Agreement with Johnson &amp; Johnson</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 28, 2018, the Company entered into a diagnostics development agreement with Johnson and Johnson Services, Inc., or JJSI, (i) to cooperate on a program to enable the Company to use JJSI samples and clinical data to develop a next generation bronchial genomic classifier diagnostic for lung cancer diagnosis, or Percepta v.2, and a nasal genomic classifier diagnostic for lung cancer and (ii) for JJSI to use Veracyte data generated in two Veracyte development programs for therapeutic purposes and for purposes of developing a companion diagnostic product used in conjunction with a JJSI therapeutic.  The Company granted a license to JJSI with the right to use data and under the Company's intellectual property rights for JJSI's therapeutic purposes, including the development and commercialization of a companion diagnostic for its products, from the Percepta v.2 and Nasal programs.  The license granted to JJSI is not distinct from other performance obligations as JJSI receives benefit only when other performance obligations are met.</span></div><div style="text-indent:36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the agreement, the Company will provide data from its RNA whole-transcriptome sequencing platform to JJSI in exchange for $<ix:nonFraction unitRef="usd" contextRef="i86e73a154d594043a095b33e4c98e484_I20200331" decimals="-5" format="ixt:numdotdecimal" name="vcyt:ContractAgreementReceivableForServices" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNzcwNDY_32feae21-d9be-462a-b34e-2b8da431129b">7.0</ix:nonFraction> million in payments from JJSI.  The Company is also entitled to additional payments from JJSI of up to $<ix:nonFraction unitRef="usd" contextRef="i86e73a154d594043a095b33e4c98e484_I20200331" decimals="-5" format="ixt:numdotdecimal" name="vcyt:ContractAgreementConditionalAdditionalReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNzcwNjA_49b170fd-a8dc-4061-86c9-550a3da1e0e1">13.0</ix:nonFraction> million, conditioned upon the achievement of certain milestones relating to the development and reimbursement of the Percepta v.2 and Nasal tests.  For a period of ten years commencing with the first commercial sale of the Percepta v.2 and Nasal tests, respectively, the Company will make payments to JJSI of <ix:nonFraction unitRef="number" contextRef="i0926623973444c5caf73d3278c08787f_D20200101-20200331" decimals="2" format="ixt-sec:numwordsen" name="vcyt:ContractAgreementFeePercentageOfCashCollections" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNzcwNzU_17008b68-6284-43e4-a96e-b24d4d7e8906">one</ix:nonFraction> percent of net cash collections for Percepta v.2 and in the low-single digits of net cash collections for the Nasal test, depending on the number and timing of JJSI samples and associated clinical data the Company receives from JJSI.</span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The JJSI agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the JJSI agreement and has analogized to ASC 606 for the delivery of RNA whole-transcriptome sequencing data to JJSI under the collaborative arrangement, which the Company believes is a distinct service for which JJSI meets the definition of a customer. Using the concepts of ASC 606, the Company has identified the delivery of data as its only performance obligation. The Company further determined that the transaction price under the arrangement was the $<ix:nonFraction unitRef="usd" contextRef="i86e73a154d594043a095b33e4c98e484_I20200331" decimals="-5" format="ixt:numdotdecimal" name="vcyt:ContractAgreementReceivableForServices" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNzc3OTU_32feae21-d9be-462a-b34e-2b8da431129b">7.0</ix:nonFraction> million in payments which was allocated to the obligation to deliver data.  The $<ix:nonFraction unitRef="usd" contextRef="i86e73a154d594043a095b33e4c98e484_I20200331" decimals="-5" format="ixt:numdotdecimal" name="vcyt:ContractAgreementConditionalAdditionalReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNzc4MTE_49b170fd-a8dc-4061-86c9-550a3da1e0e1">13.0</ix:nonFraction> million in future potential payments is considered variable consideration because the Company determined that the potential payments are contingent upon </span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:69.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="ia163c1a2ae65479082313f4dd7fce0e5" continuedAt="i37e19f8f34fb4499be6307d73b7bb87f"><ix:continuation id="i16a7a69107b944e99b372744f7e4c352" continuedAt="ia71929119f2b4046b0c0d9dbd6a93164"><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">regulatory and commercialization milestones that are uncertain to occur and, as such, were not included in the transaction price, and will be recognized accordingly as each potential payment becomes probable.</span></div><div><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i9b710a4a5abe4993a9278aad2ed6ed6c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjU1MQ_f703ca01-a91e-41d9-8d0a-e75a11877dd4">7.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i665bf3400edb456f9bf74af9d39ee05e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjU2NQ_cc62fe52-f87f-48ff-9a4d-81d3bbdfecf6">4.0</ix:nonFraction>&#160;million during 2019 for the provision of data and fulfillment of obligations relating to Percepta v.2 and Nasal program development milestones, respectively.  There was <ix:nonFraction unitRef="usd" contextRef="i68d35cb702de4592a9e6b6b1b313c182_D20200101-20200331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjU5NQ_e6dacf82-c488-4b58-a528-4bc3d99ee48b">no</ix:nonFraction> revenue for the three months ended March 31, 2020.  For the three months ended March 31, 2019, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i01413ef04119474ea6616ffa333f811c_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjUyMw_09183a76-7b3c-4cc8-a7da-24a3ce983112">3.8</ix:nonFraction>&#160;million for the provision of data relating to Percepta v.2, classified under biopharmaceutical revenue in the consolidated statement of operations and comprehensive loss. There was <ix:nonFraction unitRef="usd" contextRef="i86e73a154d594043a095b33e4c98e484_I20200331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AccountsReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjYwNQ_b65aa3b3-dd44-4818-9e60-56cabcaa20bc">no</ix:nonFraction> accounts receivable from JJSI at March 31, 2020 and accounts receivable from JJSI was $<ix:nonFraction unitRef="usd" contextRef="i548a24efc9604bf5b1230a9363724472_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjUzNw_016b96ec-9bf4-4eca-97a8-d8bdba3a84e5">2.0</ix:nonFraction>&#160;million at December&#160;31, 2019.  There was no deferred revenue related to this agreement at March 31, 2020 and December&#160;31, 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration Agreement with AstraZeneca Group</span></div><div><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 23, 2019, the Company entered into an agreement with Acerta Pharma B.V., or Acerta, a member of AstraZeneca Group whereby the Company agreed to provide genomic information that will support Acerta&#8217;s development of oncology therapeutics.  Acerta will pay the Company for certain development activities and pay milestones to the Company for the achievement of development milestones.  For the three months ended March 31, 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i2b8be7bd0c98463195fa2424ea5db120_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjQ5NQ_8feff1e6-71c0-4645-b8e3-53c6823a4a02">0.1</ix:nonFraction>&#160;million of revenue for certain development costs activities and accounts receivable from Acerta was $<ix:nonFraction unitRef="usd" contextRef="i8c3fe671598544568e5396dda599a8f9_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjUwOQ_6117a675-0327-43dc-a867-108141d06e8d">0.1</ix:nonFraction>&#160;million at March 31, 2020.  The agreement will be accounted for in accordance with the policy on collaborative arrangements, as mentioned in this footnote.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Biopharmaceutical Services Agreement</span></div><div><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the quarter ended March 31, 2020, the Company entered into an agreement to provide research and development services of $<ix:nonFraction unitRef="usd" contextRef="ia18208097ace4d03aa3886966d7c6b01_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="vcyt:ContractAgreementAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjU3OQ_7f1f3b52-f99c-4ab9-8f56-3cdf6a29728a">0.5</ix:nonFraction>&#160;million for which the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i8f0a5d6bb3934b7eb407eca1fae3f16a_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjYxMw_deb59e1c-d9ba-4cbe-bdbb-784e7d5091bb">0.3</ix:nonFraction>&#160;million of biopharmaceutical revenue for the three months ended March 31, 2020. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Testing Revenue</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of our cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation and amortization, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test. Cost of testing revenue for the three months ended March 31, 2020 included $<ix:nonFraction unitRef="usd" contextRef="i1e857cb02e9a491ea7ee7312b9dd0c9e_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY4MzM3Nw_42b63cb2-de57-40a8-9a2f-ad180425448d">1.1</ix:nonFraction>&#160;million write-down of supplies for the potential expiration of reagents due to an anticipated decline in volumes resulting from the COVID-19 pandemic.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Product Revenue </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of product revenue consists primarily of costs of purchasing instruments and consumables from third-party contract manufacturers, installation, warranty, service and packaging and delivery costs. In addition, cost of product includes royalty costs for licensed technologies included in the Company&#8217;s products and labor expenses. Cost of product revenue for instruments and consumables is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the consolidated statements of operations.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Biopharmaceutical Revenue </span></div></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ia71929119f2b4046b0c0d9dbd6a93164">Cost of biopharmaceutical revenue consists of costs of performing activities under arrangements that require the Company to perform research and development services on behalf of a customer pursuant to a biopharmaceutical service agreement.</ix:continuation> </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNTc_eba072ff-8d2b-4262-abfc-96fb3b7631d2" continuedAt="i22209f426d93481d9c229ce667db51a8" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This ASU requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:69.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i37e19f8f34fb4499be6307d73b7bb87f" continuedAt="ic7b9b55e4b994bc8a2c708f09a1a940a"><ix:continuation id="i22209f426d93481d9c229ce667db51a8" continuedAt="i2f29474041a84f10a65ffcce13249e50">risks. This guidance became effective for the Company beginning January 1, 2020.  Based on the composition of its trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures.</ix:continuation></ix:continuation></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><ix:continuation id="ic7b9b55e4b994bc8a2c708f09a1a940a" continuedAt="if61c90ab42cd441c94cf71f91409946f"><ix:continuation id="i2f29474041a84f10a65ffcce13249e50" continuedAt="iaedecc0419f642518a7308b9762d90ba"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (Topic 808). </span></ix:continuation></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="if61c90ab42cd441c94cf71f91409946f"><ix:continuation id="iaedecc0419f642518a7308b9762d90ba">Under&#160;this ASU,&#160;transactions in collaborative arrangements are to be accounted for under ASC 606 if the counterparty is a customer for a good or service (or bundle of goods and services) that is a distinct unit of account. Also, entities are precluded from presenting consideration from transactions with a counterparty that is not a customer together with revenue recognized from ASC 606.  This ASU is effective for all interim and annual reporting periods beginning on or after December 15, 2019, with early adoption permitted.  The Company adopted this ASU in 2019 with no cumulative-effect adjustments or retrospective impact.</ix:continuation></ix:continuation> </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018 the FASB issued ASU No. 2018-15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard became effective for the Company on January 1, 2020, and was adopted on a prospective basis with no material impact on the Company's condensed consolidated financial statements.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="ide126ddc4fe34b88b9204d0512399caf_46"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RleHRyZWdpb246YzYyZWU5NDQwZjFiNDBkMmI0YzkzYmExNTkwZGUwYmRfNjY5_090f6851-d7a4-4877-ad53-1d02dca4ef1c" continuedAt="ieb4832de35d24aeca00bf6034526f9c3" escape="true">Net Loss Per Common Share</ix:nonNumeric></span></div><ix:continuation id="ieb4832de35d24aeca00bf6034526f9c3"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RleHRyZWdpb246YzYyZWU5NDQwZjFiNDBkMmI0YzkzYmExNTkwZGUwYmRfNjY1_24cdc34c-9e1c-49cd-9ba0-9d94e635d0a6" continuedAt="i403c1e432a664380bf1f7d911a95d905" escape="true">The following outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive:</ix:nonNumeric></span></div><ix:continuation id="i403c1e432a664380bf1f7d911a95d905"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"></td><td style="width:72.408%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.426%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.427%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares of common stock subject to outstanding options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i275dbe7307a1449492e85c3747f396b1_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfMi0xLTEtMS0w_aea8027a-32dd-4530-b980-fbd4872f9c7c">4,760,128</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i70ec834c26f14e2d905193c57ed86a8c_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfMi0zLTEtMS0w_99ac7b05-c8d5-41e3-8644-974a7b31cfe2">5,670,819</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i89b2f2d36fb04fcdb8a12000d2357117_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfMy0xLTEtMS0w_e63243b3-9af2-4ddc-86be-48769ede65ba">19,857</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i661cf60c28f348a588855e09824e1932_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfMy0zLTEtMS0w_2a61599d-3acb-4d26-803c-3db79f6b81a3">25,672</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5031ee348bd54e3eb46dbeeabe6bced0_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfNC0xLTEtMS0w_76691314-2b38-4233-bfcd-0960a81e79b5">936,524</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia20f4af3d960436784dac385c143e839_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfNC0zLTEtMS0w_867a94bb-cfe7-49a3-8ca9-2103cc3aea23">538,759</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total common stock equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfNS0xLTEtMS0w_efb0fe08-fce4-436c-8c09-f6e8febe144f">5,716,509</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfNS0zLTEtMS0w_89c947d0-180e-4416-8c09-e30697d0e192">6,235,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ide126ddc4fe34b88b9204d0512399caf_49"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RleHRyZWdpb246YTJlODAwYTBkNTYwNDM5NmE3ZjYyYjAzYmIyODBlMTdfMTE0_a5133929-09df-4c3d-b9c3-7d2e22fd415e" continuedAt="ice90e8156c0a4f3f86fbf47d40ad0548" escape="true">Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="ice90e8156c0a4f3f86fbf47d40ad0548"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RleHRyZWdpb246YTJlODAwYTBkNTYwNDM5NmE3ZjYyYjAzYmIyODBlMTdfMTEw_58a492a1-1c94-4713-98e8-036cb183c988" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consisted of the following (in thousands of dollars):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RhYmxlOmI1YzFhN2VmOGM4YjQ0ZDJiY2Y5MTBiMGNiMTExYWIyL3RhYmxlcmFuZ2U6YjVjMWE3ZWY4YzhiNDRkMmJjZjkxMGIwY2IxMTFhYjJfMS0xLTEtMS0w_c89335bb-1cd0-45fe-9449-6e2943a300c5">7,497</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RhYmxlOmI1YzFhN2VmOGM4YjQ0ZDJiY2Y5MTBiMGNiMTExYWIyL3RhYmxlcmFuZ2U6YjVjMWE3ZWY4YzhiNDRkMmJjZjkxMGIwY2IxMTFhYjJfMS0zLTEtMS0w_7baf43c5-1448-457f-b4ee-94e32fe77936">10,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RhYmxlOmI1YzFhN2VmOGM4YjQ0ZDJiY2Y5MTBiMGNiMTExYWIyL3RhYmxlcmFuZ2U6YjVjMWE3ZWY4YzhiNDRkMmJjZjkxMGIwY2IxMTFhYjJfMi0xLTEtMS0w_92679e30-53b8-47e5-8299-a03d538e6104">2,582</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RhYmxlOmI1YzFhN2VmOGM4YjQ0ZDJiY2Y5MTBiMGNiMTExYWIyL3RhYmxlcmFuZ2U6YjVjMWE3ZWY4YzhiNDRkMmJjZjkxMGIwY2IxMTFhYjJfMi0zLTEtMS0w_2430c1c2-49de-4466-9d87-74fcb231fcef">3,634</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RhYmxlOmI1YzFhN2VmOGM4YjQ0ZDJiY2Y5MTBiMGNiMTExYWIyL3RhYmxlcmFuZ2U6YjVjMWE3ZWY4YzhiNDRkMmJjZjkxMGIwY2IxMTFhYjJfMy0xLTEtMS0w_0da566f2-cf6b-4729-9f53-a854ce7e2505">10,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RhYmxlOmI1YzFhN2VmOGM4YjQ0ZDJiY2Y5MTBiMGNiMTExYWIyL3RhYmxlcmFuZ2U6YjVjMWE3ZWY4YzhiNDRkMmJjZjkxMGIwY2IxMTFhYjJfMy0zLTEtMS0w_4d98852f-e893-40db-b56a-f0dbfd7fd7b1">13,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_1312"></div><hr style="page-break-after:always"/><div style="height:69.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NDQw_a624d955-e5c1-46ff-b4b8-3032ebd5fb7c" continuedAt="i36f2c039ac5b4d2fb8b0d30e8f46e15a" escape="true">Business Combination</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i36f2c039ac5b4d2fb8b0d30e8f46e15a"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On December 3, 2019, the Company executed an agreement with NanoString for the exclusive global diagnostics license to the nCounter FLEX Analysis System, and the acquisition of the Prosigna breast cancer prognostic gene signature assay, and the LymphMark lymphoma subtyping assay. The strategic transaction positions the Company to expand its genomic diagnostics business globally, with the ability to deliver its advanced genomic tests to physicians and their patients via hospital and clinical laboratories throughout the European Union and other parts of the world. The Company has accounted for this agreement under Accounting Standards Codification 805, Business Combinations. Pursuant to the terms of the agreement, Veracyte paid NanoString $<ix:nonFraction unitRef="usd" contextRef="i581ad647641b4236a34ecb7f297c1e30_D20191203-20191203" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NDU3_d14cb807-7b58-46ae-af8a-e8f1eea238c0">40.0</ix:nonFraction>&#160;million in cash and $<ix:nonFraction unitRef="usd" contextRef="idcc713d7148f45709edd0e4def2fa275_D20191203-20191203" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NDg2_cf5a150c-a1aa-4839-9ea8-5d18bb15d1a0">10.0</ix:nonFraction>&#160;million in Veracyte common stock, and may pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="i4d4f80e336944a3588df9f7c63718be8_I20191203" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NDQy_98af0980-cbeb-47d8-8113-5d3cd36651da">10.0</ix:nonFraction>&#160;million in cash, contingent upon the commercial launch of Veracyte diagnostic tests for use on the platform. This contingency was valued at $<ix:nonFraction unitRef="usd" contextRef="i1709eba571e842b192e2031b1c4d9b08_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NDcy_879056f1-1d72-46e3-98df-b5119c18cf9b"><ix:nonFraction unitRef="usd" contextRef="i4d4f80e336944a3588df9f7c63718be8_I20191203" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NDcy_d66ba2a6-d12f-41b6-9946-8e01ed839801">6.1</ix:nonFraction></ix:nonFraction>&#160;million as of the acquisition date and as of December 31, 2019, recorded as a liability, and will be remeasured to fair value at each reporting date until the contingent consideration is settled.  As of March 31, 2020, this contingency was remeasured to $<ix:nonFraction unitRef="usd" contextRef="icd2f25cb091b48ca8213a9a4df7ffbe1_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTkzNTQ0_a11eef62-6c98-4e5f-be44-797a396805bf">5.6</ix:nonFraction>&#160;million with the corresponding change included in general and administrative expense in the Company's condensed consolidated statements of operations and comprehensive loss.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets acquired are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and the resulting amount of goodwill. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTkyMjY2_5b95b301-2503-4e46-a6eb-2b56cf35a03e" continuedAt="i163e905d0ca24b59a3744e1fbad0ee4c" escape="true">The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):</ix:nonNumeric></span></div><div style="text-indent:36pt;text-align:center;"><span><br/></span></div><div style="text-align:center;"><ix:continuation id="i163e905d0ca24b59a3744e1fbad0ee4c"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:84.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.422%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prosigna product technology</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d9f79d4992742aeaaa9c1d70d147220_I20191203" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY18wLTEtMS0xLTIyMjg_4255b29f-eb94-4b8c-902c-3deb69d22058">4,120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prosigna customer relationships</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b4444e9fe9f4984a86852673528284b_I20191203" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY18xLTEtMS0xLTIyMzI_230afd59-f474-4f97-b752-7e2e0340aff1">2,430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">nCounter FLEX Dx license</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i366c70e66aab457da18751b8d033eb24_I20191203" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY18yLTEtMS0xLTIyMzI_b6d37d7e-043a-41db-b0cc-3c8b0beae1db">46,880</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LymphMark product technology</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i414932941beb4ee4b26024d1b7d17b04_I20191203" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY18zLTEtMS0xLTIyMzI_afc561eb-0b34-4960-aad9-3777ffb38f27">990</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total identifiable intangible assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d4f80e336944a3588df9f7c63718be8_I20191203" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY180LTEtMS0xLTIyMzI_7f7c297e-33d7-4b82-bc24-5c8fccd280b6">54,420</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d4f80e336944a3588df9f7c63718be8_I20191203" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY181LTEtMS0xLTIyMzI_f637fe0e-6166-4dac-8824-5c5c67ac411d">1,668</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d4f80e336944a3588df9f7c63718be8_I20191203" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY182LTEtMS0xLTIyMzI_235c1ab4-7dba-4ec1-b58a-26c8ff16014a">56,088</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTkyMjY3_9350ee90-fc54-418d-8b83-90962b635834" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Identifiable acquisition-related intangibles included in the above table are finite-lived and are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows:</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099%;"><tr><td style="width:1.0%;"></td><td style="width:69.535%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:26.465%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Useful life (In Years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prosigna product technology</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i95a54fa194e14f688292b523de39ca15_D20191203-20191203" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6YzRjZTk3NmQ4NGEwNDcxZTllZWU3NWUxZjFjMTIxYzMvdGFibGVyYW5nZTpjNGNlOTc2ZDg0YTA0NzFlOWVlZTc1ZTFmMWMxMjFjM18xLTEtMS0xLTIyMzU_74b270ba-e398-4484-86dd-5837ad66a144">15</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prosigna customer relationships</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i4a158a8048db4ff2b300dcd76423ba63_D20191203-20191203" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6YzRjZTk3NmQ4NGEwNDcxZTllZWU3NWUxZjFjMTIxYzMvdGFibGVyYW5nZTpjNGNlOTc2ZDg0YTA0NzFlOWVlZTc1ZTFmMWMxMjFjM18yLTEtMS0xLTIyMzU_8db119b9-f18c-4e6a-a304-8c27001dea19">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">nCounter FLEX Dx license</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id7052d1e1ab243a6bd6b0fe4e6245e27_D20191203-20191203" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6YzRjZTk3NmQ4NGEwNDcxZTllZWU3NWUxZjFjMTIxYzMvdGFibGVyYW5nZTpjNGNlOTc2ZDg0YTA0NzFlOWVlZTc1ZTFmMWMxMjFjM18zLTEtMS0xLTIyMzU_639b4c2f-183e-4af4-abf4-033ff7e79497">15</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LymphMark product technology</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i15687bf922754ae2adfc9ec81a395382_D20191203-20191203" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6YzRjZTk3NmQ4NGEwNDcxZTllZWU3NWUxZjFjMTIxYzMvdGFibGVyYW5nZTpjNGNlOTc2ZDg0YTA0NzFlOWVlZTc1ZTFmMWMxMjFjM180LTEtMS0xLTIyMzU_fc68b8fd-ae44-40b9-8052-6a19cf29c1e5">7</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. This acquisition includes $<ix:nonFraction unitRef="usd" contextRef="i4d4f80e336944a3588df9f7c63718be8_I20191203" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NTAx_564ac6d4-23c2-46ed-b817-e972e916853e">1.7</ix:nonFraction>&#160;million of goodwill which the Company believes consists principally of the organized workforce that will help the Company execute its strategic plans in relation to the assets acquired. In accordance with ASC 350, goodwill will not be amortized but will be tested for impairment at least annually. As of March 31, 2020, goodwill is not deductible for tax purposes, however, if contingent consideration is paid at a future date, the portions of contingent consideration paid and allocated to the intangible assets for tax purposes will be tax deductible. The accounting for this acquisition is preliminary and will be finalized upon completion of the analysis of certain contracts acquired and executed as part of this acquisition along with the impact on goodwill, should there be any.</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_52"></div><hr style="page-break-after:always"/><div style="height:69.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfNzE0NjgyNTU4NTI1Mw_84916405-d377-40f4-88a6-ead0dfe004be" continuedAt="i047efe7beb3649d288637a601916442e" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i047efe7beb3649d288637a601916442e"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company records its financial assets and liabilities at fair value. The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;I: Inputs which include quoted prices in active markets for identical assets and liabilities;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;II: Inputs other than Level&#160;I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Company&#8217;s financial assets includes money market funds, overnight reverse repurchase agreements and a deposit for the lease of the Company's South San Francisco facility.  Money market funds, included in cash and cash equivalents in the accompanying condensed consolidated balance sheets, were $<ix:nonFraction unitRef="usd" contextRef="i5d59ef541093494588d84ced75c2fef2_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfMjIwMA_572c43ed-e056-44c1-8194-beaaa7077994">150.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i972755a8c17f424e96cf5cd3044f60ec_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfMjIwNw_a91ac1df-aed9-4e68-94c9-07dbd81236e7">57.6</ix:nonFraction> million as of March&#160;31, 2020 and December&#160;31, 2019, respectively, and are Level&#160;I assets as described above.  Overnight reverse repurchase agreements, included in cash and cash equivalents in the accompanying condensed consolidated balance sheets, were <ix:nonFraction unitRef="usd" contextRef="i884ba2e362494397a39b4b3ac9d4454e_I20200331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfMjQxNQ_8c14cac8-57a5-4f50-b53a-c9b75ddbfbc0">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie698dd87420e44ce95964e6db3c81371_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfMjQyMg_a9a204df-fc2c-498d-8c14-e4153af1435c">100.0</ix:nonFraction> million as of March&#160;31, 2020 and December&#160;31, 2019, respectively, and are Level II assets as described above.  There were <ix:nonFraction unitRef="usd" contextRef="ia9b90e1ed4f74cacaf0797329a68769b_D20190101-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfNzE0NjgyNTU4NTI4Mw_20bcb016-6e2e-4989-b860-684a549da393"><ix:nonFraction unitRef="usd" contextRef="i0a0c568ab03f4e8d8092811c74c0250c_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfNzE0NjgyNTU4NTI4Mw_5b5ca42d-dd30-479d-9919-a74fdebcc057">no</ix:nonFraction></ix:nonFraction> unrealized gains or losses from overnight reverse repurchase agreements at March&#160;31, 2020 and December&#160;31, 2019. The deposit for the lease, included in restricted cash in the accompanying condensed consolidated balance sheets, was $<ix:nonFraction unitRef="usd" contextRef="i4ba4c8f0affe47d8b51e983b2a35f24d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfMjYwNg_acc5e03c-48ba-4421-b939-1519807f0889"><ix:nonFraction unitRef="usd" contextRef="i674973e8b33f469b92b9f3edb0c4eba2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfMjYwNg_e51b0ce7-cb0e-464b-b270-f9ef0fd250bf">603,000</ix:nonFraction></ix:nonFraction> as of March&#160;31, 2020 and December&#160;31, 2019, and is a Level I asset as described above. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The contingent consideration in Note 4, Business Combination, associated with the agreement with NanoString on December 3, 2019, is a Level III financial liability. The estimation of the fair value of the contingent consideration is based on the present value of the expected payments calculated by assessing the likelihood of when the related milestones would be achieved, discounted using the Company's estimated borrowing rate. These estimates form the basis for making judgments about the carrying value of the contingent consideration that are not readily apparent from other sources. Changes to the forecasts for the achievement of the milestones and the estimates of the borrowing rate can significantly affect the estimated fair value of the contingent consideration.</span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div id="ide126ddc4fe34b88b9204d0512399caf_58"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMzMwOA_c57bd3af-867b-4794-97f1-afb67133f835" continuedAt="if57a599e151f4cd39a10620a763cc0d6" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="if57a599e151f4cd39a10620a763cc0d6" continuedAt="i1f67f2995f25426290d6ca7437c0263e"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Leases</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company leases its headquarters and laboratory facilities in South San Francisco, California under a non-cancelable lease agreement for approximately <ix:nonFraction unitRef="sqft" contextRef="i3f2a64c5183543af9a4e1523c2354584_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="vcyt:LesseeLeasingArrangementsOperatingLeasesSpaceLeased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMjEz_788a080e-c325-45f8-863a-c28bb9ad5df3">59,000</ix:nonFraction> square feet. The lease began in June&#160;2015 and ends in March&#160;2026 and contains extension of lease term and expansion options.  The Company had deposits of $<ix:nonFraction unitRef="usd" contextRef="id6c4077b693b4c71a9881ad0c593d17e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMzcw_27f7bc7a-cf68-4a9d-87c9-e8939ab83cdf"><ix:nonFraction unitRef="usd" contextRef="ic6c280c6cf154f7ea8dd819b86f85a73_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMzcw_d0b2dec1-c286-4ec6-8bef-542a334b9a40">603,000</ix:nonFraction></ix:nonFraction> included in long-term assets as of March&#160;31, 2020 and December&#160;31, 2019, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the South San Francisco facility.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also leases laboratory and office space in Austin, Texas under a lease that expires in January 2029 and includes options for expansion and early termination in 2025.  The Company provided a cash security deposit for this lease of $<ix:nonFraction unitRef="usd" contextRef="i40fdccc0cedd4d23b306a72908b22980_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfODQ3_5db13825-0a2f-497c-9531-95c7f2c4f3a0"><ix:nonFraction unitRef="usd" contextRef="i6e241de3601549a39ba5ab3def105dc5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfODQ3_e98079d4-96fb-4d99-bc1a-594e0ad3aa7e">139,000</ix:nonFraction></ix:nonFraction>, included in other assets in the Company&#8217;s condensed consolidated balance sheets as of March&#160;31, 2020 and December&#160;31, 2019. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMzMwNA_643101ed-1399-4275-9372-c2f1f8e76686" continuedAt="i743c6b49264a42edb0a61e66e4e1680f" escape="true">Future minimum lease payments under non-cancelable operating leases as of March&#160;31, 2020 are as follows (in thousands of dollars):</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:69.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i1f67f2995f25426290d6ca7437c0263e"><ix:continuation id="i743c6b49264a42edb0a61e66e4e1680f"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.953%;"><tr><td style="width:1.0%;"></td><td style="width:85.014%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.986%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Year&#160;Ending&#160;December&#160;31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfMS0xLTEtMS0w_b3c6f4d1-6b35-4c3c-943f-dfda423ac459">1,760</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfMi0xLTEtMS0w_20e7c835-93c5-47a6-9944-994881524c24">2,401</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfMy0xLTEtMS0w_8d6d3f5c-8d40-4939-b690-2030ff4f6261">2,472</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfNC0xLTEtMS0w_82dc738f-7789-41b8-b2c4-cb70a803a255">2,543</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfNS0xLTEtMS0w_1f488d77-e7ed-4211-aab9-156513a9e216">2,614</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfNi0xLTEtMS0w_f2cd99a5-bc99-478e-8865-434b851b8c87">4,227</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total future minimum lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfNy0xLTEtMS0w_479eccf2-2070-49de-901d-74de4e3e8515">16,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: amount representing interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfOC0xLTEtMS00OTg_78b50ba5-713e-48f2-8771-e1585569f696">3,435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of future lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfOS0xLTEtMS00OTg_f10d3fd6-fe41-4f2a-b938-480e38aa59df">12,582</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: short-term lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfMTAtMS0xLTEtNDk4_f8c6a99c-a4d9-4e84-91be-8f79bc554bbf">1,450</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfMTEtMS0xLTEtNDk4_7c859d8c-afb0-4659-bfd6-9952376fd812">11,132</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes operating lease expense on a straight-line basis over the non-cancelable lease period.  Operating lease expense was $<ix:nonFraction unitRef="usd" contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMTgzOA_faba2868-1437-4e19-88f4-9a5f2dbf7ee9">474,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMTg0NQ_1a429e41-678c-4ee5-803a-98c85d602be1">476,000</ix:nonFraction> for the three months ended March&#160;31, 2020 and 2019, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingencies</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its condensed consolidated financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company believes there is no legal proceeding pending that could have, either individually or in the aggregate, a material adverse effect on the Company&#8217;s condensed consolidated financial statements.</span></div></ix:continuation><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="ide126ddc4fe34b88b9204d0512399caf_64"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfNDA1OA_dc11c4a3-2353-4ad0-8271-9db71a998335" continuedAt="iec16b6c7295f46e0bc4202465d815d08" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="iec16b6c7295f46e0bc4202465d815d08" continuedAt="ibc9e5ad26d72447ea60414701b50205d"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Loan and Security Agreement</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 3, 2017, the Company entered into a loan and security agreement, or Loan and Security Agreement, with Silicon Valley Bank.  The Loan and Security Agreement allows the Company to borrow up to $<ix:nonFraction unitRef="usd" contextRef="ib4a031c3845c42609372921e497cac2e_I20171103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMjUx_f27ed2a6-0331-4e2d-8a2d-b2137f35eb2c">35.0</ix:nonFraction> million, with a $<ix:nonFraction unitRef="usd" contextRef="i1f90c73b3c3144378fa37effee913e4a_I20171103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMjYy_441b25bb-7492-464d-bfa1-3aa936294b2a">25.0</ix:nonFraction> million advance term loan, or Term Loan Advance, and a revolving line of credit of up to $<ix:nonFraction unitRef="usd" contextRef="i4e69109f224f45f78b4f86b7853a4f9c_I20171103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMzUw_65afcf60-1cbc-4af2-8f4c-5d7f888c9e5f">10.0</ix:nonFraction> million, or Revolving Line of Credit.  The Term Loan Advance was advanced upon the closing of the Loan and Security Agreement and was used to pay the outstanding balance of the Company&#8217;s existing long-term debt, which was canceled at that date.  The Company had not drawn on the Revolving Line of Credit as of March&#160;31, 2020.  Borrowings under the Loan and Security Agreement mature on October 1, 2022.  Amounts may be borrowed and repaid under the Revolving Line of Credit up until the earliest of full repayment or maturity of the Loan and Security Agreement, termination of the Loan and Security Agreement, or October 1, 2022.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Term Loan Advance bears interest at a variable rate equal to (i) the thirty-day U.S. London Interbank Offer Rate, or LIBOR, plus (ii) <ix:nonFraction unitRef="number" contextRef="i65e0aac4a63e44328e46b91201a0cd91_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTEwNQ_87cc19ca-50d5-4487-8523-2f9731e2d040">4.20</ix:nonFraction>%, with a minimum rate of <ix:nonFraction unitRef="number" contextRef="id07f35bf3b6d4efdb97d4f802d200950_I20200331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTEzMg_c92c4fec-f2dc-4b15-ab71-dd845e513b4e">5.43</ix:nonFraction>% per annum. Principal amounts outstanding under the Revolving Line of Credit bear interest at a variable rate equal to (i) LIBOR plus (ii) <ix:nonFraction unitRef="number" contextRef="idc5e731438a1449ba3564ed90fd6f856_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTI3Mw_6c66dc06-5891-43f1-8662-6ebc611875ec">3.50</ix:nonFraction>%, with a minimum rate of <ix:nonFraction unitRef="number" contextRef="i85b76fac63ed4337ba3f066627f9ee21_I20200331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTMwMA_6330af7a-c54f-4f0a-afba-d707875bb7a7">4.70</ix:nonFraction>% per annum.  The average Term Loan Advance interest rate for the three months ended March&#160;31, 2020 was <ix:nonFraction unitRef="number" contextRef="ie9151d6a99994c3d8ad8137c5404513a_I20200331" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTM5Mg_24999f96-3a51-422b-b9c6-c2a4d2464ca9">5.8</ix:nonFraction>%. </span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company may prepay the outstanding principal amount under the Term Loan Advance plus accrued and unpaid interest and, if the Term Loan Advance is repaid in full, a prepayment premium. The prepayment premium will be (i) $<ix:nonFraction unitRef="usd" contextRef="ife6d0673632e406b88baa85353a6ce0a_I20200331" decimals="INF" format="ixt:numdotdecimal" name="vcyt:DebtInstrumentPrepaymentPremium" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTYyMQ_b16bf6d8-860e-41ad-a2cf-f420e928bf25">750,000</ix:nonFraction> if prepayment is made prior to November 3, 2018, (ii) $<ix:nonFraction unitRef="usd" contextRef="icb52a798d3dd45b0824f09f89f25bc71_I20200331" decimals="INF" format="ixt:numdotdecimal" name="vcyt:DebtInstrumentPrepaymentPremium" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTY3OA_f1e5edca-ddf3-4359-9b9b-dc6532b6e18a">500,000</ix:nonFraction> if the prepayment is made after November 3, 2018 but on or before November 3, 2019, or (iii) $<ix:nonFraction unitRef="usd" contextRef="i45329572800d48e7b228e61199a1894c_I20200331" decimals="INF" format="ixt:numdotdecimal" name="vcyt:DebtInstrumentPrepaymentPremium" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTc3NA_52d1a3b5-70ed-43d3-82d6-114fa58b9040">250,000</ix:nonFraction> if the prepayment is made after November 3, 2019.  In January 2019 and May 2019, the Company prepaid $<ix:nonFraction unitRef="usd" contextRef="i62c415d1690e4049ba06ee9e1047930c_D20190101-20190131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTg3OA_85339157-69c7-493e-b423-70dac29d4d11">12.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2f773b17ae664fd1bf7ca8e49fdcbe3a_D20190501-20190531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTg4NQ_2e75bae4-bd11-486e-ace2-4d3bbda0e75a">12.4</ix:nonFraction> million, respectively, of the principal amount of the Term Loan Advance.  These prepayments did not trigger any prepayment premium because they were partial, not full, repayments of the principal amount.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, a final payment on the Term Loan Advance in the amount of $<ix:nonFraction unitRef="usd" contextRef="i1f90c73b3c3144378fa37effee913e4a_I20171103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMjE1Ng_fb1d9210-bc67-43c0-86b9-bd1344371080">1.2</ix:nonFraction> million is due upon the earlier of the maturity date of the Term Loan Advance or its payment in full.  The Loan and Security Agreement contains customary </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:69.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="ibc9e5ad26d72447ea60414701b50205d"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">representations, warranties, and events of default such as a material adverse change in the Company's business, operations or financial condition, as well as affirmative and negative covenants. The negative covenants include, among other provisions, covenants that limit or restrict the Company's ability to incur liens, make investments, incur indebtedness, merge with or acquire other entities, dispose of assets, make dividends or other distributions to holders of its equity interests, engage in any new line of business, or enter into certain transactions with affiliates, in each case subject to certain exceptions. The Company&#8217;s obligations under the Loan and Security Agreement are secured by substantially all of its assets (excluding intellectual property), subject to certain customary exceptions.  The Loan and Security Agreement also requires the Company to achieve certain revenue levels tested quarterly on a trailing twelve-month basis.  However, failure to maintain the revenue levels will not be considered a default if the sum of the Company&#8217;s unrestricted cash and cash equivalents maintained with Silicon Valley Bank and amount available under the Revolving Line of Credit is at least $<ix:nonFraction unitRef="usd" contextRef="ia2da177f87084aacb8ec54951c03d633_I20200331" decimals="INF" format="ixt:numdotdecimal" name="vcyt:LiquidityRequirementMinimum" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMzUxMQ_5815fad6-e181-4e18-ae4e-85c65b74a9f0">40.0</ix:nonFraction> million.  As of March&#160;31, 2020, the Company was in compliance with the loan covenants.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfNDA1OQ_9e98eae7-3ab4-42be-973d-23a0fa884c1a" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The net debt obligation for borrowings made under the Loan and Security Agreement was as follows (in thousands of dollars):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"><tr><td style="width:1.0%;"></td><td style="width:70.848%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.908%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.135%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.909%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt principal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5dc6c074bbd1456a915067e4fec93c91_I20200331" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RhYmxlOjcwNDgxNjQ5M2RjZTRiNTdhYTM4NjBlNjNlYjBmZjcwL3RhYmxlcmFuZ2U6NzA0ODE2NDkzZGNlNGI1N2FhMzg2MGU2M2ViMGZmNzBfMS0xLTEtMS0w_a3ed8e2e-815d-421d-b8bf-8c4edf82842f">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i179ded5835fe44c58d0e2db0f9f7bf28_I20191231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RhYmxlOjcwNDgxNjQ5M2RjZTRiNTdhYTM4NjBlNjNlYjBmZjcwL3RhYmxlcmFuZ2U6NzA0ODE2NDkzZGNlNGI1N2FhMzg2MGU2M2ViMGZmNzBfMS0zLTEtMS0w_54b2c02f-9e6a-439e-a0ad-ce6984686566">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">End-of-term debt obligation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5dc6c074bbd1456a915067e4fec93c91_I20200331" decimals="-3" name="vcyt:DebtInstrumentEndOfTermInterestObligationAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RhYmxlOjcwNDgxNjQ5M2RjZTRiNTdhYTM4NjBlNjNlYjBmZjcwL3RhYmxlcmFuZ2U6NzA0ODE2NDkzZGNlNGI1N2FhMzg2MGU2M2ViMGZmNzBfMi0xLTEtMS0w_56e0642a-cd75-4ceb-9a9f-6458a9a8d9c2">648</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i179ded5835fe44c58d0e2db0f9f7bf28_I20191231" decimals="-3" name="vcyt:DebtInstrumentEndOfTermInterestObligationAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RhYmxlOjcwNDgxNjQ5M2RjZTRiNTdhYTM4NjBlNjNlYjBmZjcwL3RhYmxlcmFuZ2U6NzA0ODE2NDkzZGNlNGI1N2FhMzg2MGU2M2ViMGZmNzBfMi0zLTEtMS0w_987247b7-bb3e-46fa-9803-240839667e97">594</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net debt obligation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5dc6c074bbd1456a915067e4fec93c91_I20200331" decimals="-3" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RhYmxlOjcwNDgxNjQ5M2RjZTRiNTdhYTM4NjBlNjNlYjBmZjcwL3RhYmxlcmFuZ2U6NzA0ODE2NDkzZGNlNGI1N2FhMzg2MGU2M2ViMGZmNzBfNC0xLTEtMS0w_925a8d13-446e-4f50-aee5-307718320d5c">748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i179ded5835fe44c58d0e2db0f9f7bf28_I20191231" decimals="-3" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RhYmxlOjcwNDgxNjQ5M2RjZTRiNTdhYTM4NjBlNjNlYjBmZjcwL3RhYmxlcmFuZ2U6NzA0ODE2NDkzZGNlNGI1N2FhMzg2MGU2M2ViMGZmNzBfNC0zLTEtMS0w_7ad74d74-533d-4085-87e3-8de0393ed277">694</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future principal and end-of-term debt obligation payments under the Loan and Security Agreement are $<ix:nonFraction unitRef="usd" contextRef="i5dc6c074bbd1456a915067e4fec93c91_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMzgxNQ_7d7fe96c-abc8-4c7d-beec-f59f01392539">1.3</ix:nonFraction> million and due in 2022. &#160;</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The end-of-term debt obligation accretes over the term of the Loan and Security Agreement until maturity and is included in interest expense in the Company's condensed consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="ide126ddc4fe34b88b9204d0512399caf_67"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">8. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RleHRyZWdpb246ZjhiMzA3ZDAzOTljNDhkMDk5OTI1MjJlM2FjYjY0MDFfMTI2_1061e380-bfa8-4a0e-a908-a8b68b903c1a" continuedAt="ibd84535e1a9341a4a00c9100e3982bb3" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="ibd84535e1a9341a4a00c9100e3982bb3"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="vcyt:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RleHRyZWdpb246ZjhiMzA3ZDAzOTljNDhkMDk5OTI1MjJlM2FjYjY0MDFfMTIy_dcd2fbc5-3eb2-40f1-b001-c19e2ee8dd09" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had reserved shares of common stock for issuance as follows:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options and restricted stock units issued and outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfMS0xLTEtMS0w_e93abd66-27f2-4920-947b-74a2788c4725">5,988,461</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfMS0zLTEtMS0w_b43351fe-30a9-43ed-8e62-10084393a929">5,562,484</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options and restricted stock units available for grant under stock option plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iec64d800410545c29d93cac8e2c172ed_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfMi0xLTEtMS0w_a56ccbaf-fa39-47d6-b191-87803d4a79f8">3,200,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i26afcedec6c048e392712b52100ee027_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfMi0zLTEtMS0w_41244253-52d0-454f-95ef-f5fd73dd1526">1,954,804</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock available for the Employee Stock Purchase Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3a47e06c25734fcba6d9adaae38a2200_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfMy0xLTEtMS0w_10ce7037-97fc-4b34-a926-7c8974a53247">112,226</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i27b942a33cc641c39da58598bca5025d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfMy0zLTEtMS0w_32b20ece-8c27-4578-898e-dc4c64bf2633">173,168</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfNC0xLTEtMS0w_1001b177-1a3a-4b7f-a6e9-58378dbdcb38">9,300,887</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfNC0zLTEtMS0w_60f9c151-aaac-479c-90fe-21d1598d4b34">7,690,456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ide126ddc4fe34b88b9204d0512399caf_70"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">9. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:LongTermContractsOrProgramsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl83MC9mcmFnOmE2MmVhNDgyOGI2ZTQ0YzA4MjBiNzhmZWQ1OTg4NzczL3RleHRyZWdpb246YTYyZWE0ODI4YjZlNDRjMDgyMGI3OGZlZDU5ODg3NzNfMTY4MQ_8f6414d4-3f1c-4a63-84e0-f5e7bd188b06" continuedAt="i995972ae32e24aecb6f5969493f2c9da" escape="true">Thyroid Cytopathology Partners </ix:nonNumeric></span></div><ix:continuation id="i995972ae32e24aecb6f5969493f2c9da" continuedAt="i044f3ee9c47941ba917a1bce649fbaa9"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has an agreement with a specialized pathology practice, Thyroid Cytopathology Partners, ("TCP"), to provide testing services to the Company, or TCP Agreement.&#160; The TCP Agreement is effective through October 31, 2022, and thereafter automatically renews every year unless either party provides notice of intent not to renew at least <ix:nonNumeric contextRef="i4c5d2c55989a46b98b6de9830693a3d5_D20200101-20200331" format="ixt-sec:durmonth" name="vcyt:AgreementTermsNonRenewalNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl83MC9mcmFnOmE2MmVhNDgyOGI2ZTQ0YzA4MjBiNzhmZWQ1OTg4NzczL3RleHRyZWdpb246YTYyZWE0ODI4YjZlNDRjMDgyMGI3OGZlZDU5ODg3NzNfMzkw_4898a8d6-6ae1-4214-9dff-ee1ca43e7492">12</ix:nonNumeric> months prior to the end of the then-current term.  Under the TCP Agreement, the Company pays TCP based on a fixed price per test schedule which is reviewed periodically for changes in market pricing, and the TCP Agreement included a clause allowing TCP to sublease a portion of the Company's facility in Austin, Texas. &#160;The Company does not have an ownership interest in or provide any form of financial or other support to TCP. &#160;The Company previously concluded that TCP represented a variable interest entity as a result of the facility arrangement clause, but that the Company was not the primary beneficiary as it did not have the ability to direct the activities that most significantly impacted TCP's economic performance, and therefore did not consolidate TCP.&#160; On February 14, 2019, the TCP Agreement was amended to remove the facility clause.&#160; Accordingly, the Company believes TCP was no longer a variable interest entity as of that date.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:69.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ide126ddc4fe34b88b9204d0512399caf_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VERACYTE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i044f3ee9c47941ba917a1bce649fbaa9">TCP's portion of rent and related operating expenses reimbursed to the Company for the shared space at the Austin, Texas facility was $<ix:nonFraction unitRef="usd" contextRef="i371cedf5a91b4b2abbfb835bb66de072_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="vcyt:OtherIncomeRentReimbursement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl83MC9mcmFnOmE2MmVhNDgyOGI2ZTQ0YzA4MjBiNzhmZWQ1OTg4NzczL3RleHRyZWdpb246YTYyZWE0ODI4YjZlNDRjMDgyMGI3OGZlZDU5ODg3NzNfMTQ3MQ_88ade00d-adbc-417a-abdc-bfa1a6a7a3d0">11,000</ix:nonFraction> for the three months ended March&#160;31, 2019, and is included in other income, net in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss.</ix:continuation></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div id="ide126ddc4fe34b88b9204d0512399caf_73"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">10. <ix:nonNumeric contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl83My9mcmFnOmI5NDRkYjFjN2IwMjRkYmI4Yjg2NTU1NzI5ZDYwYWMzL3RleHRyZWdpb246Yjk0NGRiMWM3YjAyNGRiYjhiODY1NTU3MjlkNjBhYzNfMTI1NQ_f0f3e30e-8f1f-4835-8b62-cb82e22cd564" continuedAt="i2cf80de2bcd74332bd04e167a9303413" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i2cf80de2bcd74332bd04e167a9303413"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not record a provision or benefit for income taxes during the three months ended March&#160;31, 2020 and 2019. The Company continues to maintain a full valuation allowance against its net deferred tax assets.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The Company does not expect the provisions of the legislation to have a significant impact on the effective tax rate of the Company.</span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_76"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 2.&#160; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following discussion and analysis of financial condition and results of operations should be read together with the condensed consolidated financial statements and the related notes included in Item 1 of Part I of this Quarterly Report on Form 10-Q, and with our audited financial statements and the related notes included in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this report, the words "expects," "anticipates," "intends," "estimates," "plans," "believes," "continuing," "ongoing," and similar expressions are intended to identify forward-looking statements. These are statements that relate to future events and include, but are not limited to, the factors that may impact our financial results; our expectations regarding revenue; our expectations with respect to our future research and development, general and administrative and selling and marketing expenses and our anticipated uses of our funds; the impact of the COVID-19 pandemic on our business and the U.S. and global economies; our beliefs with respect to the optimization of our processes for the analysis of ribonucleic acid, or RNA, samples; our integration of the assets acquired from NanoString Technologies, Inc.; our ability to deploy the nCounter FLEX Analysis System successfully and run our tests on this platform worldwide; our beliefs with respect to the optimization of our processes for the analysis of ribonucleic acid, or RNA, samples; our collaboration with Johnson &amp; Johnson Services, Inc.; our belief in the importance of maintaining libraries of clinical evidence; our expectations regarding capital expenditures; our anticipated cash needs and our estimates regarding our capital requirements; the timing and success of our transition to a single platform for all of our classifiers and tests; our ability to maintain Medicare coverage for each of our tests; our need for additional financing; potential future sources of cash; our business strategy and our ability to execute our strategy; our ability to achieve and maintain reimbursement from third-party payers at acceptable levels and our expectations regarding the timing of reimbursement; the estimated size of the global markets for our tests; the estimated number of patients who receive uncertain diagnoses who are candidates for our test; the attributes and potential benefits of our tests and any future tests we may develop to patients, physicians and payers; the factors we believe drive demand for and reimbursement of our tests; our ability to sustain or increase demand for our tests; our intent to expand into other clinical areas; our ability to develop new tests, and the timeframes for development or commercialization; our ability to get our data and clinical studies accepted in peer-reviewed publications; our dependence on and the terms of our agreement with TCP, and on other strategic relationships, and the success of those relationships; our beliefs regarding our laboratory capacity; the potential for future clinical studies to contradict or undermine previously published clinical study results; the applicability of clinical results to actual outcomes; our expectations regarding our international expansion; the occurrence, timing, outcome or success of clinical trials or studies; the ability of our tests to impact treatment decisions; our beliefs regarding our competitive position; our compliance with federal, state and international regulations; the potential impact of regulation of our tests by the Food and Drug Administration, or FDA, or other regulatory bodies; the impact of new or changing policies, regulation or legislation, or of judicial decisions, on our business; the impact of seasonal fluctuations and economic conditions on our business; our belief that we have taken reasonable steps to protect our intellectual property; our belief that our intellectual property will develop and maintain our competitive position; the impact of accounting pronouncements and our critical accounting policies, judgments, estimates, models and assumptions on our financial results; and anticipated trends and challenges in our business and the markets in which we operate.  We caution you that the foregoing list does not contain all of the forward-looking statements made in this report.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Forward-looking statements are based on our current plans and expectations and involve risks and uncertainties which could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, those risks discussed in Part II, Item 1A of this report. These forward-looking statements speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">When used in this report, all references to "Veracyte," the "company," "we," "our" and "us" refer to Veracyte,&#160;Inc.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Veracyte, Afirma, Percepta, Envisia, Prosigna, LymphMark, and Know by Design, and the Veracyte, Afirma, Percepta, Envisia and Prosigna logos are our trademarks. We also refer to trademarks of other corporations or organizations in this report.</span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This report contains statistical data and estimates that we obtained from industry publications and reports. These publications typically indicate that they have obtained their information from sources they believe to be reliable, but do not guarantee the accuracy and completeness of their information. Some data contained in this report is also based on our internal estimates.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_79"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We are a global genomic diagnostics company that improves patient care by providing answers to clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The Company&#8217;s growing menu of genomic tests leverage advances in genomic science and technology to change care for patients, enabling them to avoid risky, costly procedures and quicken time to appropriate treatment. With Veracyte&#8217;s exclusive global access to a best-in-class diagnostics instrument platform, the Company is positioned to deliver its tests to patients worldwide through laboratories and hospitals that can perform the tests locally.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We perform our genomic tests for thyroid cancer, lung cancer and idiopathic pulmonary fibrosis, or IPF, in our CLIA-certified laboratory in South San Francisco, California. In December 2019, we announced an exclusive global diagnostics license to the nCounter&#174; FLEX Analysis System from NanoString Technologies, Inc., or NanoString, as well as the acquisition of the Prosigna&#174; breast cancer prognostic gene signature assay, which is commercially available, and the LymphMark&#8482; lymphoma subtyping assay, which is in development. Both tests are designed for use on the nCounter system. We believe this strategic transaction positions us to expand our business globally with a broad menu of advanced genomic tests that may be offered as distributed kits and performed in local laboratories worldwide. We believe our current and pipeline products address a collective $40 billion global market.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We develop our genomic tests using advanced scientific methods, such as RNA whole-transcriptome sequencing and machine learning, and then optimize the assay and classifier results for the platform on which the test will be performed. Historically, that platform has been RNA sequencing, performed in our CLIA lab. In the future, we expect this to also include the nCounter platform for international distribution of our tests.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our classifiers are designed to improve diagnostic and prognostic clarity for cancer and other diseases. In its 2015 report, &#8220;Improving Diagnostic Errors in Medicine,&#8221; the Institute of Medicine concluded that most people will experience at least one diagnostic error in their lifetime, sometimes with devastating consequences. Annually, of the hundreds of thousands of patients who are evaluated for suspected disease in our thyroid and lung indications, diagnosis can be ambiguous in 15-70% of cases. This diagnostic uncertainty can lead to additional, invasive procedures that are often unnecessary, delayed or incorrect treatment, increased healthcare costs and patient anxiety.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We position our tests to fit into the way physicians currently evaluate patients in order to facilitate adoption. We also design our tests to improve patient care and outcomes, while delivering clinical and economic utility to physicians, payers and the healthcare system in general.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe our powerful scientific platform provides multiple vectors to create value for patients, providers and payers, as well as stockholders, and to help advance precision medicine:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Unique Biorepositories - When we develop new tests, we build extensive, robust biorepositories of patient-consented samples and well-curated clinical, radiological, outcome and other information from Institutional Review Board-approved clinical trials to inform our discovery efforts. Our biorepositories are designed to encompass the broad spectrum of disease that our tests may encounter when used in clinical practice, as well as the wide range of conditions associated with patients who are suspected of having a particular disease. We extract extensive genomic information from these patient samples using our RNA whole-transcriptome sequencing platform. </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Proprietary Technology and Bioinformatics - For biomarker discovery and product development, we utilize machine learning to select the genomic, clinical or other features from our biorepository that best distinguish the condition we are trying to identify. This enables us to develop high-performing genomic classifiers that can answer specific clinical questions. In addition, our bioinformatics pipelines are built to extract genomic variant content from the same assay to inform therapeutic selection.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">High-Performing Commercial Genomic Tests &#8211; With the exception of Prosigna, which competes with a first-to-market test in a highly competitive environment, our genomic tests generally serve large, untapped markets where they are changing the diagnostic and treatment paradigm for patients. We believe the nCounter platform affords us the opportunity to adapt our test menu for multiple markets globally, providing flexibility for a global distributed testing model and potentially increased efficiency in our United States-based CLIA lab. Regardless of the testing platform used for diagnosis, our RNA sequencing platform enables us to offer testing from our CLIA lab for a broad range of gene alterations, which can inform treatment decisions using the same pre-surgical patient sample that was used in diagnosis.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe our ability to leverage RNA whole-transcriptome sequencing data in large biorepositories of patient-consented samples in oncology and other indications presents an opportunity for biopharmaceutical companies to enhance their research and development capabilities. In April 2018, we announced a collaboration with Loxo Oncology (now a wholly owned subsidiary of Eli Lilly and Company) to advance its development of highly selective medicines for patients with genetically defined cancers, including thyroid cancer. In December 2018, we entered into a long-term strategic collaboration with Johnson &amp; Johnson Innovation and the Lung Cancer Initiative at Johnson &amp; Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable. The collaboration builds upon foundational "field of injury" science whereby genomic changes associated with lung cancer can be identified with a simple brushing of a person's airway to develop new interventions that can save lives. Additionally, in January 2020, we announced an agreement with Acerta Pharma, the hematology research and development arm of AstraZeneca, to provide genomic information that will support its development of oncology therapeutics in lymphoma.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our collaboration with the Lung Cancer Initiative at Johnson &amp; Johnson has helped accelerate two of our key lung cancer programs: (i) commercialization of the Percepta GSC on our RNA whole-transcriptome sequencing platform, and (ii) development of the first non-invasive nasal swab test for early lung cancer detection. We began making the Percepta GSC available to customers in June 2019. In October 2019, we announced preliminary data for our nasal swab classifier, which demonstrated the test&#8217;s potential to identify patients at low risk of lung cancer so they can potentially avoid unnecessary procedures and those at high risk so they can receive prompt diagnosis and treatment.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The published evidence supporting our tests demonstrates the robustness of our science and clinical studies, which we believe is key to driving adoption and reimbursement. Patients and physicians can access our full list of publications on our website. Over 45 clinical studies covering our products have been published, including three landmark clinical validation papers published in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The New England Journal of Medicine</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for the Afirma and Percepta classifiers, respectively, and in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The Lancet Respiratory Medicine</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for the Envisia classifier. We continue to build upon our extensive library of clinical evidence.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe our focus on developing clinically useful tests that change patient care is enabling the company to set new standards in genomic test reimbursement. Our genomic classifiers in thyroid cancer, lung cancer and IPF, as well as the Prosigna breast cancer assay are covered by Medicare. Our Afirma classifier, for use in thyroid cancer diagnosis, is now covered by every major health plan in the United States, which collectively insure more than 275 million people. We are contracted as an in-network service provider to health plans representing over 225 million people in the United States. We believe that our in-network status with private payers will help facilitate private insurer reimbursement for our Percepta and Envisia classifiers. The Prosigna test is covered by leading private payers in the United States and is widely reimbursed by government and private payers in the countries where it is available.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We also expect to continue expanding our offerings in thyroid cancer, lung cancer, interstitial lung diseases such as IPF, breast cancer and lymphoma, as well as other indications that we believe will benefit from our technology and approach.  Our product development pipelines address what we believe to be significant market opportunities for addressing clinical questions in early detection, diagnosis, staging/prognosis, therapy selection/surgery and disease monitoring across the aforementioned indications.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Impact of COVID-19</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In December 2019, a strain of coronavirus was reported in Wuhan, China, and began to spread globally, including to the United States and Europe, in the following months. The World Health Organization has declared COVID-19 to be a pandemic and a public health emergency of international concern. The full impact of the COVID-19 outbreak is inherently uncertain at the time of this report. The COVID-19 outbreak has resulted in travel restrictions and in some cases, prohibitions of non-essential activities, disruption and shutdown of businesses and greater uncertainty in global financial markets. As COVID-19 has spread, it has significantly impacted the health and economic environment around the world and many governments have closed most public establishments, including restaurants, workplaces and schools. Our customers, third-party contract manufacturers, suppliers and collaboration partners may be affected by the closure of hospitals, doctors offices, manufacturing sites, or country borders, among other measures being put in place around the world. Consequent increases in layoffs and furloughs in the medical industry and otherwise during the shutdown are having, and will continue to have, negative impact on the demand for medical care and diagnostic tests, which affects the frequency with which tests are prescribed, and the ability of doctors and hospitals to administer such tests. Further the inability to travel and conduct face-to-face meetings can also make it more difficult to expand utilization of our products into new geographies and to drive awareness of our products. Any of these circumstances will potentially have a negative impact on our financial results and liquidity in fiscal 2020. </span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As for our own business, during the second half of March 2020 through the date of this filing, we experienced a significant decline in the volume of samples received resulting in a significant decline in revenue and it is currently unclear how long we will continue to experience decreased sample volumes and levels of revenue.  The COVID-19 pandemic has also caused us to modify our business practices, including taking proactive steps to protect our employees and the broader community (including but not limited to curtailing or modifying employee travel, moving to full remote work wherever possible, and cancelling physical participation in meetings, events and conferences), while ensuring our ability to deliver genomic test results to physicians and their patients who need them.  Given the significant challenges we face from COVID-19, we have taken actions to reduce expenses and preserve the health of our business, including our board of directors, executive team, including our Chairman and CEO, and certain other employees taking a reduction in pay until we are able to resume normal operations.  We have also put approximately 60 employees on a temporary furlough with a current goal of bringing them back from furlough in the future, terminated a small number of employees, and instituted a temporary hiring freeze.  We may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, customers and business partners.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The extent of the impact of the COVID-19 on our future liquidity and operational performance will depend on certain developments, including the duration and spread of the outbreak, the impact on our customers' operations and the impact to our sales and renewal cycles.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">First Quarter 2020 Financial Results</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">For the first quarter of 2020, as compared with the first quarter of 2019:</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;">Total Testing and Product Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> was $30.4 million, an increase of 20%; including biopharmaceutical revenue, total revenue was $31.1 million, an increase of 5%; </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;">Gross Margin </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">was 61%, which included a $1.1 million write-down of supplies; </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;">Operating Expenses, Excluding Cost of Revenue,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> were $31.1 million, an increase of 35%;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;">Net Loss and Comprehensive Loss</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> was $(11.7) million, versus $(1.9) million;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;">Basic and Diluted Net Loss Per Common Share </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">was $(0.24), versus $(0.05);</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;">Net Cash Used in Operating Activities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> was $5.3 million, versus $1.0 million; and</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;">Cash and Cash Equivalents</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> were $153.1 million at March 31, 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">.</span></div><div style="text-indent:4.5pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">First Quarter 2020 and Recent Business Highlights</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Core Diagnostics Business:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Grew total genomic test volume (Afirma, Percepta and Envisia) by 15% to 10,559 tests.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Launched &#8220;More About You,&#8221; a national campaign to help patients navigate the work-up of thyroid nodules and ask for Afirma testing by name. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Announced that data accepted for oral presentation at the ENDO 2020 conference identified novel or rare gene fusions that are included in the newly expanded Afirma Xpression Atlas and may potentially be targeted with drugs that are approved or under development. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Reported new data published in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">npj Breast Cancer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, which suggest potential growth opportunities for the Prosigna</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;"> </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">test in global markets where the test reports intrinsic breast cancer subtypes. Additionally, data published in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Clinical Breast Cancer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> suggest the Prosigna test&#8217;s ability to provide significant prognostic information beyond clinicopathologic factors in patients with invasive lobular breast cancer, a major breast cancer histopathologic subtype.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Strategic Collaborations and Pipeline Advancement:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Secured an exclusive licensing and research agreement with Yale University to advance the first genomic monitoring test for idiopathic pulmonary fibrosis prognosis, complementing our Envisia classifier for improved early diagnosis of the disease. The non-invasive, blood-based test was developed for use on our nCounter diagnostic platform.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Signed an exclusive licensing agreement with Boston University for technology that will help advance development of the first-ever, non-invasive nasal swab test for lung cancer early detection.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Announced a multi-year collaboration with Acerta Pharma, the hematology research and development arm of AstraZeneca plc, to provide genomic information that will support the biopharmaceutical company&#8217;s development of oncology therapeutics in lymphoma. </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span><br/></span></div><div id="ide126ddc4fe34b88b9204d0512399caf_82"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Factors Affecting Our Performance</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Impact of COVID-19</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The extent of the impact of the COVID-19 outbreak on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on our customers and our sales cycles, employee or industry events, and effect on our vendors, all of which are uncertain and cannot be predicted. The COVID-19 pandemic and its adverse effects have become more prevalent in the locations where we, our customers, suppliers or third-party business partners conduct business and as a result, we have begun to experience more pronounced disruptions in our operations. We may experience constrained supply or curtailed customer demand that could materially adversely impact our business, results of operations and overall financial performance in future periods. Specifically, we may experience impact from changes in how hospital and physicians treat their patients and the frequency of their interaction with their patients, our ability to have in-person meetings with physicians and other customers and drive education and interest in our tests, and difficulties and changes to our sales, logistics, testing, customer support and other processes.  As of the filing date of this Form 10-Q, the extent to which COVID-19 may impact our financial condition or results of operations or guidance is uncertain. The effect of the COVID-19 pandemic will not be fully reflected in our results of operations and overall financial performance until future periods. See Risk Factors for further discussion of the possible impact of the COVID-19 pandemic on our business.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Reported Genomic Test Volume</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our performance depends on the number of genomic tests that we perform and report as completed in our CLIA laboratories. Factors impacting the number of tests that we report as completed include, but are not limited to: </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-22.5pt;padding-left:72pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt;">the impact of COVID-19 on patients seeking to have tests performed;</span></div><div style="text-indent:-22.5pt;padding-left:72pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt;">the number of samples that we receive that meet the medical indication for each test performed; </span></div><div style="text-indent:-22.5pt;padding-left:72pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt;">the quantity and quality of the sample received; </span></div><div style="text-indent:-22.5pt;padding-left:72pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt;">receipt of the necessary documentation, such as physician order and patient consent, required to perform, bill and collect for our tests; </span></div><div style="text-indent:-22.5pt;padding-left:72pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt;">the patient's ability to pay or provide necessary insurance coverage for the tests performed; </span></div><div style="text-indent:-22.5pt;padding-left:72pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt;">the time it takes us to perform our tests and report the results;  </span></div><div style="text-indent:-22.5pt;padding-left:72pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt;">the seasonality inherent in our business, such as the impact of work days per period, timing of industry conferences and the timing of when patient deductibles are exceeded, which also impacts the reimbursement we receive from insurers; and </span></div><div style="text-indent:-22.5pt;padding-left:72pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt;">our ability to obtain prior authorization or meet other requirements instituted by payers, benefit managers, or regulators necessary to be paid for our tests.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We generate substantially all our revenue from genomic testing services, including the rendering of a cytopathology diagnosis as part of the Afirma solution. For the Afirma classifier, we do not accrue revenue for approximately 5% - 10% of the tests that we perform and report as complete due principally to insufficient RNA from which to render a result and tests performed for which we do not reasonably expect to be paid. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Continued Adoption of and Reimbursement for our Products</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;Revenue growth depends on our ability to secure coverage decisions, achieve broader reimbursement at increased levels from third-party payers, expand our base of prescribing physicians and increase our penetration in existing accounts. Because some payers consider our products experimental and investigational, we may not receive payment for tests and payments we receive may not be at acceptable levels. We expect our revenue growth to increase if more payers make a positive coverage decision and as payers enter into contracts with us, which should enhance our revenue and cash collections. To drive increased adoption of our products, we increased our sales force and marketing efforts over the last several years. Our sales team is structured to sell all of our products; we do not maintain a separate sales force for each product. If we are unable to expand the base of prescribing physicians and penetration within these accounts at an acceptable rate, or if we are not able to execute our strategy for increasing reimbursement, we may not be able to effectively increase our revenue. We expect to continue to see pressure from payers to limit the utilization of tests, generally, and we believe more payers are deploying cost containment tactics, such as pre-authorization, reduction of the payer portion of reimbursement and employing laboratory benefit managers to reduce utilization rates.</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Integrating acquired assets and advances to our collaborations</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue growth, operational results and advances to our business strategy depends on our ability to integrate the assets acquired into our existing business. The integration of acquired assets may impact our revenue growth, increase the cost of operations, cause significant write-offs of intangible assets, or may require management resources that otherwise would be available for ongoing development of our existing business. The integration of assets acquired from NanoString in December </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2019 may impact our revenue and operating results through integration of a sales force, development of a product supply operation and the expansion of our business internationally with a broad menu of advanced genomic tests that may be offered.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue growth or reimbursement from our collaborations depends on our ability to deliver services or information and achieve milestones required from our collaborative partners. Our collaboration partners pay us for the provision of data, other services and the achievement of milestones. Under a collaboration with Johnson &amp; Johnson in 2018, we provided data services required under this agreement for $7.0 million in 2019, however, there remains $9.0 of revenue associated with development and commercialization milestones yet to be achieved.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">How We Recognize Revenue</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Testing Revenue</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize testing revenue in accordance with the provisions of ASC 606, Revenue from Contracts with Customers.  Most of our revenue is generated from the provision of diagnostic testing services. These services are completed upon the delivery of test results to the prescribing physician, at which time we bill for the services. We recognize revenue related to billings on an accrual basis based on estimates of the amount that will ultimately be realized.  In determining the amount to accrue for a delivered test, we consider factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and us, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Prior to the adoption of ASC 606, for our testing services we recognized a portion of our revenue not at the time of delivery of test results, on an accrual-basis of accounting, but upon the ultimate payment for those services, on the cash-basis of accounting. Through December 31, 2019, cumulative amounts billed at list price for tests processed which were not recognized as revenue upon delivery of a patient report because our accrual revenue recognition criteria were not met and for which we have not collected cash or written off as uncollectible, totaled approximately $159.3&#160;million.  Of this amount, we did not collect any amounts in the three months ended March&#160;31, 2020 and we have no expectation of future collection because we began accruing for substantially all revenue upon delivery of a patient report in the third quarter of 2016. Under ASC 606, we recognize revenue at the time we deliver test results based upon what we reasonably expect to collect and the list price of a test may not be indicative of what we ultimately expect to collect.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Generally, cash we receive is collected within 12&#160;months of the date the test is billed. We cannot provide any assurance as to when, if ever, or to what extent any of these amounts will be collected. Notwithstanding our efforts to obtain payment for these tests, payers may deny our claims, in whole or in part, and we may never receive payment for these tests. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We bill list price regardless of contract rate, but only recognize revenue from amounts that we estimate are collectible and meet our revenue recognition criteria.&#160;Revenue may not be equal to the billed amount due to a number of factors that we consider when determining revenue accrual rates, including differences in reimbursement rates, the amounts of patient co-payments and co-insurance, the existence of secondary payers, claims denials and the amount we expect to ultimately collect. Finally, when we increase our list price, it will increase the cumulative amounts billed but may not positively impact accrued revenue.  In addition, payer contracts generally include the right of offset and payers may offset payments prior to resolving disputes over tests performed.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Generally, we calculate the average reimbursement from our products from all payers, for tests that are on average a year old, since it can take a significant period of time to collect from some payers. Except in situations where we believe the rate we reasonably expect to collect to vary due to a coverage decision, contract, more recent reimbursement data or evidence to the contrary, we use an average of reimbursement for tests provided over four quarters as it reduces the effects of temporary volatility and seasonal effects. Thus, the average reimbursement per product represents the total cash collected to date against genomic classifier tests, including variants, performed during the relevant period divided by the number of these tests performed during that same period.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The average Afirma genomic classifier reimbursement rate will change over time due to a number of factors, including medical coverage decisions by payers, the effects of contracts signed with payers, changes in allowed amounts by payers, our ability to successfully win appeals for payment, and our ability to collect cash payments from third-party payers and individual patients. Historical average reimbursement is not necessarily indicative of future average reimbursement.  For the three months ended March&#160;31, 2020, we accrued, on average, between $2,800 and $2,900 for the Afirma genomic classifier tests, including variants, that met our revenue recognition standard, which was between 90% - 95% of the reported Afirma classifier test volume.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From the first quarter of 2019 to the first quarter of 2020, we accrued between $1.0 million and $2.4 million in revenue per quarter from providing cytopathology services associated with our Afirma solution. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We incur expense for tests in the period in which the test is conducted and recognize revenue for tests in the period in which our revenue recognition criteria are met. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Product Revenue</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We began recognizing product revenue in December 2019 in accordance with the provisions of ASC 606, Revenue from Contracts with Customers, when we executed an agreement with NanoString for the exclusive worldwide license to the nCounter platform and the acquisition of products for in vitro diagnostic use.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize product revenue when control of the promised goods is transferred to our customers, in an amount that reflects the consideration expected to be received in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once we have transferred control of a product to the customer, meaning the customer has the ability to use and obtain the benefit of the product. We recognize product revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control.  Shipping and handling costs incurred for product shipments are charged to our customers and included in product revenue.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our products consist of the Prosigna breast cancer assay, the nCounter FLEX Analysis System and related consumables. Revenues are presented net of the taxes that are collected from customers and remitted to governmental authorities. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#160;Biopharmaceutical and Collaboration Revenues</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">From time to time, we enter into arrangements to license or provide access to our assets or services, including testing services, clinical and medical services, research and development and other services. Such arrangements may require us to deliver various rights, data, services, access and/or testing services to leading biopharmaceutical companies. The underlying terms of these arrangements generally provide for consideration paid to us in the form of nonrefundable fees, performance milestone payments, expense reimbursements and possibly royalty and/or other payments.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of our collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales of licensed products. Each of these payments may result in collaboration revenues or an offset against research and development expense.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Arrangements with partners may fall under the scope of ASC Topic 808, Collaborative Arrangements, or ASC 808. While these arrangements are in the scope of ASC 808, we may analogize to ASC 606 for some aspects of these arrangements.  We analogize to ASC 606 for certain activities within the collaborative arrangement for the delivery to a customer of a good or service (i.e., a unit of account) that is part of our ongoing major or central operations. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods is transferred or services are performed. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, we utilize the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net sales of data or other services to our customers are classified under biopharmaceutical revenue, and all other non-customer revenue, such as milestones, are classified under collaboration revenue in our consolidated statements of operations and comprehensive loss.  Payments made to us that are not net sales of data or other services to our customers are recorded as an offset against research and development expense in our consolidated statements of operations and comprehensive loss.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Development of Additional Tests</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We continue to advance our portfolio of diagnostic tests that leverage innovations in genomic science, sequencing technology, machine learning and leveraging our new nCounter Analysis System to further improve patient care globally.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In May 2017, we introduced the Afirma GSC, supported by rigorous clinical validation data showing that the RNA sequencing-based test can help significantly more patients avoid unnecessary surgery in thyroid cancer diagnosis, compared to the original Afirma classifier. The Afirma GSC and Xpression Atlas, originally launched in March 2018 with an expanded version launched in April 2020, provide physicians with a comprehensive solution for thyroid nodule diagnosis. The Afirma GSC was developed with RNA whole-transcriptome sequencing and machine learning and helps identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to help patients avoid unnecessary diagnostic thyroid surgery. For those with suspected thyroid cancer, the Afirma Xpression Atlas provides physicians with genomic alteration content from the same fine needle aspiration samples that are used in Afirma GSC testing and may help physicians decide with greater confidence on the surgical or therapeutic pathway for their patients.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The expanded Afirma XA test, launched in April 2020, provides physicians with additional gene alteration content &#8211; including novel or rare NTRK, ALK, RET and BRAF fusions to further inform surgery and treatment decisions for patients with suspected or confirmed thyroid cancer. The Afirma XA utilizes RNA sequencing on the same FNA sample used for Afirma GSC testing. Compared to the original gene alteration panel, the expanded Afirma XA now reports 905 DNA variants (versus 761) and 235 RNA fusion partners (versus 130) in 593 genes (versus 511).</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Together with our Afirma GSC and our tests for the BRAF v600E mutation and medullary thyroid cancer, or Malignancy Classifiers, the Afirma XA rounds out a comprehensive solution for physicians evaluating thyroid nodules. This innovation also enables us to enter into research collaborations with biopharmaceutical companies, which is intended to support their development of targeted therapies for genetically defined cancers, including thyroid cancer.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have also expanded our ability to provide important clinical answers - without the need for surgery - into pulmonology. Our Percepta Bronchial Genomic Classifier, introduced in April 2015, is the first genomic test to receive Medicare coverage for use in lung cancer diagnosis, where it improves the performance of diagnostic bronchoscopy.  In June 2019, we began making our &#8220;next-generation&#8221; Percepta Genomic Sequencing Classifier available to physicians, providing them with expanded lung cancer risk information that can further guide next steps for patients with suspicious lung nodules, as compared to the Percepta Bronchial Genomic Classifier.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, our Envisia Genomic Classifier, launched in October 2016, is the first commercial test to improve the diagnosis of IPF among patients with a suspected interstitial lung disease.  In March 2019, we received final Medicare coverage for the Envisia classifier through the MolDX program, with an effective date of April 1, 2019. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also believe our Xpression Atlas platform can be transferred to our pulmonology indications, to further improve patient care and advance precision medicine in lung cancer and IPF.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are currently exploring opportunities to utilize the same &#8220;field of injury&#8221; technology that powers our Percepta classifier to develop a nasal swab test that can enable earlier lung cancer detection - and ultimately help reduce lung cancer deaths.  In October 2019, we announced preliminary clinical data for our noninvasive nasal swab classifier - the first test of its kind. The findings show that the novel genomic test can accurately classify lung cancer risk in patients with lung nodules so that these patients can obtain the prompt diagnosis and potential treatment they need or may be monitored noninvasively.  </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Timing of Our Research and Development Expenses</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We deploy state-of-the-art and costly genomic technologies in our biomarker discovery experiments, and our spending on these technologies may vary substantially from quarter to quarter. We also spend a significant amount to secure clinical samples that can be used in discovery and product development as well as clinical validation studies. The timing of these research and development activities is difficult to predict, as is the timing of sample acquisitions. If a substantial number of clinical samples are acquired in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">timing of these expenses can affect our financial results. We conduct clinical studies to validate our new products as well as on-going clinical studies to further the published evidence to support our commercialized tests. As these studies are initiated, start-up costs for each site can be significant and concentrated in a specific quarter. Spending on research and development, for both experiments and studies, may vary significantly by quarter depending on the timing of these various expenses.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div id="ide126ddc4fe34b88b9204d0512399caf_85"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Financial Overview</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Through March&#160;31, 2020, we had derived most of our revenue from the sale of Afirma, delivered primarily to physicians in the United States. We generally invoice third-party payers upon delivery of a patient report to the prescribing physician. As such, we take the assignment of benefits and the risk of cash collection from the third-party payer and individual patients. Third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.198%;"><tr><td style="width:1.0%;"></td><td style="width:69.884%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.525%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.559%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.832%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Johnson and Johnson Services, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">UnitedHealthcare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For tests performed, we recognize the related revenue upon delivery of a patient report to the prescribing physician based on the amount that we expect to ultimately receive. In determining the amount to accrue for a delivered test, we consider factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and us, payment as a percentage of agreed upon reimbursement rate (if applicable), amount paid per test and any current development or changes that could impact reimbursement. Upon ultimate collection, the amount received is compared to previous estimates and the amount accrued is adjusted accordingly. Our ability to increase our revenue will depend on our ability to penetrate the market, obtain positive coverage policies from additional third-party payers, obtain reimbursement and/or enter into contracts with additional third-party payers for our current and new tests, and increase reimbursement rates for tests performed. Finally, should the judgments underlying our estimated reimbursement change, our accrued revenue and financial results could be negatively impacted in future periods.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Revenue</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of our cost of testing revenue are laboratory expenses, kit costs, sample collection expenses, compensation expense, license fees and royalties, depreciation and amortization, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are recorded as the test is processed regardless of whether and when revenue is recognized with respect to that test. As a result, our cost of revenue as a percentage of revenue may vary significantly from period to period because we may not recognize all revenue in the period in which the associated costs are incurred. We expect cost of revenue in absolute dollars to increase as the number of tests we perform increases. However, we expect that the cost per test will decrease over time due to leveraging fixed costs, efficiencies we may gain as test volume increases and from automation, process efficiencies and other cost reductions. As we introduce new tests, initially our cost of revenue will be high as we expect to run suboptimal batch sizes, run quality control batches, test batches, registry samples and generally incur costs that may suppress or reduce gross margins. This will disproportionately increase our aggregate cost of revenue until we achieve efficiencies in processing these new tests.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our cost of product revenue consists primarily of costs of purchasing instruments and consumables from third-party contract manufacturers, installation, warranty, service and packaging and delivery costs. In addition, cost of product includes royalty costs for licensed technologies included in our products and labor expenses. As our Prosigna kits are sold in various configurations with different number of tests, our product cost per test will vary based on the specific kit configuration purchased by customers.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our cost of biopharmaceutical revenue are the costs of performing activities under arrangements that require us to perform research and development services on behalf of a customer pursuant to a biopharmaceutical service agreement, and is mainly comprised of compensation expense and pass through costs.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses include expenses incurred to develop our technology, collect clinical samples and conduct clinical studies to develop and support our products and pipeline. These expenses consist of compensation expenses, direct research and development expenses such as prototype materials, laboratory supplies and costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation and amortization, other miscellaneous expenses and allocation of facility and information technology expenses. We expense all research and development costs in the periods in which they are incurred. We expect to incur significant research and development expenses as we continue to invest in research and development activities related to developing additional products and evaluating various platforms. We incurred research and development expenses on ongoing evidence development for our Afirma, Percepta and Envisia classifiers in 2019. We incurred a majority of our research and development expenses in the three months ended March 31, 2020 in support of our pipeline products, and expect this to continue in the remainder of 2020 and beyond.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Selling and Marketing</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selling and marketing expenses consist of compensation expenses, direct marketing expenses, professional fees, other expenses such as travel and communications costs and allocation of facility and information technology expenses. We have expanded our internal sales force as we invest in our multi-product sales strategy to assign a single point of contact to successfully develop and implement relationships with our customers and increased our marketing spending. We have also incurred increased selling and marketing expense as a result of investments in our lung product portfolio and believe total selling and marketing expenses will continue to increase as we launch and promote our new tests.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses include compensation expenses for executive officers and administrative, billing and client service personnel, professional fees for legal and audit services, occupancy costs, depreciation and amortization, and other expenses such as information technology and miscellaneous expenses offset by allocation of facility and information technology expenses to other functions.  For the three months ended March&#160;31, 2020, approximately 68% of the average headcount classified as general and administrative encompass our billing and customer care teams.  We expect general and administrative expenses to continue to increase as we build our general and administration infrastructure and to stabilize thereafter.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible Asset Amortization</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our finite-lived intangible assets, acquired in business combinations, are being amortized over 5 to 15 years, using the straight-line method. Amortization expense is expected to be approximately $5.1 million per year through 2024 and decrease thereafter.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Expense</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense is attributable to our borrowings under debt agreements and capital leases as well as costs associated with the prepayment of debt.  </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income, Net</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income, net consists primarily of sublease rental income and interest income from our cash held in interest bearing accounts.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="ide126ddc4fe34b88b9204d0512399caf_88"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comparison of the three months ended March 31, 2020 and 2019 (in thousands of dollars, except percentages and genomic classifiers reported):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.684%;"><tr><td style="width:1.0%;"></td><td style="width:63.037%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.037%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.540%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.703%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.540%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.851%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.540%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.152%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue:</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Testing revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,409&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,409&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NM</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biopharmaceutical revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">722&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,140&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,418)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(83)%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,122&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,529&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,593&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expense:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of testing revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,568&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,513&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of product revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NM</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of biopharmaceutical revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NM</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">972&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,584&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,107&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,904&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible asset amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">267&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">378%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,596&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,200)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,067)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,133)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">490%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(55)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(303)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(82)%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">539&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">453&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss and comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,716)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,917)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,799)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">511%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other Operating Data:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Genomic classifiers reported</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,162&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,397&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,972&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">945&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,027&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">109%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,905&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,759&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,146&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">During the second half of March 2020, we experienced a significant decline in the volume of samples received resulting in a significant decline in revenue due to COVID-19.  In spite of this, revenue increased $1.6 million, or 5%, for the three months ended March 31, 2020 compared to the same period in 2019.  This was primarily due to $3.4 million of sales of Prosigna, a product that we acquired the rights to from NanoString in December 2019, and a $1.6 million increase in testing revenue from a 15% increase in our Afirma, Percepta, and Envisia genomic classifiers reported.  We also make adjustments, as necessary, for testing revenue accrued in prior periods as collections are made if the amount we expect to collect changes.  The adjustment for testing revenue accrued in prior periods decreased revenue by $0.1 million and increased revenue by $0.6 million for the three months ended March 31, 2020 and 2019, respectively, a net decrease of $0.7 million between the periods.  Biopharmaceutical revenue decreased $3.4 million, mainly due to the performance of data sequencing services for Johnson &amp; Johnson in the prior year period that did not recur in the three months ended March 31, 2020.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of revenue</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comparison of the three months ended March 31, 2020 and 2019 is as follows (in thousands of dollars, except percentages):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:62.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.235%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.235%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.235%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.238%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of testing revenue:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory costs</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,220&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,664&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sample collection costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,221&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,815&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License fees and royalties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">600%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">253&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">470&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allocations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">611&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">572&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,568&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,513&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of product revenue:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product costs</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,220&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,220&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NM</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License fees and royalties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">339&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">339&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NM</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NM</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of biopharmaceutical revenue:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NM</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NM</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NM</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of testing revenue increased $2.1 million, or 24%, for the three months ended March 31, 2020 compared to the same period in 2019.  The increase in laboratory costs was due to a $1.1 million write-down of supplies for the potential expiration of reagents due to an anticipated decline in volumes resulting from the COVID-19 pandemic. The increase in sample collection costs primarily relates to a 15% increase in the volume of genomic classifiers reported. The increase in compensation expense primarily relates to an average laboratory headcount increase of 16%.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of product revenue is related to sales of Prosigna.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of biopharmaceutical revenue includes labor costs incurred by our employees working on biopharmaceutical customer projects and pass-through expenses incurred on these projects.  Biopharmaceutical revenue recognized in the prior year period was mainly for the sale of sequencing data and had no related costs.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comparison of the three months ended March 31, 2020 and 2019 is as follows (in thousands of dollars, except percentages):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"><tr><td style="width:1.0%;"></td><td style="width:64.121%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.320%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.542%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.320%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.542%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.320%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.542%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.693%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,130&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">740&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Direct research and development expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">941&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Professional fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">201&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(76)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(38)%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(80)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51)%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allocations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">315&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">301&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">972&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Research and development expense increased $1.0 million, or 28%, for the three months ended March 31, 2020 compared to the same period in 2019.  The increase in compensation expense was primarily due to an 18% increase in average headcount and higher stock-based compensation expense from the increase in our stock price over the last two years.  The increase in direct research and development expense was mainly due to an increase in clinical trial activity for our pipeline products.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling and marketing</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comparison of the three months ended March 31, 2020 and 2019 is as follows (in thousands of dollars, except percentages):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.245%;"><tr><td style="width:1.0%;"></td><td style="width:64.517%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.184%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.544%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.184%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.544%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.184%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.544%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.699%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing expense:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,515&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,714&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,801&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Direct marketing expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,587&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(435)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27)%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Professional fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">325&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">364&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11)%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allocations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">762&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,584&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,107&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selling and marketing expense increased $5.1 million, or 41%, for the three months ended March 31, 2020 compared to the same period in 2019.  The increase in compensation expense was primarily due to an average headcount increase of 60%, higher incentive compensation and higher stock-based compensation expense.  The decrease in direct marketing expense was due to lower general marketing expenditures.  The increase in other expenses was primarily due to travel and entertainment expenses related to the increase in headcount, as was the increase in allocations.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and administrative</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comparison of the three months ended March 31, 2020 and 2019 is as follows (in thousands of dollars, except percentages):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099%;"><tr><td style="width:1.0%;"></td><td style="width:64.020%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.345%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.545%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.345%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.545%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.345%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.545%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.710%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,988&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">788&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Professional fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">670&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Occupancy expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">623&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">367&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">764&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,075&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(311)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29)%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allocations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,922)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,635)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(287)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,904&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expense increased $1.6 million, or 24%, for the three months ended March 31, 2020 compared to the same period in 2019.  The increase in compensation expense was primarily due to higher stock-based compensation expense from the increase in our stock price over the last two years. The increase in professional fees was primarily accounting and legal-related. The decrease in other expenses was primarily due to the revaluation of the contingent consideration for the NanoString transaction.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest expense</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense decreased $248,000, or 82%, for the three months ended March 31, 2020 compared to the same period in 2019, mainly due to the prepayments of $12.5 million and $12.4 million of the principal amount of our Term Loan Advance in January 2019 and May 2019, respectively.  The average Term Loan Advance interest rate was 5.80% and 6.68% for the three months ended March 31, 2020 and 2019, respectively. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other income, net</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income, net, increased $86,000 for the three months ended March 31, 2020 compared to the same period in 2019 primarily due to higher interest income from our cash and cash equivalents, which had higher balances in 2020, partially offset by lower interest rates.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="ide126ddc4fe34b88b9204d0512399caf_91"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From inception through March&#160;31, 2020, we have been financed primarily through net proceeds from the sale of our equity securities and borrowings under our credit facilities. We have incurred net losses since our inception. For the three months ended March&#160;31, 2020, we had a net loss of $11.7 million, and as of March&#160;31, 2020, we had an accumulated deficit of $258.4 million.  We expect to incur additional losses for the remainder of 2020 and potentially in future years.</span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We believe our existing cash and cash equivalents of $153.1&#160;million as of March&#160;31, 2020, our available revolving line of credit, and our revenue during the next 12 months will be sufficient to meet our anticipated cash requirements for at least the next 12 months.  We expect that our near- and longer-term liquidity requirements will continue to consist of costs to run our laboratories, research and development expenses, selling and marketing expenses, general and administrative expenses, working capital, costs to service our Loan and Security Agreement (See Note 7 to our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for more information about our Loan and Security Agreement), capital expenditures and general corporate expenses associated with the growth of our business. However, we may also use cash to acquire or invest in complementary businesses, technologies, services or products that would change our cash requirements. If we are not able to generate revenue to finance our cash requirements, including due to the impacts of the COVID-19 pandemic, we will need to finance future cash needs primarily through public or private equity offerings, debt financings, borrowings or strategic collaborations or licensing arrangements. If we raise funds by issuing equity securities, dilution to stockholders could result. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings could impose significant restrictions on our operations. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, restrictions on our cash pursuant to the terms of our Loan and Security Agreement and other operating restrictions that could adversely affect our ability to conduct our business. Our Loan and Security Agreement imposes restrictions on our operations, increases our fixed payment obligations and has restrictive covenants. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third-party on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives, or forgo potential acquisitions or investments. In addition, we may have to work with a partner on one or more of our products or development programs, which could lower the economic value of those programs to us. </span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Public Offering of Common Stock</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 7, 2019, we issued and sold 6,325,000 shares of common stock in a registered public offering, including 825,000 shares issued and sold upon the underwriters&#8217; exercise in full of their option to purchase additional shares, at a price to the public of&#160;$23.25&#160;per share. Our net proceeds from the offering were approximately&#160;$137.8 million, after deducting underwriting discounts and commissions and offering expenses of $9.2 million.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Loan and Security Agreement</span></div><div style="text-indent:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 3, 2017, we entered into the Loan and Security Agreement with Silicon Valley Bank.  The Loan and Security Agreement allows us to borrow up to $35.0 million, with a $25.0 million term loan, or Term Loan, and a revolving line of credit of up to $10.0 million, or the Revolving Line of Credit, subject to, with respect to the Revolving Line of Credit, a borrowing base of 85% of eligible accounts receivable.  The Term Loan was advanced upon the closing of the Loan and Security Agreement. Borrowings under the Loan and Security Agreement mature in October 2022.  The Term Loan bears interest at a variable rate equal to (i) the thirty-day U.S. London Interbank Offer Rate, or LIBOR, plus (ii) 4.20%, with a minimum rate of 5.43% per annum.  Principal amounts outstanding under the Revolving Line of Credit bear interest at a variable rate equal to (i) LIBOR plus (ii) 3.50%, with a minimum rate of 4.70% per annum.  We are also required to pay an annual facility fee on the Revolving Line of Credit of $25,000.  The average Term Loan Advance interest rate for the three months ended March&#160;31, 2020 was 5.8%.  </span></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may prepay the outstanding principal amount under the Term Loan Advance plus accrued and unpaid interest and, if the Term Loan Advance is repaid in full, a prepayment premium.  The prepayment premium will equal (i)&#160;$750,000, if the prepayment is made on or before November 3, 2018, (ii) $500,000, if the prepayment is made after November 3, 2018 and on or prior to November 3, 2019 and (iii)&#160;$250,000, if the prepayment is made after November 3, 2019.  In addition, a final payment on the Term Loan Advance in the amount of $1.2 million is due upon the earlier of the maturity date of the Term Loan Advance or its payment in full.  In January 2019 and May 2019, we prepaid $12.5 million and $12.4 million of the principal amount of the Term Loan Advance, respectively, and did not incur any prepayment premium as we did not repay the Term Loan Advance in full. These prepayments cover scheduled principal payments from November 2019 to September 2022.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Loan and Security Agreement contains customary representations, warranties, and events of default such as a material adverse change in our business, operations or financial conditions, as well as affirmative and negative covenants.  The negative covenants include, among other provisions, covenants that limit or restrict our ability to incur liens, make investments, incur indebtedness, merge with or acquire other entities, dispose of assets, make dividends or other distributions to holders of our equity interests, engage in any new line of business, or enter into certain transactions with affiliates, in each case subject to certain exceptions.  As of March&#160;31, 2020, the principal balance outstanding was $0.1 million and we were in compliance with our debt covenants. </span></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Loan and Security Agreement also requires us to comply with certain financial covenants, including achieving certain revenue levels tested quarterly on a trailing twelve-month basis.  However, failure to maintain the revenue levels will not be considered a default if the sum of our unrestricted cash and cash equivalents maintained with Silicon Valley Bank and amount available under the Revolving Line of Credit is at least $40.0 million.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our obligations under the Loan and Security Agreement are secured by substantially all of our assets (excluding intellectual property), subject to certain customary exceptions.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our cash flows for the three months ended March&#160;31, 2020 and 2019 (in thousands of dollars):&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"></td><td style="width:71.520%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.869%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.872%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash used in operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,301)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,011)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(665)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(749)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(219)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,394)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="ide126ddc4fe34b88b9204d0512399caf_94"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash Flows from Operating Activities</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash used in operating activities for the three months ended March 31, 2020 was $5.3 million. The net loss of $11.7 million includes non-cash charges of $2.9 million of stock-based compensation expense, $2.0 million of depreciation and amortization, which includes $1.3 million of intangible asset amortization, a $1.1 million write-down of supplies, and a $0.5 million credit for the revaluation of the contingent consideration related to the NanoString transaction.  Cash provided as a result of changes in operating assets and liabilities was $0.9 million, primarily comprised of an increase in accounts payable of $5.5 million, partially offset by a decrease in accrued liabilities of $3.7 million and increase in prepaid expense and other current assets of $0.8 million.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash used in operating activities for the three months ended March 31, 2019 was $1.0 million. The net loss of $1.9 million includes non-cash charges of $1.8 million of stock-based compensation expense and $0.9 million of depreciation and amortization, which includes $0.3 million of intangible asset amortization. Cash used as a result of changes in operating assets and liabilities was $1.8 million, comprised of an increase in accounts receivable of $3.4 million and increase in supplies of $0.4 million, partially offset by increases in accounts payable and accrued liabilities of $1.7 million and $0.3 million, respectively.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div id="ide126ddc4fe34b88b9204d0512399caf_97"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash Flows from Investing Activities</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash used in investing activities for the three months ended March 31, 2020 was $0.7 million for the acquisition of property and equipment. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cash used in investing activities for the three months ended March 31, 2019 was $0.7 million for the acquisition of property and equipment, net of proceeds from the disposal of property and equipment.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="ide126ddc4fe34b88b9204d0512399caf_100"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash Flows from Financing Activities</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash used in financing activities for the three months ended March 31, 2020 was $0.2 million, consisting of $2.3 million in tax payments related to the vesting of restricted stock units granted to employees, partially offset by $2.1 million in proceeds from the exercise of options to purchase our common stock and purchase of stock under our Employee Stock Purchase Plan, or ESPP, during the period.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash used in financing activities for the three months ended March 31, 2019 was $8.4 million, consisting of $12.5 million of loan principal repayments and finance lease payments of $0.1 million, partially offset by $4.2 million in proceeds from the exercise of options to purchase our common stock and purchase of stock under our Employee Stock Purchase Plan, or ESPP, during the period.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div id="ide126ddc4fe34b88b9204d0512399caf_103"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual Obligations</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> In January 2019 and May 2019, we prepaid $12.5 million and $12.4 million of the principal amount of the Term Loan Advance, respectively, under our Loan and Security Agreement.  As of March&#160;31, 2020, future principal and end-of-term debt obligation payments due under the Loan and Security Agreement are limited to $1.3 million in 2022.  There were no material changes during the interim period in the contractual obligations presented in our Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on February 25, 2020. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="ide126ddc4fe34b88b9204d0512399caf_106"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-balance Sheet Arrangements</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not entered into any off-balance sheet arrangements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="ide126ddc4fe34b88b9204d0512399caf_109"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> Recent Accounting Pronouncements</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This ASU requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. This guidance became effective for us beginning January 1, 2020.  Based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (Topic 808). </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under&#160;this ASU,&#160;transactions in collaborative arrangements are to be accounted for under ASC 606 if the counterparty is a customer for a good or service (or bundle of goods and services) that is a distinct unit of account. Also, entities are precluded from presenting consideration from transactions with a counterparty that is not a customer together with revenue recognized from ASC 606.  This ASU is effective for all interim and annual reporting periods beginning on or after December 15, 2019, with early adoption permitted.  We adopted this ASU in 2019 with no cumulative-effect adjustments or retrospective impact. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018 the FASB issued ASU No. 2018-15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard became effective for us on January 1, 2020, and was adopted on a prospective basis with no material impact on our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div id="ide126ddc4fe34b88b9204d0512399caf_112"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 3.&#160; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rates. We had cash and cash equivalents of $153.1 million as of March&#160;31, 2020 which include bank deposits and money market funds. Such interest-bearing instruments carry a degree of risk; however, a hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our unaudited interim condensed financial statements. Under our Loan and Security Agreement, we pay interest on any outstanding balances under this agreement based on a variable market rate. A significant change in these market rates may adversely affect our operating results.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="ide126ddc4fe34b88b9204d0512399caf_115"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 4.&#160; CONTROLS AND PROCEDURES</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(a)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt;">Evaluation of Disclosure Controls and Procedures</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, or Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(b)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt;">Changes in Internal Control over Financial Reporting</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) identified in connection with the evaluation identified above that occurred during the three months ended March&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_118"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II. &#8212; OTHER INFORMATION</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="ide126ddc4fe34b88b9204d0512399caf_121"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 1A.&#160; RISK FACTORS</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="ide126ddc4fe34b88b9204d0512399caf_124"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Business </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have a history of losses, and we expect to incur net losses for the foreseeable future and may never achieve or sustain profitability.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred net losses since our inception. For the three months ended March&#160;31, 2020, we had a net loss of $11.7 million and as of March&#160;31, 2020, we had an accumulated deficit of $258.4 million.  We expect to incur additional losses in the future, and we may never achieve revenue sufficient to offset our expenses. Over the next couple of years, we expect to continue to devote substantially all of our resources to increase adoption of, and reimbursement for our Afirma, Percepta and Envisia classifiers and Prosigna test, and the development of additional tests. We may never achieve or sustain profitability, and our failure to achieve and sustain profitability in the future could cause the market price of our common stock to decline.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The outbreak of COVID-19 could have an adverse effect on our business, results of operations and financial condition.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">COVID-19 has caused significant volatility in financial markets and has raised the prospect of an extended global recession. Public health problems resulting from COVID-19 and precautionary measures instituted by governments and businesses to mitigate its spread, including travel restrictions and quarantines, could contribute to a general slowdown in the global economy, adversely impact patients, physicians, customers, suppliers, third-party contract manufacturers, and collaboration partners, and disrupt our operations. Changes in our operations in response to COVID-19 or employee illnesses resulting from the pandemic may result in inefficiencies or delays, including in sales and product development efforts and additional costs related to business continuity initiatives, that cannot be fully mitigated through succession planning, employees working remotely or teleconferencing technologies. In addition, during the second half of March 2020 through the date of this filing, we experienced a significant decline in the volume of samples received resulting in a significant decline in revenue and it is currently unclear how long we will continue to experience decreased sample volumes and levels of revenue.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">COVID-19 and related governmental reactions have had, and may continue to have a negative impact on our business, liquidity, results of operations, and stock price due to the occurrence of some or all of the following events or circumstances among others:</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">We may not be able to manage our business effectively due to key employees becoming ill, working from home inefficiently and being unable to travel to our facilities.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">We and our customers, suppliers, third-party contract manufacturers, and collaboration partners may be prevented from operating worksites, including manufacturing facilities, due to employee illness or reluctance to appear at work and &#8220;stay-at-home&#8221; regulations.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">Interruptions in manufacturing (including the sourcing of reagents) and shipment of our products.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">Reduced patient demand for, or provider capacity to deliver, diagnostic testing and elective procedures generally.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">Disruptions of the operations of our third-party contract manufacturers and suppliers, which could impact our ability to purchase components at efficient prices and in sufficient amounts.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">We may need to raise capital, and if we raise capital by issuing equity securities, our common stock may be diluted.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">The market price of our common stock may drop or remain volatile.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">We may incur significant employee health care costs under our insurance programs. </span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The extent of the impact of COVID-19 on our business and financial results will depend largely on future developments, including the duration of the spread of the outbreak, the impact on capital and financial markets and the related impact on the financial circumstances of patients, physicians, suppliers, third-party contract manufacturers, and collaboration partners, all of which are highly uncertain and cannot be predicted. This situation is changing rapidly, and additional impacts may arise that we are not aware of at this time.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our financial results currently depend mainly on sales of our Afirma tests, and we will need to generate sufficient revenue from this and other diagnostic solutions to grow our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Most of our revenue to date has been derived from the sale of our Afirma tests, which are used in the diagnosis of thyroid cancer.  Over the next few years, we expect to continue to derive a substantial portion of our revenue from sales of our </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Afirma tests.  In the third quarter of 2017, we began recognizing revenue from the sale of our Percepta test, used in the diagnosis of lung cancer.  We also launched our Envisia test to help improve the diagnosis of interstitial lung disease, specifically IPF, and began recognizing revenue from Envisia in the second quarter of 2019. In December 2019, we acquired the rights to the Prosigna test from NanoString Technologies, Inc. and commenced marketing and selling Prosigna test kits to U.S. and international customers.  Once genomic tests are clinically validated and commercially available for patient testing, we must continue to develop and publish evidence that our tests are informing clinical decisions in order for them to receive positive coverage decisions by payers.  Without coverage policies, our tests may not be reimbursed and we will not be able to recognize revenue. We cannot guarantee that tests we commercialize will gain and maintain positive coverage decisions and therefore, we may never realize revenue from tests we commercialize.  In addition, we are in various stages of research and development for other diagnostic solutions that we may offer, but there can be no assurance that we will be able to identify other diseases that can be effectively addressed or, if we are able to identify such diseases, whether or when we will be able to successfully commercialize solutions for these diseases and obtain the evidence and coverage decisions from payers. If we are unable to increase sales and expand reimbursement for our Afirma, Percepta, Envisia and Prosigna tests, or develop and commercialize other solutions, our revenue and our ability to achieve and sustain profitability would be impaired, and the market price of our common stock could decline.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We depend on a few payers for a significant portion of our revenue and if one or more significant payers stops providing reimbursement or decreases the amount of reimbursement for our tests, our revenue could decline.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue for tests performed on patients covered by Medicare and UnitedHealthcare was 24% and 11%, respectively, of our revenue for the three months ended March&#160;31, 2020, compared with 28% and 12%, respectively, for the three months ended  March&#160;31, 2019.  The percentage of our revenue derived from significant payers is expected to fluctuate from period to period as our revenue fluctuates, as additional payers provide reimbursement for our tests or if one or more payers were to stop reimbursing for our tests or change their reimbursed amounts. Effective January 2012, Palmetto GBA, the regional Medicare Administrative Contractor, or MAC, that handled claims processing for Medicare services over our jurisdiction at that time, issued coverage and payment determinations for our Afirma Classifiers now covered by Noridian Healthcare Solutions, the current MAC for our jurisdiction, through the Molecular Diagnostics Services Program, or MolDX program, administered by Palmetto GBA, under a Local Coverage Determination, or LCD. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Noridian Healthcare Solutions issued an LCD for Percepta effective for services performed on or after May 2017. This coverage policy requires us to establish and maintain a Certification and Training Registry program and make Percepta available only to certain Medicare patients through physicians who participate in this program. Failure by us or physicians to comply with the requirements of the Certification and Training Registry program could lead to loss of Medicare coverage for Percepta, which could have an adverse effect on our revenue. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We submitted the dossier of clinical evidence needed to obtain Medicare coverage for the Envisia Genomic Classifier through the MolDX technical assessment process in 2018, and received final Medicare coverage for the classifier in the first quarter of 2019, with an effective date of April 1, 2019. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An LCD was issued for Prosigna by Palmetto GBA in August 2015, which has been in effect since October 1, 2015.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On a five-year rotational basis, Medicare requests bids for its regional MAC services. Any future changes in the MAC processing or coding for Medicare claims for the Afirma, Percepta or Envisia classifiers, or for Prosigna, could result in a change in the coverage or reimbursement rates for such products, or the loss of coverage, and could also result in increased difficulties in obtaining and maintaining coverage for future products. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 1, 2015, an American Medical Association Current Procedural Terminology code, or CPT code, 81545 for the Afirma GEC was issued. On January 1, 2018, the Medicare Clinical Laboratory Fee Schedule payment rate for the Afirma classifier increased from $3,220 to $3,600.  This rate is based on the volume-weighted median of private payer rates based on final payments made between January 1 and June 30, 2016, which we reported to the Centers for Medicare &amp; Medicaid Services, or CMS, in 2017 as required under the Protecting Access to Medicare Act of 2014, or PAMA. In December 2019, through the Further Consolidated Appropriations Act of 2020, Congress delayed the next data reporting period from 2020 to 2021 for final payments made between January 1 and June 30, 2019, extending the applicability of the payment rates based on 2017 reporting by one year through December 31, 2021.  Afirma will continue to be paid at $3,600 through that date. The volume-weighted median of private payer rates for final payments made from January through June 2019 (and now reported January through March 2021) will set the Medicare payment rate for the Afirma classifier from January 1, 2022 through December 31, 2024.  There can be no assurance that the Afirma or Prosigna rates will not decrease during this or a subsequent reporting cycle under PAMA.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We submit claims to Medicare for Percepta and Envisia using unlisted codes under the MolDX program. Specific CPT codes assigned to Percepta and Envisia may be required to go through the national payment determination process, and there can be no assurance that the Medicare payment rates the tests receive through this process will not be lower than their current rates. There can also be no assurance that the Medicare payment rates for the tests will not be reduced when they are set based on the volume-weighted medians of private payer rates when we are required to report those rates under PAMA. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Moreover, federal Medicare funding and state budgets are limited and have been placed under tremendous strain in recent years, which is likely to be further exacerbated as a result in reduced tax receipts and greater deficit spending as a result of the COVID-19 pandemic. Such budgetary pressures may force Medicare or state agencies to reduce payment rates or change coverage policies. If there is a decrease in the Medicare or other payers&#8217; payment rates for our tests, our revenue from Medicare and such payers will decrease and the payment rates for some of our commercial payers may also decrease if they tie their allowable rates to the Medicare rates.  These changes could have an adverse effect on our business, financial condition and results of operations. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we have entered into contracts with certain third-party payers that establish in-network allowable rates of reimbursement for our Afirma tests, payers may suspend or discontinue reimbursement at any time, may require or increase co-payments from patients, or may reduce the reimbursement rates paid to us.  Reductions in private payer amounts could decrease the Medicare payment rates for our tests under PAMA.  In addition, private payers have begun requiring prior authorization for molecular diagnostic tests.  Potential reductions in reimbursement rates or increases in the difficulty of achieving payment could have a negative effect on our revenue.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If payers do not provide reimbursement, rescind or modify their reimbursement policies, delay payments for our tests, recoup past payments, or if we are unable to successfully negotiate additional reimbursement contracts, our commercial success could be compromised.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Physicians might not order our tests unless payers reimburse a substantial portion of the test price. There is significant uncertainty concerning third-party reimbursement of any test incorporating new technology, including our tests. Reimbursement by a payer may depend on a number of factors, including a payer&#8217;s determination that these tests are:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">not experimental or investigational;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">pre-authorized and appropriate for the specific patient;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">cost-effective;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">supported by peer-reviewed publications; and</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">included in clinical practice guidelines.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since each payer makes its own decision as to whether to establish a coverage policy or enter into a contract to reimburse our tests, seeking these approvals is a time-consuming and costly process.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not have a contracted rate of reimbursement with some payers for our tests. Without a contracted rate for reimbursement, our claims are often denied upon submission, and we must appeal the claims. The appeals process is time consuming and expensive, and may not result in payment. In cases where there is no contracted rate for reimbursement, there is typically a greater patient co-insurance or co-payment requirement which may result in further delay or decreased likelihood of collection. Payers may attempt to recoup prior payments after review, sometimes after significant time has passed, which would impact future revenue.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to focus substantial resources on increasing adoption, coverage and reimbursement for the Afirma, Percepta, and Envisia classifiers, Prosigna and any other future tests we may develop. We believe it will take several years to achieve coverage and contracted reimbursement with a majority of third-party payers. However, we cannot predict whether, under what circumstances, or at what payment levels payers will reimburse for our tests. Also, payer consolidation is underway and creates uncertainty as to whether coverage and contracts with existing payers will remain in effect. Finally, if there is a decrease in the Medicare payment rates for our tests, the payment rates for some of our commercial payers may also decrease if they tie their allowable rates to the Medicare rates. Reductions in private payer amounts could decrease the Medicare payment rates for our tests under PAMA.  Our failure to establish broad adoption of and reimbursement for our tests, or our inability to maintain existing reimbursement from payers, will negatively impact our ability to generate revenue and achieve profitability, as well as our future prospects and our business.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may experience limits on our revenue if physicians decide not to order our tests.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to create or maintain demand for our tests in sufficient volume, we may not become profitable. To generate demand, we will need to continue to educate physicians about the benefits and cost-effectiveness of our tests through published papers, presentations at scientific conferences, marketing campaigns and one-on-one education by our sales force. In addition, our ability to obtain and maintain adequate reimbursement from third-party payers will be critical to generating revenue.  Moreover, many patients have been deferring elective procedures and medical visits as a result of the COVID-19 pandemic, and we have experienced, and may continue to experience, a significant reduction in patient demand or physician recommendations, which has and may continue to adversely affect our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Afirma genomic classifier is included in most physician practice guidelines in the United States for the assessment of patients with thyroid nodules. However, historical practice recommended a full or partial thyroidectomy in cases where cytopathology results were indeterminate to confirm a diagnosis. Our lung products are not yet integrated into practice guidelines and physicians may be reluctant to order tests that are not recommended in these guidelines. The Prosigna test is included in practice guidelines in the United States and internationally but faces competition from other products.  Because our Afirma, Percepta and Envisia testing services are performed by our certified laboratory under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, rather than by the local laboratory or pathology practice, pathologists may be reluctant to support our testing services as well. Guidelines that include our tests currently may subsequently be revised to recommend another testing protocol, and these changes may result in physicians deciding not to use our tests. Lack of guideline inclusion could limit the adoption of our tests and our ability to generate revenue and achieve profitability. To the extent international markets have existing practices and standards of care that are different than those in the United States, we may face challenges with the adoption of our tests in international markets.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">We may experience limits on our revenue if patients decide not to use our tests.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Some patients may decide not to use our tests because of price, all or part of which may be payable directly by the patient if the patient&#8217;s insurer denies reimbursement in full or in part. There is a growing trend among insurers to shift more of the cost of healthcare to patients in the form of higher co-payments or premiums, and this trend is accelerating which puts patients in the position of having to pay more for our tests. We expect to continue to see pressure from payers to limit the utilization of tests, generally, and we believe more payers are deploying costs containment tactics, such as pre-authorization and employing laboratory benefit managers to reduce utilization rates. Implementation of provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, collectively the ACA, has also resulted in increases in premiums and reductions in coverage for some patients. In addition, Congressional efforts to repeal the ACA could result in an increase in uninsured patients. These events may result in patients delaying or forgoing medical checkups or treatment due to their inability to pay for our tests, which could have an adverse effect on our revenue.  Many patients have been deferring elective procedures and medical visits as a result of the COVID-19 pandemic, and we have experienced, and may continue to experience, a significant reduction in patient demand, which has and may continue to adversely affect our business.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with federal and state licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations mandate specific personnel qualifications, facilities administration, quality systems, inspections, and proficiency testing. CLIA certification is also required for us to be eligible to bill state and federal healthcare programs, as well as many private third-party payers. To renew these certifications, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our clinical reference laboratories.  If we in the future fail to maintain CLIA certificates in our South San Francisco or Austin, Texas laboratory locations we would be unable to bill for services provided by state and federal healthcare programs, as well as many private third-party payers, which may have an adverse effect on our business, financial condition and results of operations.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also required to maintain state licenses to conduct testing in our laboratories. California, New York, and Texas, among other states&#8217; laws, require that we maintain a license and comply with state regulation as a clinical laboratory. Other states may have similar requirements or may adopt similar requirements in the future. In addition, both of our clinical laboratories are required to be licensed on a test-specific basis by New York State. We have received approval for the Afirma, Percepta and Envisia tests. We will be required to obtain approval for other tests we may offer in the future. If we were to lose our CLIA certificate or California license for our South San Francisco laboratory, whether as a result of revocation, suspension </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">or limitation, we would no longer be able to perform our molecular tests, which would eliminate our primary source of revenue and harm our business. If we fail to meet the state licensing requirements for our Austin laboratory, we would need to move the receipt and storage of FNAs, as well as the slide preparation for cytopathology, to South San Francisco, which could result in a delay in processing tests during that transition and increased costs. If we were to lose our licenses issued by New York or by other states where we are required to hold licenses, we would not be able to test specimens from those states. New tests we may develop may be subject to new approvals by regulatory bodies such as New York State, and we may not be able to offer our new tests until such approvals are received. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we are not successful in integrating the assets acquired from NanoString or if our general strategy of seeking growth through such acquisitions and collaborations is not successful, our prospects and financial condition will suffer.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have recently acquired assets, such as the nCounter FLEX Analysis System and Prosigna in December 2019, and we may pursue additional acquisitions of complementary businesses or assets as part of our business strategy. To date, we have limited experience with respect to acquisitions and the formation of strategic alliances and joint ventures. There can be no assurance that we will successfully integrate the assets acquired from NanoString successfully into our existing business, or that our exclusive worldwide license to the nCounter system for in vitro diagnostic use will allow us to expand our international reach as anticipated. This and any future acquisitions made by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. Integration of acquired companies or businesses we may acquire in the future also may require management resources that otherwise would be available for ongoing development of our existing business. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, joint venture or investment.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To finance any acquisitions or investments, we have previously and may choose in the future to issue shares of our stock as consideration, which would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. Alternatively, it may be necessary for us to raise additional funds for these activities through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all. If these funds are raised through the sale of equity or convertible debt securities, dilution to our stockholders could result. Our Loan and Security Agreement with Silicon Valley Bank contains covenants that could limit our ability to sell debt securities or obtain additional debt financing arrangements, which could affect our ability to finance acquisitions or investments other than through the issuance of stock.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are not successful in advancing our collaborations with Johnson &amp; Johnson and others, or if our general strategy of seeking growth through such collaborations is not successful, our prospects and financial condition will suffer.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have previously entered into technology licensing and collaboration arrangements, such as our collaboration with Johnson &amp; Johnson in December 2018 and with Acerta Pharma, the hematology research and development arm of AstraZeneca, in December 2019, reflecting important elements of our business strategy. We also may pursue additional strategic alliances that leverage our core technology and industry experience to expand our offerings or distribution, or make investments in other companies. However, we have limited experience with respect to the formation of strategic alliances and joint ventures. There can be no assurance that we will successfully identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any technology license, strategic alliance, joint venture or investment.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely on sole suppliers for some of the reagents, equipment, chips and other materials used to perform our tests, and we may not be able to find replacements or transition to alternative suppliers.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on sole suppliers for critical supply of reagents, equipment, chips and other materials that we use to perform our tests and for the manufacture of the nCounter FLEX Dx systems and Prosigna test kits sold to customers. We also purchase components used in our collection kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. In addition, we utilize a sole source to assemble and distribute our sample collection kits. We rely on NanoString for the supply of the nCounter FLEX Dx System and Prosigna test kits. While we have developed alternate sourcing strategies for these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. If these suppliers can no longer provide us with the materials we need to perform the tests and for our collection kits, if the materials do not meet our quality specifications or are otherwise unusable, if we cannot obtain acceptable substitute materials, or if we elect to change suppliers, an interruption in test processing or system and test kit deliveries could occur, we may not be able to deliver patient reports and we may incur higher one-time switching costs. Any such interruption may significantly affect our future revenue, cause us to incur higher costs, and harm our customer </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">relationships and reputation. In addition, in order to mitigate these risks, we maintain inventories of these supplies at higher levels than would be the case if multiple sources of supplies were available. If our test volume decreases or we switch suppliers, we may hold excess supplies with expiration dates that occur before use which would adversely affect our losses and cash flow position. As we introduce any new test, we may experience supply issues as we ramp test volume.  Moreover, the COVID-19 pandemic has disrupted supply chains globally, and could adversely affect our ability to source essential reagents, equipment, chips and other materials in a timely manner or at all.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We depend on a specialized cytopathology practice to perform the cytopathology component of our Afirma test, and our ability to perform our diagnostic solution would be harmed if we were required to secure a replacement.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on TCP to provide cytopathology professional diagnoses on thyroid FNA samples pursuant to a pathology services agreement. Pursuant to this agreement, as amended, TCP has the exclusive right to provide our cytopathology diagnoses on FNA samples at a fixed price per test.  Until February 2019, TCP also previously subleased a portion of our facility in Austin, Texas. Our agreement with TCP is effective through October 31, 2022, and thereafter automatically renews every year unless either party provides notice of intent not to renew at least 12 months prior to the end of the then-current term.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If TCP were not able to support our current test volume or future increases in test volume or to provide the quality of services we require, or if we were unable to agree on commercial terms and our relationship with TCP were to terminate, our business would be harmed until we were able to secure the services of another cytopathology provider. There can be no assurance that we would be successful in finding a replacement that would be able to conduct cytopathology diagnoses at the same volume or with the same high-quality results as TCP. Locating another suitable cytopathology provider could be time consuming and would result in delays in processing Afirma tests until a replacement was fully integrated with our test processing operations.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Due to how we recognize revenue, our quarterly operating results are likely to fluctuate.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize test revenue upon delivery of the patient report to the prescribing physician based on the amount we expect to ultimately realize. We determine the amount we expect to ultimately realize based on payer reimbursement history, contracts, and coverage. Upon ultimate collection, the amount received is compared to the estimates and the amount accrued is adjusted accordingly. We cannot be certain as to when we will receive payment for our diagnostic tests, and we must appeal negative payment decisions, which delays collections. Should judgments underlying estimated reimbursement change or were incorrect at the time we accrued such revenue, our financial results could be negatively impacted in future quarters. As a result, comparing our operating results on a period-to-period basis may not be meaningful. You should not rely on our past results as an indication of our future performance. In addition, these fluctuations in revenue may make it difficult for us, for research analysts and for investors to accurately forecast our revenue and operating results. If our revenue or operating results fall below expectations, the price of our common stock would likely decline.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the need to scale our testing capacity, future growth, including our transition to a multi-product company with international operations, will impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees with the necessary skills to support the growing complexities of our business. Rapid and significant growth may place strain on our administrative, financial and operational infrastructure. Our ability to manage our business and growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We have implemented an internally-developed data warehouse, which is critical to our ability to track our diagnostic services and patient reports delivered to physicians, as well as to support our financial reporting systems. The time and resources required to optimize these systems is uncertain, and failure to complete optimization in a timely and efficient manner could adversely affect our operations. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to support demand for our commercial tests, our business could suffer.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As demand for our tests grows, we will need to continue to scale our testing capacity and processing technology, expand customer service, billing and systems processes and enhance our internal quality assurance program. We will also need additional certified laboratory scientists and other scientific and technical personnel to process higher volumes of our tests. We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available. Failure to implement necessary procedures, transition to new processes or hire the necessary personnel could result in higher costs of processing tests, quality control issues or inability to meet demand. There can be no assurance that we will be able to perform our testing on a timely basis at a level consistent with demand, or that our efforts to scale our operations will not negatively affect the quality of test results. If we encounter difficulty meeting market demand or quality standards, our reputation could be harmed and our future prospects and our business could suffer.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in healthcare policy, including legislation reforming the U.S. healthcare system, may have a material adverse effect on our financial condition and operations.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The ACA, enacted in March 2010, made changes that significantly affected the pharmaceutical and medical device industries and clinical laboratories. Along with the now-repealed 2.3% excise tax on the sale of certain medical devices sold outside of the retail setting, other significant measures contained in the ACA include, for example, coordination and promotion of research on comparative clinical effectiveness of different technologies and procedures, initiatives to revise Medicare payment methodologies, such as bundling of payments across the continuum of care by providers and physicians, and initiatives to promote quality indicators in payment methodologies. The ACA also includes significant new fraud and abuse measures, including required disclosures of financial arrangements with physician customers, lower thresholds for violations and increasing potential penalties for such violations. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the beginning of 2017, the U.S. Congress and the Administration took actions to repeal the ACA and indicated an intent to replace it with another act and efforts to repeal or amend the ACA are ongoing. We cannot predict if, or when, the ACA will be repealed or amended, and cannot predict the impact that an amendment or repeal of the ACA will have on our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the ACA, various healthcare reform proposals have also periodically emerged from federal and state governments. For example, in February 2012, Congress passed the Middle Class Tax Relief and Job Creation Act of 2012, which in part reset the clinical laboratory payment rates on the Medicare Clinical Laboratory Fee Schedule, or CLFS, by 2% in 2013. In addition, under the Budget Control Act of 2011, which is effective for dates of service on or after April 1, 2013, Medicare payments, including payments to clinical laboratories, are subject to a reduction of 2% due to the automatic expense reductions (sequester) until fiscal year 2024. Reductions resulting from the Congressional sequester are applied to total claims payment made; however, they do not currently result in a rebasing of the negotiated or established Medicare or Medicaid reimbursement rates.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">State legislation on reimbursement applies to Medicaid reimbursement and managed Medicaid reimbursement rates within that state. Some states have passed or proposed legislation that would revise the reimbursement methodology for clinical laboratory payment rates under those Medicaid programs.  For example, effective July 2015, California&#8217;s Department of Health Care Services implemented a new rate methodology for clinical laboratories and laboratory services. This methodology involves the use of a range of rates that fell between zero and 80% of the calculated California-specific Medicare rate and the calculation of a weighted average (based on units billed) of such rates. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot predict whether future healthcare initiatives will be implemented at the federal or state level or in countries outside of the United States in which we may do business, or the effect any future legislation or regulation will have on us. The taxes imposed by the new federal legislation, cost reduction measures and the expansion in the role of the U.S. government in the healthcare industry may result in decreased revenue, lower reimbursement by payers for our tests or reduced medical procedure volumes, all of which may adversely affect our business, financial condition and results of operations. In addition, sales of our tests outside the United States subject our business to foreign regulatory requirements and cost-reduction measures, which may also change over time.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ongoing calls for deficit reduction at the federal government level and reforms to programs such as the Medicare program to pay for such reductions may affect the pharmaceutical, medical device and clinical laboratory industries. Currently, clinical laboratory services are excluded from the Medicare Part B co-insurance and co-payment as preventative services. Any requirement for clinical laboratories to collect co-payments from patients may increase our costs and reduce the amount ultimately collected.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CMS bundles payments for clinical laboratory diagnostic tests together with other services performed during hospital outpatient visits under the Hospital Outpatient Prospective Payment System. CMS currently maintains an exemption for molecular pathology tests from this bundling provision. It is possible that this exemption could be removed by CMS in future rule making, which might result in lower reimbursement for tests performed in this setting.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">PAMA includes a substantial new payment system for clinical laboratory tests under the CLFS. Under PAMA, laboratories that receive the majority of their Medicare revenues from payments made under the CLFS and the Physician Fee Schedule would report on triennial bases (or annually for advanced diagnostic laboratory tests, or ADLTs), private payer rates and volumes for their tests with specific CPT codes based on final payments made during a set data collection period (the first of which was January 1 through June 30, 2016).  We believe that PAMA and its implementing regulations are generally favorable to us.&#160;We reported to CMS the data required under PAMA before the March 31, 2017 deadline. The new payment rate for the Afirma genomic classifier based on the volume-weighted median of private payer rates took effect January 1, 2018, increasing from $3,220 to $3,600 through December 31, 2020.  In December 2019, through the Further Consolidated Appropriations Act of 2020, Congress delayed the next data reporting period from 2020 to 2021 for final payments made between January 1 and June 30, 2019, extending the applicability of the current rate for Afirma through December 31, 2021. The volume-weighted median of the private payer rates between January 1 and June 30, 2019 will now set the Medicare payment rate for the Afirma classifier from January 1, 2022 through December 31, 2024.  There can be no assurance that the payment rate for Afirma or Prosigna will not decrease in the future or that the payment rates for Percepta or Envisia will not be adversely affected by the PAMA law and regulations.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe our Afirma genomic classifier as well as our Percepta and Envisia classifiers would be considered ADLTs under PAMA. The initial payment rate (for a period not to exceed nine months) under PAMA for a new ADLT (an ADLT for which payment has not been made under the CLFS prior to January 1, 2018) will be set at the &#8220;actual list charge&#8221; for the test as reported by the laboratory. Insofar as the actual list charge substantially exceeds private payer rates (by more than 30%), CMS will have the ability to recoup excess payments made during the initial nine-month payment period.&#160; We can determine whether to seek ADLT status for our tests, but there can be no assurance that our tests will be designated ADLTs or that the payment rates for our tests will not be adversely affected by such designation.  &#160;&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have also been recent and substantial changes to the payment structure for physicians, including those passed as part of the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, which was signed into law on April 16, 2015. MACRA created the Merit-Based Incentive Payment System which, beginning in 2019, more closely aligns physician payments with composite performance on performance metrics similar to three existing incentive programs (i.e., the Physician Quality Reporting System, the Value-based modifier program and the Electronic Health Record Meaningful Use program) and incentivizes physicians to enroll in alternative payment methods. At this time, we do not know whether these changes to the physician payment systems will have any impact on orders or payments for our tests.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2016, Congress passed the 21st Century Cures Act, which, among other things, revised the process for LCDs. Additionally, effective June 11, 2017, a MAC is required to, among other things, publish a summary of the evidence that it considered when developing an LCD, including a list of sources, and an explanation of the rationale that supports the MAC&#8217;s determinations. In October 2018, CMS issued additional guidance revising the requirements for the development of LCDs. We cannot predict whether these revisions will delay future LCDs and result in impeded coverage for our test products, which could have a material negative impact on revenue.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Congress is considering legislation to limit balance billing of patients who receive services from out-of-network providers (including laboratories) at in-network facilities and to set a methodology for payment of the out-of-network provider in such circumstances. This legislation, if enacted, could limit our ability to achieve payment in full for our testing services.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Because of Medicare billing rules, we may not receive reimbursement for all tests provided to Medicare patients. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under previous Medicare billing rules, hospitals were required to bill for our tests when performed on Medicare beneficiaries who were hospital outpatients at the time of tissue specimen collection when these tests were ordered less than 14 days following the date of the patient's discharge. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective January 1, 2018, CMS revised its billing rules to allow the performing laboratory to bill Medicare directly for molecular pathology tests performed on specimens collected from hospital outpatients, even when those tests are ordered less than 14 days after the date of discharge, if certain conditions are met. We believe that our Afirma, Percepta, and Envisia classifiers, along with Prosigna, should be covered by this policy.  Accordingly, we bill Medicare for these tests when we perform them on specimens collected from hospital outpatients and meet the conditions set forth in CMS's revised billing rules.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This change does not apply to tests performed on specimens collected from hospital inpatients. We will continue to bill hospitals for tests performed on specimens collected from hospital inpatients when the test was ordered less than 14 days after the date of discharge.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the CY 2020 Hospital Outpatient Prospective Payment System Proposed Rule, CMS solicited comments on potential revisions to these billing rules that could have impacted our ability to bill Medicare directly for our Afirma, Percepta, and Envisia classifiers, as well as for Prosigna, when performed on specimens collected from hospital outpatients.  Although these changes were not finalized, if CMS makes similar changes in the future, it could negatively impact our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we must maintain CLIA compliance and certification to sell our tests and be eligible to bill for diagnostic services provided to Medicare beneficiaries. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If the FDA were to begin regulating those of our tests that are not currently regulated, we could incur substantial costs and delays associated with trying to obtain premarket clearance or approval.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Clinical laboratory tests have long been subject to comprehensive regulations under CLIA, as well as by applicable state laws. Most laboratory developed tests, or LDTs, are not currently subject to regulation under the FDA's enforcement discretion policy, although reagents, instruments, software or components provided by third parties and used to perform LDTs may be subject to regulation.  While the FDA maintains its authority to regulate LDTs, it has chosen to exercise its enforcement discretion not to enforce the premarket review and other applicable medical device requirements for LDTs. We believe that the Afirma, Percepta and Envisia classifiers are LDTs that fall under the FDA's enforcement discretion policy.  In October 2014, the FDA issued draft guidance, entitled "Framework for Regulatory Oversight of LDTs," proposing a risk-based framework of oversight and a phased-in enforcement of premarket review requirements for most LDTs. In 2016, the FDA announced that it would not be finalizing the guidance. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FDA issued a "Discussion Paper on Laboratory Developed Tests" following input it received from multiple stakeholders who had commented on its 2014 draft guidance. The FDA specifically states in its Discussion Paper that the proposals contained in the document do not represent a final version of the LDT draft guidance documents and are only designed to provide a possible approach to spark further dialogue. The suggested LDT framework could grandfather many types of LDTs without requiring new premarket review or quality management requirements. It also suggests a four-year phased implementation of the premarket review requirements for some types of tests.  In a December 2018 statement, the FDA said that there is a need for &#8220;a unified approach to the regulation of in vitro clinical tests to protect patient safety, support innovation, and keep pace with the rapidly evolving technology that&#8217;s helping us find new treatments for disease.&#8221; The FDA listed key principles of an approach it would support.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2017, a draft bill on the regulation of LDTs, entitled "The Diagnostics Accuracy and Innovation Act", or DAIA, was released for discussion.  In December 2018, the sponsors of DAIA released a new version of the legislation called the &#8220;Verifying Accurate, Leading-edge IVCT Development Act, or VALID Act.  The VALID Act proposes a risk-based approach to regulate LDTs and creates a new in vitro clinical test category, which includes LDTs, and a regulatory structure under the FDA. As proposed, the bill would create a precertification program for lower risk tests not otherwise required to go through premarket review. It would grandfather existing tests but would allow the FDA to subject otherwise grandfathered tests to premarket review under certain conditions.  We cannot predict whether this draft bill will become legislation and cannot quantify the effect of this draft bill on our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If the FDA were to require us to seek clearance or approval for our existing tests or any of our future products for clinical use, we may not be able to obtain such approvals on a timely basis, or at all. While we believe our Afirma, Percepta and Envisia classifiers would likely qualify for the &#8220;grandfathered&#8221; tests treatment, there can be no assurance of what the FDA might ultimately require if it issued final guidance. If premarket reviews were required, our business could be negatively impacted if we were required to stop selling our products pending their clearance or approval.  In addition, the launch of any new products that we develop could be delayed by the implementation of future FDA guidance. The cost of complying with premarket review requirements, including obtaining clinical data, could be significant. In addition, future regulation by the FDA could subject our business to further regulatory risks and costs. Failure to comply with applicable regulatory requirements of the FDA could result in enforcement action, including receiving untitled or warning letters, fines, injunctions, or civil or criminal penalties. Any such enforcement action would have a material adverse effect on our business, financial condition and operations. In addition, our sample collection containers are listed as Class I devices with the FDA. If the FDA were to determine that they are not Class I devices, we would be required to file 510(k) applications and obtain FDA clearance to use the containers, which could be time consuming and expensive.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some of the materials we use for our tests and that we may use for future tests are labeled for research-use only, or RUO, or investigational-use only, or IUO. In November 2013, the FDA finalized guidance regarding the sale and use of products labeled RUO or IUO. Among other things, the guidance advises that the FDA continues to be concerned about distribution of research or investigational-use only products intended for clinical diagnostic use and that the manufacturer&#8217;s objective intent for the product&#8217;s intended use will be determined by examining the totality of circumstances, including advertising, instructions for clinical interpretation, presentations that describe clinical use, and specialized technical support, surrounding the distribution of the product in question. The FDA has advised that if evidence demonstrates that a product is inappropriately labeled for research or investigational-use only, the device would be considered misbranded and adulterated within the meaning of the Federal Food, Drug and Cosmetic Act. Some of the reagents, instruments, software or components obtained by us from suppliers for use in our products are currently labeled as RUO or IUO. If the FDA were to determine that any of these reagents, instruments, software or components are improperly labeled RUO or IUO and undertake enforcement actions, some of our suppliers might cease selling these reagents, instruments, software or components to us, and any failure to obtain an acceptable substitute could significantly and adversely affect our business, financial condition and results of operations, including increasing the cost of testing or delaying, limiting or prohibiting the purchase of reagents, instruments, software or components necessary to perform testing.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Obtaining marketing authorization by the FDA and foreign regulatory authorities for our diagnostic tests will take significant time and require significant research, development and clinical study expenditures and ultimately may not succeed.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Before we begin to label and market some of our products for use as clinical diagnostics in the United States, unless an exemption applies, we are required to obtain clearance from FDA by submitting a premarket notification under section 510(k) of the FDC Act, or 510(k), or approval from FDA by submitting a PMA. We may also be able to obtain marketing authorization through a de novo classification process rather than through a PMA if the 510(k) pathway is not available.  In September 2013, Prosigna obtained FDA 510(k) clearance as a prognostic indicator for distant recurrence-free survival at ten years in post-menopausal women with Stage I/II lymph node-negative or Stage II lymph node-positive (1-3 positive nodes), hormone receptor-positive breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors after they have undergone surgery in conjunction with locoregional treatment and consistent with the standard of care.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2014, the FDA issued a final guidance document titled In Vitro Companion Diagnostic Devices. In the guidance, FDA defined an IVD companion diagnostic device as an in vitro diagnostic device that provides information that is essential for the safe and effective use of a corresponding therapeutic product. The use of an IVD companion diagnostic device with a therapeutic product is stipulated in the instructions for use in the labeling of both the diagnostic device and the corresponding therapeutic product, including the labeling of any generic equivalents of the therapeutic product.  FDA stated that an IVD companion diagnostic should be submitted for review and approved or cleared through an appropriate device submission contemporaneously with the review and approval of the therapeutic product to facilitate concurrent review.   The FDA guidance also stated that while there may be cases when a companion diagnostic could come to market through the 510(k) pathway, FDA expects that most companion diagnostics will be Class III devices.  Class III devices generally require the approval of a PMA before they can be marketed. An IVD diagnostic device that is not a companion diagnostic device because it is not essential for the safe and effective use of a corresponding therapeutic product, may still be beneficial for use with a therapeutic product but may not be identified in the labeling of the therapeutic product.  It is possible that revenue from a cleared or approved beneficial or complementary IVD diagnostic device may be less than revenue from a cleared or approved IVD companion diagnostic device.   There is no assurance that we would be able to obtain clearance or approval for any of our diagnostic devices in development as a companion diagnostic device.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any marketing authorization we obtain for any future device product would be subject to regulatory requirements that would affect how we are able to market and sell the device. The FDC Act and FDA regulations place considerable requirements on our products, including, but not limited to, compliance with the QSR, establishment registration and product listing with the FDA, and compliance with labeling, marketing, complaint handling, medical device reporting requirements, and reporting certain corrections and removals. Obtaining FDA clearance or approval for diagnostics can be expensive and uncertain, generally may take several months to several years, and generally requires detailed and comprehensive scientific and clinical data, as well as compliance with FDA regulations for investigational devices. In addition, we have limited experience in obtaining PMA approval from the FDA and are therefore supplementing our operational capabilities to manage the more complex processes needed to obtain and maintain PMAs. Notwithstanding the expense, these efforts may never result in FDA clearance or approval. Even if we were to obtain marketing authorization, it may not be for the uses we believe are important or commercially attractive, in which case we would not market our product for those uses.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales of our diagnostic products outside the United States are subject to foreign regulatory requirements governing clinical studies, vigilance reporting, marketing approval, manufacturing, regulatory inspections, product licensing, pricing and reimbursement. These regulatory requirements vary greatly from country to country. As a result, the time required to obtain approvals outside the United States may differ from that required to obtain FDA marketing authorization, and we may not be able to obtain foreign regulatory approvals on a timely basis or at all. Marketing authorization from the FDA does not ensure approval by regulatory authorities in other countries, and approval by any foreign regulatory authority does not ensure marketing authorization by regulatory authorities in other countries or by the FDA. Foreign regulatory authorities could require additional testing beyond what the FDA requires. In addition, the FDC Act imposes requirements on the export of medical devices, such as labeling requirements, and foreign governments impose requirements on the import of medical devices from the United States. Failure to comply with these regulatory requirements or to obtain required approvals, clearances, and export certifications could impair our ability to commercialize our diagnostic products outside of the United States.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to obtain marketing authorizations to market Prosigna in additional countries or if regulatory limitations are placed on our diagnostic kit products, our business and growth will be harmed.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">FDA cleared the Prosigna test for marketing in the United States; Prosigna also has a CE mark which permits us to market the test in the European Union; and Prosigna received marketing authorizations in selected other jurisdictions. We intend to seek regulatory authorizations for Prosigna in other jurisdictions and, potentially, for other indications.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, pursuant to our collaborations with pharmaceutical companies for the development of companion diagnostic tests for use with their drugs, we are responsible for obtaining regulatory authorizations to use the companion diagnostic tests in clinical trials as well as the marketing authorizations to sell the companion diagnostic tests following completion of such trials. Some of the compensation we expect to receive pursuant to these collaborations is based on the receipt of marketing authorizations. Any failure to obtain marketing authorizations for our diagnostic kits in a particular jurisdiction may also reduce sales of our nCounter systems for clinical use in that jurisdiction, as the lack of a robust menu of available diagnostic tests would make those systems less attractive to testing laboratories.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot assure investors that we will be successful in obtaining regulatory clearances, approvals, or marketing authorizations. If we do not obtain regulatory clearances, approvals, or marketing authorizations for future kit products or expand future indications for diagnostic purposes, if additional regulatory limitations are placed on our kit products or if we fail to successfully commercialize such products, the market potential for our diagnostic kit products would be constrained, and our business and growth prospects would be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are subject to ongoing and extensive regulatory requirements, and our failure to comply with these requirements could substantially harm our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain of our products are regulated as in vitro diagnostic medical devices, including Prosigna and the nCounter FLEX  Analysis System. Accordingly, we and certain of our contract manufacturers are subject to ongoing International Organization for Standardization, or ISO, obligations as well as requirements under the FDC Act and device regulations enforced by the FDA and other statutory and regulatory requirements enforced by other government authorities. These may include routine inspections by Notified Bodies, FDA, and other health authorities, of our manufacturing facilities and our records for compliance with standards  such as ISO 13485 and QSR regulations, which establish extensive requirements for quality assurance and control as well as manufacturing and change control procedures, among other things. We are also subject to other regulatory obligations, such as  registration of our company offices and facilities and the listing of our devices with the FDA; continued adverse event and malfunction reporting; reporting certain corrections and removals; and labeling and promotional requirements. Other regulatory bodies may also issue guidelines and regulations that could impact the development of our products, including companion diagnostic tests. For example, the European Medicines Agency, a European Union agency which is responsible for the scientific evaluation of medicines used in the European Union, recently launched an initiative to determine guidelines for the use of genomic biomarkers in the development and life-cycle of drugs. On April 5, 2017, the European Union Parliament passed Regulation (EU) 2017/746, referred to as the IVD Device Regulation, or IVDR, which increases the regulatory requirements applicable to in vitro diagnostics in the EU and would require that we re-classify and obtain approval, registration, or clearance for our existing CE-marked IVD products within a five-year grace period (by May 25, 2022).</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We  may also be subject to additional FDA or global regulatory authority post-marketing obligations or requirements by the FDA or global regulatory authority to change our current product classifications which would impose additional regulatory obligations on us. The promotional claims we can make for Prosigna are limited to the indications for use in the United States as cleared by FDA or outside the United States as authorized by the applicable regulatory authority. If we are not able to maintain regulatory compliance, we may not be permitted to market our medical device products and/or may be subject </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to enforcement actions by the FDA or other governmental authorities such as the issuance of warning or untitled letters, fines, injunctions, and civil penalties; recall or seizure of products; operating restrictions; and criminal prosecution. In addition, we may be subject to similar regulatory regimes of foreign jurisdictions as we continue to commercialize our products in new markets outside of the United States and Europe.  Adverse Notified Body, EU Competent Authority or FDA or global regulatory authority action in any of these areas could significantly increase our expenses and limit our revenue and profitability.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our principal competition for our tests comes from traditional methods used by physicians to diagnose and manage patient care decisions. For example, with our Afirma genomic classifier, practice guidelines in the United States have historically recommended that patients with indeterminate diagnoses from cytopathology results be considered for surgery to remove all or part of the thyroid to rule out cancer. This practice has been the standard of care in the United States for many years, and we need to continue to educate physicians about the benefits of the Afirma genomic classifier to change clinical practice.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also face competition from companies and academic institutions that use next generation sequencing technology or other methods to measure mutational markers such as BRAF and KRAS, along with numerous other mutations. These organizations include Interpace Diagnostics Group, Inc., CBLPath, Inc./University of Pittsburgh Medical Center and others who are developing new products or technologies that may compete with our tests. In the future, we may also face competition from companies developing new products or technologies.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We believe our primary competition in pulmonology with our Percepta and Envisia classifiers will similarly come from traditional methods used by physicians to diagnose the related diseases. For the Percepta test, we expect competition from companies focused on lung cancer such as Oncocyte Corporation and Biodesix, Inc.  We believe our principal competitor in the breast cancer diagnostics market is Exact Sciences, Inc. (having combined with Genomic Health, Inc.), which currently commands a substantial majority of the market. As we expand our portfolio of tests to address clinical questions across the clinical care continuum, we may also face competition from companies focused on screening at-risk patients for cancer or companies informing treatment decisions such as Guardant Health or GRAIL.  Competition could also emerge using alternative samples, such as blood, urine or sputum.  However, such &#8220;liquid biopsies&#8221; are currently being used to gauge risk of recurrence or response to treatment in patients already diagnosed with lung cancer.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In general, we also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings and Sonic Healthcare USA, with strong infrastructure to support the commercialization of diagnostic services. We face potential competition from companies such as Illumina,&#160;Inc. and Thermo Fisher Scientific&#160;Inc., both of which have entered the clinical diagnostics market. Other potential competitors include companies that develop diagnostic products, such as Roche Diagnostics, a division of Roche Holding&#160;Ltd, Siemens AG and Qiagen&#160;N.V.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, competitors may develop their own versions of our solutions in countries we may seek to enter where we do not have patents or where our intellectual property rights are not recognized and compete with us in those countries, including encouraging the use of their solutions by physicians in other countries.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To compete successfully, we must be able to demonstrate, among other things, that our diagnostic test results are accurate and cost effective, and we must secure a meaningful level of reimbursement for our products.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development resources, and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by physicians and payers as functionally equivalent to our solutions, or offer solutions at prices designed to promote market penetration, which could force us to lower the list price of our solutions and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market price of our common stock to decline. As we add new tests and services, we will face many of these same competitive risks for these new tests.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The loss of members of our senior management team or our inability to attract and retain key personnel could adversely affect our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success depends largely on the skills, experience and performance of key members of our executive management team and others in key management positions. The efforts of each of these persons together will be critical to us as we continue </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to develop our technologies and test processes and focus on our growth. If we were to lose one or more of these key employees, including due to illness resulting from COVID-19, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our research and development programs and commercial laboratory operations depend on our ability to attract and retain highly skilled scientists. We may not be able to attract or retain qualified scientists and technicians in the future due to the intense competition for qualified personnel among life science businesses, particularly in the San Francisco Bay Area. Our success in the development and commercialization of advanced diagnostics requires a significant medical and clinical staff to conduct studies and educate physicians and payers on the merits of our tests in order to achieve adoption and reimbursement. We are in a highly competitive industry to attract and retain this talent. Additionally, our success depends on our ability to attract and retain qualified sales people. We recently significantly expanded our sales force as we invest in our multi-product sales strategy, which includes assignment of a single contact to successfully develop and implement relationships with our customers. There can be no assurance that we will be successful in maintaining and growing our business. Additionally, as we increase our sales channels for new tests we commercialize, including the Percepta and Envisia tests, or acquire, such as Prosigna, we may have difficulties recruiting and training additional sales personnel or retaining qualified salespeople, which could cause a delay or decline in the rate of adoption of our tests. As a public company located in the San Francisco Bay Area, we also face intense competition for highly skilled finance and accounting personnel. If we are unable to attract and retain finance and accounting personnel experienced in public company financial reporting, we risk being unable to close our books and file our public documents on a timely basis.  Finally, our business requires specialized capabilities in reimbursement, billing, and other areas and there may be a shortage of qualified individuals. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that could adversely affect our ability to support our research and development, clinical laboratory, sales and reimbursement, billing and finance efforts. All of our employees are at will, which means that either we or the employee may terminate their employment at any time. We do not carry key man insurance for any of our employees.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Billing for our diagnostic tests is complex, and we must dedicate substantial time and resources to the billing process to be paid.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Billing for clinical laboratory testing services is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payers, including Medicare, insurance companies and patients, all of which have different billing requirements. We generally bill third-party payers for our diagnostic tests and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. To the extent laws or contracts require us to bill patient co-payments or co-insurance, we must also comply with these requirements. We may also face increased risk in our collection efforts, including potential write-offs of accounts receivable and long collection cycles, which could adversely affect our business, results of operations and financial condition.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Several factors make the billing process complex, including:</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">differences between the list price for our tests and the reimbursement rates of payers;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;padding-left:14.5pt;">&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">compliance with complex federal and state regulations related to billing government payers, such as Medicare and Medicaid, including requirements to have an active CLIA certificate;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">risk of government audits related to billing Medicare and other government payers;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">disputes among payers as to which party is responsible for payment;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">differences in coverage and in information and billing requirements among payers, including the need for prior authorization and/or advanced notification;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the effect of patient co-payments or co-insurance;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes to billing codes used for our tests;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">incorrect or missing billing information; and</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the resources required to manage the billing and claims appeals process.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We use standard industry billing codes, known as CPT codes, to bill for cytopathology.  In addition, we use the CPT code 81545 to bill for our Afirma classifier.  CPT codes do not exist for our other proprietary molecular diagnostic tests. Therefore, until such time that we are assigned and are able to use a designated CPT code specific to Percepta and Envisia, we use &#8220;unlisted&#8221; codes for claim submissions, which can lead to delays in payers adjudicating our claims or denying payment altogether. Moreover, these codes can change over time. When codes change, there is a risk of an error being made in the claim adjudication process. These errors can occur with claims submission, third-party transmission or in the processing of the claim by the payer. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment received. Coding changes, therefore, may have an adverse effect on our revenues. Even when we receive a designated CPT code specific to our tests, such as the 81545 code for the Afirma GEC that became effective January 1, 2016, there can be no assurance that payers will recognize these codes in a timely manner or that the process of transitioning to such a code and updating their billing systems and ours will not result in errors, delays in payments and a related increase in accounts receivable balances.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As we introduce new tests, we will need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Correct coding is subject to the coding policies of the American Medical Association CPT Editorial Panel, or AMA CPT. With respect to claims submitted to Medicare and Medicaid, it is also subject to coding policies developed through the National Correct Coding Initiative, or NCCI. Other payers may develop their own payer-specific coding policies.  The broader coding policies of the AMA CPT, NCCI, and other payers are subject to change.  For instance, the NCCI recently adopted an update to its Coding Policy Manual effective January 1, 2019, to limit instances when multiple codes may be billed for molecular pathology testing.  Although the NCCI appears to have moderated this change in its updates effective January 1, 2020, such coding policy changes may negatively affect our revenues and cash flow.   </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, challenge coverage and payment denials, assist patients in appealing claims, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. Payers also conduct external audits to evaluate payments, which add further complexity to the billing process. If the payer makes an overpayment determination, there is a risk that we may be required to return some portion of prior payments we have received.  Additionally, the ACA established a requirement for providers and suppliers to report and return any overpayments received from government payers under the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or supplier to liability under federal false claims laws.  These billing complexities, and the related uncertainty in obtaining payment for our tests, could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely on a third-party provider to transmit claims to payers, and any delay in transmitting claims could have an adverse effect on our revenue.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we manage the overall processing of claims, we rely on a third-party provider to transmit the actual claims to payers based on the specific payer billing format. We have previously experienced delays in claims processing when our third-party provider made changes to its invoicing system, and again when it did not submit claims to payers within the timeframe we require. Additionally, coding for diagnostic tests may change, and such changes may cause short-term billing errors that may take significant time to resolve. If claims are not submitted to payers on a timely basis or are erroneously submitted, or if we are required to switch to a different provider to handle claim submissions, we may experience delays in our ability to process these claims and receipt of payments from payers, or possibly denial of claims for lack of timely submission, which would have an adverse effect on our revenue and our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our internal sales force is less successful than anticipated, our business expansion plans could suffer and our ability to generate revenues could be diminished. In addition, we have limited history selling our molecular diagnostics tests on a direct basis and our limited history makes forecasting difficult.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We acquired several international sales employees from NanoString, and expect to build upon this team as we offer additional tests internationally in the future.  If our internal sales force is not successful, however, or new additions to our sales team fail to gain traction among our customers, we may not be able to increase market awareness and sales of our molecular diagnostic tests. If we fail to establish our molecular diagnostic tests in the marketplace, it could have a negative effect on our ability to sell subsequent molecular diagnostic tests and hinder the desired expansion of our business. We have growing, however limited, historical experience forecasting the direct sales of our molecular diagnostics products. Our ability to produce test volumes that meet customer demand is dependent upon our ability to forecast accurately and plan production capacities accordingly.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Developing new products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other products we are developing.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We continually seek to develop enhancements to our current test offerings and additional diagnostic solutions that requires us to devote considerable resources to research and development. There can be no assurance that we will be able to identify other diseases that can be effectively addressed with our molecular cytology platform. In addition, if we identify such diseases, we may not be able to develop products with the diagnostic accuracy necessary to be clinically useful and commercially successful. We may face challenges obtaining sufficient numbers of samples to validate a genomic signature for a molecular diagnostic product. After launching new products, we still must complete studies that meet the clinical evidence required to obtain reimbursement.  Moreover, we may experience delays in the development and introduction of new products due to the effects of the current COVID-19 outbreak.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to develop and commercialize diagnostic tests, we need to:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">expend significant funds to conduct substantial research and development;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">conduct successful analytical and clinical studies;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">scale our laboratory processes to accommodate new tests; and</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">build the commercial infrastructure to market and sell new products.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product development process involves a high degree of risk and may take several years. Our product development efforts may fail for many reasons, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure to identify a genomic signature in biomarker discovery;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">inability to secure sufficient numbers of samples at an acceptable cost and on an acceptable timeframe to conduct analytical and clinical studies; or</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure of clinical validation studies to support the effectiveness of the test.</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Typically, few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a product candidate or we may be required to expend considerable resources repeating clinical studies, which would adversely affect the timing for generating potential revenue from a new product and our ability to invest in other products in our pipeline. If a clinical validation study fails to demonstrate the prospectively-defined endpoints of the study or if we fail to sufficiently demonstrate analytical validity, we might choose to abandon the development of the product, which could harm our business. In addition, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we cannot enter into new clinical study collaborations, our product development and subsequent commercialization could be delayed.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the past, we have entered into clinical study collaborations, and our success in the future depends in part on our ability to enter into additional collaborations with highly regarded institutions. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may limit the number of collaborations they have with any one company so as to not be perceived as biased or conflicted. Organizations may also have insufficient administrative and related infrastructure to enable collaboration with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Moreover, it may take longer to obtain the samples we need which could delay our trials, publications, and product launches and reimbursement. Additionally, organizations often insist on retaining the rights to publish </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the clinical data resulting from the collaboration. The publication of clinical data in peer-reviewed journals is a crucial step in commercializing and obtaining reimbursement for our diagnostic tests, and our inability to control when and if results are published may delay or limit our ability to derive sufficient revenue from them.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to develop products to keep pace with rapid technological, medical and scientific change, our operating results and competitive position could be harmed.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In recent years, there have been numerous advances in technologies relating to diagnostics, particularly diagnostics that are based on genomic information. These advances require us to continuously develop our technology and to work to develop new solutions to keep pace with evolving standards of care. Our solutions could become obsolete unless we continually innovate and expand our product offerings to include new clinical applications. If we are unable to develop new products or to demonstrate the applicability of our products for other diseases, our sales could decline and our competitive position could be harmed.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our Loan and Security Agreement provides our lenders with a first-priority lien against substantially all of our assets, excluding our intellectual property, and contains financial covenants and other restrictions on our actions, which could limit our operational flexibility and otherwise adversely affect our financial condition.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Loan and Security Agreement restricts our ability to, among other things,&#160;incur liens, make investments, incur indebtedness, merge with or acquire other entities, dispose of assets, make dividends or other distributions to holders of its equity interests, engage in any new line of business, or enter into certain transactions with affiliates, in each case subject to certain exceptions.  It also requires us to achieve certain revenue levels tested quarterly on a trailing twelve-month basis. However, failure to maintain the revenue levels will not be considered a default if the sum of our unrestricted cash and cash equivalents maintained with Silicon Valley Bank and amount available under the revolving line of credit is at least $40.0 million. Our ability to comply with these and other covenants is dependent upon a number of factors, some of which are beyond our control.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our failure to comply with the financial covenants, or the occurrence of other events specified in our Loan and Security Agreement, could result in an event of default under the Loan and Security Agreement, which would give our lenders the right to terminate their commitments to provide additional loans under the Loan and Security Agreement and to declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be immediately due and payable. In addition, we have granted our lenders a first-priority lien against all of our assets, excluding our intellectual property, as collateral. Failure to comply with the covenants or other restrictions in the Loan and Security Agreement could result in a default. If the debt under our Loan and Security Agreement was to be accelerated, we may not have sufficient cash on hand or be able to sell sufficient collateral to repay it, which would have an immediate adverse effect on our business and operating results. This could potentially cause us to cease operations and result in a complete loss of your investment in our common stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Complying with numerous statutes and regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operations are subject to other extensive federal, state, local, and foreign laws and regulations, all of which are subject to change. These laws and regulations currently include, among others:</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which established comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions, and amendments made in 2013 to HIPAA under the Health Information Technology for Economic and Clinical Health Act, or HITECH, which strengthen and expand HIPAA privacy and security compliance requirements, increase penalties for violators, extend enforcement authority to state attorneys general, and impose requirements for breach notification;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Medicare billing and payment regulations applicable to clinical laboratories, including requirements to have an active CLIA certificate;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the Federal Anti-kickback Statute (and state equivalents), which prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal healthcare program;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the Eliminating Kickbacks in Recovery Act of 2018, which prohibits the solicitation, receipt, payment or offering of any remuneration in return for referring a patient or patronage to a recovery home, clinical treatment facility, or laboratory for services covered by both government and private payers;</span></div><div style="padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the Federal Stark physician self-referral law (and state equivalents), which prohibits a physician from making a referral for certain designated health services covered by the Medicare program, including laboratory and pathology services, if the physician or an immediate family member has a financial relationship with the entity providing the designated health services, unless the financial relationship falls within an applicable exception to the prohibition;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the Federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;</span></div><div style="padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the Federal False Claims Act, which imposes liability on any person or entity who knowingly presents, or causes to be presented, a false, fictitious, or fraudulent claim for payment to the federal government;</span></div><div style="padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, fee-splitting restrictions, prohibitions on the provision of products at no or discounted cost to induce physician or patient adoption, and false claims acts, which may extend to services reimbursable by any third-party payer, including private insurers;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the prohibition on reassignment of Medicare claims, which, subject to certain exceptions, precludes the reassignment of Medicare claims to any other party;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the Protecting Access to Medicare Act of 2014, which requires us to report private payer rates and test volumes for specific CPT codes on a triennial basis and imposes penalties for failures to report, omissions, or misrepresentations;</span></div><div style="padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the rules&#160;regarding billing for diagnostic tests reimbursable by the Medicare program, which prohibit a physician or other supplier from marking up the price of the technical component or professional component of a diagnostic test ordered by the physician or other supplier and supervised or performed by a physician who does not &#8220;share a practice&#8221; with the billing physician or supplier;</span></div><div style="padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">state laws that prohibit other specified practices related to billing such as billing physicians for testing that they order, waiving co-insurance, co-payments, deductibles, and other amounts owed by patients, and billing a state Medicaid program at a price that is higher than what is charged to other payers;</span></div><div style="padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the Foreign Corrupt Practices Act of 1977, and other similar laws, which apply to our international activities;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">unclaimed property (escheat) laws and regulations, which may require us to turn over to governmental authorities the property of others held by us that has been unclaimed for a specified period of time; and</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">enforcing our intellectual property rights.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have adopted policies and procedures designed to comply with applicable laws and regulations. In the ordinary course of our business, we conduct internal reviews of our compliance with these laws. Our compliance with some of these laws and regulations is also subject to governmental review. The growth of our business and sales organization and our expansion outside of the United States may increase the potential of violating these laws or our internal policies and procedures. We believe that we are in material compliance with all statutory and regulatory requirements, but there is a risk that one or more government agencies could take a contrary position. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In recent years U.S. Attorneys&#8217; Offices have increased scrutiny of the healthcare industry, as have Congress, the Department of Justice, the Department of Health and Human Services&#8217; Office of the Inspector General and the Department of Defense. These bodies have all issued subpoenas and other requests for information to conduct investigations of, and commenced civil and criminal litigation against, healthcare companies based on financial arrangements with health care providers, regulatory compliance, product promotional practices and documentation, and coding and billing practices. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Whistleblowers have filed numerous qui tam lawsuits against healthcare companies under the federal and state False Claims Acts in recent years, in part because the whistleblower can receive a portion of the government&#8217;s recovery under such suits. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These laws and regulations are complex and are subject to interpretation by the courts and by government agencies. If one or more such agencies alleges that we may be in violation of any of these requirements, regardless of the outcome, it could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations and other commercial third-party payers. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of these laws and regulations, we may be subject to any applicable penalty associated with the violation, including civil and criminal penalties, damages and fines, we could be required to refund payments received by us, and we could be required to curtail or cease our operations. Any of the foregoing consequences could seriously harm our business and our financial results.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to federal, state and local laws, rules&#160;and regulations governing the use, discharge, storage, handling and disposal of biological material, chemicals and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, remediation costs and any related penalties or fines, and any liability could exceed our resources or any applicable insurance coverage we may have. The cost of compliance with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, and either could negatively affect our operating results.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-4.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business strategy includes international expansion in select countries, and may include developing and maintaining physician outreach and education capabilities outside of the United States, establishing agreements with laboratories, and expanding our relationships with international payers. Doing business internationally involves a number of risks, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">multiple, conflicting and changing laws and regulations such as tax laws, privacy laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure by us to obtain regulatory approvals where required for the use of our solutions in various countries;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">complexities associated with managing multiple payer reimbursement regimes, government payers or patient self-pay systems;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">logistics and regulations associated with shipping tissue samples, including infrastructure conditions and transportation delays;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">challenges associated with establishing laboratory partners, including proper sample collection techniques, management of supplies, sample logistics, billing and promotional activities;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">limits on our ability to penetrate international markets if we are not able to process tests locally;</span></div><div style="text-indent:36pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">financial risks, such as longer payment cycles, difficulty in collecting from payers, the effect of local and regional financial crises, and exposure to foreign currency exchange rate fluctuations;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">natural disasters, political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, including COVID-19, boycotts, curtailment of trade and other business restrictions; and</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory and compliance risks that relate to maintaining accurate information and control over activities that may fall within the purview of the Foreign Corrupt Practices Act of 1977, including both its books and records provisions and its anti-bribery provisions.</span></div><div style="text-indent:36pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any of these factors could significantly harm our future international expansion and operations and, consequently, our revenue and results of operations.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our reliance on distributors for sales of our products outside of the United States, and on clinical laboratories for delivery of Prosigna testing services, could limit or prevent us from selling our products and impact our revenue.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have established distribution agreements for our nCounter FLEX Analysis System and related consumable products in certain countries where we do not sell directly. We intend to continue to grow our business internationally, and to do so we must attract additional distributors and retain existing distributors to maximize the commercial opportunity for our products. There is no guarantee that we will be successful in attracting or retaining desirable sales and distribution partners or that we will be able to enter into such arrangements on favorable terms. Distributors may not commit the necessary resources to market and sell our products to the level of our expectations or may choose to favor marketing the products of our competitors. If current or future distributors do not perform adequately, or we are unable to enter into effective arrangements with distributors in particular geographic areas, we may not realize long-term international revenue growth.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Similarly, we or our distributors have entered into agreements with clinical laboratories globally to provide Prosigna testing services. We do not provide testing services directly and, thus, we are reliant on these clinical laboratories to actively promote and sell Prosigna testing services. These clinical laboratories may take longer than anticipated to begin offering Prosigna testing services and may not commit the necessary resources to market and sell Prosigna testing services to the level of our expectations. Furthermore, we intend to contract with additional clinical laboratories to offer Prosigna testing services, including physician-owned laboratories, and we may be unsuccessful in attracting and contracting with new clinical laboratory providers. If current or future Prosigna testing service providers do not perform adequately, or we are unable to enter into contracts with additional clinical laboratories to provide Prosigna testing services, we may not be successful selling Prosigna and our future revenue prospects may be adversely affected.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we are sued for product liability or errors and omissions liability, we could face substantial liabilities that exceed our resources.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The marketing, sale and use of our current or future tests could lead to product liability claims if someone were to allege that the tests failed to perform as they were designed. We may also be subject to liability for errors in the results we provide to physicians or for a misunderstanding of, or inappropriate reliance upon, the information we provide. Our Afirma classifiers are performed on FNA samples that are diagnosed as indeterminate by standard cytopathology review. We report results as benign or suspicious to the prescribing physician. Under certain circumstances, we might report a result as benign that later proves to have been malignant. This could be the result of the physician having poor nodule sampling in collecting the FNA, performing the FNA on a different nodule than the one that is malignant or failure of the classifier to perform as intended. We may also be subject to similar types of claims related to our Percepta, Envisia and Prosigna tests, as well as tests we may develop or acquire in the future. A product liability or errors and omissions liability claim could result in substantial damages and be costly and time consuming for us to defend. Although we maintain product liability and errors and omissions insurance, we cannot assure you that our insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any such claims. Any product liability or errors and omissions liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause injury to our reputation or cause us to suspend sales of our products and solutions. The occurrence of any of these events could have an adverse effect on our business and results of operations.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our business is subject to the risk of disruptions caused by pandemics, political events, war, terrorism, earthquakes, fire, power outages, floods, and other catastrophic events.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">War, terrorism, geopolitical uncertainties, trade restrictions, public health issues, natural disasters and other catastrophic events may cause damage or disruption to the economy and commerce on a global, regional or country-specific basis, and could disrupt supply or delivery of, or demand for, our products. For example, the recent COVID-19 outbreak, could have a negative effect on consumer confidence and spending, and other impacts, which could adversely affect our business. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If a catastrophe strikes either of our laboratories or if either of our laboratories becomes inoperable for any other reason, we will be unable to perform our testing services and our business will be harmed.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We perform all of the Afirma, Percepta and Envisia genomic classifier testing at our laboratory in South San Francisco, California, near major earthquake faults known for seismic activity. Our laboratory in Austin, Texas accepts and stores the majority of our Afirma FNA samples pending transfer to our California laboratory for genomic test processing. The laboratories and equipment we use to perform our tests would be costly to replace and could require substantial lead time to replace and qualify for use if they became inoperable. Either of our facilities may be harmed or rendered inoperable by natural </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">or man-made disasters, including earthquakes, flooding and power outages, which may render it difficult or impossible for us to perform our testing services for some period of time or to receive and store samples. The inability to perform our tests for even a short period of time may result in the loss of customers or harm our reputation, and we may be unable to regain those customers in the future. Although we maintain insurance for damage to our property and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, if at all.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize new solutions and technologies and expand our operations.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect continued capital expenditures and operating losses over the next few years as we expand our infrastructure, commercial operations and research and development activities. We may seek to raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements. Additional funding may not be available to us on acceptable terms, or at all. If we raise funds by issuing equity securities, dilution to our stockholders could result. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings could impose significant restrictions on our operations. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. Our Loan and Security Agreement imposes restrictions on our operations, increases our fixed payment obligations, and has restrictive covenants. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third-party on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. The trading prices for our common stock and other biotechnology companies have been highly volatile as a result of the COVID-19 pandemic, which may reduce our ability to access capital on favorable terms or at all. In addition, a recession, depression or other sustained adverse market event resulting from the spread of COVID-19 could materially and adversely affect our business and the value of our common stock.  If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives. In addition, we may have to work with a partner on one or more of our products or development programs, which could lower the economic value of those programs to our company.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Security breaches, loss of data and other disruptions to us or our third-party service providers could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In the ordinary course of our business, we and our third-party service providers collect and store sensitive data, including legally protected health information, personally identifiable information about our patients, credit card information, intellectual property, and our proprietary business and financial information. We manage and maintain our applications and data utilizing a combination of on-site systems, managed data center systems and cloud-based data center systems. We face a number of risks related to our protection of, and our service providers&#8217; protection of, this critical information, including loss of access, inappropriate disclosure and inappropriate access, as well as risks associated with our ability to identify and audit such events.  System failures or outages, including any potential disruptions due to significantly increased global demand on certain cloud based systems during the COVID-19 pandemic, could compromise our ability to perform these functions in a timely manner, which could harm our ability to conduct business or delay our financial reporting. Such failures could materially adversely affect our operating results and financial condition.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or otherwise breached due to employee error, malfeasance or other activities. While we are not aware of any such attack or breach, if such event would occur and cause interruptions in our operations, our networks would be compromised and the information we store on those networks could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under federal, state, and international laws that protect the privacy of personal information, such as HIPAA, and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process tests, provide test results, bill payers or patients, process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our tests and </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">other patient and physician education and outreach efforts through our website, manage the administrative aspects of our business and damage our reputation, any of which could adversely affect our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the interpretation and application of consumer, health-related and data protection laws in the United States, Europe and elsewhere are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business.  In addition, we are subject to various state laws, including the California Consumer Privacy Act, or CCPA, which was enacted in California in 2018 and components of which went into effect on January 1, 2020.&#160; The CCPA, among other things, requires covered companies to provide disclosures to California consumers concerning the collection and sale of personal information, and gives such consumers the right to opt-out of certain sales of personal information. Amendments to the CCPA have been made since its enactment, and it remains unclear what, if any, further amendments will be made to this legislation or how it will be interpreted. We cannot yet predict the impact of the CCPA on our business or operations, but it may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recent developments in Europe have created compliance uncertainty regarding the processing of personal data from Europe.  For example, the General Data Protection Regulation, or GDPR, which became effective in the European Union on May 25, 2018, applies to our activities conducted from an establishment in the EU or related to products and services that we offer to European Union users. The GDPR creates new compliance obligations applicable to our business, which could cause us to change our business practices, and increases financial penalties for noncompliance (including possible fines of up to 4% of global annual turnover for the preceding financial year or &#8364;20 million (whichever is higher) for the most serious infringements). As a result, we may need to modify the way we treat such information. </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we cannot license rights to use technologies on reasonable terms, we may not be able to commercialize new products in the future.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the future, we may license third-party technology to develop or commercialize new products. In return for the use of a third-party&#8217;s technology, we may agree to pay the licensor royalties based on sales of our solutions. Royalties are a component of cost of revenue and affect the margins on our solutions. We may also need to negotiate licenses to patents and patent applications after introducing a commercial product. Our business may suffer if we are unable to enter into the necessary licenses on acceptable terms, or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the license or fail to prevent infringement by third parties, or if the licensed patents or other rights are found to be invalid or unenforceable.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to protect our intellectual property effectively, our business would be harmed.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We apply for and in-license patents covering our products and technologies and uses thereof, as we deem appropriate, however we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. Our issued patents expire between 2029 and 2035 and are related to methods used in thyroid diagnostics, lung diagnostics, breast cancer diagnostics, and the nCounter FLEX analysis platform.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is possible that others will design around our current or future patented technologies. We may not be successful in defending any challenges made against our patents or patent applications. Any successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents and increased competition to our business. The outcome of patent litigation can be uncertain and any attempt by us to enforce our patent rights against others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies&#8217; patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">biotechnology field that may affect the patentability of certain inventions or discoveries, including opinions that may affect the patentability of methods for analyzing or comparing nucleic acids.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In particular, the patent positions of companies engaged in the development and commercialization of genomic diagnostic tests are particularly uncertain. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to certain diagnostic tests and related methods. These decisions state, among other things, that patent claims that recite laws of nature (for example, the relationship between blood levels of certain metabolites and the likelihood that a dosage of a specific drug will be ineffective or cause harm) are not themselves patentable. What constitutes a law of nature is uncertain, and it is possible that certain aspects of genomic diagnostics tests would be considered natural laws. Accordingly, the evolving case law in the United States may adversely affect our ability to obtain patents and may facilitate third-party challenges to any owned and licensed patents.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties protecting and defending such rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Changes in either the patent laws or in interpretations of patent laws in the United States or other countries may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. We may not develop additional proprietary products, methods and technologies that are patentable.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisors. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. If we are required to assert our rights against such party, it could result in significant cost and distraction.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third-party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also be subject to claims that our employees have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights and face increased competition to our business. A loss of key research personnel work product could hamper or prevent our ability to commercialize potential products, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, competitors could attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. Others may independently develop similar or alternative products and technologies or replicate any of our products and technologies. If our intellectual property does not adequately protect us against competitors&#8217; products and methods, our competitive position could be adversely affected, as could our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not registered certain of our trademarks in all of our potential markets. If we apply to register these trademarks, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate coverage of our competitors&#8217; products, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time consuming and expensive.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be involved in litigation related to intellectual property, which could be time-intensive and costly and may adversely affect our business, operating results or financial condition.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may receive notices of claims of direct or indirect infringement or misappropriation or misuse of other parties&#8217; proprietary rights from time to time. Some of these claims may lead to litigation. We cannot assure you that we will prevail in such actions, or that other actions alleging misappropriation or misuse by us of third-party trade secrets, infringement by us of third-party patents and trademarks or other rights, or the validity of our patents, trademarks or other rights, will not be asserted or prosecuted against us.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings, or other post-grant proceedings declared by the U.S. Patent and Trademark Office that could result in substantial cost to us. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, recent changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Litigation may be necessary for us to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. The outcome of any litigation or other proceeding is inherently uncertain and might not be favorable to us, and we might not be able to obtain licenses to technology that we require on acceptable terms or at all. Further, we could encounter delays in product introductions, or interruptions in product sales, as we develop alternative methods or products. In addition, if we resort to legal proceedings to enforce our intellectual property rights or to determine the validity, scope and coverage of the intellectual property or other proprietary rights of others, the proceedings could be burdensome and expensive, even if we were to prevail. Any litigation that may be necessary in the future could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As we move into new markets and applications for our products, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. Our competitors and others may now and, in the future, have significantly larger and more mature patent portfolios than we currently have. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product revenue and against whom our own patents may provide little or no deterrence or protection. Therefore, our commercial success may depend in part on our non-infringement of the patents or proprietary rights of third parties. Numerous significant intellectual property issues have been litigated, and will likely continue to be litigated, between existing and new participants in our existing and targeted markets and competitors may assert that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into or growth in those markets. Third parties may assert that we are employing their proprietary technology without authorization. In addition, our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell or importing our products infringes these patents. We could incur substantial costs and divert the attention of our management and technical personnel in defending against any of these claims. Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products, and could result in the award of substantial damages against us. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties, and obtain one or more licenses from third parties, or be prohibited from selling certain products. We may not be able to obtain these licenses on acceptable terms, if at all. We could incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our financial results. In addition, we could encounter delays in product introductions while we attempt to develop alternative methods or products to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products, and the prohibition of sale of any of our products could materially affect our business and our ability to gain market acceptance for our products.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results, or financial condition.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to use our net operating loss carryforwards may be limited and may result in increased future tax liability to us.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred net losses since our inception and may never achieve profitability.  As of December 31, 2019, we had net operating loss, or NOL, carryforwards of approximately $236.9 million, $58.3 million and $45.2 million available to reduce future taxable income, if any, for federal, California and other state income tax purposes, respectively.  The U.S. federal NOL carryforwards will begin to expire in 2026 while for state purposes, the NOL carryforwards begin to expire in 2028.  These NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Tax Cuts and Jobs Acts, or Tax Act, which was enacted in December 2017, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited.&#160; It is uncertain if and to what extent various states will conform to the newly enacted federal tax law. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. We may be limited in the portion of NOL carryforwards that we can use in the future to offset taxable income for U.S. federal and state income tax purposes, and federal tax credits to offset federal tax liabilities.  Sections 382 and 383 of Internal Revenue Code limit the use of NOLs and tax credits after a cumulative change in corporate ownership of more than 50% occurs within a three-year period.  The limitation could prevent a corporation from using some or all its NOL and tax credits before they expire within their normal 20-year lifespan, as it places a formula limit of how much NOL and tax credits a loss corporation can use in a tax year.  In the event we have undergone an ownership change under Section 382 of the Internal Revenue Code, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax liability to us.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, was signed into law. The CARES Act changes certain provisions of the 2017 Tax Act. Under the CARES Act, NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminates the limitation on the deduction of NOLs to 80% of current year taxable income for taxable years beginning before January 1, 2021, and increases the amount of interest expense that may be deducted to 50% of adjusted taxable income for taxable years beginning in 2019 or 2020. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act, as modified by the CARES Act, is uncertain and our business, financial conditions, results of operations and growth prospects could be materially and adversely affected. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, as modified by the CARES Act. The impact of the Tax Act, as modified by the CARES Act, on holders of our common stock is also uncertain and could be adverse.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our goodwill or intangible assets become impaired, we may be required to record a significant charge to earnings.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We review our goodwill and intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable, such as declines in stock price, market capitalization, or cash flows and slower growth rates in our industry. Goodwill is required to be tested for impairment at least annually. If we are required to record a significant charge in our consolidated financial statements during the period in which any impairment of our goodwill or intangible assets is determined, that would negatively affect our operating results.</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported operating results.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">U.S. GAAP is subject to interpretation by the Financial Accounting Standards Board, the Securities and Exchange Commission, or the SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in accounting standards or practices can have a significant effect on our reported results and may even affect our reporting of transactions completed before the change is effective. New accounting pronouncements and varying interpretations of accounting pronouncements have occurred and may occur in the future. Changes to existing rules or the questioning of current practices may adversely affect our reported financial results or the way we conduct our business. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our condensed consolidated financial statements are subject to change and if our estimates or judgments relating to our critical accounting policies prove to be incorrect, our operating results could be adversely affected.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and related notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, as provided in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Quarterly Report on Form 10-Q.  The results of these estimates form the basis for making judgments about the carrying values of assets, liabilities, and equity, and the amount of revenue and expenses that are not readily apparent from other sources. Critical accounting policies and estimates used in preparing our condensed consolidated financial statements include those related to revenue recognition, finite-lived intangible assets, goodwill, and stock-based compensation expense. Our operating results may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our operating results to fall below the expectations of securities analysts and investors, resulting in a decline in the price of our common stock.</span></div><div id="ide126ddc4fe34b88b9204d0512399caf_127"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Being a Public Company</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will continue to incur increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which could harm our operating results.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a public company, we will continue to incur significant legal, accounting, consulting and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements. In addition, the Sarbanes-Oxley Act of 2002 and the Dodd-Frank Act of 2010, as well as rules&#160;implemented by the SEC, and The Nasdaq Stock Market, impose a number of requirements on public companies, including with respect to corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance and disclosure obligations. Moreover, these rules&#160;and regulations have and will continue to increase our legal, accounting and financial compliance costs and make some activities more complex, time-consuming and costly. We also expect that it will continue to be expensive for us to maintain director and officer liability insurance.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to implement and maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section&#160;404 of the Sarbanes-Oxley Act of 2002 requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on our internal controls on an annual basis. If we have material weaknesses in our internal control over financial reporting, we may not detect errors on a timely basis and our consolidated financial statements may be materially misstated. We have only recently compiled the systems, processes and documentation necessary to comply with Section&#160;404 of the Sarbanes-Oxley Act. We will need to maintain and enhance these processes and controls as we grow, and we will require additional management and staff resources to do so. Additionally, even if we conclude our internal controls are effective for a given period, we may in the future identify one or more material weaknesses in our internal controls, in which case our management will be unable to conclude that our internal control over financial reporting is effective.  We are now required to include an attestation report from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting annually.  Even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm may conclude that there are material weaknesses with respect to our internal controls or the level at which our internal controls are documented, designed, implemented or reviewed.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to conclude that our internal control over financial reporting is effective, or if our auditors were to express an adverse opinion on the effectiveness of our internal control over financial reporting because we had one or more material weaknesses, investors could lose confidence in the accuracy and completeness of our financial disclosures, which could cause the price of our common stock to decline. Irrespective of compliance with Section&#160;404, any failure of our internal control over financial reporting could have a material adverse effect on our reported operating results and harm our reputation. Internal control deficiencies could also result in a restatement of our financial results.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_130"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Common Stock</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading price of our common stock is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include:</span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">actual or anticipated variations in our and our competitors&#8217; results of operations</span></div><div style="padding-left:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the global macroeconomic impact of the current COVID-19 outbreak;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">announcements by us or our competitors of new products, commercial relationships or capital commitments;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in reimbursement by current or potential payers, including governmental payers;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">issuance of new securities analysts&#8217; reports or changed recommendations for our stock;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">fluctuations in our revenue, due in part to the way in which we recognize revenue;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">actual or anticipated changes in regulatory oversight of our products;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">developments or disputes concerning our intellectual property or other proprietary rights;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">commencement of, or our involvement in, litigation;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">announced or completed acquisitions of businesses or technologies by us or our competitors;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any major change in our management; and</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">general economic conditions and slow or negative growth of our markets.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the stock market in general, and the market for stock of life sciences companies and other emerging growth companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced if the trading volume of our stock remains low. In addition, in the past, following periods of volatility in the overall market and the market price of a particular company&#8217;s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and resources.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If securities or industry analysts issue an adverse opinion regarding our stock or do not publish research or reports about our company, our stock price and trading volume could decline.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading market for our common stock will depend in part on the research and reports that equity research analysts publish about us, our business and our competitors. We do not control these analysts or the content and opinions or financial models included in their reports. Securities analysts may elect not to provide research coverage of our company, and such lack of research coverage may adversely affect the market price of our common stock. The price of our common stock could also decline if one or more equity research analysts downgrade our common stock or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business. If one or more equity research analysts cease coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Anti-takeover provisions in our charter documents and under Delaware law could discourage, delay or prevent a change in control and may affect the trading price of our common stock.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provisions in our restated certificate of incorporation and our amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our management. Our restated certificate of incorporation and amended and restated bylaws include provisions that:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">authorize our board of directors to issue, without further action by the stockholders, up to 5.0&#160;million shares of undesignated preferred stock;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">specify that special meetings of our stockholders can be called only by our board of directors, our chairman of the board, or our chief executive officer;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">establish that our board of directors is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with each class serving staggered terms;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">provide that our directors may be removed only for cause;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">provide that vacancies on our board of directors may, except as otherwise required by law, be filled only by a majority of directors then in office, even if less than a quorum;</span></div><div style="padding-left:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">provide that the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended;</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">specify that no stockholder is permitted to cumulate votes at any election of directors; and</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">require a super-majority of votes to amend certain of the above-mentioned provisions.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law regulating corporate takeovers. Section&#160;203 generally prohibits us from engaging in a business combination with an interested stockholder subject to certain exceptions.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never paid dividends on any of our capital stock and currently intend to retain any future earnings to fund the growth of our business. In addition, our Loan and Security Agreement restricts our ability to pay cash dividends on our common stock and we may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_133"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 6.&#160; EXHIBITS</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.836%;"><tr><td style="width:1.0%;"></td><td style="width:10.440%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.587%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:84.773%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit<br/>Number</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1384101/000138410120000046/vcyt-8xk3x13x20exhibit.htm">3.1</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1384101/000138410120000046/vcyt-8xk3x13x20exhibit.htm">Amended and Restated Bylaws of the Registrant</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="vcyt-03312020xex311.htm">31.1*</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="vcyt-03312020xex311.htm">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="vcyt-03312020xex312.htm">31.2*</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="vcyt-03312020xex312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="vcyt-03312020xex321.htm">32.1**</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="vcyt-03312020xex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. &#167; 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="vcyt-03312020xex322.htm">32.2**</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="vcyt-03312020xex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. &#167; 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101).</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">In accordance with Item&#160;601(b)(32)(ii)&#160;of Regulation&#160;S-K and SEC Release No.&#160;34-47986, the certifications furnished in Exhibits&#160;32.1 and 32.2 hereto are deemed to accompany this Form&#160;10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except to the extent that the registrant specifically incorporates it by reference.</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><div id="ide126ddc4fe34b88b9204d0512399caf_136"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date: May&#160;6, 2020 </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:47.413%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.722%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VERACYTE,&#160;INC.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ MARK HO</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Mark Ho</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Principal Accounting Officer</span></div><div><span><br/></span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>vcyt-03312020xex311.htm
<DESCRIPTION>VCYT - 10Q Q1 2020 EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="iff9ea022fe314e2d9ba6529da6a795ac_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;31.1</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PRINCIPAL EXECUTIVE OFFICER&#8217;S CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Bonnie H. Anderson, certify that&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> I have reviewed this quarterly report on Form&#160;10-Q of Veracyte,&#160;Inc. for the quarter ended March&#160;31, 2020&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.417%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.948%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.635%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Bonnie H. Anderson</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bonnie H. Anderson</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chairman and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>vcyt-03312020xex312.htm
<DESCRIPTION>VCYT - 10Q Q1 2020 EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i7a813035a44e447abd48e22fa4676441_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;31.2</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PRINCIPAL FINANCIAL OFFICER&#8217;S CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Keith Kennedy, certify that&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> I have reviewed this quarterly report on Form&#160;10-Q of Veracyte,&#160;Inc. for the quarter ended March&#160;31, 2020&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;padding-right:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;padding-right:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:36pt;padding-left:36pt;padding-right:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:36pt;padding-left:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.417%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.948%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.635%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Keith Kennedy</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Keith Kennedy</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Operating Officer and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>vcyt-03312020xex321.htm
<DESCRIPTION>VCYT - 10Q Q1 2020 EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i4bd469833b69441b903e9169e1fa43ea_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;32.1</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the quarterly report of Veracyte,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the quarter ended March&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to such officer&#8217;s knowledge&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.417%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.948%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.635%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Bonnie H. Anderson</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bonnie H. Anderson</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chairman and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>vcyt-03312020xex322.htm
<DESCRIPTION>VCYT - 10Q Q1 2020 EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i2cb860af2ac340999cb37a5d0a9e792f_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;32.2</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the quarterly report of Veracyte,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the quarter ended March&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to such officer&#8217;s knowledge&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.417%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.948%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.635%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Keith Kennedy</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Keith Kennedy</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Operating Officer and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>vcyt-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:0005b3b4-1d3d-4b06-88c1-edf8f62a1620,g:32b86441-5460-4f29-850a-a85559dff3e5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vcyt="http://www.veracyte.com/20200331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.veracyte.com/20200331">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vcyt-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vcyt-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vcyt-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vcyt-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.veracyte.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessPolicies" roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies">
        <link:definition>2202201 - Disclosure - Organization and Description of Business (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessTables" roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessTables">
        <link:definition>2303301 - Disclosure - Organization and Description of Business (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessNarrativeDetails" roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails">
        <link:definition>2404401 - Disclosure - Organization and Description of Business - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessCreditRiskDetails" roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails">
        <link:definition>2405402 - Disclosure - Organization and Description of Business - Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShare" roleURI="http://www.veracyte.com/role/NetLossPerCommonShare">
        <link:definition>2106102 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareTables" roleURI="http://www.veracyte.com/role/NetLossPerCommonShareTables">
        <link:definition>2307302 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareDetails" roleURI="http://www.veracyte.com/role/NetLossPerCommonShareDetails">
        <link:definition>2408403 - Disclosure - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.veracyte.com/role/AccruedLiabilities">
        <link:definition>2109103 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.veracyte.com/role/AccruedLiabilitiesTables">
        <link:definition>2310303 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.veracyte.com/role/AccruedLiabilitiesDetails">
        <link:definition>2411404 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombination" roleURI="http://www.veracyte.com/role/BusinessCombination">
        <link:definition>2112104 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.veracyte.com/role/BusinessCombinationsTables">
        <link:definition>2313304 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsDetails" roleURI="http://www.veracyte.com/role/BusinessCombinationsDetails">
        <link:definition>2414405 - Disclosure - Business Combinations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationAcquisitionDetails" roleURI="http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails">
        <link:definition>2415406 - Disclosure - Business Combination - Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.veracyte.com/role/FairValueMeasurements">
        <link:definition>2116105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.veracyte.com/role/FairValueMeasurementsDetails">
        <link:definition>2417407 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.veracyte.com/role/CommitmentsandContingencies">
        <link:definition>2118106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesTables">
        <link:definition>2319305 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeaseDetails" roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails">
        <link:definition>2420408 - Disclosure - Commitments and Contingencies - Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeaseDetails_1" roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails_1">
        <link:definition>2420408 - Disclosure - Commitments and Contingencies - Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.veracyte.com/role/Debt">
        <link:definition>2121107 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.veracyte.com/role/DebtTables">
        <link:definition>2322306 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.veracyte.com/role/DebtNarrativeDetails">
        <link:definition>2423409 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDebtObligationforBorrowingsDetails" roleURI="http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails">
        <link:definition>2424410 - Disclosure - Debt - Debt Obligation for Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.veracyte.com/role/StockholdersEquity">
        <link:definition>2125108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.veracyte.com/role/StockholdersEquityTables">
        <link:definition>2326307 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.veracyte.com/role/StockholdersEquityDetails">
        <link:definition>2427411 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ThyroidCytopathologyPartners" roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartners">
        <link:definition>2128109 - Disclosure - Thyroid Cytopathology Partners</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ThyroidCytopathologyPartnersDetails" roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails">
        <link:definition>2429412 - Disclosure - Thyroid Cytopathology Partners (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.veracyte.com/role/IncomeTaxes">
        <link:definition>2130110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_CommonStockAbstract" abstract="true" name="CommonStockAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_NCounterFLEXDxLicenseMember" abstract="true" name="NCounterFLEXDxLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_LymphMarkProductTechnologyMember" abstract="true" name="LymphMarkProductTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_DebtPrepaymentTrancheOneMember" abstract="true" name="DebtPrepaymentTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_ContractAgreementAmount" abstract="false" name="ContractAgreementAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_NasaRISKMember" abstract="true" name="NasaRISKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_EmployeeAndNonEmployeeStockOptionMember" abstract="true" name="EmployeeAndNonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_DebtInstrumentEndOfTermInterestObligationAmount" abstract="false" name="DebtInstrumentEndOfTermInterestObligationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_DebtPrepaymentTrancheAxis" abstract="true" name="DebtPrepaymentTrancheAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities" abstract="false" name="PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="vcyt_DevelopedProductTechnologyMember" abstract="true" name="DevelopedProductTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_AgreementTermsNonRenewalNoticePeriod" abstract="false" name="AgreementTermsNonRenewalNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vcyt_DebtPrepaymentTrancheThreeMember" abstract="true" name="DebtPrepaymentTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_InterestExpenseandPrepaymentPenalty" abstract="false" name="InterestExpenseandPrepaymentPenalty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_BiopharmaceuticalCompanyMember" abstract="true" name="BiopharmaceuticalCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_ContractAgreementReceivableForServices" abstract="false" name="ContractAgreementReceivableForServices" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_ContractAgreementConditionalAdditionalReceivable" abstract="false" name="ContractAgreementConditionalAdditionalReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_TerminationPeriodContractAgreement" abstract="false" name="TerminationPeriodContractAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vcyt_LaboratoryFacilitiesAustinTexasMember" abstract="true" name="LaboratoryFacilitiesAustinTexasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_NumberofTissueSampleDeliveries" abstract="false" name="NumberofTissueSampleDeliveries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vcyt_LiquidityRequirementMinimum" abstract="false" name="LiquidityRequirementMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" abstract="true" name="HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_NanoStringMember" abstract="true" name="NanoStringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" abstract="false" name="IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_DebtInstrumentPrepaymentPremium" abstract="false" name="DebtInstrumentPrepaymentPremium" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_NumberOfDiseaseAreasWithGenomicTesting" abstract="false" name="NumberOfDiseaseAreasWithGenomicTesting" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_TestingMember" abstract="true" name="TestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_DebtPrepaymentTrancheTwoMember" abstract="true" name="DebtPrepaymentTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_SiliconValleyBankMember" abstract="true" name="SiliconValleyBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability" abstract="false" name="IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" abstract="false" name="ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased" abstract="false" name="LesseeLeasingArrangementsOperatingLeasesSpaceLeased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="vcyt_ServicesAgreementAbstract" abstract="true" name="ServicesAgreementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" abstract="false" name="NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vcyt_ContractAgreementFeePercentageOfCashCollections" abstract="false" name="ContractAgreementFeePercentageOfCashCollections" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="vcyt_JohnsonJohnsonServicesInc.Member" abstract="true" name="JohnsonJohnsonServicesInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_OvernightRepurchaseAgreementsMember" abstract="true" name="OvernightRepurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_TermContractAgreement" abstract="false" name="TermContractAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vcyt_NoncashLeaseExpenses" abstract="false" name="NoncashLeaseExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_PerceptaV2Member" abstract="true" name="PerceptaV2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_InventoryReserveEffectOnIncomeNet" abstract="false" name="InventoryReserveEffectOnIncomeNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vcyt_RevenueRecognitionMember" abstract="true" name="RevenueRecognitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_UnitedHealthcareMember" abstract="true" name="UnitedHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_CapitalExpendituresIncurredButNotYetPaidNet" abstract="false" name="CapitalExpendituresIncurredButNotYetPaidNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_BiopharmaceuticalMember" abstract="true" name="BiopharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_OtherIncomeRentReimbursement" abstract="false" name="OtherIncomeRentReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_AutomaticRenewalPeriodContractAgreement" abstract="false" name="AutomaticRenewalPeriodContractAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vcyt_DebtPaymentTrancheDomain" abstract="true" name="DebtPaymentTrancheDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>vcyt-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:0005b3b4-1d3d-4b06-88c1-edf8f62a1620,g:32b86441-5460-4f29-850a-a85559dff3e5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.veracyte.com/role/Cover" xlink:type="simple" xlink:href="vcyt-20200331.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fdc1671f-e19b-4d0a-8467-73f336ec46da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0adb27d9-f8e0-4890-9394-1ea8c7fdf467" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fdc1671f-e19b-4d0a-8467-73f336ec46da" xlink:to="loc_us-gaap_AccountsPayableCurrent_0adb27d9-f8e0-4890-9394-1ea8c7fdf467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_53f336d3-2b39-4ce0-8c80-6d907ea97cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fdc1671f-e19b-4d0a-8467-73f336ec46da" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_53f336d3-2b39-4ce0-8c80-6d907ea97cdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_894345f3-68ad-4586-927c-4bf745e3c80c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fdc1671f-e19b-4d0a-8467-73f336ec46da" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_894345f3-68ad-4586-927c-4bf745e3c80c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a8ef70fc-04ec-4f52-b6bc-58152d21683c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_965d330f-1295-4945-b510-575c888aaba5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a8ef70fc-04ec-4f52-b6bc-58152d21683c" xlink:to="loc_us-gaap_Liabilities_965d330f-1295-4945-b510-575c888aaba5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2bb15856-f76b-4ff3-8a65-3397457d4021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a8ef70fc-04ec-4f52-b6bc-58152d21683c" xlink:to="loc_us-gaap_StockholdersEquity_2bb15856-f76b-4ff3-8a65-3397457d4021" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_059e3a7f-3194-4bd9-aa44-89b8364af883" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a8ef70fc-04ec-4f52-b6bc-58152d21683c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_059e3a7f-3194-4bd9-aa44-89b8364af883" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2b74c89e-af85-46e7-9726-a468468b561e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7d79ff79-9a60-40f1-a0f8-fc0b3c676a9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b74c89e-af85-46e7-9726-a468468b561e" xlink:to="loc_us-gaap_AssetsCurrent_7d79ff79-9a60-40f1-a0f8-fc0b3c676a9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8b1d45ed-02b2-41a3-8b6f-606bc5a697c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b74c89e-af85-46e7-9726-a468468b561e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8b1d45ed-02b2-41a3-8b6f-606bc5a697c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1bfe93ea-751c-4c2c-ba9f-ffc8b3aaf668" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b74c89e-af85-46e7-9726-a468468b561e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1bfe93ea-751c-4c2c-ba9f-ffc8b3aaf668" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d96a0799-9062-44c7-a30d-49e8e72e1f40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b74c89e-af85-46e7-9726-a468468b561e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d96a0799-9062-44c7-a30d-49e8e72e1f40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7dedf017-baa1-424d-8f2a-b16d22f87f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b74c89e-af85-46e7-9726-a468468b561e" xlink:to="loc_us-gaap_Goodwill_7dedf017-baa1-424d-8f2a-b16d22f87f4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2bc12b35-acb4-4a69-a3f9-0d84bddf67dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b74c89e-af85-46e7-9726-a468468b561e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2bc12b35-acb4-4a69-a3f9-0d84bddf67dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_05007118-af75-4b62-8925-0cf2a4af462a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b74c89e-af85-46e7-9726-a468468b561e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_05007118-af75-4b62-8925-0cf2a4af462a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b4f8d4df-dc6b-47fd-823f-4423e1370979" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d2d7cf25-0d9a-47b1-b098-7e8289109eba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b4f8d4df-dc6b-47fd-823f-4423e1370979" xlink:to="loc_us-gaap_CommonStockValue_d2d7cf25-0d9a-47b1-b098-7e8289109eba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7cb18f4a-2639-4df0-b6c1-061a01b45523" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b4f8d4df-dc6b-47fd-823f-4423e1370979" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7cb18f4a-2639-4df0-b6c1-061a01b45523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_be96d088-ee87-4bb1-b6c8-15868a11f176" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b4f8d4df-dc6b-47fd-823f-4423e1370979" xlink:to="loc_us-gaap_PreferredStockValue_be96d088-ee87-4bb1-b6c8-15868a11f176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a68d501c-398b-471b-926e-0d1b5d1124e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b4f8d4df-dc6b-47fd-823f-4423e1370979" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a68d501c-398b-471b-926e-0d1b5d1124e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_923158d9-ecf7-4489-989a-3a4674badd09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e081705-8782-4769-b285-406879867927" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_923158d9-ecf7-4489-989a-3a4674badd09" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e081705-8782-4769-b285-406879867927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ba24b222-e2f1-42a6-8d30-dc94409ac166" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_923158d9-ecf7-4489-989a-3a4674badd09" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ba24b222-e2f1-42a6-8d30-dc94409ac166" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4e1c6b84-b8a3-4b19-a46d-5ee7a8124779" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_923158d9-ecf7-4489-989a-3a4674badd09" xlink:to="loc_us-gaap_InventoryNet_4e1c6b84-b8a3-4b19-a46d-5ee7a8124779" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_27d884eb-84bd-400e-9394-28db22853a04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_923158d9-ecf7-4489-989a-3a4674badd09" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_27d884eb-84bd-400e-9394-28db22853a04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_445b5be0-1bb4-48ad-936f-7c358c8de2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ff5bc353-b79e-49af-b3db-28e69341160b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_445b5be0-1bb4-48ad-936f-7c358c8de2b4" xlink:to="loc_us-gaap_LiabilitiesCurrent_ff5bc353-b79e-49af-b3db-28e69341160b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_061862c7-6eed-42d3-8574-e0ecca328556" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_445b5be0-1bb4-48ad-936f-7c358c8de2b4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_061862c7-6eed-42d3-8574-e0ecca328556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_86be844f-ffd3-4e72-ad44-e8bb90e159e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_445b5be0-1bb4-48ad-936f-7c358c8de2b4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_86be844f-ffd3-4e72-ad44-e8bb90e159e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_06cc264f-d49f-4040-97e5-5089255b76db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_445b5be0-1bb4-48ad-936f-7c358c8de2b4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_06cc264f-d49f-4040-97e5-5089255b76db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b96f0340-7c76-4241-8abb-53fdaaef253d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_efc32bc4-ae6c-46de-91c8-9bf1d010c138" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b96f0340-7c76-4241-8abb-53fdaaef253d" xlink:to="loc_us-gaap_OperatingIncomeLoss_efc32bc4-ae6c-46de-91c8-9bf1d010c138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_85ce3d52-d339-41f6-ba35-3145e037cd03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b96f0340-7c76-4241-8abb-53fdaaef253d" xlink:to="loc_us-gaap_InterestExpense_85ce3d52-d339-41f6-ba35-3145e037cd03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8ee8910a-f228-42a6-85a4-0f2b0813ceb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b96f0340-7c76-4241-8abb-53fdaaef253d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8ee8910a-f228-42a6-85a4-0f2b0813ceb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_281e72a6-11ec-4058-957f-0786699e3499" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_372962cf-6634-4a55-a9e0-a190fa29fddf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_281e72a6-11ec-4058-957f-0786699e3499" xlink:to="loc_us-gaap_CostOfRevenue_372962cf-6634-4a55-a9e0-a190fa29fddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_58c81576-f000-486a-9883-302d5a76f410" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_281e72a6-11ec-4058-957f-0786699e3499" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_58c81576-f000-486a-9883-302d5a76f410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_6340d801-05c5-449b-8b38-7b80d49056a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_281e72a6-11ec-4058-957f-0786699e3499" xlink:to="loc_us-gaap_SellingAndMarketingExpense_6340d801-05c5-449b-8b38-7b80d49056a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_136901c3-180a-4276-8b67-fdde50fe13d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_281e72a6-11ec-4058-957f-0786699e3499" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_136901c3-180a-4276-8b67-fdde50fe13d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_05e8dc10-1d55-4a70-91a3-343a818f1edb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_281e72a6-11ec-4058-957f-0786699e3499" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_05e8dc10-1d55-4a70-91a3-343a818f1edb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3d954aeb-92f4-4fe4-a94c-e0e0007dbb17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ebccf322-1433-46da-bee7-c862003ef388" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3d954aeb-92f4-4fe4-a94c-e0e0007dbb17" xlink:to="loc_us-gaap_CostsAndExpenses_ebccf322-1433-46da-bee7-c862003ef388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_30058e0a-9360-4130-8343-51a6e7ba3b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3d954aeb-92f4-4fe4-a94c-e0e0007dbb17" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_30058e0a-9360-4130-8343-51a6e7ba3b8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1678327b-a15b-4b38-88ee-9354ecc5928d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1fdc4e47-47eb-4c77-8e4d-7cab2a32297d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1678327b-a15b-4b38-88ee-9354ecc5928d" xlink:to="loc_us-gaap_OperatingIncomeLoss_1fdc4e47-47eb-4c77-8e4d-7cab2a32297d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9c5872a3-0d27-49e7-85cb-ed2d3dc29f87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1678327b-a15b-4b38-88ee-9354ecc5928d" xlink:to="loc_us-gaap_InterestExpense_9c5872a3-0d27-49e7-85cb-ed2d3dc29f87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2b5956a7-3e80-4236-86ae-696a34892e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1678327b-a15b-4b38-88ee-9354ecc5928d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2b5956a7-3e80-4236-86ae-696a34892e1b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_157e4cb8-aa5c-4819-add4-d2d4d17985fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_63ddfb80-3993-4301-9157-8c0a61846b03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_157e4cb8-aa5c-4819-add4-d2d4d17985fa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_63ddfb80-3993-4301-9157-8c0a61846b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_01eece13-05f8-4ed9-8854-cd9d4b54e018" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_157e4cb8-aa5c-4819-add4-d2d4d17985fa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_01eece13-05f8-4ed9-8854-cd9d4b54e018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_47052ce8-203c-44a5-af85-6ebca643fd57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_157e4cb8-aa5c-4819-add4-d2d4d17985fa" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_47052ce8-203c-44a5-af85-6ebca643fd57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_280655f2-d684-420e-8141-4cd1c6979854" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_157e4cb8-aa5c-4819-add4-d2d4d17985fa" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_280655f2-d684-420e-8141-4cd1c6979854" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_304b5f98-6f58-44df-9e32-b59d08e9c6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6f2f5277-03b0-4dcd-a632-ab184391c444" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_304b5f98-6f58-44df-9e32-b59d08e9c6bd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6f2f5277-03b0-4dcd-a632-ab184391c444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8c3021b7-7878-4af4-adb6-3bfd91faec65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_304b5f98-6f58-44df-9e32-b59d08e9c6bd" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8c3021b7-7878-4af4-adb6-3bfd91faec65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be1e0845-1d73-43cf-9e7c-24b7475e1d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dfcd1eef-fb1b-4143-a75f-c8b541f3126a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be1e0845-1d73-43cf-9e7c-24b7475e1d6c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dfcd1eef-fb1b-4143-a75f-c8b541f3126a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9ed2ade4-2435-4f6d-91d1-2df475ac005a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be1e0845-1d73-43cf-9e7c-24b7475e1d6c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9ed2ade4-2435-4f6d-91d1-2df475ac005a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b3826f1-7a3c-45de-a449-567554f3a4c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be1e0845-1d73-43cf-9e7c-24b7475e1d6c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b3826f1-7a3c-45de-a449-567554f3a4c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_c9f93ff4-b184-426f-88fa-481100ebd9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_c9f93ff4-b184-426f-88fa-481100ebd9ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8c55332f-1ab0-4d47-a312-43258ba7dea2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8c55332f-1ab0-4d47-a312-43258ba7dea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0df649ba-5448-4b5c-b241-5debd5ff46a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0df649ba-5448-4b5c-b241-5debd5ff46a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6c4ef106-1a05-4b9a-a01f-08e64104b180" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6c4ef106-1a05-4b9a-a01f-08e64104b180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_320938e7-a583-407a-9c5b-e1773445d21e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_320938e7-a583-407a-9c5b-e1773445d21e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_419e8cbe-2cb6-4713-9f56-279faea63b36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_419e8cbe-2cb6-4713-9f56-279faea63b36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9ad9e153-902b-45ad-a5df-50560ae80eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9ad9e153-902b-45ad-a5df-50560ae80eb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_InterestExpenseandPrepaymentPenalty_6ef8ccd2-dda9-4569-9810-c1b7744cb87f" xlink:href="vcyt-20200331.xsd#vcyt_InterestExpenseandPrepaymentPenalty"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_vcyt_InterestExpenseandPrepaymentPenalty_6ef8ccd2-dda9-4569-9810-c1b7744cb87f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_36d8c96c-d630-4795-8aba-9505ac51c83f" xlink:href="vcyt-20200331.xsd#vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_36d8c96c-d630-4795-8aba-9505ac51c83f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7c3c4a0e-6823-45b8-b199-e2a14d382d98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_us-gaap_ShareBasedCompensation_7c3c4a0e-6823-45b8-b199-e2a14d382d98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability_54a8557d-848d-4884-838d-bc66a7779ad0" xlink:href="vcyt-20200331.xsd#vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability_54a8557d-848d-4884-838d-bc66a7779ad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8f052a60-f8e2-4456-a7e4-d3e22f55df06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8f052a60-f8e2-4456-a7e4-d3e22f55df06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_55f6283a-3c82-4a73-83ab-3bd04eb875d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_55f6283a-3c82-4a73-83ab-3bd04eb875d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_791f61a1-cd6f-4029-8158-4be13aea1b94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_791f61a1-cd6f-4029-8158-4be13aea1b94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_InventoryReserveEffectOnIncomeNet_af8fe215-d75e-42e2-8a95-b57ce78d8a98" xlink:href="vcyt-20200331.xsd#vcyt_InventoryReserveEffectOnIncomeNet"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_vcyt_InventoryReserveEffectOnIncomeNet_af8fe215-d75e-42e2-8a95-b57ce78d8a98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NoncashLeaseExpenses_52c43b8c-738e-421a-9526-057a5d87af51" xlink:href="vcyt-20200331.xsd#vcyt_NoncashLeaseExpenses"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b634080c-a667-415b-8d5c-eb10124d1e62" xlink:to="loc_vcyt_NoncashLeaseExpenses_52c43b8c-738e-421a-9526-057a5d87af51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1833c4c-fe9d-4e5f-8954-ea8699e86c90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b070fca9-c18e-4dd8-b592-7e031b09611f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1833c4c-fe9d-4e5f-8954-ea8699e86c90" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b070fca9-c18e-4dd8-b592-7e031b09611f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_a0bf3041-a47d-4d75-8eea-a1bf426ca628" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1833c4c-fe9d-4e5f-8954-ea8699e86c90" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_a0bf3041-a47d-4d75-8eea-a1bf426ca628" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusinessPolicies"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusinessTables"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusinessNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusinessCreditRiskDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerCommonShare" xlink:type="simple" xlink:href="vcyt-20200331.xsd#NetLossPerCommonShare"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/NetLossPerCommonShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerCommonShareTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#NetLossPerCommonShareTables"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/NetLossPerCommonShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerCommonShareDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#NetLossPerCommonShareDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/NetLossPerCommonShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="vcyt-20200331.xsd#AccruedLiabilities"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/AccruedLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#AccruedLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/AccruedLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0581ac83-9bfc-4314-ab74-1c73f43ed189" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_913e4704-6d87-44f2-885e-236f3865f671" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0581ac83-9bfc-4314-ab74-1c73f43ed189" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_913e4704-6d87-44f2-885e-236f3865f671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ef55c7cc-27b3-4a70-9013-994bf6adf082" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0581ac83-9bfc-4314-ab74-1c73f43ed189" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ef55c7cc-27b3-4a70-9013-994bf6adf082" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombination" xlink:type="simple" xlink:href="vcyt-20200331.xsd#BusinessCombination"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BusinessCombination" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#BusinessCombinationsTables"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationsDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#BusinessCombinationsDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#BusinessCombinationAcquisitionDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c16ec6fd-ab9b-4841-9705-814bd60b92be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bca10609-dac6-473e-bfed-26a238c9e41f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c16ec6fd-ab9b-4841-9705-814bd60b92be" xlink:to="loc_us-gaap_Goodwill_bca10609-dac6-473e-bfed-26a238c9e41f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_25195ea7-8d41-48dd-9489-bec220346f87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c16ec6fd-ab9b-4841-9705-814bd60b92be" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_25195ea7-8d41-48dd-9489-bec220346f87" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="vcyt-20200331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/FairValueMeasurementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CommitmentsandContingenciesOperatingLeaseDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9f8cef91-2ba7-421b-a9e0-bd003207adbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_420009e5-9e05-41d2-9dfd-fc6e88389cee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9f8cef91-2ba7-421b-a9e0-bd003207adbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_420009e5-9e05-41d2-9dfd-fc6e88389cee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c7ac905e-e628-4799-82e3-491ba5bbb40f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9f8cef91-2ba7-421b-a9e0-bd003207adbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c7ac905e-e628-4799-82e3-491ba5bbb40f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79fecfc8-9a72-471f-b655-b2da80990ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9f8cef91-2ba7-421b-a9e0-bd003207adbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79fecfc8-9a72-471f-b655-b2da80990ab1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bce16863-d790-46ac-a711-50c11c4099fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9f8cef91-2ba7-421b-a9e0-bd003207adbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bce16863-d790-46ac-a711-50c11c4099fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a74849d5-ccf7-4541-a937-7bcee9d6f210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9f8cef91-2ba7-421b-a9e0-bd003207adbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a74849d5-ccf7-4541-a937-7bcee9d6f210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_abaff947-4315-4c7d-aac9-c3c49fe3f045" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9f8cef91-2ba7-421b-a9e0-bd003207adbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_abaff947-4315-4c7d-aac9-c3c49fe3f045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_48ecc3ff-94c2-4865-8e2e-2fa261095d22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_05a30a4d-0b31-4a0e-adf1-26a3be354fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_48ecc3ff-94c2-4865-8e2e-2fa261095d22" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_05a30a4d-0b31-4a0e-adf1-26a3be354fdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f4a612a2-ec21-46a0-830d-d800b1f3edbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_48ecc3ff-94c2-4865-8e2e-2fa261095d22" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f4a612a2-ec21-46a0-830d-d800b1f3edbb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails_1" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CommitmentsandContingenciesOperatingLeaseDetails_1"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_234acbba-0a5a-4890-ac62-8f4748a4612a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9e413c4a-694b-40f8-8ab5-eaffde69081a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_234acbba-0a5a-4890-ac62-8f4748a4612a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9e413c4a-694b-40f8-8ab5-eaffde69081a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_38481610-2472-4cd7-8681-ad2f0449c9df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_234acbba-0a5a-4890-ac62-8f4748a4612a" xlink:to="loc_us-gaap_OperatingLeaseLiability_38481610-2472-4cd7-8681-ad2f0449c9df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/Debt" xlink:type="simple" xlink:href="vcyt-20200331.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#DebtTables"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/DebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#DebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/DebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#DebtDebtObligationforBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2c81078a-c7ca-446d-820c-33ceb26a912d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_260f9091-a24f-4db9-b8ae-6d55f04d8132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2c81078a-c7ca-446d-820c-33ceb26a912d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_260f9091-a24f-4db9-b8ae-6d55f04d8132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_9c1ea803-529e-4058-926f-1db08f82dd4b" xlink:href="vcyt-20200331.xsd#vcyt_DebtInstrumentEndOfTermInterestObligationAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2c81078a-c7ca-446d-820c-33ceb26a912d" xlink:to="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_9c1ea803-529e-4058-926f-1db08f82dd4b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquity" xlink:type="simple" xlink:href="vcyt-20200331.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#StockholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartners" xlink:type="simple" xlink:href="vcyt-20200331.xsd#ThyroidCytopathologyPartners"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/ThyroidCytopathologyPartners" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#ThyroidCytopathologyPartnersDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxes" xlink:type="simple" xlink:href="vcyt-20200331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/IncomeTaxes" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>vcyt-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:0005b3b4-1d3d-4b06-88c1-edf8f62a1620,g:32b86441-5460-4f29-850a-a85559dff3e5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/Cover" xlink:type="simple" xlink:href="vcyt-20200331.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/Cover" xlink:type="extended" id="id96ca77dd9f04678b7f6c60899bb3593_Cover"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i852e3db04e584437b757708fa5df3b94_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i1693d06ec62248b286e384de8c03b92c_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="i34279eb30a9f48f99a0d4972f1c1167d_CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12c516f5-cda7-479f-9a89-e20196b5ec9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12c516f5-cda7-479f-9a89-e20196b5ec9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_b1ce895e-e6d4-4c3f-9a2a-cacf47160455" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:to="loc_us-gaap_CostOfRevenue_b1ce895e-e6d4-4c3f-9a2a-cacf47160455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4324d54e-6aee-45c6-97f5-216e33bd9c96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4324d54e-6aee-45c6-97f5-216e33bd9c96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_d87851a2-c9eb-4fb9-a71c-040f02939ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:to="loc_us-gaap_SellingAndMarketingExpense_d87851a2-c9eb-4fb9-a71c-040f02939ea1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cef3d179-f29d-4a38-8f27-094a64fbae74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cef3d179-f29d-4a38-8f27-094a64fbae74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_fcc52be3-374f-418e-be60-ac85109d445f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_fcc52be3-374f-418e-be60-ac85109d445f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_24af77e6-61a7-4621-8702-dca5b0b031de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:to="loc_us-gaap_CostsAndExpenses_24af77e6-61a7-4621-8702-dca5b0b031de" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_183b52a5-db04-43c9-8187-db5f109321f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_OperatingIncomeLoss_183b52a5-db04-43c9-8187-db5f109321f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e819d302-8229-40bc-8d88-c7409f9c68bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_InterestExpense_e819d302-8229-40bc-8d88-c7409f9c68bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_752ef8bf-0d03-4a25-9602-b7784f79ef3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_752ef8bf-0d03-4a25-9602-b7784f79ef3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4e4f95d0-7bdd-4fbf-97ae-051aea00e467" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4e4f95d0-7bdd-4fbf-97ae-051aea00e467" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_19dbf0e2-8566-46d4-82a9-5dd182132496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_19dbf0e2-8566-46d4-82a9-5dd182132496" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_dfe04514-a49b-44e3-bd98-152114787303" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_dfe04514-a49b-44e3-bd98-152114787303" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b631ce22-e06c-45f0-87b3-e1820eca40c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b631ce22-e06c-45f0-87b3-e1820eca40c5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8d0eb6c-8fb2-4fd3-b255-b13a3f081bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_StatementTable_e8d0eb6c-8fb2-4fd3-b255-b13a3f081bdf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4068f2e0-3e11-492b-bb7e-aadde794c339" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e8d0eb6c-8fb2-4fd3-b255-b13a3f081bdf" xlink:to="loc_srt_ProductOrServiceAxis_4068f2e0-3e11-492b-bb7e-aadde794c339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4068f2e0-3e11-492b-bb7e-aadde794c339_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4068f2e0-3e11-492b-bb7e-aadde794c339" xlink:to="loc_srt_ProductsAndServicesDomain_4068f2e0-3e11-492b-bb7e-aadde794c339_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_779353c7-c06d-4614-860f-9419d39d123f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4068f2e0-3e11-492b-bb7e-aadde794c339" xlink:to="loc_srt_ProductsAndServicesDomain_779353c7-c06d-4614-860f-9419d39d123f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TestingMember_38d92106-3cb4-46e9-bb4f-f78afdb6d685" xlink:href="vcyt-20200331.xsd#vcyt_TestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_779353c7-c06d-4614-860f-9419d39d123f" xlink:to="loc_vcyt_TestingMember_38d92106-3cb4-46e9-bb4f-f78afdb6d685" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e3f23df8-a6c6-4c28-a48a-84643f6dca8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_779353c7-c06d-4614-860f-9419d39d123f" xlink:to="loc_us-gaap_ProductMember_e3f23df8-a6c6-4c28-a48a-84643f6dca8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalMember_b948bdce-80d4-4fdd-bea5-c72f67b17c5a" xlink:href="vcyt-20200331.xsd#vcyt_BiopharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_779353c7-c06d-4614-860f-9419d39d123f" xlink:to="loc_vcyt_BiopharmaceuticalMember_b948bdce-80d4-4fdd-bea5-c72f67b17c5a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i5bae67785ca5478a828c3e8121b6e35f_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eccfcebb-797d-4509-869e-0019e8c173a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eccfcebb-797d-4509-869e-0019e8c173a3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eedca5ea-9bb1-4c8a-9a77-8432afc3aa12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_StockholdersEquity_eedca5ea-9bb1-4c8a-9a77-8432afc3aa12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1c7d6334-cfac-46b1-8366-8b5f122929bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_SharesOutstanding_1c7d6334-cfac-46b1-8366-8b5f122929bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0da933f1-218f-4ec6-9994-de76727a4d64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0da933f1-218f-4ec6-9994-de76727a4d64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_b127cc9b-17b6-456d-8e36-dabe22d7a16c" xlink:href="vcyt-20200331.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_b127cc9b-17b6-456d-8e36-dabe22d7a16c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_62fe516b-0c72-44f8-84e1-ab20d56d2669" xlink:href="vcyt-20200331.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_62fe516b-0c72-44f8-84e1-ab20d56d2669" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_628d96b1-5809-48e5-83aa-c4c3c42d67ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_628d96b1-5809-48e5-83aa-c4c3c42d67ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8878fb11-d5da-4806-a86a-aea3bcdb3762" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8878fb11-d5da-4806-a86a-aea3bcdb3762" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d6a820e5-54be-436e-a03c-e4de5bab48dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d6a820e5-54be-436e-a03c-e4de5bab48dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_38055e57-2850-4af2-adae-130f9bf49c15" xlink:href="vcyt-20200331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_38055e57-2850-4af2-adae-130f9bf49c15" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_e0ba65b6-e4c0-444c-a94d-0bbe409137b4" xlink:href="vcyt-20200331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_e0ba65b6-e4c0-444c-a94d-0bbe409137b4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_0db889c6-5632-4706-89cd-d08d488c94f7" xlink:href="vcyt-20200331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_0db889c6-5632-4706-89cd-d08d488c94f7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9abceb83-0cef-4180-82b1-99c4a44cbe81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9abceb83-0cef-4180-82b1-99c4a44cbe81" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d5ba4b37-5a78-4d32-949b-a41c31e4087c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d5ba4b37-5a78-4d32-949b-a41c31e4087c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7b769763-7b28-4478-acfc-4b29e1a7c352" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3f7f5596-2cde-4ceb-8d8a-2c717386ee89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3fb8dd32-74cf-41f1-8209-ad0ee8e10833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_eccfcebb-797d-4509-869e-0019e8c173a3" xlink:to="loc_us-gaap_StatementTable_3fb8dd32-74cf-41f1-8209-ad0ee8e10833" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2282f7b4-7432-43db-ac4e-e5b332285c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3fb8dd32-74cf-41f1-8209-ad0ee8e10833" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2282f7b4-7432-43db-ac4e-e5b332285c5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2282f7b4-7432-43db-ac4e-e5b332285c5f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2282f7b4-7432-43db-ac4e-e5b332285c5f" xlink:to="loc_us-gaap_EquityComponentDomain_2282f7b4-7432-43db-ac4e-e5b332285c5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_55bf4089-0cef-4fee-abf3-08845f1486cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2282f7b4-7432-43db-ac4e-e5b332285c5f" xlink:to="loc_us-gaap_EquityComponentDomain_55bf4089-0cef-4fee-abf3-08845f1486cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4fb07205-edf0-4265-aafb-b5c989705769" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55bf4089-0cef-4fee-abf3-08845f1486cb" xlink:to="loc_us-gaap_CommonStockMember_4fb07205-edf0-4265-aafb-b5c989705769" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_36ae3f5f-acc7-4a5b-a2de-0f3fbc4a0321" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55bf4089-0cef-4fee-abf3-08845f1486cb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_36ae3f5f-acc7-4a5b-a2de-0f3fbc4a0321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e6d455c9-dd52-4bde-82eb-4bff52dd03b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55bf4089-0cef-4fee-abf3-08845f1486cb" xlink:to="loc_us-gaap_RetainedEarningsMember_e6d455c9-dd52-4bde-82eb-4bff52dd03b4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i53dc15a9516a46cf828df8993f98d358_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended" id="i186271b6ef4a4ddc957df7a081ed5476_OrganizationandDescriptionofBusiness"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusinessPolicies"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies" xlink:type="extended" id="i483542a042c64127ad6219c5d3358315_OrganizationandDescriptionofBusinessPolicies"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusinessTables"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessTables" xlink:type="extended" id="i1db9bbc547f841a8aa75e5cf9b96611f_OrganizationandDescriptionofBusinessTables"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusinessNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails" xlink:type="extended" id="i0e640c34621b42dd893631a97de2588c_OrganizationandDescriptionofBusinessNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c8811065-4618-43d6-8e0c-5c251dbf5dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c8811065-4618-43d6-8e0c-5c251dbf5dd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NumberOfDiseaseAreasWithGenomicTesting_325f1846-ac9e-4cce-8709-8895b2328cba" xlink:href="vcyt-20200331.xsd#vcyt_NumberOfDiseaseAreasWithGenomicTesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_NumberOfDiseaseAreasWithGenomicTesting_325f1846-ac9e-4cce-8709-8895b2328cba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_88820be3-3caa-4769-8e64-f365b880d663" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_88820be3-3caa-4769-8e64-f365b880d663" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6da4dc1-b5a8-4eea-ae5a-df186409bd60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6da4dc1-b5a8-4eea-ae5a-df186409bd60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a306a756-a82e-43e2-b204-4b978207093f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a306a756-a82e-43e2-b204-4b978207093f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7b065f07-b4d9-4cc1-839d-bf991f6de637" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7b065f07-b4d9-4cc1-839d-bf991f6de637" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f6ae5c1c-c813-408c-9e30-dd8e2e00ee49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f6ae5c1c-c813-408c-9e30-dd8e2e00ee49" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities_e6817204-8ba6-408d-97e9-355e87590ee4" xlink:href="vcyt-20200331.xsd#vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities_e6817204-8ba6-408d-97e9-355e87590ee4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_6854ec8c-7e94-409c-9daa-7cfd5617d34b" xlink:href="vcyt-20200331.xsd#vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_6854ec8c-7e94-409c-9daa-7cfd5617d34b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bfa5f176-81f4-40d2-b533-0a03f7e1980c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bfa5f176-81f4-40d2-b533-0a03f7e1980c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b6023d63-2136-4039-aa9a-d905694a3d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b6023d63-2136-4039-aa9a-d905694a3d0d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4e054958-c19d-4971-a93a-b9d2a94fb07b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_OperatingIncomeLoss_4e054958-c19d-4971-a93a-b9d2a94fb07b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3b4c7d54-101d-4d3c-8250-0ff516d42362" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3b4c7d54-101d-4d3c-8250-0ff516d42362" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1bb7b324-f7d4-44fd-b84a-239515f1b05f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1bb7b324-f7d4-44fd-b84a-239515f1b05f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TermContractAgreement_624284c0-5597-4c0b-b455-bae125d1d64a" xlink:href="vcyt-20200331.xsd#vcyt_TermContractAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_TermContractAgreement_624284c0-5597-4c0b-b455-bae125d1d64a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AutomaticRenewalPeriodContractAgreement_9bc30471-4e7d-468c-8909-7b8dc31e88bb" xlink:href="vcyt-20200331.xsd#vcyt_AutomaticRenewalPeriodContractAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_AutomaticRenewalPeriodContractAgreement_9bc30471-4e7d-468c-8909-7b8dc31e88bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TerminationPeriodContractAgreement_5f554916-a445-48a4-b8ab-05d2b221e9e5" xlink:href="vcyt-20200331.xsd#vcyt_TerminationPeriodContractAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_TerminationPeriodContractAgreement_5f554916-a445-48a4-b8ab-05d2b221e9e5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NumberofTissueSampleDeliveries_43612435-a9fa-4e58-ac6b-ec7ed62dca3d" xlink:href="vcyt-20200331.xsd#vcyt_NumberofTissueSampleDeliveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_NumberofTissueSampleDeliveries_43612435-a9fa-4e58-ac6b-ec7ed62dca3d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_db4533ff-d919-4e16-b1c0-9df0f45b5c39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_db4533ff-d919-4e16-b1c0-9df0f45b5c39" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ContractAgreementReceivableForServices_d2fdad2d-02cb-4b0b-a632-c8604e93e608" xlink:href="vcyt-20200331.xsd#vcyt_ContractAgreementReceivableForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_ContractAgreementReceivableForServices_d2fdad2d-02cb-4b0b-a632-c8604e93e608" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ContractAgreementConditionalAdditionalReceivable_8b524bf5-8e73-4fac-84fc-b4ba92f5a5f7" xlink:href="vcyt-20200331.xsd#vcyt_ContractAgreementConditionalAdditionalReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_ContractAgreementConditionalAdditionalReceivable_8b524bf5-8e73-4fac-84fc-b4ba92f5a5f7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ContractAgreementFeePercentageOfCashCollections_baf822c7-a92a-4ac4-a78c-281f418fb081" xlink:href="vcyt-20200331.xsd#vcyt_ContractAgreementFeePercentageOfCashCollections"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_ContractAgreementFeePercentageOfCashCollections_baf822c7-a92a-4ac4-a78c-281f418fb081" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ca3374a9-5fe8-457f-97fe-50bf2b1762b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ca3374a9-5fe8-457f-97fe-50bf2b1762b7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b89c5363-0ce7-4d8d-81ab-f803b81376e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b89c5363-0ce7-4d8d-81ab-f803b81376e1" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_72545c9f-40c2-4f33-b474-078ed0014390" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_OperatingLeaseLiability_72545c9f-40c2-4f33-b474-078ed0014390" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_8757859f-5cca-42d2-a2ec-a5f9fd84f22e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_AccountsReceivableNet_8757859f-5cca-42d2-a2ec-a5f9fd84f22e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ContractAgreementAmount_c356b3ae-aee0-4420-9d8a-7181509d157c" xlink:href="vcyt-20200331.xsd#vcyt_ContractAgreementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_ContractAgreementAmount_c356b3ae-aee0-4420-9d8a-7181509d157c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_8c85e355-e6f4-4912-9eba-f56e75341b65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_InventoryWriteDown_8c85e355-e6f4-4912-9eba-f56e75341b65" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_eb8eaa7a-f0be-4095-985d-74d92dc1067d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_eb8eaa7a-f0be-4095-985d-74d92dc1067d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb8eaa7a-f0be-4095-985d-74d92dc1067d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_eb8eaa7a-f0be-4095-985d-74d92dc1067d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb8eaa7a-f0be-4095-985d-74d92dc1067d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce1901c7-1e5e-493f-a7d2-6dcc06524e38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_eb8eaa7a-f0be-4095-985d-74d92dc1067d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce1901c7-1e5e-493f-a7d2-6dcc06524e38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_bc058eef-93d1-4130-abd5-415b232e0c68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce1901c7-1e5e-493f-a7d2-6dcc06524e38" xlink:to="loc_us-gaap_OverAllotmentOptionMember_bc058eef-93d1-4130-abd5-415b232e0c68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a0491436-4c53-48cd-9310-dfb6753b1826" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_srt_MajorCustomersAxis_a0491436-4c53-48cd-9310-dfb6753b1826" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a0491436-4c53-48cd-9310-dfb6753b1826_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a0491436-4c53-48cd-9310-dfb6753b1826" xlink:to="loc_srt_NameOfMajorCustomerDomain_a0491436-4c53-48cd-9310-dfb6753b1826_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1b90fb4f-c086-40e6-a2f7-5ac8340692f7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a0491436-4c53-48cd-9310-dfb6753b1826" xlink:to="loc_srt_NameOfMajorCustomerDomain_1b90fb4f-c086-40e6-a2f7-5ac8340692f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_JohnsonJohnsonServicesInc.Member_bde86ad5-b8df-4ee4-a730-680e3f7ac629" xlink:href="vcyt-20200331.xsd#vcyt_JohnsonJohnsonServicesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b90fb4f-c086-40e6-a2f7-5ac8340692f7" xlink:to="loc_vcyt_JohnsonJohnsonServicesInc.Member_bde86ad5-b8df-4ee4-a730-680e3f7ac629" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AstraZenecaMember_39abb9ec-f0a2-47a1-860f-c915e9a2ec81" xlink:href="vcyt-20200331.xsd#vcyt_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b90fb4f-c086-40e6-a2f7-5ac8340692f7" xlink:to="loc_vcyt_AstraZenecaMember_39abb9ec-f0a2-47a1-860f-c915e9a2ec81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalCompanyMember_d250f3c0-0386-42b8-9114-ed111c4b664d" xlink:href="vcyt-20200331.xsd#vcyt_BiopharmaceuticalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b90fb4f-c086-40e6-a2f7-5ac8340692f7" xlink:to="loc_vcyt_BiopharmaceuticalCompanyMember_d250f3c0-0386-42b8-9114-ed111c4b664d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_868f8fac-cb35-45f4-9433-aabb1d66278b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_srt_ProductOrServiceAxis_868f8fac-cb35-45f4-9433-aabb1d66278b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_868f8fac-cb35-45f4-9433-aabb1d66278b_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_868f8fac-cb35-45f4-9433-aabb1d66278b" xlink:to="loc_srt_ProductsAndServicesDomain_868f8fac-cb35-45f4-9433-aabb1d66278b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_868f8fac-cb35-45f4-9433-aabb1d66278b" xlink:to="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b29bb709-4609-45a3-a7ae-4a65d1e4aab6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:to="loc_us-gaap_ProductMember_b29bb709-4609-45a3-a7ae-4a65d1e4aab6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_3b8bf837-aa81-4394-a911-78c2efdbc060" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:to="loc_us-gaap_ServiceMember_3b8bf837-aa81-4394-a911-78c2efdbc060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TestingMember_26a4a844-0512-4e34-a0fa-7d2434e7b054" xlink:href="vcyt-20200331.xsd#vcyt_TestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:to="loc_vcyt_TestingMember_26a4a844-0512-4e34-a0fa-7d2434e7b054" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_PerceptaV2Member_fcd5f6ed-5f5a-482e-92d4-6b9701d8ea5a" xlink:href="vcyt-20200331.xsd#vcyt_PerceptaV2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:to="loc_vcyt_PerceptaV2Member_fcd5f6ed-5f5a-482e-92d4-6b9701d8ea5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NasaRISKMember_5334e902-cc3f-4b6a-b4ff-fc788d58c6f3" xlink:href="vcyt-20200331.xsd#vcyt_NasaRISKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:to="loc_vcyt_NasaRISKMember_5334e902-cc3f-4b6a-b4ff-fc788d58c6f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalMember_06993c8a-4cb1-4a1d-8e5a-1b94ed2f6963" xlink:href="vcyt-20200331.xsd#vcyt_BiopharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:to="loc_vcyt_BiopharmaceuticalMember_06993c8a-4cb1-4a1d-8e5a-1b94ed2f6963" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_825a22c9-9a85-478d-bc60-98e8cffdc5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_825a22c9-9a85-478d-bc60-98e8cffdc5ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_825a22c9-9a85-478d-bc60-98e8cffdc5ea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_825a22c9-9a85-478d-bc60-98e8cffdc5ea" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_825a22c9-9a85-478d-bc60-98e8cffdc5ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fe7a0806-643c-4d7b-8194-8e752efb2a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_825a22c9-9a85-478d-bc60-98e8cffdc5ea" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fe7a0806-643c-4d7b-8194-8e752efb2a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0f74ffd0-b79e-447f-bb61-f2ea781f7824" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fe7a0806-643c-4d7b-8194-8e752efb2a6d" xlink:to="loc_us-gaap_SalesRevenueNetMember_0f74ffd0-b79e-447f-bb61-f2ea781f7824" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d37992be-cdab-4c0b-8127-93307bcd2344" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d37992be-cdab-4c0b-8127-93307bcd2344" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d37992be-cdab-4c0b-8127-93307bcd2344_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d37992be-cdab-4c0b-8127-93307bcd2344" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d37992be-cdab-4c0b-8127-93307bcd2344_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b9ae44b7-067b-46aa-92ea-b1bea17afab4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d37992be-cdab-4c0b-8127-93307bcd2344" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b9ae44b7-067b-46aa-92ea-b1bea17afab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_9c52c4d9-97c7-422b-82eb-45b448eb0703" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b9ae44b7-067b-46aa-92ea-b1bea17afab4" xlink:to="loc_us-gaap_AccountsReceivableMember_9c52c4d9-97c7-422b-82eb-45b448eb0703" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8c5dc65d-9147-426f-b80f-fe83a3183027" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_srt_CounterpartyNameAxis_8c5dc65d-9147-426f-b80f-fe83a3183027" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c5dc65d-9147-426f-b80f-fe83a3183027_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8c5dc65d-9147-426f-b80f-fe83a3183027" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c5dc65d-9147-426f-b80f-fe83a3183027_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16136921-616e-438e-af79-5101e732cc70" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8c5dc65d-9147-426f-b80f-fe83a3183027" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16136921-616e-438e-af79-5101e732cc70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalCompanyMember_7d98f91c-1952-4fe8-9d00-bab19b01de1f" xlink:href="vcyt-20200331.xsd#vcyt_BiopharmaceuticalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16136921-616e-438e-af79-5101e732cc70" xlink:to="loc_vcyt_BiopharmaceuticalCompanyMember_7d98f91c-1952-4fe8-9d00-bab19b01de1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_e1a4a9ba-e93c-4583-a457-26c52162d88b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_e1a4a9ba-e93c-4583-a457-26c52162d88b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_e1a4a9ba-e93c-4583-a457-26c52162d88b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_e1a4a9ba-e93c-4583-a457-26c52162d88b" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_e1a4a9ba-e93c-4583-a457-26c52162d88b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_4ccaf117-bb15-4473-8640-a9cc399f14b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_e1a4a9ba-e93c-4583-a457-26c52162d88b" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_4ccaf117-bb15-4473-8640-a9cc399f14b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_RevenueRecognitionMember_4eb024be-ab8f-44f5-9e80-c601bb32f2b0" xlink:href="vcyt-20200331.xsd#vcyt_RevenueRecognitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_4ccaf117-bb15-4473-8640-a9cc399f14b7" xlink:to="loc_vcyt_RevenueRecognitionMember_4eb024be-ab8f-44f5-9e80-c601bb32f2b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e825c561-720b-49bf-ab4a-3bbc65eb7f2b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_srt_StatementGeographicalAxis_e825c561-720b-49bf-ab4a-3bbc65eb7f2b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e825c561-720b-49bf-ab4a-3bbc65eb7f2b_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e825c561-720b-49bf-ab4a-3bbc65eb7f2b" xlink:to="loc_srt_SegmentGeographicalDomain_e825c561-720b-49bf-ab4a-3bbc65eb7f2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a636f36c-8474-45aa-b5db-e5f3ce585432" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e825c561-720b-49bf-ab4a-3bbc65eb7f2b" xlink:to="loc_srt_SegmentGeographicalDomain_a636f36c-8474-45aa-b5db-e5f3ce585432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_23c362b7-6452-42f8-b378-edcf6bc08987" xlink:href="vcyt-20200331.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a636f36c-8474-45aa-b5db-e5f3ce585432" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_23c362b7-6452-42f8-b378-edcf6bc08987" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusinessCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails" xlink:type="extended" id="ib9fb8d0085704aedbfc4762e7a0cc8a3_OrganizationandDescriptionofBusinessCreditRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_0b219af5-800f-4299-b5fb-c8aa6bc951e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4b327aca-0b99-47af-a534-fa7bff4e5419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0b219af5-800f-4299-b5fb-c8aa6bc951e6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4b327aca-0b99-47af-a534-fa7bff4e5419" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_6cd77097-051f-4e58-943b-5920d40b8048" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0b219af5-800f-4299-b5fb-c8aa6bc951e6" xlink:to="loc_us-gaap_ConcentrationRiskTable_6cd77097-051f-4e58-943b-5920d40b8048" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_461d9bd1-3913-4522-9651-fc5ac1ab82fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_6cd77097-051f-4e58-943b-5920d40b8048" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_461d9bd1-3913-4522-9651-fc5ac1ab82fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_461d9bd1-3913-4522-9651-fc5ac1ab82fa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_461d9bd1-3913-4522-9651-fc5ac1ab82fa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_461d9bd1-3913-4522-9651-fc5ac1ab82fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f60b3f01-016a-44a5-a3d9-e93568284c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_461d9bd1-3913-4522-9651-fc5ac1ab82fa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f60b3f01-016a-44a5-a3d9-e93568284c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7f646c65-ed39-4722-a27a-9a9b45e42241" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f60b3f01-016a-44a5-a3d9-e93568284c4c" xlink:to="loc_us-gaap_SalesRevenueNetMember_7f646c65-ed39-4722-a27a-9a9b45e42241" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8aa35ce1-55ae-4846-a085-f1c77b79f2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f60b3f01-016a-44a5-a3d9-e93568284c4c" xlink:to="loc_us-gaap_AccountsReceivableMember_8aa35ce1-55ae-4846-a085-f1c77b79f2ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_68c96885-61b9-421e-9322-7cda6628d471" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_6cd77097-051f-4e58-943b-5920d40b8048" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_68c96885-61b9-421e-9322-7cda6628d471" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_68c96885-61b9-421e-9322-7cda6628d471_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_68c96885-61b9-421e-9322-7cda6628d471" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_68c96885-61b9-421e-9322-7cda6628d471_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8fc454bb-c0fc-4c54-a260-02364c2734df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_68c96885-61b9-421e-9322-7cda6628d471" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8fc454bb-c0fc-4c54-a260-02364c2734df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_39bede73-f330-4fcf-a7f6-76315e6b0070" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8fc454bb-c0fc-4c54-a260-02364c2734df" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_39bede73-f330-4fcf-a7f6-76315e6b0070" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_6969fe59-0433-4140-9566-6c5d862ab4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8fc454bb-c0fc-4c54-a260-02364c2734df" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_6969fe59-0433-4140-9566-6c5d862ab4c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_18771c24-b30a-4250-b248-0fd25cf1bfdd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_6cd77097-051f-4e58-943b-5920d40b8048" xlink:to="loc_srt_MajorCustomersAxis_18771c24-b30a-4250-b248-0fd25cf1bfdd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_18771c24-b30a-4250-b248-0fd25cf1bfdd_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_18771c24-b30a-4250-b248-0fd25cf1bfdd" xlink:to="loc_srt_NameOfMajorCustomerDomain_18771c24-b30a-4250-b248-0fd25cf1bfdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f3473e15-f044-485c-a061-cc9e7d7c82d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_18771c24-b30a-4250-b248-0fd25cf1bfdd" xlink:to="loc_srt_NameOfMajorCustomerDomain_f3473e15-f044-485c-a061-cc9e7d7c82d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_MedicareMember_28048dc6-f279-4e70-95ae-31a50a051ab2" xlink:href="vcyt-20200331.xsd#vcyt_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3473e15-f044-485c-a061-cc9e7d7c82d6" xlink:to="loc_vcyt_MedicareMember_28048dc6-f279-4e70-95ae-31a50a051ab2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_JohnsonJohnsonServicesInc.Member_b765dd6a-62b1-4742-9895-7eabf18632dc" xlink:href="vcyt-20200331.xsd#vcyt_JohnsonJohnsonServicesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3473e15-f044-485c-a061-cc9e7d7c82d6" xlink:to="loc_vcyt_JohnsonJohnsonServicesInc.Member_b765dd6a-62b1-4742-9895-7eabf18632dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_UnitedHealthcareMember_c2de4e40-17ae-41af-8297-dfed349aa22f" xlink:href="vcyt-20200331.xsd#vcyt_UnitedHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3473e15-f044-485c-a061-cc9e7d7c82d6" xlink:to="loc_vcyt_UnitedHealthcareMember_c2de4e40-17ae-41af-8297-dfed349aa22f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerCommonShare" xlink:type="simple" xlink:href="vcyt-20200331.xsd#NetLossPerCommonShare"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/NetLossPerCommonShare" xlink:type="extended" id="i737ac54f5b0a4b92a47f29e766a423c0_NetLossPerCommonShare"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerCommonShareTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#NetLossPerCommonShareTables"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/NetLossPerCommonShareTables" xlink:type="extended" id="i1ee36fed077e41aba54931f49fb1a68c_NetLossPerCommonShareTables"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerCommonShareDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#NetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/NetLossPerCommonShareDetails" xlink:type="extended" id="iacaa835fa20846c883f44598ca62a4cb_NetLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fa7e594f-85de-474b-8d70-1ee43923cb0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d32530ae-61c2-4f0e-8291-618344df8d91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fa7e594f-85de-474b-8d70-1ee43923cb0d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d32530ae-61c2-4f0e-8291-618344df8d91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c32d5b15-460d-4e21-a1ce-1e91f8f41dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fa7e594f-85de-474b-8d70-1ee43923cb0d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c32d5b15-460d-4e21-a1ce-1e91f8f41dbf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c193b099-162e-4cf0-bf45-9f7444e79825" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c32d5b15-460d-4e21-a1ce-1e91f8f41dbf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c193b099-162e-4cf0-bf45-9f7444e79825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c193b099-162e-4cf0-bf45-9f7444e79825_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c193b099-162e-4cf0-bf45-9f7444e79825" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c193b099-162e-4cf0-bf45-9f7444e79825_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e87a6054-f1ed-4f0f-902f-27afe810fa17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c193b099-162e-4cf0-bf45-9f7444e79825" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e87a6054-f1ed-4f0f-902f-27afe810fa17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_326e8eb1-bbed-406f-9f47-89d580a5c976" xlink:href="vcyt-20200331.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e87a6054-f1ed-4f0f-902f-27afe810fa17" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_326e8eb1-bbed-406f-9f47-89d580a5c976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2ee23796-16a8-45b4-9f37-b1f0dd4995b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e87a6054-f1ed-4f0f-902f-27afe810fa17" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2ee23796-16a8-45b4-9f37-b1f0dd4995b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_53b50c78-282f-4d6e-8eb5-1ee0a23680ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e87a6054-f1ed-4f0f-902f-27afe810fa17" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_53b50c78-282f-4d6e-8eb5-1ee0a23680ea" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="vcyt-20200331.xsd#AccruedLiabilities"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/AccruedLiabilities" xlink:type="extended" id="if7556ad443f44f2d8ee4fc902e4425c8_AccruedLiabilities"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#AccruedLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/AccruedLiabilitiesTables" xlink:type="extended" id="i0f3a3ef1236c4f479d355e9e93afbeb2_AccruedLiabilitiesTables"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#AccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/AccruedLiabilitiesDetails" xlink:type="extended" id="i84b363990571426e950369ec909ded75_AccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombination" xlink:type="simple" xlink:href="vcyt-20200331.xsd#BusinessCombination"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BusinessCombination" xlink:type="extended" id="ie177e8e26f154f999a9e30977c6ad790_BusinessCombination"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#BusinessCombinationsTables"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BusinessCombinationsTables" xlink:type="extended" id="i5299fbfc6ac94600a62edd9afa40747d_BusinessCombinationsTables"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationsDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#BusinessCombinationsDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BusinessCombinationsDetails" xlink:type="extended" id="i8c34879c7a7b4cbfa1e04a46289dc9c0_BusinessCombinationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_be105bc9-2468-40c4-8182-1ce82263329f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_be105bc9-2468-40c4-8182-1ce82263329f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_5e5182d4-6ca6-4316-a49a-cd19699e3fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_5e5182d4-6ca6-4316-a49a-cd19699e3fe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_ea170961-f859-4009-9769-69f9460c390a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_ea170961-f859-4009-9769-69f9460c390a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d96b5452-3ce7-4268-bc88-ed9e8def4450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d96b5452-3ce7-4268-bc88-ed9e8def4450" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3b0105f8-4f6e-4f87-8d2b-d51b72d92ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:to="loc_us-gaap_Goodwill_3b0105f8-4f6e-4f87-8d2b-d51b72d92ad8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fee3eb95-efe1-4c0c-96eb-0423f6dd3eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fee3eb95-efe1-4c0c-96eb-0423f6dd3eb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9c06dfb9-06b0-40cf-8f2a-3dd615aeca8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fee3eb95-efe1-4c0c-96eb-0423f6dd3eb3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9c06dfb9-06b0-40cf-8f2a-3dd615aeca8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9c06dfb9-06b0-40cf-8f2a-3dd615aeca8a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9c06dfb9-06b0-40cf-8f2a-3dd615aeca8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9c06dfb9-06b0-40cf-8f2a-3dd615aeca8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44631479-bce1-48d4-bb4d-743284096250" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9c06dfb9-06b0-40cf-8f2a-3dd615aeca8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44631479-bce1-48d4-bb4d-743284096250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NanoStringMember_db5b4f5c-4ba5-4dde-9b88-f1f41705564a" xlink:href="vcyt-20200331.xsd#vcyt_NanoStringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44631479-bce1-48d4-bb4d-743284096250" xlink:to="loc_vcyt_NanoStringMember_db5b4f5c-4ba5-4dde-9b88-f1f41705564a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fdf96453-2897-4c5a-acf5-9ad99180d81a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fee3eb95-efe1-4c0c-96eb-0423f6dd3eb3" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fdf96453-2897-4c5a-acf5-9ad99180d81a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_fdf96453-2897-4c5a-acf5-9ad99180d81a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fdf96453-2897-4c5a-acf5-9ad99180d81a" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_fdf96453-2897-4c5a-acf5-9ad99180d81a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0cc52c40-65cb-4bc4-8c4d-6d47abed2862" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fdf96453-2897-4c5a-acf5-9ad99180d81a" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0cc52c40-65cb-4bc4-8c4d-6d47abed2862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2290e0ef-8140-4d9d-aa69-32012ad17b75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0cc52c40-65cb-4bc4-8c4d-6d47abed2862" xlink:to="loc_us-gaap_CommonStockMember_2290e0ef-8140-4d9d-aa69-32012ad17b75" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#BusinessCombinationAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails" xlink:type="extended" id="i0739bb672cc743d49ace6cbc72e9293c_BusinessCombinationAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b101b169-4221-478b-9091-5edf4edbf6f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1276c568-993e-4fe1-9b62-febee2962784" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b101b169-4221-478b-9091-5edf4edbf6f1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1276c568-993e-4fe1-9b62-febee2962784" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5698c5c3-68c4-41c6-bb3f-dfbcd147f7fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b101b169-4221-478b-9091-5edf4edbf6f1" xlink:to="loc_us-gaap_Goodwill_5698c5c3-68c4-41c6-bb3f-dfbcd147f7fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ceba4353-011c-40dc-ba23-e55017a3c555" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b101b169-4221-478b-9091-5edf4edbf6f1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ceba4353-011c-40dc-ba23-e55017a3c555" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5d9f9ba5-34f7-4341-b275-1e80d00e058f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b101b169-4221-478b-9091-5edf4edbf6f1" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5d9f9ba5-34f7-4341-b275-1e80d00e058f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d5f7f14-2f10-408e-bf15-f68edc8bcfad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b101b169-4221-478b-9091-5edf4edbf6f1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d5f7f14-2f10-408e-bf15-f68edc8bcfad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_79101e95-6cc1-4ad0-bf4c-81a10d9bc37a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d5f7f14-2f10-408e-bf15-f68edc8bcfad" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_79101e95-6cc1-4ad0-bf4c-81a10d9bc37a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_79101e95-6cc1-4ad0-bf4c-81a10d9bc37a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79101e95-6cc1-4ad0-bf4c-81a10d9bc37a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_79101e95-6cc1-4ad0-bf4c-81a10d9bc37a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e284fe1f-1cd7-4f13-89e8-4bb8b59e0870" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79101e95-6cc1-4ad0-bf4c-81a10d9bc37a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e284fe1f-1cd7-4f13-89e8-4bb8b59e0870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NanoStringMember_e7807388-e70b-4305-9d56-8445f7e47562" xlink:href="vcyt-20200331.xsd#vcyt_NanoStringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e284fe1f-1cd7-4f13-89e8-4bb8b59e0870" xlink:to="loc_vcyt_NanoStringMember_e7807388-e70b-4305-9d56-8445f7e47562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2172cd39-b043-4f79-9ea6-c7d4e7d4a1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d5f7f14-2f10-408e-bf15-f68edc8bcfad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2172cd39-b043-4f79-9ea6-c7d4e7d4a1c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2172cd39-b043-4f79-9ea6-c7d4e7d4a1c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2172cd39-b043-4f79-9ea6-c7d4e7d4a1c8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2172cd39-b043-4f79-9ea6-c7d4e7d4a1c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58279d8f-172e-4ae0-bb4c-1e2bc130c5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2172cd39-b043-4f79-9ea6-c7d4e7d4a1c8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58279d8f-172e-4ae0-bb4c-1e2bc130c5ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DevelopedProductTechnologyMember_8011bd13-291b-49ec-84eb-2ebbf16f0dc4" xlink:href="vcyt-20200331.xsd#vcyt_DevelopedProductTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58279d8f-172e-4ae0-bb4c-1e2bc130c5ba" xlink:to="loc_vcyt_DevelopedProductTechnologyMember_8011bd13-291b-49ec-84eb-2ebbf16f0dc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_34cbac98-23c7-48c5-9ad9-479de0a3c9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58279d8f-172e-4ae0-bb4c-1e2bc130c5ba" xlink:to="loc_us-gaap_CustomerRelationshipsMember_34cbac98-23c7-48c5-9ad9-479de0a3c9c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NCounterFLEXDxLicenseMember_c419983f-ab17-43ec-b657-a0147cfe40a7" xlink:href="vcyt-20200331.xsd#vcyt_NCounterFLEXDxLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58279d8f-172e-4ae0-bb4c-1e2bc130c5ba" xlink:to="loc_vcyt_NCounterFLEXDxLicenseMember_c419983f-ab17-43ec-b657-a0147cfe40a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LymphMarkProductTechnologyMember_7b676dc1-c09a-4666-a9f5-a5b82a005a5f" xlink:href="vcyt-20200331.xsd#vcyt_LymphMarkProductTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58279d8f-172e-4ae0-bb4c-1e2bc130c5ba" xlink:to="loc_vcyt_LymphMarkProductTechnologyMember_7b676dc1-c09a-4666-a9f5-a5b82a005a5f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="vcyt-20200331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/FairValueMeasurements" xlink:type="extended" id="ie6e71a1eb8be42718ac7aebd4aff35ce_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="ia49bd420f5fd46f5b3b5833aa74164e6_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7d5f092c-723b-4be7-8bd1-08a60c1f57b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7d5f092c-723b-4be7-8bd1-08a60c1f57b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_477bbeee-0870-46a4-83bf-f3f6c82c1816" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_477bbeee-0870-46a4-83bf-f3f6c82c1816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_23ce2294-a87f-48f0-9eef-a8d5c60c5bca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_23ce2294-a87f-48f0-9eef-a8d5c60c5bca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c21a4cfe-016d-4bd8-a8b6-09ca7688d9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c21a4cfe-016d-4bd8-a8b6-09ca7688d9c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_f9209dc9-c451-4001-8722-56d6a467cc17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_f9209dc9-c451-4001-8722-56d6a467cc17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a71a6af5-2c05-4a61-8ea8-2eb66e8fdec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a71a6af5-2c05-4a61-8ea8-2eb66e8fdec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a71a6af5-2c05-4a61-8ea8-2eb66e8fdec7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a71a6af5-2c05-4a61-8ea8-2eb66e8fdec7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a71a6af5-2c05-4a61-8ea8-2eb66e8fdec7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c093be89-7f33-4e2d-8680-579b9a2e0925" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a71a6af5-2c05-4a61-8ea8-2eb66e8fdec7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c093be89-7f33-4e2d-8680-579b9a2e0925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OvernightRepurchaseAgreementsMember_5d4bc53e-d270-49d1-acdd-f8dfde057e85" xlink:href="vcyt-20200331.xsd#vcyt_OvernightRepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c093be89-7f33-4e2d-8680-579b9a2e0925" xlink:to="loc_vcyt_OvernightRepurchaseAgreementsMember_5d4bc53e-d270-49d1-acdd-f8dfde057e85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41bb6f70-d10f-4e10-9444-d994eaad6cea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41bb6f70-d10f-4e10-9444-d994eaad6cea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41bb6f70-d10f-4e10-9444-d994eaad6cea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41bb6f70-d10f-4e10-9444-d994eaad6cea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41bb6f70-d10f-4e10-9444-d994eaad6cea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1156b02a-7ccf-491d-b82f-78350b4e5266" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41bb6f70-d10f-4e10-9444-d994eaad6cea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1156b02a-7ccf-491d-b82f-78350b4e5266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7bca2416-3897-4bad-8ad5-a728a0f01151" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1156b02a-7ccf-491d-b82f-78350b4e5266" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7bca2416-3897-4bad-8ad5-a728a0f01151" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b1350d62-d0fb-46fe-8040-875cb971f5b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1156b02a-7ccf-491d-b82f-78350b4e5266" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b1350d62-d0fb-46fe-8040-875cb971f5b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_daf2d2d8-8ce4-45cd-8fa9-c70ac96f2c5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_daf2d2d8-8ce4-45cd-8fa9-c70ac96f2c5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_daf2d2d8-8ce4-45cd-8fa9-c70ac96f2c5a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_daf2d2d8-8ce4-45cd-8fa9-c70ac96f2c5a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_daf2d2d8-8ce4-45cd-8fa9-c70ac96f2c5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f945223c-6866-4a97-b5c0-29f53684c6ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_daf2d2d8-8ce4-45cd-8fa9-c70ac96f2c5a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f945223c-6866-4a97-b5c0-29f53684c6ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9353a72a-6657-4aae-85de-526ce32110a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f945223c-6866-4a97-b5c0-29f53684c6ee" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9353a72a-6657-4aae-85de-526ce32110a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_879d2d6b-f20f-420d-aaeb-3f7cd04dfcb6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:to="loc_srt_StatementGeographicalAxis_879d2d6b-f20f-420d-aaeb-3f7cd04dfcb6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_879d2d6b-f20f-420d-aaeb-3f7cd04dfcb6_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_879d2d6b-f20f-420d-aaeb-3f7cd04dfcb6" xlink:to="loc_srt_SegmentGeographicalDomain_879d2d6b-f20f-420d-aaeb-3f7cd04dfcb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5d0e82fa-cd94-4413-8ce3-930f027daf98" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_879d2d6b-f20f-420d-aaeb-3f7cd04dfcb6" xlink:to="loc_srt_SegmentGeographicalDomain_5d0e82fa-cd94-4413-8ce3-930f027daf98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_7efa0f90-1dfe-479d-aed2-c38a7d8a35bc" xlink:href="vcyt-20200331.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d0e82fa-cd94-4413-8ce3-930f027daf98" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_7efa0f90-1dfe-479d-aed2-c38a7d8a35bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2b65deac-9500-4c4f-a786-3bb059f8c0df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2b65deac-9500-4c4f-a786-3bb059f8c0df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b65deac-9500-4c4f-a786-3bb059f8c0df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2b65deac-9500-4c4f-a786-3bb059f8c0df" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b65deac-9500-4c4f-a786-3bb059f8c0df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af67eb66-e57a-45c2-860a-d263bb6e2814" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2b65deac-9500-4c4f-a786-3bb059f8c0df" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af67eb66-e57a-45c2-860a-d263bb6e2814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NanoStringMember_9d5ef204-9b0a-4444-aea1-059efeab53dd" xlink:href="vcyt-20200331.xsd#vcyt_NanoStringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af67eb66-e57a-45c2-860a-d263bb6e2814" xlink:to="loc_vcyt_NanoStringMember_9d5ef204-9b0a-4444-aea1-059efeab53dd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingencies" xlink:type="extended" id="i13ca707487c944d5a2c00aa2ac7455a9_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="ib56c33fccf1d445eb9afc9f20ce8cb88_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CommitmentsandContingenciesOperatingLeaseDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails" xlink:type="extended" id="i4f19ee7d9d1a41949a1c7016869b02b4_CommitmentsandContingenciesOperatingLeaseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_6433b478-236b-4f34-a16c-c314f1a2e0f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_26b95ee4-a9f7-46c9-9ee9-ead8ee0487f5" xlink:href="vcyt-20200331.xsd#vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6433b478-236b-4f34-a16c-c314f1a2e0f2" xlink:to="loc_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_26b95ee4-a9f7-46c9-9ee9-ead8ee0487f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_85297618-90f1-4f6e-b9cd-a08e2868c6cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6433b478-236b-4f34-a16c-c314f1a2e0f2" xlink:to="loc_us-gaap_SecurityDeposit_85297618-90f1-4f6e-b9cd-a08e2868c6cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6433b478-236b-4f34-a16c-c314f1a2e0f2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ea4119e9-7c78-42b1-bec7-ad9ff515d3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ea4119e9-7c78-42b1-bec7-ad9ff515d3c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_10f12148-f722-4988-a77f-0b93c4b7bba8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_10f12148-f722-4988-a77f-0b93c4b7bba8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_70bf13c9-b603-46b9-b755-beea03e3f704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_70bf13c9-b603-46b9-b755-beea03e3f704" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f738e2bc-d84f-4bc7-b447-726858619699" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f738e2bc-d84f-4bc7-b447-726858619699" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d432ae74-3bf1-4150-b475-dc59f3b7fa27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d432ae74-3bf1-4150-b475-dc59f3b7fa27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b609be53-1e35-48c4-958d-bdb19330ead0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b609be53-1e35-48c4-958d-bdb19330ead0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f5bbe393-a031-47d7-8577-bd40797b5f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f5bbe393-a031-47d7-8577-bd40797b5f2b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37dfb829-71db-4b3e-952d-a15367dae455" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37dfb829-71db-4b3e-952d-a15367dae455" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f5321115-5754-4797-ba22-7934aba3ddd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_OperatingLeaseLiability_f5321115-5754-4797-ba22-7934aba3ddd5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8be72e53-19f8-4748-b24a-3a332d50cc37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8be72e53-19f8-4748-b24a-3a332d50cc37" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b10999b-60ed-44ae-8287-fbd67095fabb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b10999b-60ed-44ae-8287-fbd67095fabb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_45746965-28a2-4b7e-b75c-d42bb538122d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6433b478-236b-4f34-a16c-c314f1a2e0f2" xlink:to="loc_us-gaap_OperatingLeaseExpense_45746965-28a2-4b7e-b75c-d42bb538122d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24078995-8407-441e-9603-2d4c7f105dba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6433b478-236b-4f34-a16c-c314f1a2e0f2" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24078995-8407-441e-9603-2d4c7f105dba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e3db2578-d1a9-4efc-ba6c-fae1168fbe5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24078995-8407-441e-9603-2d4c7f105dba" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e3db2578-d1a9-4efc-ba6c-fae1168fbe5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e3db2578-d1a9-4efc-ba6c-fae1168fbe5d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e3db2578-d1a9-4efc-ba6c-fae1168fbe5d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e3db2578-d1a9-4efc-ba6c-fae1168fbe5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_23d0f862-52ee-4d4e-be55-31e21fc38e28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e3db2578-d1a9-4efc-ba6c-fae1168fbe5d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_23d0f862-52ee-4d4e-be55-31e21fc38e28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e694536d-8a43-4e8d-aeef-41efe80fa719" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_23d0f862-52ee-4d4e-be55-31e21fc38e28" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e694536d-8a43-4e8d-aeef-41efe80fa719" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3a1e0b01-fca8-4936-a06a-78bb29494bd8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24078995-8407-441e-9603-2d4c7f105dba" xlink:to="loc_srt_StatementGeographicalAxis_3a1e0b01-fca8-4936-a06a-78bb29494bd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3a1e0b01-fca8-4936-a06a-78bb29494bd8_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3a1e0b01-fca8-4936-a06a-78bb29494bd8" xlink:to="loc_srt_SegmentGeographicalDomain_3a1e0b01-fca8-4936-a06a-78bb29494bd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_194d0297-0c23-4e03-9475-b1b9b0f7c307" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3a1e0b01-fca8-4936-a06a-78bb29494bd8" xlink:to="loc_srt_SegmentGeographicalDomain_194d0297-0c23-4e03-9475-b1b9b0f7c307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_5500a973-8e7a-49a1-a4c0-61ee9abc1e62" xlink:href="vcyt-20200331.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_194d0297-0c23-4e03-9475-b1b9b0f7c307" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_5500a973-8e7a-49a1-a4c0-61ee9abc1e62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LaboratoryFacilitiesAustinTexasMember_5e859be5-e94b-4cbe-a3db-1fbffc5ec2fd" xlink:href="vcyt-20200331.xsd#vcyt_LaboratoryFacilitiesAustinTexasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_194d0297-0c23-4e03-9475-b1b9b0f7c307" xlink:to="loc_vcyt_LaboratoryFacilitiesAustinTexasMember_5e859be5-e94b-4cbe-a3db-1fbffc5ec2fd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/Debt" xlink:type="simple" xlink:href="vcyt-20200331.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/Debt" xlink:type="extended" id="i4192970d20ae4c3bbd39e5c41993469d_Debt"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#DebtTables"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/DebtTables" xlink:type="extended" id="i0c62d6912b3045708749f0a8986a2b37_DebtTables"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/DebtNarrativeDetails" xlink:type="extended" id="icf9736e0a0e248aa8988b246eb8c9364_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ab373d6d-3b6b-4bad-a5a4-be84de9a2c35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ab373d6d-3b6b-4bad-a5a4-be84de9a2c35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b1e8d741-4d69-47d3-8a71-e8a9207b55d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b1e8d741-4d69-47d3-8a71-e8a9207b55d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fd626685-8bc3-4068-b109-75f89c1fe80a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fd626685-8bc3-4068-b109-75f89c1fe80a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_72d285d3-03dd-488e-b9bb-6f231e309b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_72d285d3-03dd-488e-b9bb-6f231e309b5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtInstrumentPrepaymentPremium_a04e03a5-7c5b-41d2-bcbf-ff23f97131cb" xlink:href="vcyt-20200331.xsd#vcyt_DebtInstrumentPrepaymentPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_vcyt_DebtInstrumentPrepaymentPremium_a04e03a5-7c5b-41d2-bcbf-ff23f97131cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8143c571-b268-4329-a959-73e8008d68ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8143c571-b268-4329-a959-73e8008d68ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_980b7e29-8f24-4ca7-8934-15a88531e3b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_980b7e29-8f24-4ca7-8934-15a88531e3b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LiquidityRequirementMinimum_8efebf3e-9af5-4d11-8c62-34b444d3540b" xlink:href="vcyt-20200331.xsd#vcyt_LiquidityRequirementMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_vcyt_LiquidityRequirementMinimum_8efebf3e-9af5-4d11-8c62-34b444d3540b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_18e913ed-12cd-4cf1-9616-d2f9c76a9e72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_18e913ed-12cd-4cf1-9616-d2f9c76a9e72" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPrepaymentTrancheAxis_590ca394-be37-40df-8cf6-8c6f32ac29fd" xlink:href="vcyt-20200331.xsd#vcyt_DebtPrepaymentTrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:to="loc_vcyt_DebtPrepaymentTrancheAxis_590ca394-be37-40df-8cf6-8c6f32ac29fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPaymentTrancheDomain_590ca394-be37-40df-8cf6-8c6f32ac29fd_default" xlink:href="vcyt-20200331.xsd#vcyt_DebtPaymentTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vcyt_DebtPrepaymentTrancheAxis_590ca394-be37-40df-8cf6-8c6f32ac29fd" xlink:to="loc_vcyt_DebtPaymentTrancheDomain_590ca394-be37-40df-8cf6-8c6f32ac29fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPaymentTrancheDomain_4da1b98e-cee2-433e-a721-6a6a79be6cbd" xlink:href="vcyt-20200331.xsd#vcyt_DebtPaymentTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vcyt_DebtPrepaymentTrancheAxis_590ca394-be37-40df-8cf6-8c6f32ac29fd" xlink:to="loc_vcyt_DebtPaymentTrancheDomain_4da1b98e-cee2-433e-a721-6a6a79be6cbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPrepaymentTrancheOneMember_4681ff7a-2955-4200-8023-e0e50a24cf85" xlink:href="vcyt-20200331.xsd#vcyt_DebtPrepaymentTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_DebtPaymentTrancheDomain_4da1b98e-cee2-433e-a721-6a6a79be6cbd" xlink:to="loc_vcyt_DebtPrepaymentTrancheOneMember_4681ff7a-2955-4200-8023-e0e50a24cf85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPrepaymentTrancheTwoMember_2bf3b3b0-4640-4947-9c42-453426070262" xlink:href="vcyt-20200331.xsd#vcyt_DebtPrepaymentTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_DebtPaymentTrancheDomain_4da1b98e-cee2-433e-a721-6a6a79be6cbd" xlink:to="loc_vcyt_DebtPrepaymentTrancheTwoMember_2bf3b3b0-4640-4947-9c42-453426070262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPrepaymentTrancheThreeMember_baf71a2a-6a34-42ae-a7fa-cbf309323615" xlink:href="vcyt-20200331.xsd#vcyt_DebtPrepaymentTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_DebtPaymentTrancheDomain_4da1b98e-cee2-433e-a721-6a6a79be6cbd" xlink:to="loc_vcyt_DebtPrepaymentTrancheThreeMember_baf71a2a-6a34-42ae-a7fa-cbf309323615" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_990b2f33-0732-424b-b35b-43babad12990" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:to="loc_us-gaap_CreditFacilityAxis_990b2f33-0732-424b-b35b-43babad12990" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_990b2f33-0732-424b-b35b-43babad12990_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_990b2f33-0732-424b-b35b-43babad12990" xlink:to="loc_us-gaap_CreditFacilityDomain_990b2f33-0732-424b-b35b-43babad12990_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_53aa4555-02f4-4766-9183-6806ad64b0ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_990b2f33-0732-424b-b35b-43babad12990" xlink:to="loc_us-gaap_CreditFacilityDomain_53aa4555-02f4-4766-9183-6806ad64b0ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_36c973ca-b378-43c0-8b85-33cb6e791d64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_53aa4555-02f4-4766-9183-6806ad64b0ea" xlink:to="loc_us-gaap_SecuredDebtMember_36c973ca-b378-43c0-8b85-33cb6e791d64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2a754ec2-bcd2-4c9d-b7c8-4bfa65b25929" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_53aa4555-02f4-4766-9183-6806ad64b0ea" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2a754ec2-bcd2-4c9d-b7c8-4bfa65b25929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_4b589af9-381c-410b-bf07-4cea2913376e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_4b589af9-381c-410b-bf07-4cea2913376e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_4b589af9-381c-410b-bf07-4cea2913376e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_4b589af9-381c-410b-bf07-4cea2913376e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_4b589af9-381c-410b-bf07-4cea2913376e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8b0dd2a2-1197-4b22-91d0-21c721ef6b87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_4b589af9-381c-410b-bf07-4cea2913376e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8b0dd2a2-1197-4b22-91d0-21c721ef6b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_SiliconValleyBankMember_5643a38b-b7de-4300-97f0-8a8a6cc2e1de" xlink:href="vcyt-20200331.xsd#vcyt_SiliconValleyBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8b0dd2a2-1197-4b22-91d0-21c721ef6b87" xlink:to="loc_vcyt_SiliconValleyBankMember_5643a38b-b7de-4300-97f0-8a8a6cc2e1de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ac30727e-94df-4532-8e34-5dca3d70ce52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ac30727e-94df-4532-8e34-5dca3d70ce52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ac30727e-94df-4532-8e34-5dca3d70ce52_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ac30727e-94df-4532-8e34-5dca3d70ce52" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ac30727e-94df-4532-8e34-5dca3d70ce52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d657d93c-2c26-4979-b2b2-6e000262665c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ac30727e-94df-4532-8e34-5dca3d70ce52" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d657d93c-2c26-4979-b2b2-6e000262665c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d3798cfe-d7e7-4f32-9d0d-ff3f62c335e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d657d93c-2c26-4979-b2b2-6e000262665c" xlink:to="loc_us-gaap_LineOfCreditMember_d3798cfe-d7e7-4f32-9d0d-ff3f62c335e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7568f1e5-0010-4d3b-bbc8-5c2161738a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:to="loc_us-gaap_VariableRateAxis_7568f1e5-0010-4d3b-bbc8-5c2161738a6b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7568f1e5-0010-4d3b-bbc8-5c2161738a6b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_7568f1e5-0010-4d3b-bbc8-5c2161738a6b" xlink:to="loc_us-gaap_VariableRateDomain_7568f1e5-0010-4d3b-bbc8-5c2161738a6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a522b94a-0062-4e3d-9bc1-b3d478024f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_7568f1e5-0010-4d3b-bbc8-5c2161738a6b" xlink:to="loc_us-gaap_VariableRateDomain_a522b94a-0062-4e3d-9bc1-b3d478024f1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a6d2cebc-4e83-488e-8995-b01447242f87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a522b94a-0062-4e3d-9bc1-b3d478024f1b" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a6d2cebc-4e83-488e-8995-b01447242f87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b6394d01-b1b2-48e6-8c12-6d4d9fc45b4d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:to="loc_srt_RangeAxis_b6394d01-b1b2-48e6-8c12-6d4d9fc45b4d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b6394d01-b1b2-48e6-8c12-6d4d9fc45b4d_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b6394d01-b1b2-48e6-8c12-6d4d9fc45b4d" xlink:to="loc_srt_RangeMember_b6394d01-b1b2-48e6-8c12-6d4d9fc45b4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45f9da30-45e8-4b98-9fed-01b6d3fdf275" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b6394d01-b1b2-48e6-8c12-6d4d9fc45b4d" xlink:to="loc_srt_RangeMember_45f9da30-45e8-4b98-9fed-01b6d3fdf275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_12110a05-610d-4aa5-8f89-68cd7f2978e9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45f9da30-45e8-4b98-9fed-01b6d3fdf275" xlink:to="loc_srt_MinimumMember_12110a05-610d-4aa5-8f89-68cd7f2978e9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#DebtDebtObligationforBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails" xlink:type="extended" id="i17e87cc5d2e74be7ae2d95346189343e_DebtDebtObligationforBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_331e02ab-b130-47b7-97b4-47e91ebf4ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_905108d2-b23d-4dd9-9db1-472a21cb84a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_331e02ab-b130-47b7-97b4-47e91ebf4ea2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_905108d2-b23d-4dd9-9db1-472a21cb84a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_baff8475-3ddb-4808-b53f-c55a13a2cf61" xlink:href="vcyt-20200331.xsd#vcyt_DebtInstrumentEndOfTermInterestObligationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_331e02ab-b130-47b7-97b4-47e91ebf4ea2" xlink:to="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_baff8475-3ddb-4808-b53f-c55a13a2cf61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9a9a27bd-a53d-453d-8aa6-858b0bbf70b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_331e02ab-b130-47b7-97b4-47e91ebf4ea2" xlink:to="loc_us-gaap_LongTermDebt_9a9a27bd-a53d-453d-8aa6-858b0bbf70b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a3818229-e99b-4885-b78c-a3b42c7f818d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_331e02ab-b130-47b7-97b4-47e91ebf4ea2" xlink:to="loc_us-gaap_DebtInstrumentTable_a3818229-e99b-4885-b78c-a3b42c7f818d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2ef38a05-f479-4fee-b855-f5b1b0b10bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a3818229-e99b-4885-b78c-a3b42c7f818d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2ef38a05-f479-4fee-b855-f5b1b0b10bc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2ef38a05-f479-4fee-b855-f5b1b0b10bc3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2ef38a05-f479-4fee-b855-f5b1b0b10bc3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2ef38a05-f479-4fee-b855-f5b1b0b10bc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9c9f3720-920c-4027-accd-5c7ea5abb234" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2ef38a05-f479-4fee-b855-f5b1b0b10bc3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9c9f3720-920c-4027-accd-5c7ea5abb234" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d99fa05e-b074-4742-84c2-65b47d141186" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c9f3720-920c-4027-accd-5c7ea5abb234" xlink:to="loc_us-gaap_LineOfCreditMember_d99fa05e-b074-4742-84c2-65b47d141186" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquity" xlink:type="simple" xlink:href="vcyt-20200331.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockholdersEquity" xlink:type="extended" id="i1904f2c89a4f46dcb6f3b2b19e77cc2f_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockholdersEquityTables" xlink:type="extended" id="i46863c990e6c4a3ea2772cd2e5a54225_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="extended" id="i86f750177f6b4e6f8ec8922b06f52c8a_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_65e77eac-feae-4e39-b34e-da3532a623e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_CommonStockAbstract_b877c2f9-755f-4fd5-b38d-2097de508f9e" xlink:href="vcyt-20200331.xsd#vcyt_CommonStockAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_65e77eac-feae-4e39-b34e-da3532a623e0" xlink:to="loc_vcyt_CommonStockAbstract_b877c2f9-755f-4fd5-b38d-2097de508f9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4f0a574c-91e1-4a7b-8e88-66a6b284a9e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_b877c2f9-755f-4fd5-b38d-2097de508f9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4f0a574c-91e1-4a7b-8e88-66a6b284a9e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e99faab7-0232-4530-8236-02e71309dd21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_b877c2f9-755f-4fd5-b38d-2097de508f9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e99faab7-0232-4530-8236-02e71309dd21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ac704050-1535-4323-bd30-61e708c39243" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_b877c2f9-755f-4fd5-b38d-2097de508f9e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ac704050-1535-4323-bd30-61e708c39243" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5438c2f4-b989-4d2e-852c-3078b5b8bc8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_65e77eac-feae-4e39-b34e-da3532a623e0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5438c2f4-b989-4d2e-852c-3078b5b8bc8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3f773db7-c8fd-4c1f-b18a-4b3d20fefcbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5438c2f4-b989-4d2e-852c-3078b5b8bc8c" xlink:to="loc_us-gaap_AwardTypeAxis_3f773db7-c8fd-4c1f-b18a-4b3d20fefcbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f773db7-c8fd-4c1f-b18a-4b3d20fefcbd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3f773db7-c8fd-4c1f-b18a-4b3d20fefcbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f773db7-c8fd-4c1f-b18a-4b3d20fefcbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633b0ebc-2bde-46b4-a710-4ab09f408614" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3f773db7-c8fd-4c1f-b18a-4b3d20fefcbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633b0ebc-2bde-46b4-a710-4ab09f408614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_b18b638a-8279-49eb-9c60-c2147ca692f6" xlink:href="vcyt-20200331.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633b0ebc-2bde-46b4-a710-4ab09f408614" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_b18b638a-8279-49eb-9c60-c2147ca692f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bdaabb01-1bed-4397-ac39-2519cfebd339" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633b0ebc-2bde-46b4-a710-4ab09f408614" xlink:to="loc_us-gaap_EmployeeStockMember_bdaabb01-1bed-4397-ac39-2519cfebd339" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartners" xlink:type="simple" xlink:href="vcyt-20200331.xsd#ThyroidCytopathologyPartners"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/ThyroidCytopathologyPartners" xlink:type="extended" id="i0f4fdcc54ca04497966878b451643b7f_ThyroidCytopathologyPartners"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#ThyroidCytopathologyPartnersDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails" xlink:type="extended" id="i143f159b6c9b4bdebd6864d52c95dcc7_ThyroidCytopathologyPartnersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_880c860c-da89-441a-9786-81ccdfb3e7e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AgreementTermsNonRenewalNoticePeriod_9513704c-2a93-4bea-9704-5b7d2b15e3b9" xlink:href="vcyt-20200331.xsd#vcyt_AgreementTermsNonRenewalNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_880c860c-da89-441a-9786-81ccdfb3e7e7" xlink:to="loc_vcyt_AgreementTermsNonRenewalNoticePeriod_9513704c-2a93-4bea-9704-5b7d2b15e3b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherIncomeRentReimbursement_0ab1ab07-ea0a-4269-b44e-f7d7c54ba720" xlink:href="vcyt-20200331.xsd#vcyt_OtherIncomeRentReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_880c860c-da89-441a-9786-81ccdfb3e7e7" xlink:to="loc_vcyt_OtherIncomeRentReimbursement_0ab1ab07-ea0a-4269-b44e-f7d7c54ba720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_835f197b-d5e4-4cf5-a64b-2150bc807d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_880c860c-da89-441a-9786-81ccdfb3e7e7" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_835f197b-d5e4-4cf5-a64b-2150bc807d2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_37c557a0-8a49-4955-bc8c-2b9fdedd1be3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_835f197b-d5e4-4cf5-a64b-2150bc807d2d" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_37c557a0-8a49-4955-bc8c-2b9fdedd1be3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_37c557a0-8a49-4955-bc8c-2b9fdedd1be3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_37c557a0-8a49-4955-bc8c-2b9fdedd1be3" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_37c557a0-8a49-4955-bc8c-2b9fdedd1be3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_3319e65e-0047-4a23-bde0-a7af51192bef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_37c557a0-8a49-4955-bc8c-2b9fdedd1be3" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_3319e65e-0047-4a23-bde0-a7af51192bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_5bf4f38a-a0df-4766-a54a-cd38a81a6cac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_3319e65e-0047-4a23-bde0-a7af51192bef" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_5bf4f38a-a0df-4766-a54a-cd38a81a6cac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxes" xlink:type="simple" xlink:href="vcyt-20200331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/IncomeTaxes" xlink:type="extended" id="i07099145a97049c09bc789a785a78cb8_IncomeTaxes"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>vcyt-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:0005b3b4-1d3d-4b06-88c1-edf8f62a1620,g:32b86441-5460-4f29-850a-a85559dff3e5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_56237bab-213c-4989-8b72-26f54d57ccfe_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prosigna customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_NumberOfDiseaseAreasWithGenomicTesting_562fec98-18e8-4b34-b583-14542537a064_terseLabel_en-US" xlink:label="lab_vcyt_NumberOfDiseaseAreasWithGenomicTesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of disease areas with genomic testing</link:label>
    <link:label id="lab_vcyt_NumberOfDiseaseAreasWithGenomicTesting_label_en-US" xlink:label="lab_vcyt_NumberOfDiseaseAreasWithGenomicTesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Disease Areas With Genomic Testing</link:label>
    <link:label id="lab_vcyt_NumberOfDiseaseAreasWithGenomicTesting_documentation_en-US" xlink:label="lab_vcyt_NumberOfDiseaseAreasWithGenomicTesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Disease Areas With Genomic Testing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NumberOfDiseaseAreasWithGenomicTesting" xlink:href="vcyt-20200331.xsd#vcyt_NumberOfDiseaseAreasWithGenomicTesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NumberOfDiseaseAreasWithGenomicTesting" xlink:to="lab_vcyt_NumberOfDiseaseAreasWithGenomicTesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ea7f4ac6-cfc4-4c6f-ae7b-dde9e4280b94_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_220c2b71-0982-4daa-a374-fa8185ca248b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_dcc7345e-5e2c-4be9-a028-4c4b3c08d833_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thyroid Cytopathology Partners</link:label>
    <link:label id="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Contracts or Programs Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermContractsOrProgramsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:to="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_InterestExpenseandPrepaymentPenalty_09b9e929-90aa-4bbe-9da2-058b43d02fdd_terseLabel_en-US" xlink:label="lab_vcyt_InterestExpenseandPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on end-of-term debt obligation</link:label>
    <link:label id="lab_vcyt_InterestExpenseandPrepaymentPenalty_label_en-US" xlink:label="lab_vcyt_InterestExpenseandPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense and Prepayment Penalty</link:label>
    <link:label id="lab_vcyt_InterestExpenseandPrepaymentPenalty_documentation_en-US" xlink:label="lab_vcyt_InterestExpenseandPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense and Prepayment Penalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_InterestExpenseandPrepaymentPenalty" xlink:href="vcyt-20200331.xsd#vcyt_InterestExpenseandPrepaymentPenalty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_InterestExpenseandPrepaymentPenalty" xlink:to="lab_vcyt_InterestExpenseandPrepaymentPenalty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_82936b8d-2bca-4607-aba1-70da4783fe0e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d02ef2eb-6d3c-44c3-af78-52a94b8dba8b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5034d16c-4d50-4d17-8d52-fb0d1208728e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3f61808c-bdbb-4ff4-985a-c87210c7c779_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_fdb77d9c-ec74-4fda-b3cf-fe9b3cc4a2ff_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior period reclassification adjustment</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Period Reclassification Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustment" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6915d879-b9b3-489c-a581-ed64b4d7803e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d075a1b1-a2a6-4e98-9961-865e02f3138e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_614b1626-6a6c-430d-9b3f-822fbd71e7c2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheOneMember_f6f41063-ca68-430b-9ebc-efd5d1de946b_terseLabel_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt prepayment tranche one</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheOneMember_label_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Tranche One [Member]</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheOneMember_documentation_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPrepaymentTrancheOneMember" xlink:href="vcyt-20200331.xsd#vcyt_DebtPrepaymentTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtPrepaymentTrancheOneMember" xlink:to="lab_vcyt_DebtPrepaymentTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5767c60f-f47d-47ee-b9a4-19792adc5848_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_3eda8ae0-3f8f-42c1-b3ac-3672c8d3b065_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_d67b63db-2ca5-4811-92c5-e5fec78d4909_terseLabel_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_label_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_980fa82b-4b84-4d6a-9700-7e49947931d2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_4320de87-294f-4dc0-a3b8-53c66824b380_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_aab87858-5968-4554-87f9-4087fcf5909d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3246b7db-6100-4b62-a563-c37278abde5b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_AstraZenecaMember_eb987f17-fbe6-423a-b61c-f132416a8727_terseLabel_en-US" xlink:label="lab_vcyt_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_vcyt_AstraZenecaMember_label_en-US" xlink:label="lab_vcyt_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_vcyt_AstraZenecaMember_documentation_en-US" xlink:label="lab_vcyt_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AstraZenecaMember" xlink:href="vcyt-20200331.xsd#vcyt_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AstraZenecaMember" xlink:to="lab_vcyt_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_298871a4-d0f1-40a5-ac44-8172e75c86b5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d66aa54f-3f0d-4f18-8134-52a65ae77537_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future minimum lease payments under non-cancelable operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_RevenueRecognitionMember_bb2bd57c-cc32-4672-bb9c-d31a91b59df1_terseLabel_en-US" xlink:label="lab_vcyt_RevenueRecognitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_vcyt_RevenueRecognitionMember_label_en-US" xlink:label="lab_vcyt_RevenueRecognitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Member]</link:label>
    <link:label id="lab_vcyt_RevenueRecognitionMember_documentation_en-US" xlink:label="lab_vcyt_RevenueRecognitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_RevenueRecognitionMember" xlink:href="vcyt-20200331.xsd#vcyt_RevenueRecognitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_RevenueRecognitionMember" xlink:to="lab_vcyt_RevenueRecognitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6839e958-1e64-4016-bdb2-7d7d44086095_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_a978aace-afe1-4aa7-82c7-76715a77e87c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d7682085-22b2-4b13-83aa-e020374f92d7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_9ce28be2-71c9-4a50-93d2-d0bb3c8e30b7_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a27ee622-cfe6-4263-a47b-2f5f35fe2ef0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_683159e4-150a-46e1-a45c-2ceefab167ac_verboseLabel_en-US" xlink:label="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End-of-term debt obligation</link:label>
    <link:label id="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_label_en-US" xlink:label="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument End Of Term, Interest Obligation Amount</link:label>
    <link:label id="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_documentation_en-US" xlink:label="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument End Of Term, Interest Obligation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount" xlink:href="vcyt-20200331.xsd#vcyt_DebtInstrumentEndOfTermInterestObligationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount" xlink:to="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_f76d6f5a-09a7-49fc-ab96-5fc47cfa45fe_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_1722c68e-6f34-45df-9d8e-d06530ac82a3_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_03067a1f-94c6-4d9f-a87b-ae78c134a917_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_96a19292-1fd3-44f5-9497-b599a4b3aca6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5e34a69c-6122-42ae-8270-8607fa7d227c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_93f0f71c-39c0-48c7-a173-6f7a8f170d77_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0d56844e-f871-4a22-95f6-793f95d40611_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2e67a6f1-9418-4380-aa7f-f88613c39af3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options issued and outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dc2ed469-ab17-496c-a64a-f2c9a9f4ebdd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0a8d5aad-5106-4c06-ba89-0e085e4218d5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_33849e4f-e052-47a1-b5da-f5ab1387dffa_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9cc37152-5d8a-4010-a312-c3fab726e142_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_e2c3fbfd-94aa-4f6d-9d46-16b85c81906a_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_92fe7f2f-f10c-4ae2-be2e-9f13903c82b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_75cb91eb-804a-416f-bb7b-3abc96e231ea_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_717d6ad4-d9ca-4314-a13f-13c2bdb12159_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax portion of vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_42af6794-0c12-4590-9a0f-257320399b8d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a682e687-342b-4d4b-9ac4-11d84e65c228_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_906aa21c-c0aa-4fd3-a52e-466c6435c96b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7d7fc76d-0f8e-4dca-aaac-ba9053bcf6de_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_06b4f00b-6e55-46e9-8a1b-c3852e1a88f1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_AgreementTermsNonRenewalNoticePeriod_48df9b6c-445e-43b3-a7c1-c7f362fc6a07_terseLabel_en-US" xlink:label="lab_vcyt_AgreementTermsNonRenewalNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notice of intent not to renew period</link:label>
    <link:label id="lab_vcyt_AgreementTermsNonRenewalNoticePeriod_label_en-US" xlink:label="lab_vcyt_AgreementTermsNonRenewalNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Terms, Non-Renewal Notice Period</link:label>
    <link:label id="lab_vcyt_AgreementTermsNonRenewalNoticePeriod_documentation_en-US" xlink:label="lab_vcyt_AgreementTermsNonRenewalNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the minimum period required to provide notice of intent not to renew agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AgreementTermsNonRenewalNoticePeriod" xlink:href="vcyt-20200331.xsd#vcyt_AgreementTermsNonRenewalNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AgreementTermsNonRenewalNoticePeriod" xlink:to="lab_vcyt_AgreementTermsNonRenewalNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6d318914-efdb-4279-9252-5fc843da6e03_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: amount representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_3a2e5409-3e92-4a90-9142-e4549f2b3121_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_cc2f44cf-0a2e-4108-a680-89b9b2395e47_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share, basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_401fc6dd-b507-4a43-ac00-df0678e26a19_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_94d92ce5-4231-4253-af01-3b12dabe8552_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_78c63af6-3b58-4532-85c1-34a82ae55bc6_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9a8b54ac-85a4-4506-a298-15c357fc0b55_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_TermContractAgreement_1add6dcc-261b-4cf7-8d32-800ea0ec3c22_terseLabel_en-US" xlink:label="lab_vcyt_TermContractAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract agreement term</link:label>
    <link:label id="lab_vcyt_TermContractAgreement_label_en-US" xlink:label="lab_vcyt_TermContractAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term, Contract Agreement</link:label>
    <link:label id="lab_vcyt_TermContractAgreement_documentation_en-US" xlink:label="lab_vcyt_TermContractAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term, Contract Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TermContractAgreement" xlink:href="vcyt-20200331.xsd#vcyt_TermContractAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_TermContractAgreement" xlink:to="lab_vcyt_TermContractAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1cd5a728-6cce-4b26-9b73-79ba6162bf6b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_fe66ecb3-8f82-49c6-9974-ad82cf6e5faa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ee6bf607-50ea-40b0-8f71-c2b277eb2463_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5dd1a87c-a6d5-40af-bbbe-a0176ae9a965_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related contingent liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_baa2bcc9-ae97-4e90-b8a0-55cd08b16346_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_8954034b-2d3d-40f1-ac66-a152126810de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_cdd7ea27-4c10-4a84-89eb-0c4e44ba2a07_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_041b76c7-c233-4be0-b327-c201906e4e82_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3f951b27-653c-4dc7-9ace-9fa8c62fc617_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9377c9a-4df5-4356-8ddb-5fc65245e928_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Rollforward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_33b9824b-87c0-44cd-8260-b23b0c5cd602_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_42b9d026-1e47-4d0a-b3da-d61ad8addebf_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_29e20052-03d2-4eaf-af05-9a351e8b5c37_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_db6ca0d3-76b9-42d8-b43f-9cdc902825c0_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_bed45d7d-0966-4d8b-a13b-1529c6f1d63b_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thyroid Cytopathology Partners</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_SiliconValleyBankMember_4bb7346d-4795-45b0-b7d0-0c80009d6f79_terseLabel_en-US" xlink:label="lab_vcyt_SiliconValleyBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon Valley Bank</link:label>
    <link:label id="lab_vcyt_SiliconValleyBankMember_label_en-US" xlink:label="lab_vcyt_SiliconValleyBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon Valley Bank [Member]</link:label>
    <link:label id="lab_vcyt_SiliconValleyBankMember_documentation_en-US" xlink:label="lab_vcyt_SiliconValleyBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon Valley Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_SiliconValleyBankMember" xlink:href="vcyt-20200331.xsd#vcyt_SiliconValleyBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_SiliconValleyBankMember" xlink:to="lab_vcyt_SiliconValleyBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_77dc469b-874b-467c-8906-9a67d484cd09_terseLabel_en-US" xlink:label="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_label_en-US" xlink:label="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit and Other Risks and Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_documentation_en-US" xlink:label="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:href="vcyt-20200331.xsd#vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c9b43f53-e940-4ee1-a796-da7481de05ee_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_873a9881-a27a-49f3-b4f1-a44cb82c60a7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_6388b03c-624c-4cdb-bde9-de5e890303a8_terseLabel_en-US" xlink:label="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reserved shares of common stock for issuance</link:label>
    <link:label id="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Capital Shares Reserved for Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of number of common shares reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:href="vcyt-20200331.xsd#vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:to="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_58fe682b-d5bb-49d0-847d-c4c74be24a8c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0ff5ba45-0de9-4503-a6cd-af1e4eed146a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_BiopharmaceuticalMember_99416a31-64bd-4bc0-b2b4-b5d274f8ec17_terseLabel_en-US" xlink:label="lab_vcyt_BiopharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharmaceutical</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalMember_label_en-US" xlink:label="lab_vcyt_BiopharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharmaceutical [Member]</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalMember_documentation_en-US" xlink:label="lab_vcyt_BiopharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharmaceutical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalMember" xlink:href="vcyt-20200331.xsd#vcyt_BiopharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_BiopharmaceuticalMember" xlink:to="lab_vcyt_BiopharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b0d63d18-9837-4d0b-94f1-5dc0aec5ac4c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ab68fc42-1246-46c6-ad0a-77c98df0045e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_bc9a4921-a657-41b1-b4f6-27aeb948a105_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_8fc1c03b-d87f-45f9-b6ec-89f539c97d4d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_09480c0b-2dd9-4c03-b2d6-bcbe6a6e3dbd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a2b7bc1c-9389-4c10-997a-8ed078a7f48b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3dffc670-6acd-486d-be13-4e5ff8ee40ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b18663bf-48ef-4578-9615-a00f8472de26_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_9d737aa3-aea1-479a-9d9b-3cdaa02722d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_31d9acce-8900-4639-b9f1-9546fd4cbe35_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1cbefeb8-e5ff-406f-835f-b52a6f163465_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute net loss per common share, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheTwoMember_c15b4e8d-df11-451c-b125-8074ae4a74fa_terseLabel_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt prepayment tranche two</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheTwoMember_label_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Tranche Two [Member]</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheTwoMember_documentation_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPrepaymentTrancheTwoMember" xlink:href="vcyt-20200331.xsd#vcyt_DebtPrepaymentTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtPrepaymentTrancheTwoMember" xlink:to="lab_vcyt_DebtPrepaymentTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_51d70cff-e012-4475-9d63-70247b6409ef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_NumberofTissueSampleDeliveries_550aeafb-5b0b-4cea-aeac-c41a52a63357_terseLabel_en-US" xlink:label="lab_vcyt_NumberofTissueSampleDeliveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tissue sample deliveries (in deliveries)</link:label>
    <link:label id="lab_vcyt_NumberofTissueSampleDeliveries_label_en-US" xlink:label="lab_vcyt_NumberofTissueSampleDeliveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Tissue Sample Deliveries</link:label>
    <link:label id="lab_vcyt_NumberofTissueSampleDeliveries_documentation_en-US" xlink:label="lab_vcyt_NumberofTissueSampleDeliveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Tissue Sample Deliveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NumberofTissueSampleDeliveries" xlink:href="vcyt-20200331.xsd#vcyt_NumberofTissueSampleDeliveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NumberofTissueSampleDeliveries" xlink:to="lab_vcyt_NumberofTissueSampleDeliveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_78bc3ec3-4ada-4441-9903-a8cdcd2720a2_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_59ac19e1-846f-4d3f-916a-02ef98626eca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_10108c8b-6251-457f-b971-438c656ccbbf_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_56fe0e80-cc0d-4189-a2bf-255ede8df2d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c1c74cae-b5e5-4808-97f6-37cc48a8cc8c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_6e85b714-8ae1-45d3-9976-af3568fce476_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_c5bc830d-4a31-4623-a637-3ce569aa775b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_6818f5cc-7d1c-48d2-836b-6c257f6b2517_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bcbbc474-49ce-4adf-a6bd-c688812ef19e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b3b25268-b42f-4cf9-8e42-bdf304b95242_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_d43aed86-b393-4ed7-9e96-c3de448310db_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum lease payments under non-cancelable operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_LymphMarkProductTechnologyMember_72489e27-01e9-4737-a475-80d8e1928c73_terseLabel_en-US" xlink:label="lab_vcyt_LymphMarkProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LymphMark product technology</link:label>
    <link:label id="lab_vcyt_LymphMarkProductTechnologyMember_label_en-US" xlink:label="lab_vcyt_LymphMarkProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LymphMark Product Technology [Member]</link:label>
    <link:label id="lab_vcyt_LymphMarkProductTechnologyMember_documentation_en-US" xlink:label="lab_vcyt_LymphMarkProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LymphMark Product Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LymphMarkProductTechnologyMember" xlink:href="vcyt-20200331.xsd#vcyt_LymphMarkProductTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_LymphMarkProductTechnologyMember" xlink:to="lab_vcyt_LymphMarkProductTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ccf37dde-18f1-4401-bb3d-4c59e4f42080_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_358cc1f2-e1cd-4722-be95-e87eeeb33e34_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7564681d-10ed-41bc-bf3c-841e222b541c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_58ada98a-026c-447a-bfcb-91c5cf653414_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ddef2442-42f1-44ab-ad45-2bf1422867aa_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: short-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_NanoStringMember_7a9d0b2c-3050-4300-9329-b43bbacd23a4_terseLabel_en-US" xlink:label="lab_vcyt_NanoStringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NanoString</link:label>
    <link:label id="lab_vcyt_NanoStringMember_label_en-US" xlink:label="lab_vcyt_NanoStringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NanoString [Member]</link:label>
    <link:label id="lab_vcyt_NanoStringMember_documentation_en-US" xlink:label="lab_vcyt_NanoStringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NanoString</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NanoStringMember" xlink:href="vcyt-20200331.xsd#vcyt_NanoStringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NanoStringMember" xlink:to="lab_vcyt_NanoStringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_35755d95-56e8-404e-ade1-989746698c49_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Company's third-party payers as a percentage of total</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_768ab653-1a56-4a79-b313-53ca780d3a1a_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_1984257e-5690-44cb-975e-c1edd68317c9_terseLabel_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense (non-employee)</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_label_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital Share Based Compensation Non Employee</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_documentation_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase in additional paid-in capital (APIC) resulting from non-employee stock-based compensation expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:href="vcyt-20200331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:to="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a6d31120-2962-42e9-8228-6bb59dc1f78f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_3d2d53f4-7983-41c1-a17d-473ae36d999d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of identifiable acquisition-related intangibles</link:label>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_842d45b3-acbd-4d25-87bd-16ea3e781593_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_d873c154-a6f1-4c88-812b-dfedb56fd93d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_673e711d-0364-41e4-9808-9201daeff95e_terseLabel_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense (employee)</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_label_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital Share Based Compensation Employee</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_documentation_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase in additional paid-in capital (APIC) resulting from employee stock-based compensation expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:href="vcyt-20200331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:to="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c377414c-351c-4574-84e6-29e2dfb1a8d9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_29384db4-64a7-47d8-9082-6255ea9997f0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0706a881-a3f5-42dc-aeb2-ecde5f98ad02_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level II</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_bc90da0c-2365-498c-b6f5-8cd733f1b010_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f6eee1ef-81ea-409b-8934-2af3ff47580e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_341d8c09-6add-42f7-9139-0559495c9362_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e7a1afcd-d33e-4a7b-87ac-d16ccdb260ef_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_cbf67dd5-b8e2-4d0b-91d4-55efec29b11f_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_ServicesAgreementAbstract_93b715e8-9368-4444-81a1-3ecfab95bcc6_terseLabel_en-US" xlink:label="lab_vcyt_ServicesAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thyroid Cytopathology Partners</link:label>
    <link:label id="lab_vcyt_ServicesAgreementAbstract_label_en-US" xlink:label="lab_vcyt_ServicesAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thyroid Cytopathology Partners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ServicesAgreementAbstract" xlink:href="vcyt-20200331.xsd#vcyt_ServicesAgreementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ServicesAgreementAbstract" xlink:to="lab_vcyt_ServicesAgreementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_0c64f58a-6a0f-4a6a-90b8-1bea53929d26_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_71b9362e-b231-4518-ad68-7973b9829b03_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_003a1059-3f51-493c-bd85-0169226660c4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_ce298c59-5cca-4a2c-941a-a3272cbac4e1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_dcdbc230-5d57-41bb-9f15-1fbe890bad0d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_2c855fb9-d5b0-4a1b-9a22-9a0247db4baa_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_8fbbf956-4883-4358-a0b1-d9966f329074_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tissue Samples</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f81db9d7-fb1f-43e8-847c-5f5e247783fc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember_9553ac97-6de6-474a-adfa-71e3a5a1339a_terseLabel_en-US" xlink:label="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock subject to outstanding options</link:label>
    <link:label id="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember_label_en-US" xlink:label="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:href="vcyt-20200331.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:to="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_feec89ba-213d-4ac8-8d96-8a44c7ddab12_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f77d6663-f67e-4c52-8b93-cd906b21aadd_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be0d9a1f-befb-4a87-827b-cfcfc6d42144_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_8055a4df-5554-45b4-9aca-9e90de975de2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ed265a64-1446-4787-9c6d-7a31af3b3c8f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_ca1c583c-e836-4433-b5dc-3d995b248dec_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross receivables concentration risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_697a715e-01c5-4887-8fb3-d6f1fd03cef3_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6e351493-6674-46b3-a113-9b1c2107f7ed_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6af3feb3-b7ea-4b7f-9bc5-6451e26e2d35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_39340cd7-789d-4adc-acac-417c80e206fe_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_084994ba-bdde-486f-a00c-17e1675ec317_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net debt obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d00203e2-ba52-434d-8742-74f6ac3dc569_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_8797d9d6-7406-49d3-857c-e3ed8fa55789_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7c4caff1-244f-4d25-a0ab-394ed67cea09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_e80c3e68-2797-4f31-9bf9-59b0bc8c3969_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a2942b50-2891-49c8-855c-6cf0957f1f73_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54e49a9a-d38f-467b-b680-8695380b4679_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0425ed51-18b8-4d62-b7bd-0d29ae6c31a5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_d31b7380-0187-40db-b783-823b2035f703_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_NCounterFLEXDxLicenseMember_376f5399-a08c-45c6-afcb-cd3184270a4c_terseLabel_en-US" xlink:label="lab_vcyt_NCounterFLEXDxLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nCounter FLEX Dx license</link:label>
    <link:label id="lab_vcyt_NCounterFLEXDxLicenseMember_label_en-US" xlink:label="lab_vcyt_NCounterFLEXDxLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nCounter FLEX Dx License [Member]</link:label>
    <link:label id="lab_vcyt_NCounterFLEXDxLicenseMember_documentation_en-US" xlink:label="lab_vcyt_NCounterFLEXDxLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nCounter FLEX Dx License</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NCounterFLEXDxLicenseMember" xlink:href="vcyt-20200331.xsd#vcyt_NCounterFLEXDxLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NCounterFLEXDxLicenseMember" xlink:to="lab_vcyt_NCounterFLEXDxLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_OtherIncomeRentReimbursement_a2b56466-ae45-48af-b93c-d3e1c45e8ecc_terseLabel_en-US" xlink:label="lab_vcyt_OtherIncomeRentReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to rent expense for TCP's portion of costs for subleased space</link:label>
    <link:label id="lab_vcyt_OtherIncomeRentReimbursement_label_en-US" xlink:label="lab_vcyt_OtherIncomeRentReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Rent Reimbursement</link:label>
    <link:label id="lab_vcyt_OtherIncomeRentReimbursement_documentation_en-US" xlink:label="lab_vcyt_OtherIncomeRentReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of reimbursement from third party for rent and related operating expenses for shared space included in other income in the income statement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherIncomeRentReimbursement" xlink:href="vcyt-20200331.xsd#vcyt_OtherIncomeRentReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_OtherIncomeRentReimbursement" xlink:to="lab_vcyt_OtherIncomeRentReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6a5acb-4d66-4935-a59e-d709136530a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b904d2dc-9f98-449b-81b1-0c32fdbb8be5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7ed58479-7f31-4c74-820f-7e7b05abeac1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_0b01c92d-7589-4671-b5cc-1e0b2581d56b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balloon payment to be paid</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9411c561-0edc-40be-8a13-4e7d32fe6501_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level I</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_784ec57a-8b17-402f-a1e6-4d489e936f55_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_7a54e921-6dd8-4810-b115-5c7776e07d62_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_BiopharmaceuticalCompanyMember_7eb7b7f8-76de-46db-a89f-dc544907a362_terseLabel_en-US" xlink:label="lab_vcyt_BiopharmaceuticalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharmaceutical Company</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalCompanyMember_label_en-US" xlink:label="lab_vcyt_BiopharmaceuticalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharmaceutical Company [Member]</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalCompanyMember_documentation_en-US" xlink:label="lab_vcyt_BiopharmaceuticalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharmaceutical Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalCompanyMember" xlink:href="vcyt-20200331.xsd#vcyt_BiopharmaceuticalCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_BiopharmaceuticalCompanyMember" xlink:to="lab_vcyt_BiopharmaceuticalCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_11cd35e1-3342-45fe-96dd-43710e39ac33_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thyroid Cytopathology Partners</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities_12463c7a-8cfb-4ead-af06-29448ee08701_terseLabel_en-US" xlink:label="lab_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of principal amount needed to be collateralized by U.S. treasury and agency securities</link:label>
    <link:label id="lab_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities_label_en-US" xlink:label="lab_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of Principal Amount Needed To Be Collateralized By U.S. Treasury and Agency Securities</link:label>
    <link:label id="lab_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities_documentation_en-US" xlink:label="lab_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of Principal Amount Needed To Be Collateralized By U.S. Treasury and Agency Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities" xlink:href="vcyt-20200331.xsd#vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities" xlink:to="lab_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_2ee61137-8a29-4c21-8d6b-255336b142be_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity issued in business acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1630e243-5b4a-4f9f-b047-d9af414b198f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_54b1f31a-5ca1-42e2-8213-42a8479d3bde_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_97cb0ffc-1dd0-428b-bdf0-2efd9230c9a9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_210b62c8-8f07-4aa9-a2a1-8bc29e0ee5bb_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_aa7b4ddb-b8b5-4df4-83da-6f0bc412d65c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_LiquidityRequirementMinimum_395d95b9-6ce9-4b20-be3b-da71fb1c1132_terseLabel_en-US" xlink:label="lab_vcyt_LiquidityRequirementMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity requirement, minimum</link:label>
    <link:label id="lab_vcyt_LiquidityRequirementMinimum_label_en-US" xlink:label="lab_vcyt_LiquidityRequirementMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity Requirement, Minimum</link:label>
    <link:label id="lab_vcyt_LiquidityRequirementMinimum_documentation_en-US" xlink:label="lab_vcyt_LiquidityRequirementMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity Requirement, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LiquidityRequirementMinimum" xlink:href="vcyt-20200331.xsd#vcyt_LiquidityRequirementMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_LiquidityRequirementMinimum" xlink:to="lab_vcyt_LiquidityRequirementMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_6b6795b1-da6c-4781-888b-749f1c3b34ce_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-down of supplies</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_54663eef-d4fb-4dbb-a224-9a5a849769f6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3e46546a-01c8-4656-86fc-56157f6441f1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_DebtPaymentTrancheDomain_3dafa981-7124-499f-b91e-b95ebfe0670a_terseLabel_en-US" xlink:label="lab_vcyt_DebtPaymentTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Payment Tranche [Domain]</link:label>
    <link:label id="lab_vcyt_DebtPaymentTrancheDomain_label_en-US" xlink:label="lab_vcyt_DebtPaymentTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Payment Tranche [Domain]</link:label>
    <link:label id="lab_vcyt_DebtPaymentTrancheDomain_documentation_en-US" xlink:label="lab_vcyt_DebtPaymentTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Debt Payment Tranche [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPaymentTrancheDomain" xlink:href="vcyt-20200331.xsd#vcyt_DebtPaymentTrancheDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtPaymentTrancheDomain" xlink:to="lab_vcyt_DebtPaymentTrancheDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheThreeMember_61d9568e-8bc1-4259-a290-23709a590f4f_terseLabel_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt prepayment tranche three</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheThreeMember_label_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Tranche Three [Member]</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheThreeMember_documentation_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPrepaymentTrancheThreeMember" xlink:href="vcyt-20200331.xsd#vcyt_DebtPrepaymentTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtPrepaymentTrancheThreeMember" xlink:to="lab_vcyt_DebtPrepaymentTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f803369e-2dd5-4a9c-8041-308eda20ae5a_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_140955f7-af34-44aa-9db9-0d656e6feb4a_terseLabel_en-US" xlink:label="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters and laboratory facilities, South San Francisco, lease signed April 2015</link:label>
    <link:label id="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_label_en-US" xlink:label="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters And Laboratory Facilities South San Francisco Lease Two [Member]</link:label>
    <link:label id="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_documentation_en-US" xlink:label="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the lease for headquarters and laboratory space in South San Francisco, California that expires March 2026.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" xlink:href="vcyt-20200331.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" xlink:to="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_e1ebd02f-0847-44c9-82b6-2e29462a70ed_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b39fb935-c5d0-41fb-9bd9-c9b175dd2ee9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_56cc77d7-122e-4484-b8d2-a65683659964_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_ContractAgreementReceivableForServices_23ca11fa-f234-44ed-9e0a-f153abebecf7_terseLabel_en-US" xlink:label="lab_vcyt_ContractAgreementReceivableForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from agreement</link:label>
    <link:label id="lab_vcyt_ContractAgreementReceivableForServices_label_en-US" xlink:label="lab_vcyt_ContractAgreementReceivableForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Agreement, Receivable For Services</link:label>
    <link:label id="lab_vcyt_ContractAgreementReceivableForServices_documentation_en-US" xlink:label="lab_vcyt_ContractAgreementReceivableForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Agreement, Receivable For Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ContractAgreementReceivableForServices" xlink:href="vcyt-20200331.xsd#vcyt_ContractAgreementReceivableForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ContractAgreementReceivableForServices" xlink:to="lab_vcyt_ContractAgreementReceivableForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_53807e8e-9f0a-4c91-9fcd-47ea2060ac8c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_9032a23f-d5f5-41e3-9d5e-4cf59fa08f29_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5b837eba-228d-4115-bc52-7dacbb59af56_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b03eda92-705d-4e35-983a-cadf10752837_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_a5652484-9ddf-461e-90fe-866c7fe4ef8d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_06367004-74aa-4a2f-a8a9-749342f78e75_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_de2ab65b-7b6a-4611-bc9f-e4dc51040521_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_d97c9a13-4943-465e-b504-35b6e2935bb5_terseLabel_en-US" xlink:label="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of major financial institutions with which the company's cash and cash equivalents are deposited (in financial institutions)</link:label>
    <link:label id="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_label_en-US" xlink:label="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Major Financial Institutions with which Cash and Cash Equivalents Deposited</link:label>
    <link:label id="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_documentation_en-US" xlink:label="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of major financial institutions, with which cash and cash equivalents are deposited by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" xlink:href="vcyt-20200331.xsd#vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" xlink:to="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_75fde0cd-727d-44e1-ae68-4efd4139fce8_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_87ad54b3-efba-42e7-9981-14238d449cc6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid in business acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_CapitalExpendituresIncurredButNotYetPaidNet_024fd52b-db16-415d-83a3-7feb00f694dd_terseLabel_en-US" xlink:label="lab_vcyt_CapitalExpendituresIncurredButNotYetPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liability</link:label>
    <link:label id="lab_vcyt_CapitalExpendituresIncurredButNotYetPaidNet_label_en-US" xlink:label="lab_vcyt_CapitalExpendituresIncurredButNotYetPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred But Not Yet Paid Net</link:label>
    <link:label id="lab_vcyt_CapitalExpendituresIncurredButNotYetPaidNet_documentation_en-US" xlink:label="lab_vcyt_CapitalExpendituresIncurredButNotYetPaidNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future cash outflow (inflow) to pay for purchases of fixed assets that have occurred.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_CapitalExpendituresIncurredButNotYetPaidNet" xlink:href="vcyt-20200331.xsd#vcyt_CapitalExpendituresIncurredButNotYetPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_CapitalExpendituresIncurredButNotYetPaidNet" xlink:to="lab_vcyt_CapitalExpendituresIncurredButNotYetPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a9abd3e7-5c74-43b0-8007-fd33da386946_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_fbeb1ddb-02d5-4bcc-8c4f-27f5003ef1d9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b9594c5a-c91c-4e16-8679-7c17cce31f26_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_660c9533-80b3-4988-9696-078584b60868_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_d58e5a41-94f8-483b-87bc-7db3d9f43eb2_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_4536f59e-ccb4-4733-9e05-f690e7b0596d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2480bb81-ebdc-49c6-937a-397db68cbcbb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f3ed2ff6-6c6a-4ac6-8a94-57cef4199081_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73658357-11b7-48d5-8ce1-b72b691194af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_ContractAgreementConditionalAdditionalReceivable_96c7a62e-8eef-4fa6-a734-9022731cd214_terseLabel_en-US" xlink:label="lab_vcyt_ContractAgreementConditionalAdditionalReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual proceeds</link:label>
    <link:label id="lab_vcyt_ContractAgreementConditionalAdditionalReceivable_label_en-US" xlink:label="lab_vcyt_ContractAgreementConditionalAdditionalReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Agreement, Conditional Additional Receivable</link:label>
    <link:label id="lab_vcyt_ContractAgreementConditionalAdditionalReceivable_documentation_en-US" xlink:label="lab_vcyt_ContractAgreementConditionalAdditionalReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Agreement, Conditional Additional Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ContractAgreementConditionalAdditionalReceivable" xlink:href="vcyt-20200331.xsd#vcyt_ContractAgreementConditionalAdditionalReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ContractAgreementConditionalAdditionalReceivable" xlink:to="lab_vcyt_ContractAgreementConditionalAdditionalReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_23096226-a4f1-499b-a5b5-9683cf434c98_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of common stock options and employee stock purchases</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability_2105b9e4-2d38-4305-a73e-59bf28d05736_negatedTerseLabel_en-US" xlink:label="lab_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability_label_en-US" xlink:label="lab_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Operating Lease, Right Of Use Asset (Lease Liability)</link:label>
    <link:label id="lab_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability_documentation_en-US" xlink:label="lab_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Operating Lease, Right Of Use Asset (Lease Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability" xlink:href="vcyt-20200331.xsd#vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability" xlink:to="lab_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f2f27f64-dccf-47c5-8faa-35e875ea8014_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c0efbb7b-13a2-445e-80f7-ee722ef8b7a1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_b74c8076-622c-4c8b-a8ce-906d7b046d18_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0e9a58ec-41bf-41d5-bd7c-76bed45f9aaf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_AutomaticRenewalPeriodContractAgreement_090faf5f-8825-4955-8c05-c56e732e8217_terseLabel_en-US" xlink:label="lab_vcyt_AutomaticRenewalPeriodContractAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic renewal period of contract agreement</link:label>
    <link:label id="lab_vcyt_AutomaticRenewalPeriodContractAgreement_label_en-US" xlink:label="lab_vcyt_AutomaticRenewalPeriodContractAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic Renewal Period, Contract Agreement</link:label>
    <link:label id="lab_vcyt_AutomaticRenewalPeriodContractAgreement_documentation_en-US" xlink:label="lab_vcyt_AutomaticRenewalPeriodContractAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic Renewal Period, Contract Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AutomaticRenewalPeriodContractAgreement" xlink:href="vcyt-20200331.xsd#vcyt_AutomaticRenewalPeriodContractAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AutomaticRenewalPeriodContractAgreement" xlink:to="lab_vcyt_AutomaticRenewalPeriodContractAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_bdfc4cb2-916a-4af8-b564-53dcbf8600f2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_df60a5fd-f861-4c58-9241-45c7fa3997de_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_82011f73-3bea-4601-9606-04db5e36ecdc_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_CommonStockAbstract_d4b3babe-5bb8-4366-b33f-9316e8c60a01_terseLabel_en-US" xlink:label="lab_vcyt_CommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_vcyt_CommonStockAbstract_label_en-US" xlink:label="lab_vcyt_CommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Abstract]</link:label>
    <link:label id="lab_vcyt_CommonStockAbstract_documentation_en-US" xlink:label="lab_vcyt_CommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_CommonStockAbstract" xlink:href="vcyt-20200331.xsd#vcyt_CommonStockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_CommonStockAbstract" xlink:to="lab_vcyt_CommonStockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_20528cdc-060f-4058-ad9e-27aa4228729d_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_77223392-899b-4987-9889-f503cb0bcb3e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0ebc531e-d4b0-4104-a4ee-2725551ee27f_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e5463ee5-7475-419b-87ff-718cefea6d3f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_73e5e2bf-4b4f-40d8-ae0b-23e970c50879_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f0286baf-f847-48df-aa14-a375dc56f21a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_094590fc-c2c9-4ba9-8798-b9cfe17081fb_terseLabel_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense (ESPP)</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_label_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital Share Based Compensation ESPP</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_documentation_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase in additional paid-in capital (APIC) resulting from ESPP stock-based compensation expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:href="vcyt-20200331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:to="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a655f2dc-b621-4d16-b1df-d5343e772b24_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0c77c3b0-4800-483f-a467-0f85c70c9f7f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_6cc6532d-e215-457e-af73-55756ba8da54_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2550209a-1bf1-47e4-aa3d-d271d4ebe624_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_862b571b-2b12-46aa-a6d3-b114afce96d5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_f78dec14-eb5c-4be1-87f9-d81b9af2ce4b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, maximum to be paid</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2044a4f6-90e3-4848-8a5d-aad5d5119248_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_0eae038c-a343-4190-a611-8d803e45a3db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_3093a581-b392-42b0-bd85-08ef9eacfa85_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_TerminationPeriodContractAgreement_8fd649f5-d163-4364-9fd1-e5388f3b6553_terseLabel_en-US" xlink:label="lab_vcyt_TerminationPeriodContractAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination period</link:label>
    <link:label id="lab_vcyt_TerminationPeriodContractAgreement_label_en-US" xlink:label="lab_vcyt_TerminationPeriodContractAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Period, Contract Agreement</link:label>
    <link:label id="lab_vcyt_TerminationPeriodContractAgreement_documentation_en-US" xlink:label="lab_vcyt_TerminationPeriodContractAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Period, Contract Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TerminationPeriodContractAgreement" xlink:href="vcyt-20200331.xsd#vcyt_TerminationPeriodContractAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_TerminationPeriodContractAgreement" xlink:to="lab_vcyt_TerminationPeriodContractAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3ee58491-27e3-42a5-b112-81680e4a5704_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of taxes on vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_988b79fe-423b-4d35-8c8c-5a53560a285f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_87100469-ad23-48cf-b2e9-9877c8e529cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_99c0b021-8c79-4826-89a7-c2380563ce25_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f2707168-4bfb-4d7b-bc74-c1660ae29c39_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9ea4fb30-8634-4ec4-89b1-c5bfb6256657_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2602c396-8f33-464c-9e0b-c305921c38e3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_fa4f4c7f-47d9-474f-b519-8b1b88fbdf25_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_70e6d98d-0124-42e4-abdc-91e9b567098d_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_f66888d1-773c-4630-b735-d459bb5541df_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of credit risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_fdaeeff6-3b94-4175-822b-37a5b3dd0852_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_PerceptaV2Member_654a81b4-9c5b-4a29-9000-0d54b173d39b_terseLabel_en-US" xlink:label="lab_vcyt_PerceptaV2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percepta v.2</link:label>
    <link:label id="lab_vcyt_PerceptaV2Member_label_en-US" xlink:label="lab_vcyt_PerceptaV2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percepta v.2 [Member]</link:label>
    <link:label id="lab_vcyt_PerceptaV2Member_documentation_en-US" xlink:label="lab_vcyt_PerceptaV2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percepta v.2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_PerceptaV2Member" xlink:href="vcyt-20200331.xsd#vcyt_PerceptaV2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_PerceptaV2Member" xlink:to="lab_vcyt_PerceptaV2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1acb0aab-f410-4d75-a181-2c69a2e8e3d1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_ContractAgreementFeePercentageOfCashCollections_af1e6fb7-b257-4ae1-a2c9-18d3bfdba072_terseLabel_en-US" xlink:label="lab_vcyt_ContractAgreementFeePercentageOfCashCollections" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net cash collections, fee</link:label>
    <link:label id="lab_vcyt_ContractAgreementFeePercentageOfCashCollections_label_en-US" xlink:label="lab_vcyt_ContractAgreementFeePercentageOfCashCollections" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Agreement, Fee, Percentage Of Cash Collections</link:label>
    <link:label id="lab_vcyt_ContractAgreementFeePercentageOfCashCollections_documentation_en-US" xlink:label="lab_vcyt_ContractAgreementFeePercentageOfCashCollections" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Agreement, Fee, Percentage Of Cash Collections</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ContractAgreementFeePercentageOfCashCollections" xlink:href="vcyt-20200331.xsd#vcyt_ContractAgreementFeePercentageOfCashCollections"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ContractAgreementFeePercentageOfCashCollections" xlink:to="lab_vcyt_ContractAgreementFeePercentageOfCashCollections" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8ac52cdd-5ab9-4fc2-bbb4-a9e7ebe86c87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7423b5db-0d5d-48bf-9dc9-e1893b24abc7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_14a058b7-44dd-4f70-b4d8-48a8486c9604_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_ed893dc6-d6a2-4759-86f9-1c14e4dc41e5_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ced1637-dd86-41ae-bedf-2cd0c177de0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1225a39c-3184-43b2-9406-b0afbadda2a0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8bf1ae72-5b82-47f1-b316-a1771198a604_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4af3992e-3fca-4abc-990a-9cdacf5533ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6a19b66e-15c6-4fd4-a11b-fe9e1c436fe0_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_51efd674-59da-4680-b11c-548521fb74cc_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_62eca6d7-70c7-4df8-b0b7-e5b559840faa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (ESPP)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42b11d38-b25c-4753-a00b-9bfdbd96f5a7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock in a public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_895fb72f-05f5-4a5c-a5ba-3e18f0b6998e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued and sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fd326309-1924-4d7b-b986-b54352d72cc7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9e7a4947-6d70-41b1-855c-97d532b82dac_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e4b8abfe-1396-4bf5-b6c3-191a16441e32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_49020c52-c9c2-4047-899d-6388fdbcbef1_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_90f689c5-8cfa-41f2-ac22-51509ec06bde_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_JohnsonJohnsonServicesInc.Member_3c1ed104-392d-4f86-9435-344e60142a31_terseLabel_en-US" xlink:label="lab_vcyt_JohnsonJohnsonServicesInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson &amp; Johnson</link:label>
    <link:label id="lab_vcyt_JohnsonJohnsonServicesInc.Member_label_en-US" xlink:label="lab_vcyt_JohnsonJohnsonServicesInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson &amp; Johnson Services, Inc. [Member]</link:label>
    <link:label id="lab_vcyt_JohnsonJohnsonServicesInc.Member_documentation_en-US" xlink:label="lab_vcyt_JohnsonJohnsonServicesInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson &amp; Johnson Services, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_JohnsonJohnsonServicesInc.Member" xlink:href="vcyt-20200331.xsd#vcyt_JohnsonJohnsonServicesInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_JohnsonJohnsonServicesInc.Member" xlink:to="lab_vcyt_JohnsonJohnsonServicesInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_81d8a1bf-1da8-40e5-8808-f01ec98c391d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_1c73a065-a909-41f6-8717-d7a14fe60c74_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of debt obligation for borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_27abd860-c0f2-4c0c-b64d-e1ee66a8fffe_terseLabel_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_label_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Exercises in Period</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_documentation_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:href="vcyt-20200331.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:to="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29c6c125-4dcc-433a-bd11-f4b1dbba7818_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_512dec1a-3c23-4e3e-a058-12fd01ccc02b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_f1dceed2-b208-4801-bf55-bf0be3d2849b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3f633689-1f09-459d-8eda-8df9694c5243_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5559ca1c-a239-44fd-abf9-d1f08cb72755_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_39cf47ea-4bb6-497a-a1e8-b8dbb72dc31e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of testing revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f7c5497e-7066-4254-aa19-9aba240cfb83_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 125,000,000 shares authorized, 49,999,923 and 49,625,341 shares issued and outstanding as of March 31, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_f693a6a9-5b62-4ed7-ad6e-80c882be29de_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_63edba9f-f78d-4536-9d16-e0211a5028b7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2c9f4312-b7c0-4196-aa9e-9ff7fa953256_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_86bb1a1c-2101-4f86-afc7-59b1729375aa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_MedicareMember_1075e91a-81b0-4090-8b28-65e2ec1257c3_terseLabel_en-US" xlink:label="lab_vcyt_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_vcyt_MedicareMember_label_en-US" xlink:label="lab_vcyt_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_vcyt_MedicareMember_documentation_en-US" xlink:label="lab_vcyt_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Medicare, a significant third-party payer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_MedicareMember" xlink:href="vcyt-20200331.xsd#vcyt_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_MedicareMember" xlink:to="lab_vcyt_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_efc02b59-b501-4a79-b808-5f391530208f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_TestingMember_47e020a9-bca5-48c4-a570-6a215e80d2d0_terseLabel_en-US" xlink:label="lab_vcyt_TestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing</link:label>
    <link:label id="lab_vcyt_TestingMember_label_en-US" xlink:label="lab_vcyt_TestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing [Member]</link:label>
    <link:label id="lab_vcyt_TestingMember_documentation_en-US" xlink:label="lab_vcyt_TestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TestingMember" xlink:href="vcyt-20200331.xsd#vcyt_TestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_TestingMember" xlink:to="lab_vcyt_TestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5dd8ab14-88b6-415d-b781-1ccf8b94c8f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0a3beeeb-617e-46cc-aacb-c32faf4848d2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_d2d1f050-f934-41a6-b865-9a71029f9489_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a6b0bba3-1bb0-40e0-9052-616bb3cb4389_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f3c4bd8a-3918-44c1-a9bf-b7d87ee2fbcd_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_0edb8b08-583b-4fba-9fad-6ae2cf712141_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_NoncashLeaseExpenses_e3c11c58-9daf-427d-9634-de96b6147545_terseLabel_en-US" xlink:label="lab_vcyt_NoncashLeaseExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash lease expense</link:label>
    <link:label id="lab_vcyt_NoncashLeaseExpenses_label_en-US" xlink:label="lab_vcyt_NoncashLeaseExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expenses</link:label>
    <link:label id="lab_vcyt_NoncashLeaseExpenses_documentation_en-US" xlink:label="lab_vcyt_NoncashLeaseExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NoncashLeaseExpenses" xlink:href="vcyt-20200331.xsd#vcyt_NoncashLeaseExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NoncashLeaseExpenses" xlink:to="lab_vcyt_NoncashLeaseExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_OvernightRepurchaseAgreementsMember_d822e051-1579-47e8-8220-ada1fc03a9be_terseLabel_en-US" xlink:label="lab_vcyt_OvernightRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight repurchase agreements</link:label>
    <link:label id="lab_vcyt_OvernightRepurchaseAgreementsMember_label_en-US" xlink:label="lab_vcyt_OvernightRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight Repurchase Agreements [Member]</link:label>
    <link:label id="lab_vcyt_OvernightRepurchaseAgreementsMember_documentation_en-US" xlink:label="lab_vcyt_OvernightRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OvernightRepurchaseAgreementsMember" xlink:href="vcyt-20200331.xsd#vcyt_OvernightRepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_OvernightRepurchaseAgreementsMember" xlink:to="lab_vcyt_OvernightRepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1a1bc045-1b64-4584-a88e-8542e87f6672_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets - operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f5ec59ad-9650-451f-99fb-849532f37336_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9b523080-bd69-463f-8a81-efddc15323d6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_e83d9495-a227-4e4c-840d-fa4473ad55d6_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0110bba2-3602-4be8-b2b5-bceef1aa59e3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_47241991-5e67-4381-a27c-74c35da6e694_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_285ef8e0-5007-44b6-851a-d217923fa865_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_b7e0247c-fd33-4c7e-8ebe-e1ee3600764c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c4a7a461-99b9-42eb-b39d-00e4a9f1f9a6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d40224dd-1e46-42d4-af29-8d17f5769cb1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_96a92771-5813-4019-b1ac-f0ab084a70e9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_174b1ee5-1a73-4fb1-9d42-df65f4498070_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c68169e2-3657-4f3c-8245-6eec03e3cc2f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_55af868c-7737-44fd-88a9-c7f3823ae907_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_16263653-f19d-4a2a-85b6-71e4e304c99c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6e79e947-6940-4be5-a255-5b61d5b65eb9_terseLabel_en-US" xlink:label="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of space leased (in square feet)</link:label>
    <link:label id="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_label_en-US" xlink:label="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Space Leased</link:label>
    <link:label id="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_documentation_en-US" xlink:label="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of space leased under the terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased" xlink:href="vcyt-20200331.xsd#vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased" xlink:to="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_f0a3a404-43f6-4bd9-995f-b8cf29a5e667_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_cc931a9d-cf02-4418-94ba-60b21dc3626b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_ContractAgreementAmount_61ab3517-22da-4bea-b522-3d40245324a7_terseLabel_en-US" xlink:label="lab_vcyt_ContractAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract agreement, amount</link:label>
    <link:label id="lab_vcyt_ContractAgreementAmount_label_en-US" xlink:label="lab_vcyt_ContractAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Agreement, Amount</link:label>
    <link:label id="lab_vcyt_ContractAgreementAmount_documentation_en-US" xlink:label="lab_vcyt_ContractAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Agreement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ContractAgreementAmount" xlink:href="vcyt-20200331.xsd#vcyt_ContractAgreementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ContractAgreementAmount" xlink:to="lab_vcyt_ContractAgreementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_DebtInstrumentPrepaymentPremium_aa0474ea-fb80-4c86-8f07-308c82e3d142_terseLabel_en-US" xlink:label="lab_vcyt_DebtInstrumentPrepaymentPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium</link:label>
    <link:label id="lab_vcyt_DebtInstrumentPrepaymentPremium_label_en-US" xlink:label="lab_vcyt_DebtInstrumentPrepaymentPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium</link:label>
    <link:label id="lab_vcyt_DebtInstrumentPrepaymentPremium_documentation_en-US" xlink:label="lab_vcyt_DebtInstrumentPrepaymentPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of prepayment premium waived.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtInstrumentPrepaymentPremium" xlink:href="vcyt-20200331.xsd#vcyt_DebtInstrumentPrepaymentPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtInstrumentPrepaymentPremium" xlink:to="lab_vcyt_DebtInstrumentPrepaymentPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d590828d-8ce7-4ccd-9fb3-927675d6176a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_ef2f582b-7107-4e86-8699-96004c66c4cb_terseLabel_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock on exercise of stock options and vesting of restricted stock units</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_label_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Value, Options and Non-Option Equity Instruments, Exercises in Period</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_documentation_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Value, Options and Non-Option Equity Instruments, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:href="vcyt-20200331.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:to="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_27d9a88b-d7ea-4b8d-9946-aee4fb8d729e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5494d9fd-d4ca-4413-8a49-255e1a1d3642_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e47db247-1b34-4b3e-be35-c0b90b1287b7_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_797efb8b-fabd-4bb4-8d10-d604b7d525a5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_LaboratoryFacilitiesAustinTexasMember_5d5ed530-5c9b-4773-a793-f7e5c46fd6a4_terseLabel_en-US" xlink:label="lab_vcyt_LaboratoryFacilitiesAustinTexasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory facilities, Austin, Texas</link:label>
    <link:label id="lab_vcyt_LaboratoryFacilitiesAustinTexasMember_label_en-US" xlink:label="lab_vcyt_LaboratoryFacilitiesAustinTexasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Facilities Austin Texas [Member]</link:label>
    <link:label id="lab_vcyt_LaboratoryFacilitiesAustinTexasMember_documentation_en-US" xlink:label="lab_vcyt_LaboratoryFacilitiesAustinTexasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the lease for laboratory facilities in Austin, Texas that expires July 2018.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LaboratoryFacilitiesAustinTexasMember" xlink:href="vcyt-20200331.xsd#vcyt_LaboratoryFacilitiesAustinTexasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_LaboratoryFacilitiesAustinTexasMember" xlink:to="lab_vcyt_LaboratoryFacilitiesAustinTexasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_NasaRISKMember_a154bc92-5d16-48d2-8d89-17675e3b4899_terseLabel_en-US" xlink:label="lab_vcyt_NasaRISKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NasaRISK</link:label>
    <link:label id="lab_vcyt_NasaRISKMember_label_en-US" xlink:label="lab_vcyt_NasaRISKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NasaRISK [Member]</link:label>
    <link:label id="lab_vcyt_NasaRISKMember_documentation_en-US" xlink:label="lab_vcyt_NasaRISKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NasaRISK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NasaRISKMember" xlink:href="vcyt-20200331.xsd#vcyt_NasaRISKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NasaRISKMember" xlink:to="lab_vcyt_NasaRISKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_5ec1ec86-1579-4af3-9ccc-8e4ca3e35903_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid on debt</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4ee5e449-acc6-4d08-846d-fd4f888367cb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_91bb7840-d152-4f38-bfe9-79cf4cf50f1d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a4c9cbc1-2c25-4de3-a818-588b50b852ec_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2020 and December&#160;31, 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_aee521d2-ab77-49f4-a853-2083e6344bd9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d9ff735e-2f24-4709-ac4d-369dbd7b5bf4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and and cash equivalents, fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0e12972e-f06a-48d6-8c8b-910838f322de_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_b697d98d-ad69-4b8c-b421-cc2c669358fe_terseLabel_en-US" xlink:label="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_label_en-US" xlink:label="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Deferred Rent</link:label>
    <link:label id="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_documentation_en-US" xlink:label="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the amount of expenses incurred but not yet paid and deferred rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" xlink:href="vcyt-20200331.xsd#vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" xlink:to="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7f6b9a1b-1ef6-4c7d-a3a7-4ec30492af6b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_63a41f8b-280b-459b-b850-737a3667c390_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common stock equivalents (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_51db6f8b-7b0b-4c69-8e78-06bc70685f36_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f26ae346-f21a-4606-8eac-f0b638d27c40_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_be154e4a-9812-4a16-befa-093fd34b3f67_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheAxis_adf7890b-42a6-4129-950e-d30a5b063150_terseLabel_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Tranche [Axis]</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheAxis_label_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Tranche [Axis]</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheAxis_documentation_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Tranche [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPrepaymentTrancheAxis" xlink:href="vcyt-20200331.xsd#vcyt_DebtPrepaymentTrancheAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtPrepaymentTrancheAxis" xlink:to="lab_vcyt_DebtPrepaymentTrancheAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e205d61-4777-4f64-bbed-c6264d4faa31_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_InventoryReserveEffectOnIncomeNet_9e218a5f-fe2f-4bf7-ab7d-2a3f86642026_terseLabel_en-US" xlink:label="lab_vcyt_InventoryReserveEffectOnIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-down of excess supplies</link:label>
    <link:label id="lab_vcyt_InventoryReserveEffectOnIncomeNet_label_en-US" xlink:label="lab_vcyt_InventoryReserveEffectOnIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve, Effect on Income, Net</link:label>
    <link:label id="lab_vcyt_InventoryReserveEffectOnIncomeNet_documentation_en-US" xlink:label="lab_vcyt_InventoryReserveEffectOnIncomeNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve, Effect on Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_InventoryReserveEffectOnIncomeNet" xlink:href="vcyt-20200331.xsd#vcyt_InventoryReserveEffectOnIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_InventoryReserveEffectOnIncomeNet" xlink:to="lab_vcyt_InventoryReserveEffectOnIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_cfde0a2a-37ae-4445-a86c-354f20c7978f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_18effae4-d112-4664-a10d-65fb54db0a10_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7206d627-e586-41d2-ab87-f9f5b85a4826_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_2923ef1e-c7f7-445a-b410-0279433dbae0_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7690bb27-86ec-44f4-af4b-8d5435ef5be8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c530557f-72c7-4783-891b-7dbb1d5b57c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value of assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_338aec98-fd42-468d-84cb-19314657d419_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_153143bc-cc56-4a08-844b-82c77d0c6773_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_f8bb0d19-d313-4065-aa19-c42771f547b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_bb737ea6-42dd-4ab1-a5e2-5748c255e15f_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_a39bd8b9-9763-4387-a058-4abc7ef4ac3b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_7212fe09-95f8-456b-a46f-be9e05d4d827_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b5618093-8ba3-48fc-baab-3776220c285b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_69732633-f9ee-44b1-b7d3-a37e3106c579_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_DevelopedProductTechnologyMember_39b63b94-dbd6-481c-88ab-81576f179f6a_terseLabel_en-US" xlink:label="lab_vcyt_DevelopedProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prosigna product technology</link:label>
    <link:label id="lab_vcyt_DevelopedProductTechnologyMember_label_en-US" xlink:label="lab_vcyt_DevelopedProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Product Technology [Member]</link:label>
    <link:label id="lab_vcyt_DevelopedProductTechnologyMember_documentation_en-US" xlink:label="lab_vcyt_DevelopedProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Product Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DevelopedProductTechnologyMember" xlink:href="vcyt-20200331.xsd#vcyt_DevelopedProductTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DevelopedProductTechnologyMember" xlink:to="lab_vcyt_DevelopedProductTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e47c0830-00d0-4328-a69a-7fd5a7a62d81_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bd681325-2ce8-4bab-bbe6-16508507ad81_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_UnitedHealthcareMember_0fd775a2-14ee-4b55-aa08-8c41c6bb78f5_terseLabel_en-US" xlink:label="lab_vcyt_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UnitedHealthcare</link:label>
    <link:label id="lab_vcyt_UnitedHealthcareMember_label_en-US" xlink:label="lab_vcyt_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare [Member]</link:label>
    <link:label id="lab_vcyt_UnitedHealthcareMember_documentation_en-US" xlink:label="lab_vcyt_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to United Healthcare, a significant third-party payer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_UnitedHealthcareMember" xlink:href="vcyt-20200331.xsd#vcyt_UnitedHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_UnitedHealthcareMember" xlink:to="lab_vcyt_UnitedHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_3b3a2ef3-c915-4c06-a4d4-6d3c764626d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c922aa93-3eca-45d5-93e6-c8fdf1019290_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_eba1b51c-2ed1-4b2b-819d-586709db2aa5_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_5a2f6e62-71c8-4a9a-a512-6bb4992c464b_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>vcyt-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:0005b3b4-1d3d-4b06-88c1-edf8f62a1620,g:32b86441-5460-4f29-850a-a85559dff3e5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.veracyte.com/role/Cover" xlink:type="simple" xlink:href="vcyt-20200331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_440c31c8-f8b6-4007-98fe-41001d2c78e6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_DocumentType_440c31c8-f8b6-4007-98fe-41001d2c78e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_2aa6306e-4609-4f33-8678-cf08a57998e9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_DocumentQuarterlyReport_2aa6306e-4609-4f33-8678-cf08a57998e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b67d6acc-63c6-4750-9a0b-924ce609028c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_DocumentPeriodEndDate_b67d6acc-63c6-4750-9a0b-924ce609028c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_88148c86-5a81-4789-b53f-fc874fd8a59e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_DocumentTransitionReport_88148c86-5a81-4789-b53f-fc874fd8a59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2c8836ca-50cd-44f2-a76b-b5a8a072b261" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityFileNumber_2c8836ca-50cd-44f2-a76b-b5a8a072b261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c4610f6f-10e8-43ca-a8ae-abe67f40b393" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityRegistrantName_c4610f6f-10e8-43ca-a8ae-abe67f40b393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_55529297-4ba4-4034-99bf-bd2ac41d7769" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityIncorporationStateCountryCode_55529297-4ba4-4034-99bf-bd2ac41d7769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ff1d656f-8d08-4cb2-8b9c-fa159d1f339a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityTaxIdentificationNumber_ff1d656f-8d08-4cb2-8b9c-fa159d1f339a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2b5fe859-b2fe-4315-8ca9-83aa79179de9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityAddressAddressLine1_2b5fe859-b2fe-4315-8ca9-83aa79179de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_9777c8da-abf1-4226-ba75-c023ce122ebe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityAddressAddressLine2_9777c8da-abf1-4226-ba75-c023ce122ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_90af86cb-951c-4312-b717-341eea7cbb50" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityAddressCityOrTown_90af86cb-951c-4312-b717-341eea7cbb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_16d9ab16-91f4-4f9b-bb81-ac349df3f902" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityAddressStateOrProvince_16d9ab16-91f4-4f9b-bb81-ac349df3f902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6f426209-dd9f-4c9f-97c2-cbeacd0c2862" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityAddressPostalZipCode_6f426209-dd9f-4c9f-97c2-cbeacd0c2862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5ea2b486-8cb4-4ca1-8375-8f4a98a15db2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_CityAreaCode_5ea2b486-8cb4-4ca1-8375-8f4a98a15db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_aebbb3c0-b4eb-4680-ad76-121412fc0c09" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_LocalPhoneNumber_aebbb3c0-b4eb-4680-ad76-121412fc0c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c156453e-a3f3-46f1-863d-08dbe5fb92a1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_Security12bTitle_c156453e-a3f3-46f1-863d-08dbe5fb92a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_adba7161-d660-4c29-9176-59c8e93438a2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_TradingSymbol_adba7161-d660-4c29-9176-59c8e93438a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_298b0ad3-5d6f-4195-a4e0-25c0eb9223ab" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_SecurityExchangeName_298b0ad3-5d6f-4195-a4e0-25c0eb9223ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c5b6896e-e99c-4958-9d90-a330b11c5524" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityCurrentReportingStatus_c5b6896e-e99c-4958-9d90-a330b11c5524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6beb7f39-9d2a-4355-b0ae-6ea4981eda4f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityInteractiveDataCurrent_6beb7f39-9d2a-4355-b0ae-6ea4981eda4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0d4a44e6-d2fa-44f9-afb5-dd1b5d23201c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityFilerCategory_0d4a44e6-d2fa-44f9-afb5-dd1b5d23201c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_98a07f52-e33c-4a15-9e63-71263024ab47" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntitySmallBusiness_98a07f52-e33c-4a15-9e63-71263024ab47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9e28240b-9254-4a6f-af1b-4059a35842a8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityEmergingGrowthCompany_9e28240b-9254-4a6f-af1b-4059a35842a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_28aac1c7-32f2-4ec0-9f4c-0d59512b0857" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityShellCompany_28aac1c7-32f2-4ec0-9f4c-0d59512b0857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_62507fb5-2d40-4c30-8669-98993f48d906" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_62507fb5-2d40-4c30-8669-98993f48d906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_35d8684f-e1e0-43a0-92c1-697ac255d145" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_EntityCentralIndexKey_35d8684f-e1e0-43a0-92c1-697ac255d145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_517fa7cd-ffd0-4f69-a928-cb76fd0d84f4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_AmendmentFlag_517fa7cd-ffd0-4f69-a928-cb76fd0d84f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_0adb6d7b-8794-4872-9cdb-437e7874084c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_CurrentFiscalYearEndDate_0adb6d7b-8794-4872-9cdb-437e7874084c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5ffaec06-743e-4002-aea9-42f31d93189a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_DocumentFiscalYearFocus_5ffaec06-743e-4002-aea9-42f31d93189a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7f6aeccc-0936-42de-9764-90fe340c9220" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1dd0992-9552-45a0-83ba-0c71a8fb4656" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7f6aeccc-0936-42de-9764-90fe340c9220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5f0b3e4b-9807-4c4a-bb86-e022b2600f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c1e0eec4-ca6c-4894-91b3-52d41d7f836e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5f0b3e4b-9807-4c4a-bb86-e022b2600f6f" xlink:to="loc_us-gaap_AssetsAbstract_c1e0eec4-ca6c-4894-91b3-52d41d7f836e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_084db0b0-9292-4e11-995f-94a1f9a7a0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1e0eec4-ca6c-4894-91b3-52d41d7f836e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_084db0b0-9292-4e11-995f-94a1f9a7a0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b7b18594-6686-45a1-a673-db33f61ea5aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_084db0b0-9292-4e11-995f-94a1f9a7a0aa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b7b18594-6686-45a1-a673-db33f61ea5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f070910e-5c01-491a-9ae0-4d06c0234a69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_084db0b0-9292-4e11-995f-94a1f9a7a0aa" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f070910e-5c01-491a-9ae0-4d06c0234a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_dc0fd89f-5ef8-46f1-8dbf-780faefb4d99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_084db0b0-9292-4e11-995f-94a1f9a7a0aa" xlink:to="loc_us-gaap_InventoryNet_dc0fd89f-5ef8-46f1-8dbf-780faefb4d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b701154f-8f5f-4b71-b88c-e1c77e6ec415" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_084db0b0-9292-4e11-995f-94a1f9a7a0aa" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b701154f-8f5f-4b71-b88c-e1c77e6ec415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b1515b79-d080-48a7-9744-d85592659f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_084db0b0-9292-4e11-995f-94a1f9a7a0aa" xlink:to="loc_us-gaap_AssetsCurrent_b1515b79-d080-48a7-9744-d85592659f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_486df9f1-a5d0-4049-a71a-8d5255f3bd7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1e0eec4-ca6c-4894-91b3-52d41d7f836e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_486df9f1-a5d0-4049-a71a-8d5255f3bd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_28d40733-7e93-4ee6-b96d-00b109ca1053" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1e0eec4-ca6c-4894-91b3-52d41d7f836e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_28d40733-7e93-4ee6-b96d-00b109ca1053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9c3eac98-b4b8-42c8-ae42-20b79163437e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1e0eec4-ca6c-4894-91b3-52d41d7f836e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9c3eac98-b4b8-42c8-ae42-20b79163437e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_306fade4-de15-4dad-96bc-da86c1dcea90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1e0eec4-ca6c-4894-91b3-52d41d7f836e" xlink:to="loc_us-gaap_Goodwill_306fade4-de15-4dad-96bc-da86c1dcea90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_981aff0c-b6ce-4e6c-87a5-83c240c7333f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1e0eec4-ca6c-4894-91b3-52d41d7f836e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_981aff0c-b6ce-4e6c-87a5-83c240c7333f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4c63f277-4575-44ea-bdd3-2ad0cad1e48b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1e0eec4-ca6c-4894-91b3-52d41d7f836e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4c63f277-4575-44ea-bdd3-2ad0cad1e48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_05d8ac90-5701-4fa3-8ee5-569f2162578b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1e0eec4-ca6c-4894-91b3-52d41d7f836e" xlink:to="loc_us-gaap_Assets_05d8ac90-5701-4fa3-8ee5-569f2162578b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea6203fb-42c8-4cb5-85ff-239fe92cea14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5f0b3e4b-9807-4c4a-bb86-e022b2600f6f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea6203fb-42c8-4cb5-85ff-239fe92cea14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d2e017ea-26cf-4463-a58e-8615d461a682" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea6203fb-42c8-4cb5-85ff-239fe92cea14" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d2e017ea-26cf-4463-a58e-8615d461a682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9efaf912-ac46-4aa0-8848-4be9abd50a08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d2e017ea-26cf-4463-a58e-8615d461a682" xlink:to="loc_us-gaap_AccountsPayableCurrent_9efaf912-ac46-4aa0-8848-4be9abd50a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_24050abc-f989-45bc-93e9-1450121c70d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d2e017ea-26cf-4463-a58e-8615d461a682" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_24050abc-f989-45bc-93e9-1450121c70d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_13d429c9-72b9-4089-9dab-eb108442eb42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d2e017ea-26cf-4463-a58e-8615d461a682" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_13d429c9-72b9-4089-9dab-eb108442eb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3b34f505-269c-4b76-ae0f-82435c689c18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d2e017ea-26cf-4463-a58e-8615d461a682" xlink:to="loc_us-gaap_LiabilitiesCurrent_3b34f505-269c-4b76-ae0f-82435c689c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_eba62c7e-bab2-4a1a-92c1-920e57fb86b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea6203fb-42c8-4cb5-85ff-239fe92cea14" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_eba62c7e-bab2-4a1a-92c1-920e57fb86b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_14a97fe2-e072-48dd-8d79-25541bb7ae29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea6203fb-42c8-4cb5-85ff-239fe92cea14" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_14a97fe2-e072-48dd-8d79-25541bb7ae29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_94339872-5690-4db3-baa7-aaf7dd2ac617" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea6203fb-42c8-4cb5-85ff-239fe92cea14" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_94339872-5690-4db3-baa7-aaf7dd2ac617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ebaa716c-69e2-4b9d-badb-69eecbc68a89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea6203fb-42c8-4cb5-85ff-239fe92cea14" xlink:to="loc_us-gaap_Liabilities_ebaa716c-69e2-4b9d-badb-69eecbc68a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e024196b-d869-4442-8219-c89995bbc76c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea6203fb-42c8-4cb5-85ff-239fe92cea14" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e024196b-d869-4442-8219-c89995bbc76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9db76bd8-c170-4a6b-be64-5faa559e9273" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea6203fb-42c8-4cb5-85ff-239fe92cea14" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9db76bd8-c170-4a6b-be64-5faa559e9273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_63d0869f-fcfe-4452-9612-5a6b23924a80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9db76bd8-c170-4a6b-be64-5faa559e9273" xlink:to="loc_us-gaap_PreferredStockValue_63d0869f-fcfe-4452-9612-5a6b23924a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_96063646-a171-4388-9584-18be23c1cb94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9db76bd8-c170-4a6b-be64-5faa559e9273" xlink:to="loc_us-gaap_CommonStockValue_96063646-a171-4388-9584-18be23c1cb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_69158e86-a601-4219-8ef6-4c45e6980fea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9db76bd8-c170-4a6b-be64-5faa559e9273" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_69158e86-a601-4219-8ef6-4c45e6980fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6a52aa5e-2c13-4191-b452-be26eb085f18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9db76bd8-c170-4a6b-be64-5faa559e9273" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6a52aa5e-2c13-4191-b452-be26eb085f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6aa6e17c-a51e-4b7c-b357-a0b073fee1e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9db76bd8-c170-4a6b-be64-5faa559e9273" xlink:to="loc_us-gaap_StockholdersEquity_6aa6e17c-a51e-4b7c-b357-a0b073fee1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d6a0225a-a82c-4398-a000-4b3b0869e6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea6203fb-42c8-4cb5-85ff-239fe92cea14" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d6a0225a-a82c-4398-a000-4b3b0869e6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4b8c025e-2339-4050-a808-d99b377a28c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0317cd18-e472-40f0-a14e-6bde6bf922be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b8c025e-2339-4050-a808-d99b377a28c4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0317cd18-e472-40f0-a14e-6bde6bf922be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bdc92f4c-1a0b-4ee0-9776-e62c28470db7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b8c025e-2339-4050-a808-d99b377a28c4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bdc92f4c-1a0b-4ee0-9776-e62c28470db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e7cde0dc-618f-49b6-9633-064f4b330f26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b8c025e-2339-4050-a808-d99b377a28c4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e7cde0dc-618f-49b6-9633-064f4b330f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_b8b55991-971b-4cb7-88b6-9f46ac838bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b8c025e-2339-4050-a808-d99b377a28c4" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_b8b55991-971b-4cb7-88b6-9f46ac838bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ba45f05b-22d9-436a-972d-359c6334ca01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b8c025e-2339-4050-a808-d99b377a28c4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ba45f05b-22d9-436a-972d-359c6334ca01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a4f22683-9be7-40e0-aac7-e9ffbed03f00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b8c025e-2339-4050-a808-d99b377a28c4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a4f22683-9be7-40e0-aac7-e9ffbed03f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bc3e09a3-0e7d-4503-a51b-0dd81a14a88c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b8c025e-2339-4050-a808-d99b377a28c4" xlink:to="loc_us-gaap_CommonStockSharesIssued_bc3e09a3-0e7d-4503-a51b-0dd81a14a88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_480bf811-47a2-4092-8322-0d1ed6a715fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b8c025e-2339-4050-a808-d99b377a28c4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_480bf811-47a2-4092-8322-0d1ed6a715fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_24739ec6-54d1-4859-adc3-ea8a43e193d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8d0eb6c-8fb2-4fd3-b255-b13a3f081bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_24739ec6-54d1-4859-adc3-ea8a43e193d6" xlink:to="loc_us-gaap_StatementTable_e8d0eb6c-8fb2-4fd3-b255-b13a3f081bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4068f2e0-3e11-492b-bb7e-aadde794c339" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8d0eb6c-8fb2-4fd3-b255-b13a3f081bdf" xlink:to="loc_srt_ProductOrServiceAxis_4068f2e0-3e11-492b-bb7e-aadde794c339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_779353c7-c06d-4614-860f-9419d39d123f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4068f2e0-3e11-492b-bb7e-aadde794c339" xlink:to="loc_srt_ProductsAndServicesDomain_779353c7-c06d-4614-860f-9419d39d123f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TestingMember_38d92106-3cb4-46e9-bb4f-f78afdb6d685" xlink:href="vcyt-20200331.xsd#vcyt_TestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_779353c7-c06d-4614-860f-9419d39d123f" xlink:to="loc_vcyt_TestingMember_38d92106-3cb4-46e9-bb4f-f78afdb6d685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e3f23df8-a6c6-4c28-a48a-84643f6dca8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_779353c7-c06d-4614-860f-9419d39d123f" xlink:to="loc_us-gaap_ProductMember_e3f23df8-a6c6-4c28-a48a-84643f6dca8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalMember_b948bdce-80d4-4fdd-bea5-c72f67b17c5a" xlink:href="vcyt-20200331.xsd#vcyt_BiopharmaceuticalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_779353c7-c06d-4614-860f-9419d39d123f" xlink:to="loc_vcyt_BiopharmaceuticalMember_b948bdce-80d4-4fdd-bea5-c72f67b17c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8d0eb6c-8fb2-4fd3-b255-b13a3f081bdf" xlink:to="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12c516f5-cda7-479f-9a89-e20196b5ec9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12c516f5-cda7-479f-9a89-e20196b5ec9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_b1ce895e-e6d4-4c3f-9a2a-cacf47160455" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:to="loc_us-gaap_CostOfRevenue_b1ce895e-e6d4-4c3f-9a2a-cacf47160455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4324d54e-6aee-45c6-97f5-216e33bd9c96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4324d54e-6aee-45c6-97f5-216e33bd9c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_d87851a2-c9eb-4fb9-a71c-040f02939ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:to="loc_us-gaap_SellingAndMarketingExpense_d87851a2-c9eb-4fb9-a71c-040f02939ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cef3d179-f29d-4a38-8f27-094a64fbae74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cef3d179-f29d-4a38-8f27-094a64fbae74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_fcc52be3-374f-418e-be60-ac85109d445f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_fcc52be3-374f-418e-be60-ac85109d445f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_24af77e6-61a7-4621-8702-dca5b0b031de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_157610a0-f8a5-4123-a6f2-d87fb55658de" xlink:to="loc_us-gaap_CostsAndExpenses_24af77e6-61a7-4621-8702-dca5b0b031de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_183b52a5-db04-43c9-8187-db5f109321f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_OperatingIncomeLoss_183b52a5-db04-43c9-8187-db5f109321f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e819d302-8229-40bc-8d88-c7409f9c68bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_InterestExpense_e819d302-8229-40bc-8d88-c7409f9c68bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_752ef8bf-0d03-4a25-9602-b7784f79ef3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_752ef8bf-0d03-4a25-9602-b7784f79ef3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4e4f95d0-7bdd-4fbf-97ae-051aea00e467" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4e4f95d0-7bdd-4fbf-97ae-051aea00e467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_19dbf0e2-8566-46d4-82a9-5dd182132496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_19dbf0e2-8566-46d4-82a9-5dd182132496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_dfe04514-a49b-44e3-bd98-152114787303" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_dfe04514-a49b-44e3-bd98-152114787303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b631ce22-e06c-45f0-87b3-e1820eca40c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56b8dcc9-2f63-4761-aeae-3160e6346511" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b631ce22-e06c-45f0-87b3-e1820eca40c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_09c890f1-ed4b-490c-af39-36c44d202af1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3fb8dd32-74cf-41f1-8209-ad0ee8e10833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_09c890f1-ed4b-490c-af39-36c44d202af1" xlink:to="loc_us-gaap_StatementTable_3fb8dd32-74cf-41f1-8209-ad0ee8e10833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2282f7b4-7432-43db-ac4e-e5b332285c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3fb8dd32-74cf-41f1-8209-ad0ee8e10833" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2282f7b4-7432-43db-ac4e-e5b332285c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_55bf4089-0cef-4fee-abf3-08845f1486cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2282f7b4-7432-43db-ac4e-e5b332285c5f" xlink:to="loc_us-gaap_EquityComponentDomain_55bf4089-0cef-4fee-abf3-08845f1486cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4fb07205-edf0-4265-aafb-b5c989705769" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55bf4089-0cef-4fee-abf3-08845f1486cb" xlink:to="loc_us-gaap_CommonStockMember_4fb07205-edf0-4265-aafb-b5c989705769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_36ae3f5f-acc7-4a5b-a2de-0f3fbc4a0321" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55bf4089-0cef-4fee-abf3-08845f1486cb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_36ae3f5f-acc7-4a5b-a2de-0f3fbc4a0321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e6d455c9-dd52-4bde-82eb-4bff52dd03b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55bf4089-0cef-4fee-abf3-08845f1486cb" xlink:to="loc_us-gaap_RetainedEarningsMember_e6d455c9-dd52-4bde-82eb-4bff52dd03b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eccfcebb-797d-4509-869e-0019e8c173a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3fb8dd32-74cf-41f1-8209-ad0ee8e10833" xlink:to="loc_us-gaap_StatementLineItems_eccfcebb-797d-4509-869e-0019e8c173a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eccfcebb-797d-4509-869e-0019e8c173a3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eedca5ea-9bb1-4c8a-9a77-8432afc3aa12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_StockholdersEquity_eedca5ea-9bb1-4c8a-9a77-8432afc3aa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1c7d6334-cfac-46b1-8366-8b5f122929bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_SharesOutstanding_1c7d6334-cfac-46b1-8366-8b5f122929bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0da933f1-218f-4ec6-9994-de76727a4d64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0da933f1-218f-4ec6-9994-de76727a4d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_b127cc9b-17b6-456d-8e36-dabe22d7a16c" xlink:href="vcyt-20200331.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_b127cc9b-17b6-456d-8e36-dabe22d7a16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_62fe516b-0c72-44f8-84e1-ab20d56d2669" xlink:href="vcyt-20200331.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_62fe516b-0c72-44f8-84e1-ab20d56d2669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_628d96b1-5809-48e5-83aa-c4c3c42d67ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_628d96b1-5809-48e5-83aa-c4c3c42d67ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8878fb11-d5da-4806-a86a-aea3bcdb3762" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8878fb11-d5da-4806-a86a-aea3bcdb3762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d6a820e5-54be-436e-a03c-e4de5bab48dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d6a820e5-54be-436e-a03c-e4de5bab48dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_38055e57-2850-4af2-adae-130f9bf49c15" xlink:href="vcyt-20200331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_38055e57-2850-4af2-adae-130f9bf49c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_e0ba65b6-e4c0-444c-a94d-0bbe409137b4" xlink:href="vcyt-20200331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_e0ba65b6-e4c0-444c-a94d-0bbe409137b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_0db889c6-5632-4706-89cd-d08d488c94f7" xlink:href="vcyt-20200331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_0db889c6-5632-4706-89cd-d08d488c94f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9abceb83-0cef-4180-82b1-99c4a44cbe81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9abceb83-0cef-4180-82b1-99c4a44cbe81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d5ba4b37-5a78-4d32-949b-a41c31e4087c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d5ba4b37-5a78-4d32-949b-a41c31e4087c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7b769763-7b28-4478-acfc-4b29e1a7c352" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_StockholdersEquity_7b769763-7b28-4478-acfc-4b29e1a7c352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3f7f5596-2cde-4ceb-8d8a-2c717386ee89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b121b4-23ac-4589-854d-dc8d456a6969" xlink:to="loc_us-gaap_SharesOutstanding_3f7f5596-2cde-4ceb-8d8a-2c717386ee89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c5f5a1e5-54d0-4594-a0b8-af090ea7ec85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_460f0a34-513c-40f1-9bb6-56daee0e7feb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c5f5a1e5-54d0-4594-a0b8-af090ea7ec85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_460f0a34-513c-40f1-9bb6-56daee0e7feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_20b50732-25d4-4416-b31d-431f040132d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_460f0a34-513c-40f1-9bb6-56daee0e7feb" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_20b50732-25d4-4416-b31d-431f040132d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c88c4360-2b87-4fd8-9e81-e335c853690a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_460f0a34-513c-40f1-9bb6-56daee0e7feb" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c88c4360-2b87-4fd8-9e81-e335c853690a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_034a4759-4f6b-4fa3-b3b6-2706f9a70fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c88c4360-2b87-4fd8-9e81-e335c853690a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_034a4759-4f6b-4fa3-b3b6-2706f9a70fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_13ad14cd-c9e1-44f4-a4f3-0bcde23044d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c88c4360-2b87-4fd8-9e81-e335c853690a" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_13ad14cd-c9e1-44f4-a4f3-0bcde23044d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d7a18f37-5db0-4101-88be-2ac9381456e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c88c4360-2b87-4fd8-9e81-e335c853690a" xlink:to="loc_us-gaap_ShareBasedCompensation_d7a18f37-5db0-4101-88be-2ac9381456e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_44748b7f-cbf9-4aad-ad8f-6c3e6c787341" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c88c4360-2b87-4fd8-9e81-e335c853690a" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_44748b7f-cbf9-4aad-ad8f-6c3e6c787341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_InterestExpenseandPrepaymentPenalty_fc12d748-77c0-4ea7-a237-b3e4001c0c75" xlink:href="vcyt-20200331.xsd#vcyt_InterestExpenseandPrepaymentPenalty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c88c4360-2b87-4fd8-9e81-e335c853690a" xlink:to="loc_vcyt_InterestExpenseandPrepaymentPenalty_fc12d748-77c0-4ea7-a237-b3e4001c0c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_InventoryReserveEffectOnIncomeNet_e40a9072-06bc-4a3f-a4a1-2cbf4d60125f" xlink:href="vcyt-20200331.xsd#vcyt_InventoryReserveEffectOnIncomeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c88c4360-2b87-4fd8-9e81-e335c853690a" xlink:to="loc_vcyt_InventoryReserveEffectOnIncomeNet_e40a9072-06bc-4a3f-a4a1-2cbf4d60125f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NoncashLeaseExpenses_ce03db21-69b7-4ccd-8898-8f7ee2c6cc0e" xlink:href="vcyt-20200331.xsd#vcyt_NoncashLeaseExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c88c4360-2b87-4fd8-9e81-e335c853690a" xlink:to="loc_vcyt_NoncashLeaseExpenses_ce03db21-69b7-4ccd-8898-8f7ee2c6cc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_af6c2769-ce3f-4277-967b-508fef605d21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c88c4360-2b87-4fd8-9e81-e335c853690a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_af6c2769-ce3f-4277-967b-508fef605d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bc2cb691-5798-4196-9eed-69ee49bfa3ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_460f0a34-513c-40f1-9bb6-56daee0e7feb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bc2cb691-5798-4196-9eed-69ee49bfa3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9f6b4312-987a-4b75-970b-55c0ad5ccce8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bc2cb691-5798-4196-9eed-69ee49bfa3ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9f6b4312-987a-4b75-970b-55c0ad5ccce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4093dac3-c547-41b8-bbff-f59859abdf1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bc2cb691-5798-4196-9eed-69ee49bfa3ff" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4093dac3-c547-41b8-bbff-f59859abdf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0feb3a55-c613-4049-bd8d-2129d3fb8811" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bc2cb691-5798-4196-9eed-69ee49bfa3ff" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0feb3a55-c613-4049-bd8d-2129d3fb8811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability_459123d5-25f4-48bb-a4a0-566bfc7ab05a" xlink:href="vcyt-20200331.xsd#vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bc2cb691-5798-4196-9eed-69ee49bfa3ff" xlink:to="loc_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability_459123d5-25f4-48bb-a4a0-566bfc7ab05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2b953e0f-2900-4daa-99f6-64fee0269d01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bc2cb691-5798-4196-9eed-69ee49bfa3ff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2b953e0f-2900-4daa-99f6-64fee0269d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cf3aee3a-d374-41f0-91d5-69dbfdeb5d57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bc2cb691-5798-4196-9eed-69ee49bfa3ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cf3aee3a-d374-41f0-91d5-69dbfdeb5d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_e456ee52-3e76-4a6e-ab48-6262f47e4795" xlink:href="vcyt-20200331.xsd#vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bc2cb691-5798-4196-9eed-69ee49bfa3ff" xlink:to="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_e456ee52-3e76-4a6e-ab48-6262f47e4795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_45f72cb1-968f-4381-99d3-3c40b2cedb64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_460f0a34-513c-40f1-9bb6-56daee0e7feb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_45f72cb1-968f-4381-99d3-3c40b2cedb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f9088853-55ca-4997-ac74-30bbc9be2135" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c5f5a1e5-54d0-4594-a0b8-af090ea7ec85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f9088853-55ca-4997-ac74-30bbc9be2135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca6c5adb-dfe4-4929-a34b-a8bdbc6cdbfb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f9088853-55ca-4997-ac74-30bbc9be2135" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca6c5adb-dfe4-4929-a34b-a8bdbc6cdbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_865d2a91-da6c-42c0-82ed-e5647eff2707" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f9088853-55ca-4997-ac74-30bbc9be2135" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_865d2a91-da6c-42c0-82ed-e5647eff2707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dd0272dc-137d-4afa-89c1-db1cdcf5412a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f9088853-55ca-4997-ac74-30bbc9be2135" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dd0272dc-137d-4afa-89c1-db1cdcf5412a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_47816a65-b3ac-4338-8933-e81b1694b051" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c5f5a1e5-54d0-4594-a0b8-af090ea7ec85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_47816a65-b3ac-4338-8933-e81b1694b051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_73111f37-8b7d-4f17-bb20-af91aadab7b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_47816a65-b3ac-4338-8933-e81b1694b051" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_73111f37-8b7d-4f17-bb20-af91aadab7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_4baad425-061a-4837-9fb4-cd6dc0c87ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_47816a65-b3ac-4338-8933-e81b1694b051" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_4baad425-061a-4837-9fb4-cd6dc0c87ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_92330bb8-9827-4af1-8f79-1db1401e2d16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_47816a65-b3ac-4338-8933-e81b1694b051" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_92330bb8-9827-4af1-8f79-1db1401e2d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_28d1ef3b-d95d-4437-b852-6adfb4104681" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_47816a65-b3ac-4338-8933-e81b1694b051" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_28d1ef3b-d95d-4437-b852-6adfb4104681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b498a62-9969-4e10-a7fd-1e3d332ee92f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_47816a65-b3ac-4338-8933-e81b1694b051" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b498a62-9969-4e10-a7fd-1e3d332ee92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7ee928ca-3e48-49df-8219-7f3501f33e74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c5f5a1e5-54d0-4594-a0b8-af090ea7ec85" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7ee928ca-3e48-49df-8219-7f3501f33e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60f7f38b-ef39-4341-9425-3a47a10f6fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c5f5a1e5-54d0-4594-a0b8-af090ea7ec85" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60f7f38b-ef39-4341-9425-3a47a10f6fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_155e1c86-8250-4248-b723-0257c9fbd36a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c5f5a1e5-54d0-4594-a0b8-af090ea7ec85" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_155e1c86-8250-4248-b723-0257c9fbd36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_58603c4e-f946-440b-9032-7b0c6e24cc3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c5f5a1e5-54d0-4594-a0b8-af090ea7ec85" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_58603c4e-f946-440b-9032-7b0c6e24cc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_CapitalExpendituresIncurredButNotYetPaidNet_47aea62e-dc57-4d9e-8e76-94307d20496b" xlink:href="vcyt-20200331.xsd#vcyt_CapitalExpendituresIncurredButNotYetPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_58603c4e-f946-440b-9032-7b0c6e24cc3b" xlink:to="loc_vcyt_CapitalExpendituresIncurredButNotYetPaidNet_47aea62e-dc57-4d9e-8e76-94307d20496b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_922d20cf-8c23-4c91-a465-fa3fc4e107b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_58603c4e-f946-440b-9032-7b0c6e24cc3b" xlink:to="loc_us-gaap_InterestPaidNet_922d20cf-8c23-4c91-a465-fa3fc4e107b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b7c14f6-a492-4ba3-a439-7f51bfaec4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_58603c4e-f946-440b-9032-7b0c6e24cc3b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b7c14f6-a492-4ba3-a439-7f51bfaec4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_43b59801-662b-48e3-8616-26454ce90ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_58603c4e-f946-440b-9032-7b0c6e24cc3b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_43b59801-662b-48e3-8616-26454ce90ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae20dded-69bc-421d-8139-421496915349" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_58603c4e-f946-440b-9032-7b0c6e24cc3b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae20dded-69bc-421d-8139-421496915349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_82ea921e-9fa2-4dae-b1e4-4c2ed119aa64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0ac6a710-ce77-40ba-bc6b-bff3a378ba7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82ea921e-9fa2-4dae-b1e4-4c2ed119aa64" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0ac6a710-ce77-40ba-bc6b-bff3a378ba7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusinessPolicies"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c84468b2-1918-4fbd-9674-d87a6d59547a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_df33371c-eeeb-4884-b51a-6de131860131" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c84468b2-1918-4fbd-9674-d87a6d59547a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_df33371c-eeeb-4884-b51a-6de131860131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_96f93da4-bd8c-4e15-8330-135459d4a52a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c84468b2-1918-4fbd-9674-d87a6d59547a" xlink:to="loc_us-gaap_UseOfEstimates_96f93da4-bd8c-4e15-8330-135459d4a52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_c1c69545-5555-439d-a60c-d998760d59e1" xlink:href="vcyt-20200331.xsd#vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c84468b2-1918-4fbd-9674-d87a6d59547a" xlink:to="loc_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_c1c69545-5555-439d-a60c-d998760d59e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_91ceee00-8466-4ce4-b038-8827a108a1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c84468b2-1918-4fbd-9674-d87a6d59547a" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_91ceee00-8466-4ce4-b038-8827a108a1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_488f649e-c7bc-4376-ab1b-d10abc57cb84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c84468b2-1918-4fbd-9674-d87a6d59547a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_488f649e-c7bc-4376-ab1b-d10abc57cb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ad16a90d-f796-494c-9b1e-caf29093b273" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c84468b2-1918-4fbd-9674-d87a6d59547a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ad16a90d-f796-494c-9b1e-caf29093b273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusinessTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c9791b35-3962-498e-804c-0f3c21ee8ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4d993062-f1fe-4b4b-a703-5eb87cf13363" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9791b35-3962-498e-804c-0f3c21ee8ae0" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4d993062-f1fe-4b4b-a703-5eb87cf13363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusinessNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b80700b6-6c2e-45c3-a933-240d2301e302" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b80700b6-6c2e-45c3-a933-240d2301e302" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_eb8eaa7a-f0be-4095-985d-74d92dc1067d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_eb8eaa7a-f0be-4095-985d-74d92dc1067d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce1901c7-1e5e-493f-a7d2-6dcc06524e38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_eb8eaa7a-f0be-4095-985d-74d92dc1067d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce1901c7-1e5e-493f-a7d2-6dcc06524e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_bc058eef-93d1-4130-abd5-415b232e0c68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce1901c7-1e5e-493f-a7d2-6dcc06524e38" xlink:to="loc_us-gaap_OverAllotmentOptionMember_bc058eef-93d1-4130-abd5-415b232e0c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a0491436-4c53-48cd-9310-dfb6753b1826" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_srt_MajorCustomersAxis_a0491436-4c53-48cd-9310-dfb6753b1826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1b90fb4f-c086-40e6-a2f7-5ac8340692f7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a0491436-4c53-48cd-9310-dfb6753b1826" xlink:to="loc_srt_NameOfMajorCustomerDomain_1b90fb4f-c086-40e6-a2f7-5ac8340692f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_JohnsonJohnsonServicesInc.Member_bde86ad5-b8df-4ee4-a730-680e3f7ac629" xlink:href="vcyt-20200331.xsd#vcyt_JohnsonJohnsonServicesInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b90fb4f-c086-40e6-a2f7-5ac8340692f7" xlink:to="loc_vcyt_JohnsonJohnsonServicesInc.Member_bde86ad5-b8df-4ee4-a730-680e3f7ac629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AstraZenecaMember_39abb9ec-f0a2-47a1-860f-c915e9a2ec81" xlink:href="vcyt-20200331.xsd#vcyt_AstraZenecaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b90fb4f-c086-40e6-a2f7-5ac8340692f7" xlink:to="loc_vcyt_AstraZenecaMember_39abb9ec-f0a2-47a1-860f-c915e9a2ec81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalCompanyMember_d250f3c0-0386-42b8-9114-ed111c4b664d" xlink:href="vcyt-20200331.xsd#vcyt_BiopharmaceuticalCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b90fb4f-c086-40e6-a2f7-5ac8340692f7" xlink:to="loc_vcyt_BiopharmaceuticalCompanyMember_d250f3c0-0386-42b8-9114-ed111c4b664d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_868f8fac-cb35-45f4-9433-aabb1d66278b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_srt_ProductOrServiceAxis_868f8fac-cb35-45f4-9433-aabb1d66278b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_868f8fac-cb35-45f4-9433-aabb1d66278b" xlink:to="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b29bb709-4609-45a3-a7ae-4a65d1e4aab6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:to="loc_us-gaap_ProductMember_b29bb709-4609-45a3-a7ae-4a65d1e4aab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_3b8bf837-aa81-4394-a911-78c2efdbc060" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:to="loc_us-gaap_ServiceMember_3b8bf837-aa81-4394-a911-78c2efdbc060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TestingMember_26a4a844-0512-4e34-a0fa-7d2434e7b054" xlink:href="vcyt-20200331.xsd#vcyt_TestingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:to="loc_vcyt_TestingMember_26a4a844-0512-4e34-a0fa-7d2434e7b054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_PerceptaV2Member_fcd5f6ed-5f5a-482e-92d4-6b9701d8ea5a" xlink:href="vcyt-20200331.xsd#vcyt_PerceptaV2Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:to="loc_vcyt_PerceptaV2Member_fcd5f6ed-5f5a-482e-92d4-6b9701d8ea5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NasaRISKMember_5334e902-cc3f-4b6a-b4ff-fc788d58c6f3" xlink:href="vcyt-20200331.xsd#vcyt_NasaRISKMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:to="loc_vcyt_NasaRISKMember_5334e902-cc3f-4b6a-b4ff-fc788d58c6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalMember_06993c8a-4cb1-4a1d-8e5a-1b94ed2f6963" xlink:href="vcyt-20200331.xsd#vcyt_BiopharmaceuticalMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97193dba-8497-4d83-81e1-e970d016cad6" xlink:to="loc_vcyt_BiopharmaceuticalMember_06993c8a-4cb1-4a1d-8e5a-1b94ed2f6963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_825a22c9-9a85-478d-bc60-98e8cffdc5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_825a22c9-9a85-478d-bc60-98e8cffdc5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fe7a0806-643c-4d7b-8194-8e752efb2a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_825a22c9-9a85-478d-bc60-98e8cffdc5ea" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fe7a0806-643c-4d7b-8194-8e752efb2a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0f74ffd0-b79e-447f-bb61-f2ea781f7824" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fe7a0806-643c-4d7b-8194-8e752efb2a6d" xlink:to="loc_us-gaap_SalesRevenueNetMember_0f74ffd0-b79e-447f-bb61-f2ea781f7824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d37992be-cdab-4c0b-8127-93307bcd2344" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d37992be-cdab-4c0b-8127-93307bcd2344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b9ae44b7-067b-46aa-92ea-b1bea17afab4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d37992be-cdab-4c0b-8127-93307bcd2344" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b9ae44b7-067b-46aa-92ea-b1bea17afab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_9c52c4d9-97c7-422b-82eb-45b448eb0703" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b9ae44b7-067b-46aa-92ea-b1bea17afab4" xlink:to="loc_us-gaap_AccountsReceivableMember_9c52c4d9-97c7-422b-82eb-45b448eb0703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8c5dc65d-9147-426f-b80f-fe83a3183027" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_srt_CounterpartyNameAxis_8c5dc65d-9147-426f-b80f-fe83a3183027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16136921-616e-438e-af79-5101e732cc70" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8c5dc65d-9147-426f-b80f-fe83a3183027" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16136921-616e-438e-af79-5101e732cc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalCompanyMember_7d98f91c-1952-4fe8-9d00-bab19b01de1f" xlink:href="vcyt-20200331.xsd#vcyt_BiopharmaceuticalCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16136921-616e-438e-af79-5101e732cc70" xlink:to="loc_vcyt_BiopharmaceuticalCompanyMember_7d98f91c-1952-4fe8-9d00-bab19b01de1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_e1a4a9ba-e93c-4583-a457-26c52162d88b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_e1a4a9ba-e93c-4583-a457-26c52162d88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_4ccaf117-bb15-4473-8640-a9cc399f14b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_e1a4a9ba-e93c-4583-a457-26c52162d88b" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_4ccaf117-bb15-4473-8640-a9cc399f14b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_RevenueRecognitionMember_4eb024be-ab8f-44f5-9e80-c601bb32f2b0" xlink:href="vcyt-20200331.xsd#vcyt_RevenueRecognitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_4ccaf117-bb15-4473-8640-a9cc399f14b7" xlink:to="loc_vcyt_RevenueRecognitionMember_4eb024be-ab8f-44f5-9e80-c601bb32f2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e825c561-720b-49bf-ab4a-3bbc65eb7f2b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_srt_StatementGeographicalAxis_e825c561-720b-49bf-ab4a-3bbc65eb7f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a636f36c-8474-45aa-b5db-e5f3ce585432" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e825c561-720b-49bf-ab4a-3bbc65eb7f2b" xlink:to="loc_srt_SegmentGeographicalDomain_a636f36c-8474-45aa-b5db-e5f3ce585432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_23c362b7-6452-42f8-b378-edcf6bc08987" xlink:href="vcyt-20200331.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a636f36c-8474-45aa-b5db-e5f3ce585432" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_23c362b7-6452-42f8-b378-edcf6bc08987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_74e10255-4e7f-4337-a23c-ebb89f50abf8" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c8811065-4618-43d6-8e0c-5c251dbf5dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c8811065-4618-43d6-8e0c-5c251dbf5dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NumberOfDiseaseAreasWithGenomicTesting_325f1846-ac9e-4cce-8709-8895b2328cba" xlink:href="vcyt-20200331.xsd#vcyt_NumberOfDiseaseAreasWithGenomicTesting"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_NumberOfDiseaseAreasWithGenomicTesting_325f1846-ac9e-4cce-8709-8895b2328cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_88820be3-3caa-4769-8e64-f365b880d663" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_88820be3-3caa-4769-8e64-f365b880d663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6da4dc1-b5a8-4eea-ae5a-df186409bd60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6da4dc1-b5a8-4eea-ae5a-df186409bd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a306a756-a82e-43e2-b204-4b978207093f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a306a756-a82e-43e2-b204-4b978207093f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7b065f07-b4d9-4cc1-839d-bf991f6de637" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7b065f07-b4d9-4cc1-839d-bf991f6de637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f6ae5c1c-c813-408c-9e30-dd8e2e00ee49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f6ae5c1c-c813-408c-9e30-dd8e2e00ee49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities_e6817204-8ba6-408d-97e9-355e87590ee4" xlink:href="vcyt-20200331.xsd#vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities_e6817204-8ba6-408d-97e9-355e87590ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_6854ec8c-7e94-409c-9daa-7cfd5617d34b" xlink:href="vcyt-20200331.xsd#vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_6854ec8c-7e94-409c-9daa-7cfd5617d34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bfa5f176-81f4-40d2-b533-0a03f7e1980c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bfa5f176-81f4-40d2-b533-0a03f7e1980c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b6023d63-2136-4039-aa9a-d905694a3d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b6023d63-2136-4039-aa9a-d905694a3d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4e054958-c19d-4971-a93a-b9d2a94fb07b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_OperatingIncomeLoss_4e054958-c19d-4971-a93a-b9d2a94fb07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3b4c7d54-101d-4d3c-8250-0ff516d42362" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3b4c7d54-101d-4d3c-8250-0ff516d42362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1bb7b324-f7d4-44fd-b84a-239515f1b05f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1bb7b324-f7d4-44fd-b84a-239515f1b05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TermContractAgreement_624284c0-5597-4c0b-b455-bae125d1d64a" xlink:href="vcyt-20200331.xsd#vcyt_TermContractAgreement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_TermContractAgreement_624284c0-5597-4c0b-b455-bae125d1d64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AutomaticRenewalPeriodContractAgreement_9bc30471-4e7d-468c-8909-7b8dc31e88bb" xlink:href="vcyt-20200331.xsd#vcyt_AutomaticRenewalPeriodContractAgreement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_AutomaticRenewalPeriodContractAgreement_9bc30471-4e7d-468c-8909-7b8dc31e88bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TerminationPeriodContractAgreement_5f554916-a445-48a4-b8ab-05d2b221e9e5" xlink:href="vcyt-20200331.xsd#vcyt_TerminationPeriodContractAgreement"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_TerminationPeriodContractAgreement_5f554916-a445-48a4-b8ab-05d2b221e9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NumberofTissueSampleDeliveries_43612435-a9fa-4e58-ac6b-ec7ed62dca3d" xlink:href="vcyt-20200331.xsd#vcyt_NumberofTissueSampleDeliveries"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_NumberofTissueSampleDeliveries_43612435-a9fa-4e58-ac6b-ec7ed62dca3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_db4533ff-d919-4e16-b1c0-9df0f45b5c39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_db4533ff-d919-4e16-b1c0-9df0f45b5c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ContractAgreementReceivableForServices_d2fdad2d-02cb-4b0b-a632-c8604e93e608" xlink:href="vcyt-20200331.xsd#vcyt_ContractAgreementReceivableForServices"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_ContractAgreementReceivableForServices_d2fdad2d-02cb-4b0b-a632-c8604e93e608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ContractAgreementConditionalAdditionalReceivable_8b524bf5-8e73-4fac-84fc-b4ba92f5a5f7" xlink:href="vcyt-20200331.xsd#vcyt_ContractAgreementConditionalAdditionalReceivable"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_ContractAgreementConditionalAdditionalReceivable_8b524bf5-8e73-4fac-84fc-b4ba92f5a5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ContractAgreementFeePercentageOfCashCollections_baf822c7-a92a-4ac4-a78c-281f418fb081" xlink:href="vcyt-20200331.xsd#vcyt_ContractAgreementFeePercentageOfCashCollections"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_ContractAgreementFeePercentageOfCashCollections_baf822c7-a92a-4ac4-a78c-281f418fb081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ca3374a9-5fe8-457f-97fe-50bf2b1762b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ca3374a9-5fe8-457f-97fe-50bf2b1762b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b89c5363-0ce7-4d8d-81ab-f803b81376e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b89c5363-0ce7-4d8d-81ab-f803b81376e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_72545c9f-40c2-4f33-b474-078ed0014390" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_OperatingLeaseLiability_72545c9f-40c2-4f33-b474-078ed0014390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_8757859f-5cca-42d2-a2ec-a5f9fd84f22e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_AccountsReceivableNet_8757859f-5cca-42d2-a2ec-a5f9fd84f22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ContractAgreementAmount_c356b3ae-aee0-4420-9d8a-7181509d157c" xlink:href="vcyt-20200331.xsd#vcyt_ContractAgreementAmount"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_vcyt_ContractAgreementAmount_c356b3ae-aee0-4420-9d8a-7181509d157c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_8c85e355-e6f4-4912-9eba-f56e75341b65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ea24db9c-9115-4d27-87f6-07913073963d" xlink:to="loc_us-gaap_InventoryWriteDown_8c85e355-e6f4-4912-9eba-f56e75341b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#OrganizationandDescriptionofBusinessCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_146fda25-ee2f-4b82-b00e-eb2d650540d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_6cd77097-051f-4e58-943b-5920d40b8048" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146fda25-ee2f-4b82-b00e-eb2d650540d4" xlink:to="loc_us-gaap_ConcentrationRiskTable_6cd77097-051f-4e58-943b-5920d40b8048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_461d9bd1-3913-4522-9651-fc5ac1ab82fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6cd77097-051f-4e58-943b-5920d40b8048" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_461d9bd1-3913-4522-9651-fc5ac1ab82fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f60b3f01-016a-44a5-a3d9-e93568284c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_461d9bd1-3913-4522-9651-fc5ac1ab82fa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f60b3f01-016a-44a5-a3d9-e93568284c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7f646c65-ed39-4722-a27a-9a9b45e42241" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f60b3f01-016a-44a5-a3d9-e93568284c4c" xlink:to="loc_us-gaap_SalesRevenueNetMember_7f646c65-ed39-4722-a27a-9a9b45e42241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8aa35ce1-55ae-4846-a085-f1c77b79f2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f60b3f01-016a-44a5-a3d9-e93568284c4c" xlink:to="loc_us-gaap_AccountsReceivableMember_8aa35ce1-55ae-4846-a085-f1c77b79f2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_68c96885-61b9-421e-9322-7cda6628d471" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6cd77097-051f-4e58-943b-5920d40b8048" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_68c96885-61b9-421e-9322-7cda6628d471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8fc454bb-c0fc-4c54-a260-02364c2734df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_68c96885-61b9-421e-9322-7cda6628d471" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8fc454bb-c0fc-4c54-a260-02364c2734df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_39bede73-f330-4fcf-a7f6-76315e6b0070" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8fc454bb-c0fc-4c54-a260-02364c2734df" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_39bede73-f330-4fcf-a7f6-76315e6b0070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_6969fe59-0433-4140-9566-6c5d862ab4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8fc454bb-c0fc-4c54-a260-02364c2734df" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_6969fe59-0433-4140-9566-6c5d862ab4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_18771c24-b30a-4250-b248-0fd25cf1bfdd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6cd77097-051f-4e58-943b-5920d40b8048" xlink:to="loc_srt_MajorCustomersAxis_18771c24-b30a-4250-b248-0fd25cf1bfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f3473e15-f044-485c-a061-cc9e7d7c82d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_18771c24-b30a-4250-b248-0fd25cf1bfdd" xlink:to="loc_srt_NameOfMajorCustomerDomain_f3473e15-f044-485c-a061-cc9e7d7c82d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_MedicareMember_28048dc6-f279-4e70-95ae-31a50a051ab2" xlink:href="vcyt-20200331.xsd#vcyt_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3473e15-f044-485c-a061-cc9e7d7c82d6" xlink:to="loc_vcyt_MedicareMember_28048dc6-f279-4e70-95ae-31a50a051ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_JohnsonJohnsonServicesInc.Member_b765dd6a-62b1-4742-9895-7eabf18632dc" xlink:href="vcyt-20200331.xsd#vcyt_JohnsonJohnsonServicesInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3473e15-f044-485c-a061-cc9e7d7c82d6" xlink:to="loc_vcyt_JohnsonJohnsonServicesInc.Member_b765dd6a-62b1-4742-9895-7eabf18632dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_UnitedHealthcareMember_c2de4e40-17ae-41af-8297-dfed349aa22f" xlink:href="vcyt-20200331.xsd#vcyt_UnitedHealthcareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3473e15-f044-485c-a061-cc9e7d7c82d6" xlink:to="loc_vcyt_UnitedHealthcareMember_c2de4e40-17ae-41af-8297-dfed349aa22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_0b219af5-800f-4299-b5fb-c8aa6bc951e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6cd77097-051f-4e58-943b-5920d40b8048" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_0b219af5-800f-4299-b5fb-c8aa6bc951e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4b327aca-0b99-47af-a534-fa7bff4e5419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0b219af5-800f-4299-b5fb-c8aa6bc951e6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4b327aca-0b99-47af-a534-fa7bff4e5419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerCommonShare" xlink:type="simple" xlink:href="vcyt-20200331.xsd#NetLossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/NetLossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c54dae3e-369a-4b05-9b70-ea1bc57ed8bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_94095334-aaba-40ca-8b16-e8ba226d18a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c54dae3e-369a-4b05-9b70-ea1bc57ed8bb" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_94095334-aaba-40ca-8b16-e8ba226d18a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerCommonShareTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#NetLossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/NetLossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e5efe3ef-04d8-4c72-97d4-577be5dc3c9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ba9ca4ae-fda8-4a07-9bd7-fdd102bfc9ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e5efe3ef-04d8-4c72-97d4-577be5dc3c9b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ba9ca4ae-fda8-4a07-9bd7-fdd102bfc9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerCommonShareDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#NetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/NetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7e78ff59-25f7-4869-be0f-a9f00d292415" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c32d5b15-460d-4e21-a1ce-1e91f8f41dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7e78ff59-25f7-4869-be0f-a9f00d292415" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c32d5b15-460d-4e21-a1ce-1e91f8f41dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c193b099-162e-4cf0-bf45-9f7444e79825" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c32d5b15-460d-4e21-a1ce-1e91f8f41dbf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c193b099-162e-4cf0-bf45-9f7444e79825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e87a6054-f1ed-4f0f-902f-27afe810fa17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c193b099-162e-4cf0-bf45-9f7444e79825" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e87a6054-f1ed-4f0f-902f-27afe810fa17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_326e8eb1-bbed-406f-9f47-89d580a5c976" xlink:href="vcyt-20200331.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e87a6054-f1ed-4f0f-902f-27afe810fa17" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_326e8eb1-bbed-406f-9f47-89d580a5c976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2ee23796-16a8-45b4-9f37-b1f0dd4995b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e87a6054-f1ed-4f0f-902f-27afe810fa17" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2ee23796-16a8-45b4-9f37-b1f0dd4995b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_53b50c78-282f-4d6e-8eb5-1ee0a23680ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e87a6054-f1ed-4f0f-902f-27afe810fa17" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_53b50c78-282f-4d6e-8eb5-1ee0a23680ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fa7e594f-85de-474b-8d70-1ee43923cb0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c32d5b15-460d-4e21-a1ce-1e91f8f41dbf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fa7e594f-85de-474b-8d70-1ee43923cb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d32530ae-61c2-4f0e-8291-618344df8d91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fa7e594f-85de-474b-8d70-1ee43923cb0d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d32530ae-61c2-4f0e-8291-618344df8d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="vcyt-20200331.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_19fbbc4d-63fa-419f-805f-3bc935e89d06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_898fdcc4-aa3c-45de-b72d-67000bd54bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_19fbbc4d-63fa-419f-805f-3bc935e89d06" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_898fdcc4-aa3c-45de-b72d-67000bd54bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c32bad8b-3537-46b6-bf0c-f74581cccfda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0e824a3d-e4e1-4955-be22-a1995a247e50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c32bad8b-3537-46b6-bf0c-f74581cccfda" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0e824a3d-e4e1-4955-be22-a1995a247e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_94484a05-98bd-47df-a710-f39dc6876902" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0b0627b9-1c75-414d-adf0-5da634cc3d24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_94484a05-98bd-47df-a710-f39dc6876902" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0b0627b9-1c75-414d-adf0-5da634cc3d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7a9a89ef-0e58-4caa-b0b8-196ab019119b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_94484a05-98bd-47df-a710-f39dc6876902" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7a9a89ef-0e58-4caa-b0b8-196ab019119b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7205b139-fc77-46b8-9ffb-084311c2b45e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_94484a05-98bd-47df-a710-f39dc6876902" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7205b139-fc77-46b8-9ffb-084311c2b45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombination" xlink:type="simple" xlink:href="vcyt-20200331.xsd#BusinessCombination"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BusinessCombination" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f91087d4-7d3b-4e0c-9478-7bd29cab8f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_17657b8c-4f81-4ff1-b360-b833a562ff91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f91087d4-7d3b-4e0c-9478-7bd29cab8f1d" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_17657b8c-4f81-4ff1-b360-b833a562ff91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_0f234891-d103-4dec-b8da-4362a7063879" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_3da990b4-b618-4dff-97ed-20e78d414673" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_0f234891-d103-4dec-b8da-4362a7063879" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_3da990b4-b618-4dff-97ed-20e78d414673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_5f50a621-ec83-4622-8948-43ee95ba94e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_0f234891-d103-4dec-b8da-4362a7063879" xlink:to="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_5f50a621-ec83-4622-8948-43ee95ba94e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationsDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#BusinessCombinationsDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_80ad2a75-e872-436b-a48e-9e94d65f05ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fee3eb95-efe1-4c0c-96eb-0423f6dd3eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_80ad2a75-e872-436b-a48e-9e94d65f05ec" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fee3eb95-efe1-4c0c-96eb-0423f6dd3eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9c06dfb9-06b0-40cf-8f2a-3dd615aeca8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fee3eb95-efe1-4c0c-96eb-0423f6dd3eb3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9c06dfb9-06b0-40cf-8f2a-3dd615aeca8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44631479-bce1-48d4-bb4d-743284096250" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9c06dfb9-06b0-40cf-8f2a-3dd615aeca8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44631479-bce1-48d4-bb4d-743284096250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NanoStringMember_db5b4f5c-4ba5-4dde-9b88-f1f41705564a" xlink:href="vcyt-20200331.xsd#vcyt_NanoStringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44631479-bce1-48d4-bb4d-743284096250" xlink:to="loc_vcyt_NanoStringMember_db5b4f5c-4ba5-4dde-9b88-f1f41705564a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fdf96453-2897-4c5a-acf5-9ad99180d81a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fee3eb95-efe1-4c0c-96eb-0423f6dd3eb3" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fdf96453-2897-4c5a-acf5-9ad99180d81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0cc52c40-65cb-4bc4-8c4d-6d47abed2862" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fdf96453-2897-4c5a-acf5-9ad99180d81a" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0cc52c40-65cb-4bc4-8c4d-6d47abed2862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2290e0ef-8140-4d9d-aa69-32012ad17b75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0cc52c40-65cb-4bc4-8c4d-6d47abed2862" xlink:to="loc_us-gaap_CommonStockMember_2290e0ef-8140-4d9d-aa69-32012ad17b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fee3eb95-efe1-4c0c-96eb-0423f6dd3eb3" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_be105bc9-2468-40c4-8182-1ce82263329f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_be105bc9-2468-40c4-8182-1ce82263329f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_5e5182d4-6ca6-4316-a49a-cd19699e3fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_5e5182d4-6ca6-4316-a49a-cd19699e3fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_ea170961-f859-4009-9769-69f9460c390a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_ea170961-f859-4009-9769-69f9460c390a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d96b5452-3ce7-4268-bc88-ed9e8def4450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d96b5452-3ce7-4268-bc88-ed9e8def4450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3b0105f8-4f6e-4f87-8d2b-d51b72d92ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80c8d280-2a24-40a1-974c-6cd2e83da574" xlink:to="loc_us-gaap_Goodwill_3b0105f8-4f6e-4f87-8d2b-d51b72d92ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#BusinessCombinationAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_518dc46d-dd26-4070-bd66-e6035e6cb306" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d5f7f14-2f10-408e-bf15-f68edc8bcfad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_518dc46d-dd26-4070-bd66-e6035e6cb306" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d5f7f14-2f10-408e-bf15-f68edc8bcfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_79101e95-6cc1-4ad0-bf4c-81a10d9bc37a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d5f7f14-2f10-408e-bf15-f68edc8bcfad" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_79101e95-6cc1-4ad0-bf4c-81a10d9bc37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e284fe1f-1cd7-4f13-89e8-4bb8b59e0870" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79101e95-6cc1-4ad0-bf4c-81a10d9bc37a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e284fe1f-1cd7-4f13-89e8-4bb8b59e0870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NanoStringMember_e7807388-e70b-4305-9d56-8445f7e47562" xlink:href="vcyt-20200331.xsd#vcyt_NanoStringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e284fe1f-1cd7-4f13-89e8-4bb8b59e0870" xlink:to="loc_vcyt_NanoStringMember_e7807388-e70b-4305-9d56-8445f7e47562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2172cd39-b043-4f79-9ea6-c7d4e7d4a1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d5f7f14-2f10-408e-bf15-f68edc8bcfad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2172cd39-b043-4f79-9ea6-c7d4e7d4a1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58279d8f-172e-4ae0-bb4c-1e2bc130c5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2172cd39-b043-4f79-9ea6-c7d4e7d4a1c8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58279d8f-172e-4ae0-bb4c-1e2bc130c5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DevelopedProductTechnologyMember_8011bd13-291b-49ec-84eb-2ebbf16f0dc4" xlink:href="vcyt-20200331.xsd#vcyt_DevelopedProductTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58279d8f-172e-4ae0-bb4c-1e2bc130c5ba" xlink:to="loc_vcyt_DevelopedProductTechnologyMember_8011bd13-291b-49ec-84eb-2ebbf16f0dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_34cbac98-23c7-48c5-9ad9-479de0a3c9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58279d8f-172e-4ae0-bb4c-1e2bc130c5ba" xlink:to="loc_us-gaap_CustomerRelationshipsMember_34cbac98-23c7-48c5-9ad9-479de0a3c9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NCounterFLEXDxLicenseMember_c419983f-ab17-43ec-b657-a0147cfe40a7" xlink:href="vcyt-20200331.xsd#vcyt_NCounterFLEXDxLicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58279d8f-172e-4ae0-bb4c-1e2bc130c5ba" xlink:to="loc_vcyt_NCounterFLEXDxLicenseMember_c419983f-ab17-43ec-b657-a0147cfe40a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LymphMarkProductTechnologyMember_7b676dc1-c09a-4666-a9f5-a5b82a005a5f" xlink:href="vcyt-20200331.xsd#vcyt_LymphMarkProductTechnologyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58279d8f-172e-4ae0-bb4c-1e2bc130c5ba" xlink:to="loc_vcyt_LymphMarkProductTechnologyMember_7b676dc1-c09a-4666-a9f5-a5b82a005a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b101b169-4221-478b-9091-5edf4edbf6f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d5f7f14-2f10-408e-bf15-f68edc8bcfad" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b101b169-4221-478b-9091-5edf4edbf6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1276c568-993e-4fe1-9b62-febee2962784" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b101b169-4221-478b-9091-5edf4edbf6f1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1276c568-993e-4fe1-9b62-febee2962784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5698c5c3-68c4-41c6-bb3f-dfbcd147f7fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b101b169-4221-478b-9091-5edf4edbf6f1" xlink:to="loc_us-gaap_Goodwill_5698c5c3-68c4-41c6-bb3f-dfbcd147f7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ceba4353-011c-40dc-ba23-e55017a3c555" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b101b169-4221-478b-9091-5edf4edbf6f1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ceba4353-011c-40dc-ba23-e55017a3c555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5d9f9ba5-34f7-4341-b275-1e80d00e058f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b101b169-4221-478b-9091-5edf4edbf6f1" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5d9f9ba5-34f7-4341-b275-1e80d00e058f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="vcyt-20200331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7c03533b-df92-4a81-8da6-0407e051cdbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1cc66d24-914c-4115-9897-bfeabb750cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7c03533b-df92-4a81-8da6-0407e051cdbf" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1cc66d24-914c-4115-9897-bfeabb750cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3a6c7d99-b972-465d-8c2c-813affa1da24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3a6c7d99-b972-465d-8c2c-813affa1da24" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a71a6af5-2c05-4a61-8ea8-2eb66e8fdec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a71a6af5-2c05-4a61-8ea8-2eb66e8fdec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c093be89-7f33-4e2d-8680-579b9a2e0925" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a71a6af5-2c05-4a61-8ea8-2eb66e8fdec7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c093be89-7f33-4e2d-8680-579b9a2e0925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OvernightRepurchaseAgreementsMember_5d4bc53e-d270-49d1-acdd-f8dfde057e85" xlink:href="vcyt-20200331.xsd#vcyt_OvernightRepurchaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c093be89-7f33-4e2d-8680-579b9a2e0925" xlink:to="loc_vcyt_OvernightRepurchaseAgreementsMember_5d4bc53e-d270-49d1-acdd-f8dfde057e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41bb6f70-d10f-4e10-9444-d994eaad6cea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41bb6f70-d10f-4e10-9444-d994eaad6cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1156b02a-7ccf-491d-b82f-78350b4e5266" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41bb6f70-d10f-4e10-9444-d994eaad6cea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1156b02a-7ccf-491d-b82f-78350b4e5266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7bca2416-3897-4bad-8ad5-a728a0f01151" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1156b02a-7ccf-491d-b82f-78350b4e5266" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7bca2416-3897-4bad-8ad5-a728a0f01151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b1350d62-d0fb-46fe-8040-875cb971f5b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1156b02a-7ccf-491d-b82f-78350b4e5266" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b1350d62-d0fb-46fe-8040-875cb971f5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_daf2d2d8-8ce4-45cd-8fa9-c70ac96f2c5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_daf2d2d8-8ce4-45cd-8fa9-c70ac96f2c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f945223c-6866-4a97-b5c0-29f53684c6ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_daf2d2d8-8ce4-45cd-8fa9-c70ac96f2c5a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f945223c-6866-4a97-b5c0-29f53684c6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9353a72a-6657-4aae-85de-526ce32110a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f945223c-6866-4a97-b5c0-29f53684c6ee" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9353a72a-6657-4aae-85de-526ce32110a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_879d2d6b-f20f-420d-aaeb-3f7cd04dfcb6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:to="loc_srt_StatementGeographicalAxis_879d2d6b-f20f-420d-aaeb-3f7cd04dfcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5d0e82fa-cd94-4413-8ce3-930f027daf98" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_879d2d6b-f20f-420d-aaeb-3f7cd04dfcb6" xlink:to="loc_srt_SegmentGeographicalDomain_5d0e82fa-cd94-4413-8ce3-930f027daf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_7efa0f90-1dfe-479d-aed2-c38a7d8a35bc" xlink:href="vcyt-20200331.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d0e82fa-cd94-4413-8ce3-930f027daf98" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_7efa0f90-1dfe-479d-aed2-c38a7d8a35bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2b65deac-9500-4c4f-a786-3bb059f8c0df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2b65deac-9500-4c4f-a786-3bb059f8c0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af67eb66-e57a-45c2-860a-d263bb6e2814" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2b65deac-9500-4c4f-a786-3bb059f8c0df" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af67eb66-e57a-45c2-860a-d263bb6e2814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NanoStringMember_9d5ef204-9b0a-4444-aea1-059efeab53dd" xlink:href="vcyt-20200331.xsd#vcyt_NanoStringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af67eb66-e57a-45c2-860a-d263bb6e2814" xlink:to="loc_vcyt_NanoStringMember_9d5ef204-9b0a-4444-aea1-059efeab53dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1c4b7b8-97d7-473b-8d45-390636cad7df" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7d5f092c-723b-4be7-8bd1-08a60c1f57b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7d5f092c-723b-4be7-8bd1-08a60c1f57b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_477bbeee-0870-46a4-83bf-f3f6c82c1816" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_477bbeee-0870-46a4-83bf-f3f6c82c1816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_23ce2294-a87f-48f0-9eef-a8d5c60c5bca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_23ce2294-a87f-48f0-9eef-a8d5c60c5bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c21a4cfe-016d-4bd8-a8b6-09ca7688d9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c21a4cfe-016d-4bd8-a8b6-09ca7688d9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_f9209dc9-c451-4001-8722-56d6a467cc17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b99f4735-61a1-4d00-b0de-d51fd4d2c411" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_f9209dc9-c451-4001-8722-56d6a467cc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9896e117-346c-400d-8743-cda70e355214" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12c73b1f-ed1c-4419-acb0-80ad1aa04030" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9896e117-346c-400d-8743-cda70e355214" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12c73b1f-ed1c-4419-acb0-80ad1aa04030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5a818462-22a7-45b3-accf-44bd33dd3b40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_da15d52c-a28b-4b1f-ac2e-3fc321169478" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5a818462-22a7-45b3-accf-44bd33dd3b40" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_da15d52c-a28b-4b1f-ac2e-3fc321169478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CommitmentsandContingenciesOperatingLeaseDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_03c37e78-7376-485f-8b9c-ce7b8b2c8d20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24078995-8407-441e-9603-2d4c7f105dba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_03c37e78-7376-485f-8b9c-ce7b8b2c8d20" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24078995-8407-441e-9603-2d4c7f105dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e3db2578-d1a9-4efc-ba6c-fae1168fbe5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24078995-8407-441e-9603-2d4c7f105dba" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e3db2578-d1a9-4efc-ba6c-fae1168fbe5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_23d0f862-52ee-4d4e-be55-31e21fc38e28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e3db2578-d1a9-4efc-ba6c-fae1168fbe5d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_23d0f862-52ee-4d4e-be55-31e21fc38e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e694536d-8a43-4e8d-aeef-41efe80fa719" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_23d0f862-52ee-4d4e-be55-31e21fc38e28" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e694536d-8a43-4e8d-aeef-41efe80fa719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3a1e0b01-fca8-4936-a06a-78bb29494bd8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24078995-8407-441e-9603-2d4c7f105dba" xlink:to="loc_srt_StatementGeographicalAxis_3a1e0b01-fca8-4936-a06a-78bb29494bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_194d0297-0c23-4e03-9475-b1b9b0f7c307" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3a1e0b01-fca8-4936-a06a-78bb29494bd8" xlink:to="loc_srt_SegmentGeographicalDomain_194d0297-0c23-4e03-9475-b1b9b0f7c307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_5500a973-8e7a-49a1-a4c0-61ee9abc1e62" xlink:href="vcyt-20200331.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_194d0297-0c23-4e03-9475-b1b9b0f7c307" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_5500a973-8e7a-49a1-a4c0-61ee9abc1e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LaboratoryFacilitiesAustinTexasMember_5e859be5-e94b-4cbe-a3db-1fbffc5ec2fd" xlink:href="vcyt-20200331.xsd#vcyt_LaboratoryFacilitiesAustinTexasMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_194d0297-0c23-4e03-9475-b1b9b0f7c307" xlink:to="loc_vcyt_LaboratoryFacilitiesAustinTexasMember_5e859be5-e94b-4cbe-a3db-1fbffc5ec2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_6433b478-236b-4f34-a16c-c314f1a2e0f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24078995-8407-441e-9603-2d4c7f105dba" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_6433b478-236b-4f34-a16c-c314f1a2e0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_26b95ee4-a9f7-46c9-9ee9-ead8ee0487f5" xlink:href="vcyt-20200331.xsd#vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6433b478-236b-4f34-a16c-c314f1a2e0f2" xlink:to="loc_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_26b95ee4-a9f7-46c9-9ee9-ead8ee0487f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_85297618-90f1-4f6e-b9cd-a08e2868c6cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6433b478-236b-4f34-a16c-c314f1a2e0f2" xlink:to="loc_us-gaap_SecurityDeposit_85297618-90f1-4f6e-b9cd-a08e2868c6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6433b478-236b-4f34-a16c-c314f1a2e0f2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ea4119e9-7c78-42b1-bec7-ad9ff515d3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ea4119e9-7c78-42b1-bec7-ad9ff515d3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_10f12148-f722-4988-a77f-0b93c4b7bba8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_10f12148-f722-4988-a77f-0b93c4b7bba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_70bf13c9-b603-46b9-b755-beea03e3f704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_70bf13c9-b603-46b9-b755-beea03e3f704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f738e2bc-d84f-4bc7-b447-726858619699" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f738e2bc-d84f-4bc7-b447-726858619699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d432ae74-3bf1-4150-b475-dc59f3b7fa27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d432ae74-3bf1-4150-b475-dc59f3b7fa27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b609be53-1e35-48c4-958d-bdb19330ead0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b609be53-1e35-48c4-958d-bdb19330ead0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f5bbe393-a031-47d7-8577-bd40797b5f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f5bbe393-a031-47d7-8577-bd40797b5f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37dfb829-71db-4b3e-952d-a15367dae455" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37dfb829-71db-4b3e-952d-a15367dae455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f5321115-5754-4797-ba22-7934aba3ddd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_OperatingLeaseLiability_f5321115-5754-4797-ba22-7934aba3ddd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8be72e53-19f8-4748-b24a-3a332d50cc37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8be72e53-19f8-4748-b24a-3a332d50cc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b10999b-60ed-44ae-8287-fbd67095fabb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a29aeaec-46c1-4910-81db-98e1bb172272" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b10999b-60ed-44ae-8287-fbd67095fabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_45746965-28a2-4b7e-b75c-d42bb538122d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6433b478-236b-4f34-a16c-c314f1a2e0f2" xlink:to="loc_us-gaap_OperatingLeaseExpense_45746965-28a2-4b7e-b75c-d42bb538122d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails_1" xlink:type="simple" xlink:href="vcyt-20200331.xsd#CommitmentsandContingenciesOperatingLeaseDetails_1"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/Debt" xlink:type="simple" xlink:href="vcyt-20200331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6518dcf7-3b27-4d2f-89ef-9df73da20f92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_0964eeaf-086a-4f42-bcb7-6f67dbb21d76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6518dcf7-3b27-4d2f-89ef-9df73da20f92" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_0964eeaf-086a-4f42-bcb7-6f67dbb21d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8b3734be-de58-453b-92a7-1a0f161fe734" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_2efb5c1f-ecf2-4585-b86f-9cbaa604c725" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8b3734be-de58-453b-92a7-1a0f161fe734" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_2efb5c1f-ecf2-4585-b86f-9cbaa604c725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1e39a92c-789d-4ccd-8c68-2cbf3a947aea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1e39a92c-789d-4ccd-8c68-2cbf3a947aea" xlink:to="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPrepaymentTrancheAxis_590ca394-be37-40df-8cf6-8c6f32ac29fd" xlink:href="vcyt-20200331.xsd#vcyt_DebtPrepaymentTrancheAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:to="loc_vcyt_DebtPrepaymentTrancheAxis_590ca394-be37-40df-8cf6-8c6f32ac29fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPaymentTrancheDomain_4da1b98e-cee2-433e-a721-6a6a79be6cbd" xlink:href="vcyt-20200331.xsd#vcyt_DebtPaymentTrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_DebtPrepaymentTrancheAxis_590ca394-be37-40df-8cf6-8c6f32ac29fd" xlink:to="loc_vcyt_DebtPaymentTrancheDomain_4da1b98e-cee2-433e-a721-6a6a79be6cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPrepaymentTrancheOneMember_4681ff7a-2955-4200-8023-e0e50a24cf85" xlink:href="vcyt-20200331.xsd#vcyt_DebtPrepaymentTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_DebtPaymentTrancheDomain_4da1b98e-cee2-433e-a721-6a6a79be6cbd" xlink:to="loc_vcyt_DebtPrepaymentTrancheOneMember_4681ff7a-2955-4200-8023-e0e50a24cf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPrepaymentTrancheTwoMember_2bf3b3b0-4640-4947-9c42-453426070262" xlink:href="vcyt-20200331.xsd#vcyt_DebtPrepaymentTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_DebtPaymentTrancheDomain_4da1b98e-cee2-433e-a721-6a6a79be6cbd" xlink:to="loc_vcyt_DebtPrepaymentTrancheTwoMember_2bf3b3b0-4640-4947-9c42-453426070262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtPrepaymentTrancheThreeMember_baf71a2a-6a34-42ae-a7fa-cbf309323615" xlink:href="vcyt-20200331.xsd#vcyt_DebtPrepaymentTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_DebtPaymentTrancheDomain_4da1b98e-cee2-433e-a721-6a6a79be6cbd" xlink:to="loc_vcyt_DebtPrepaymentTrancheThreeMember_baf71a2a-6a34-42ae-a7fa-cbf309323615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_990b2f33-0732-424b-b35b-43babad12990" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:to="loc_us-gaap_CreditFacilityAxis_990b2f33-0732-424b-b35b-43babad12990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_53aa4555-02f4-4766-9183-6806ad64b0ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_990b2f33-0732-424b-b35b-43babad12990" xlink:to="loc_us-gaap_CreditFacilityDomain_53aa4555-02f4-4766-9183-6806ad64b0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_36c973ca-b378-43c0-8b85-33cb6e791d64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_53aa4555-02f4-4766-9183-6806ad64b0ea" xlink:to="loc_us-gaap_SecuredDebtMember_36c973ca-b378-43c0-8b85-33cb6e791d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2a754ec2-bcd2-4c9d-b7c8-4bfa65b25929" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_53aa4555-02f4-4766-9183-6806ad64b0ea" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2a754ec2-bcd2-4c9d-b7c8-4bfa65b25929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_4b589af9-381c-410b-bf07-4cea2913376e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_4b589af9-381c-410b-bf07-4cea2913376e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8b0dd2a2-1197-4b22-91d0-21c721ef6b87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_4b589af9-381c-410b-bf07-4cea2913376e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8b0dd2a2-1197-4b22-91d0-21c721ef6b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_SiliconValleyBankMember_5643a38b-b7de-4300-97f0-8a8a6cc2e1de" xlink:href="vcyt-20200331.xsd#vcyt_SiliconValleyBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8b0dd2a2-1197-4b22-91d0-21c721ef6b87" xlink:to="loc_vcyt_SiliconValleyBankMember_5643a38b-b7de-4300-97f0-8a8a6cc2e1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ac30727e-94df-4532-8e34-5dca3d70ce52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ac30727e-94df-4532-8e34-5dca3d70ce52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d657d93c-2c26-4979-b2b2-6e000262665c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ac30727e-94df-4532-8e34-5dca3d70ce52" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d657d93c-2c26-4979-b2b2-6e000262665c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d3798cfe-d7e7-4f32-9d0d-ff3f62c335e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d657d93c-2c26-4979-b2b2-6e000262665c" xlink:to="loc_us-gaap_LineOfCreditMember_d3798cfe-d7e7-4f32-9d0d-ff3f62c335e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7568f1e5-0010-4d3b-bbc8-5c2161738a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:to="loc_us-gaap_VariableRateAxis_7568f1e5-0010-4d3b-bbc8-5c2161738a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a522b94a-0062-4e3d-9bc1-b3d478024f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_7568f1e5-0010-4d3b-bbc8-5c2161738a6b" xlink:to="loc_us-gaap_VariableRateDomain_a522b94a-0062-4e3d-9bc1-b3d478024f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a6d2cebc-4e83-488e-8995-b01447242f87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a522b94a-0062-4e3d-9bc1-b3d478024f1b" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a6d2cebc-4e83-488e-8995-b01447242f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b6394d01-b1b2-48e6-8c12-6d4d9fc45b4d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:to="loc_srt_RangeAxis_b6394d01-b1b2-48e6-8c12-6d4d9fc45b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45f9da30-45e8-4b98-9fed-01b6d3fdf275" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b6394d01-b1b2-48e6-8c12-6d4d9fc45b4d" xlink:to="loc_srt_RangeMember_45f9da30-45e8-4b98-9fed-01b6d3fdf275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_12110a05-610d-4aa5-8f89-68cd7f2978e9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45f9da30-45e8-4b98-9fed-01b6d3fdf275" xlink:to="loc_srt_MinimumMember_12110a05-610d-4aa5-8f89-68cd7f2978e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_32254a75-5278-4967-913a-ce18ff2f6923" xlink:to="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ab373d6d-3b6b-4bad-a5a4-be84de9a2c35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ab373d6d-3b6b-4bad-a5a4-be84de9a2c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b1e8d741-4d69-47d3-8a71-e8a9207b55d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b1e8d741-4d69-47d3-8a71-e8a9207b55d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fd626685-8bc3-4068-b109-75f89c1fe80a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fd626685-8bc3-4068-b109-75f89c1fe80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_72d285d3-03dd-488e-b9bb-6f231e309b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_72d285d3-03dd-488e-b9bb-6f231e309b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtInstrumentPrepaymentPremium_a04e03a5-7c5b-41d2-bcbf-ff23f97131cb" xlink:href="vcyt-20200331.xsd#vcyt_DebtInstrumentPrepaymentPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_vcyt_DebtInstrumentPrepaymentPremium_a04e03a5-7c5b-41d2-bcbf-ff23f97131cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8143c571-b268-4329-a959-73e8008d68ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8143c571-b268-4329-a959-73e8008d68ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_980b7e29-8f24-4ca7-8934-15a88531e3b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_980b7e29-8f24-4ca7-8934-15a88531e3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LiquidityRequirementMinimum_8efebf3e-9af5-4d11-8c62-34b444d3540b" xlink:href="vcyt-20200331.xsd#vcyt_LiquidityRequirementMinimum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_vcyt_LiquidityRequirementMinimum_8efebf3e-9af5-4d11-8c62-34b444d3540b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_18e913ed-12cd-4cf1-9616-d2f9c76a9e72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77ab25be-0722-453d-a668-e64a8533a751" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_18e913ed-12cd-4cf1-9616-d2f9c76a9e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#DebtDebtObligationforBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e5b0839c-232f-486f-94b3-0dce58b36c32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a3818229-e99b-4885-b78c-a3b42c7f818d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e5b0839c-232f-486f-94b3-0dce58b36c32" xlink:to="loc_us-gaap_DebtInstrumentTable_a3818229-e99b-4885-b78c-a3b42c7f818d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2ef38a05-f479-4fee-b855-f5b1b0b10bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a3818229-e99b-4885-b78c-a3b42c7f818d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2ef38a05-f479-4fee-b855-f5b1b0b10bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9c9f3720-920c-4027-accd-5c7ea5abb234" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2ef38a05-f479-4fee-b855-f5b1b0b10bc3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9c9f3720-920c-4027-accd-5c7ea5abb234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d99fa05e-b074-4742-84c2-65b47d141186" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c9f3720-920c-4027-accd-5c7ea5abb234" xlink:to="loc_us-gaap_LineOfCreditMember_d99fa05e-b074-4742-84c2-65b47d141186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_331e02ab-b130-47b7-97b4-47e91ebf4ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a3818229-e99b-4885-b78c-a3b42c7f818d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_331e02ab-b130-47b7-97b4-47e91ebf4ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_905108d2-b23d-4dd9-9db1-472a21cb84a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_331e02ab-b130-47b7-97b4-47e91ebf4ea2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_905108d2-b23d-4dd9-9db1-472a21cb84a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_baff8475-3ddb-4808-b53f-c55a13a2cf61" xlink:href="vcyt-20200331.xsd#vcyt_DebtInstrumentEndOfTermInterestObligationAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_331e02ab-b130-47b7-97b4-47e91ebf4ea2" xlink:to="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_baff8475-3ddb-4808-b53f-c55a13a2cf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9a9a27bd-a53d-453d-8aa6-858b0bbf70b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_331e02ab-b130-47b7-97b4-47e91ebf4ea2" xlink:to="loc_us-gaap_LongTermDebt_9a9a27bd-a53d-453d-8aa6-858b0bbf70b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquity" xlink:type="simple" xlink:href="vcyt-20200331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5b3bc00f-3c60-497a-ae62-30926a8fbfa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ad949294-6301-4c5d-be5b-b235c53e1e91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5b3bc00f-3c60-497a-ae62-30926a8fbfa4" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ad949294-6301-4c5d-be5b-b235c53e1e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="vcyt-20200331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_521c58c4-ca54-44c9-b689-c0982127459f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_fc7f27d3-2fc9-452f-a957-6d1c04aa3e65" xlink:href="vcyt-20200331.xsd#vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_521c58c4-ca54-44c9-b689-c0982127459f" xlink:to="loc_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_fc7f27d3-2fc9-452f-a957-6d1c04aa3e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_44474c1c-b049-4391-9d72-d9f30c928ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5438c2f4-b989-4d2e-852c-3078b5b8bc8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_44474c1c-b049-4391-9d72-d9f30c928ad1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5438c2f4-b989-4d2e-852c-3078b5b8bc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3f773db7-c8fd-4c1f-b18a-4b3d20fefcbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5438c2f4-b989-4d2e-852c-3078b5b8bc8c" xlink:to="loc_us-gaap_AwardTypeAxis_3f773db7-c8fd-4c1f-b18a-4b3d20fefcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633b0ebc-2bde-46b4-a710-4ab09f408614" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3f773db7-c8fd-4c1f-b18a-4b3d20fefcbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633b0ebc-2bde-46b4-a710-4ab09f408614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_b18b638a-8279-49eb-9c60-c2147ca692f6" xlink:href="vcyt-20200331.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633b0ebc-2bde-46b4-a710-4ab09f408614" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_b18b638a-8279-49eb-9c60-c2147ca692f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bdaabb01-1bed-4397-ac39-2519cfebd339" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633b0ebc-2bde-46b4-a710-4ab09f408614" xlink:to="loc_us-gaap_EmployeeStockMember_bdaabb01-1bed-4397-ac39-2519cfebd339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_65e77eac-feae-4e39-b34e-da3532a623e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5438c2f4-b989-4d2e-852c-3078b5b8bc8c" xlink:to="loc_us-gaap_ClassOfStockLineItems_65e77eac-feae-4e39-b34e-da3532a623e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_CommonStockAbstract_b877c2f9-755f-4fd5-b38d-2097de508f9e" xlink:href="vcyt-20200331.xsd#vcyt_CommonStockAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_65e77eac-feae-4e39-b34e-da3532a623e0" xlink:to="loc_vcyt_CommonStockAbstract_b877c2f9-755f-4fd5-b38d-2097de508f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4f0a574c-91e1-4a7b-8e88-66a6b284a9e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_b877c2f9-755f-4fd5-b38d-2097de508f9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4f0a574c-91e1-4a7b-8e88-66a6b284a9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e99faab7-0232-4530-8236-02e71309dd21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_b877c2f9-755f-4fd5-b38d-2097de508f9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e99faab7-0232-4530-8236-02e71309dd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ac704050-1535-4323-bd30-61e708c39243" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_b877c2f9-755f-4fd5-b38d-2097de508f9e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ac704050-1535-4323-bd30-61e708c39243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartners" xlink:type="simple" xlink:href="vcyt-20200331.xsd#ThyroidCytopathologyPartners"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/ThyroidCytopathologyPartners" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ServicesAgreementAbstract_0d7f9141-cbed-49d2-b4f0-5d508f7acaf2" xlink:href="vcyt-20200331.xsd#vcyt_ServicesAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_ba1eafbe-941b-4108-b9ba-b89786b7c74d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermContractsOrProgramsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ServicesAgreementAbstract_0d7f9141-cbed-49d2-b4f0-5d508f7acaf2" xlink:to="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_ba1eafbe-941b-4108-b9ba-b89786b7c74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails" xlink:type="simple" xlink:href="vcyt-20200331.xsd#ThyroidCytopathologyPartnersDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ServicesAgreementAbstract_f894a0f6-a811-4873-9c70-b8446f481d3b" xlink:href="vcyt-20200331.xsd#vcyt_ServicesAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_835f197b-d5e4-4cf5-a64b-2150bc807d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ServicesAgreementAbstract_f894a0f6-a811-4873-9c70-b8446f481d3b" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_835f197b-d5e4-4cf5-a64b-2150bc807d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_37c557a0-8a49-4955-bc8c-2b9fdedd1be3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_835f197b-d5e4-4cf5-a64b-2150bc807d2d" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_37c557a0-8a49-4955-bc8c-2b9fdedd1be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_3319e65e-0047-4a23-bde0-a7af51192bef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_37c557a0-8a49-4955-bc8c-2b9fdedd1be3" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_3319e65e-0047-4a23-bde0-a7af51192bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_5bf4f38a-a0df-4766-a54a-cd38a81a6cac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_3319e65e-0047-4a23-bde0-a7af51192bef" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_5bf4f38a-a0df-4766-a54a-cd38a81a6cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_880c860c-da89-441a-9786-81ccdfb3e7e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_835f197b-d5e4-4cf5-a64b-2150bc807d2d" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_880c860c-da89-441a-9786-81ccdfb3e7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AgreementTermsNonRenewalNoticePeriod_9513704c-2a93-4bea-9704-5b7d2b15e3b9" xlink:href="vcyt-20200331.xsd#vcyt_AgreementTermsNonRenewalNoticePeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_880c860c-da89-441a-9786-81ccdfb3e7e7" xlink:to="loc_vcyt_AgreementTermsNonRenewalNoticePeriod_9513704c-2a93-4bea-9704-5b7d2b15e3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherIncomeRentReimbursement_0ab1ab07-ea0a-4269-b44e-f7d7c54ba720" xlink:href="vcyt-20200331.xsd#vcyt_OtherIncomeRentReimbursement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_880c860c-da89-441a-9786-81ccdfb3e7e7" xlink:to="loc_vcyt_OtherIncomeRentReimbursement_0ab1ab07-ea0a-4269-b44e-f7d7c54ba720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxes" xlink:type="simple" xlink:href="vcyt-20200331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2697e09f-8804-4993-b4ae-8ce7b7f27c02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_70b442b9-499e-4db9-9373-0c5626f4fb62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2697e09f-8804-4993-b4ae-8ce7b7f27c02" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_70b442b9-499e-4db9-9373-0c5626f4fb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791036736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents (in shares)</a></td>
<td class="nump">5,716,509<span></span>
</td>
<td class="nump">6,235,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember', window );">Shares of common stock subject to outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents (in shares)</a></td>
<td class="nump">4,760,128<span></span>
</td>
<td class="nump">5,670,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents (in shares)</a></td>
<td class="nump">19,857<span></span>
</td>
<td class="nump">25,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents (in shares)</a></td>
<td class="nump">936,524<span></span>
</td>
<td class="nump">538,759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6645024368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of debt obligation for borrowings</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The net debt obligation for borrowings made under the Loan and Security Agreement was as follows (in thousands of dollars):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"><tr><td style="width:1.0%;"/><td style="width:70.848%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.135%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.909%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt principal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">End-of-term debt obligation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">648&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net debt obligation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">694&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_A=A*W79F?^L?%9L._@UUWT7U!+ P04    " "2@Z90F5R<(Q &  "<)P
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M*#N5](-]$$^V71XO2G4PW>G<GC=]S]A?&'T>^N%D;,K7?P%02P,$%     @
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M]EG_CO0#0=OAC03C0UW\ U!+ P04    " "2@Z90I.)?*ZD#  !I$   &
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M?=^.P^^X4/(X#?;!Y;\+J[]02P,$%     @ DH.F4!M\CQD$!   %Q,  !@
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M=MO-Y5/-9:>SI_$S5'C]%K;Y'U!+ P04    " "2@Z903C$O7X$$  !&%@
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M_[*Q_S6B R]E<^5'J/4?;#8DU"X<;_W9C&,V&@Z[Z0>Q^1L7'U!+ P04
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M\1V>W31FDQ%L/_\@MGSC\C=02P,$%     @ DH.F4$>5<06T 0  T@,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL?5-A;]P@#/TKB!]0<B3=JE,2
MJ==JVJ1-.G7:^IE+G 050@;DTOW[&9)FV1;M"V#C]_QL3#X9^^(Z $]>M>I=
M03OOAR-CKNI "W=C!NCQIC%6"X^F;9D;+(@Z@K1B/$G>,2UD3\L\^LZVS,WH
ME>SA;(D;M1;VYPF4F0IZH&^.)]EV/CA8F0^BA:_@OPUGBQ9;66JIH7?2],1"
M4]#[P_&4A?@8\%W"Y#9G$BJY&/,2C$]U09,@"!14/C (W*[P $H%(I3Q8^&D
M:\H W)[?V#_$VK&6BW#P8-2SK'U7T#M*:FC$J/R3F3["4L\M)4OQG^$*"L.#
M$LQ1&>7B2JK1>:,7%I2BQ>N\RS[NTWR3I@ML'\ 7 %\!=S$/FQ-%Y8_"BS*W
M9B)V[OT@PA,?CAQ[4P5G;$6\0_$.O=>2)SQGUT"TQ)SF&+Z).:P1#-G7%'PO
MQ8G_ ^?[\'1781KAZ1\*TWV";)<@BP39?TO<B\G^2L(V/=5@VSA-CE1F[.,D
M;[SKP-[S^":_P^=I_R)L*WM'+L;CR\;^-\9X0"G)#8Y0AQ]L-10T/AS?X]G.
M8S8;W@S+#V+K-RY_ 5!+ P04    " "2@Z90'KO*Y/H!  #+!0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6QU5&%OFS 0_2N('U"#$R") *GI5&W2
M)D6=UGUVR"6@VIC:3NC^_6Q#&:/7+]AW?O?>G<U=WDOUHFL $[P)WNHBK(WI
M=H3HJ@;!])WLH+4G9ZD$,]94%Z([!>SD@P0G-(I2(EC3AF7N?0=5YO)J>-/"
M007Z*@13?_; 95^$<?CN>&HNM7$.4N8=N\!/,+^Z@[(6F5A.C8!6-[(-%)R+
M\#[>[;<.[P'/#?1ZM@]<)4<I7YSQ[52$D4L(.%3&,3"[W. !.'=$-HW7D3.<
M)%W@?/_._NAKM[4<F88'R7\W)U,7X28,3G!F5VZ>9/\5QGJ2,!B+_PXWX!;N
M,K$:E>3:?X/JJHT4(XM-1;"W86U:O_;#2;H>P_  .@;0*6#C=<@@Y#/_P@PK
M<R7[0 UWWS'WQ/&.VKNIG--?A3^SR6OKO94T2G)R<T0C9C]@Z P33PABV2<)
MBDGLZ8=PBH>OT Q7/GPU5\\RG&"-$JP]P?J_$M-%B1CF$Y$$%4D0@LU"!,-L
M<9$4%4D_$L310@3#?/)<&2J2(01T(8)A5KC(!A79( 3KA0B&27"1+2JR10B6
M#X]AE@]/9LTD0%W\&-%!):^M'V$S[S2I[JEOQG_P8<S]8.K2M#HX2F-;VC?>
M64H#-I7HSOX?M9VLD\'A;-PVLWLUS)?!,+(;1R>9YG?Y%U!+ P04    " "2
M@Z90P>NY=+<!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6QM
M4^UNVR 4?17$ Q2;I$T6V9::5M4F;5+4:=UO8E_;J'QX@./N[0?8\=S6?X![
M.>?<#R[9H,VK;0$<>I-"V1RWSG4'0FS9@F3V1G>@_$VMC63.FZ8AMC/ JDB2
M@M DN2.2<86++/I.ILAT[P17<#+(]E(R\_<(0@\Y3O'5\<R;U@4'*;*.-? 3
MW*_N9+Q%9I6*2U"6:X4,U#F^3P_';<!'P N'P2[.*%1RUOHU&-^J'"<A(1!0
MNJ# _':!!Q B"/DT_DR:> X9B,OS5?TIUNYK.3,+#UK\YI5K<[S'J(*:]<(]
MZ^$K3/7<8C05_QTN(#P\9.)CE%K8N**RMT[+2<6G(MG;N',5]V&\V5UIZP0Z
M$>A,V$<"&0/%S!^98T5F](#,V/N.A2=.#]3WI@S.V(IXYY.WWGLI:+K/R"4(
M39CCB*$+3#HCB%>?0]"U$$?ZB4[7Z9O5##>1OEE&W^W6!;:K MLHL'U7XI</
M):Y@:/(A"%GT5()IXC195.I>Q4E>>.>!O:?Q3?[#QVG_P4S#E45G[?S+QO[7
M6COPJ20W?H1:_\%F0T#MPG'GSV8<L]%PNIM^$)F_<?$/4$L#!!0    ( )*#
MIE#] IHDL@$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;&U3
MVV[;, S]%4$?4#E*NA6!;:#I4*S "@0=MCTK-GU!=7$E.6[_?I3LN%[F%XND
MSSF\B$H'8U]= ^#)NY+:9;3QOMLSYHH&E' WI@.-?RICE?#HVIJYSH(H(TE)
MQI/D"U.BU31/8^QH\]3T7K8:CI:X7BEA/PX@S9#1#;T$7MJZ\2' \K03-?P$
M_ZL[6O38K%*V"K1KC286JHS>;_:'7<!'P.\6!K>P2>CD9,QK<)[*C":A()!0
M^* @\#C# T@9A+",MTF3SBD#<6E?U!]C[]C+23AX,/)/6_HFHW>4E%")7OH7
M,WR'J9];2J;F?\ 9),)#)9BC,-+%+REZYXV:5+ 4)=['L]7Q'";]"VV=P"<"
MOR*P,5&L_)OP(D^M&8@=9]^)<,6;/<?9%"$81Q'_8?$.H^><\TW*SD%HPAQ&
M#%]@/A$,U><4?"W%@?]'Y^OT[6J%VTC?+K/?)>L"NU6!7138_=,BOVIQ#;.]
M2L(6,U5@Z[A-CA2FUW&3%]%Y8>]YO)-/^+CMS\+6K7;D9#S>;)Q_98P'+"6Y
MP15J\('-CH3*!_,KVG9<L]'QIIM>$)N?<?X74$L#!!0    ( )*#IE#W=B'6
MMP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;&U3VV[<(!#]
M%<0'A%WLI*N5;2F;*DJE5EJE:OO,VF,;!3PNX'7Z]P7L.&[J%V"&<\Y<&+(1
MS8MM 1QYU:JS.6V=ZX^,V;(%+>P-]M#YFQJ-%LZ;IF&V-R"J2-**\=WNCFDA
M.UIDT7<V18:#4[*#LR%VT%J8/R=0..9T3]\<S[)I77"P(NM% ]_!_>C/QEML
M4:FDALY*[(B!.J?W^^,I#?@(^"EAM*LS"95<$%^"\:7*Z2XD! I*%Q2$WZ[P
M $H%(9_&[UF3+B$#<7U^4W^,M?M:+L+" ZI?LG)M3@^45%"+0;EG')]@KN>6
MDKGXKW %Y>$A$Q^C1&7C2LK!.M2SBD]%B]=IEUW<Q^DF26;:-H'/!+X0#C$.
MFP+%S#\+)XK,X$C,U/M>A"?>'[GO31F<L17QSB=OO?=:<)YF[!J$9LQIPO 5
M9K\@F%=?0O"M$"?^'YUOTY/-#)-(3];1#\FV0+HID$:!])\2;S^4N(6Y^Q"$
MK7JJP31QFBPI<>CB)*^\R\#>\_@F[_!IVK\)T\C.D@LZ_[*Q_S6B Y_*[L:/
M4.L_V&(HJ%TX?O)G,XW99#CLYQ_$EF]<_ 502P,$%     @ DH.F4(? 8KK'
M 0  -P0  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL;53;;MP@$/T5
MQ <$+WO)9F5;RB:*6JF55HG2/K/VV$8!XP)>IW\?P([K;G@QS'#FG)F!<3HH
M_68: (O>I6A-AAMKNP,AIFA ,G.C.FC=2:6T9-:9NB:FT\#*$"0%H4FR(Y+Q
M%N=I\)UTGJK>"M["22/32\GTWR,(-61XA3\=S[QNK'>0/.U8#2]@7[N3=A:9
M64HNH35<M4A#E>'[U>&X]?@ ^,5A,(L]\I6<E7KSQO<RPXE/" 04UC,PMUS@
M 83P1"Z-/Q,GGB5]X'+_R?X4:G>UG)F!!R5^\](V&=YC5$+%>F&?U? -IGJV
M&$W%_X +" ?WF3B-0@D3OJCHC55R8G&I2/8^KKP-ZS">['936#R 3@%T#M@'
M'3(*A<P?F65YJM6 ]-C[CODK7AVHZTWAG:$5X<PE;YSWDE-ZFY*+)YHPQQ%#
M%YC5C"".?9:@,8DC_1).X^'K:(;K$+Y>JN]W<8)-E& 3"#;_E;B_*C&&N8N+
M;*,BVZ\$Z^1*)(:Y[B197)P$78<G:U"A^C:,R\([3\4]#1?_#SZ.U$^F:]X:
M=%;6/9]PR952%EPJR8W+I7%3/!L"*NNWMVZOQ[<\&E9UTYB2^5^1?P!02P,$
M%     @ DH.F4!)$0TNS 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL=5/;CILP$/T5RQ^P3@S;2P1(FUU5K=1*T59MGQT8P%H;4]N$[=]W
M; BE*7W!,\,Y9RX>9Z.Q+ZX%\.15J\[EM/6^/S#FRA:T<'>FAP[_U,9JX=&U
M#7.]!5%%DE:,[W9OF!:RHT468R=;9&;P2G9PLL0-6@O[ZPC*C#G=TVO@63:M
M#P%69+UHX"OX;_W)HL<6E4IJZ)PT';%0Y_1A?SBF 1\!WR6,;F63T,G9F)?@
M?*IRN@L%@8+2!P6!QP4>0:D@A&7\G#7IDC(0U_95_4/L'7LY"P>/1OV0E6]S
M^HZ2"FHQ*/]LQH\P]W-/R=S\9[B 0GBH!'.41KGX)>7@O-&S"I:BQ>MTRBZ>
MXZQ_I6T3^$S@-P0V)8J5/PDOBLR:D=AI]KT(5[P_<)Q-&8)Q%/$?%N\P>BEX
MPC-V"4(SYCAA^ JS7Q ,U9<4?"O%D?]#Y]OT9+/")-*3=?;W_Q%(-P72*)#^
MU6)RT^(6)KU)PE8SU6";N$V.E&;HXB:OHLO"/O!X)W_@T[9_$;:1G2-GX_%F
MX_QK8SQ@*;L[7*$6']CB**A],-^B;:<UFQQO^OD%L>49%[\!4$L#!!0    (
M )*#IE!29B[AN $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM
M;&U3VV[<(!#]%<0'A%WL3=*5;2F;JFJE5EJE:OK,VF,;!8P+>)W^?0?LN&[J
M%V"&<\Y<&++1V!?7 GCRJE7G<MIZWQ\9<V4+6K@;TT.'-[6Q6G@T;<-<;T%4
MD:05X[O=+=-"=K3(HN]LB\P,7LD.SI:X06MA?Y] F3&G>_KF>))-ZX.#%5DO
M&O@._D=_MFBQ1:62&CHG34<LU#E]V!]/:<!'P+.$T:W.)%1R,>8E&%^JG.Y"
M0J"@]$%!X':%1U J"&$:OV9-NH0,Q/7Y3?U3K!UKN0@'CT;]E)5O<WI/206U
M&)1_,N-GF.LY4#(7_Q6NH! >,L$8I5$NKJ0<G#=Z5L%4M'B==MG%?9QNTF2F
M;1/X3. +X3[&85.@F/E'X46163,2._6^%^&)]T>.O2F#,[8BWF'R#KW7@B>'
MC%V#T(PY31B^PNP7!$/U)03?"G'B_]'Y-CW9S#")]&0=_<-A6R#=%$BC0/I/
MB;?O2MS"W+T+PE8]U6";.$V.E&;HXB2OO,O /O#X)G_AT[1_$[:1G2,7X_%E
M8_]K8SQ@*KL;'*$6/]AB**A].-[AV4YC-AG>]/,/8LLW+OX 4$L#!!0    (
M )*#IE! &@JDN0$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;&U3VV[<(!#]%<0'!"_K-)N5;2F;JFJE5EJE:OK,VF,;!3PNX'7Z]P7LN&[J
M%V"&<\Y<&+(1S8MM 1QYU:JS.6V=ZX^,V;(%+>P-]M#YFQJ-%LZ;IF&V-R"J
M2-**\23YP+20'2VRZ#N;(L/!*=G!V1 [:"W,[Q,H''.ZHV^.)]FT+CA8D?6B
M@>_@?O1GXRVVJ%120V<E=L1 G=.'W?&4!GP$/$L8[>I,0B47Q)=@?*ERFH2$
M0$'I@H+PVQ4>0:D@Y-/X-6O2)60@KL]OZI]B[;Z6B[#PB.JGK%R;TP,E%=1B
M4.X)Q\\PUW-+R5S\5[B"\O"0B8]1HK)Q)>5@'>I9Q:>BQ>NTRR[NXW1S>S?3
MM@E\)O"%<(AQV!0H9OY1.%%D!D=BIM[W(CSQ[LA];\K@C*V(=SYYZ[W7@N\/
M&;L&H1ESFC!\A=DM".;5EQ!\*\2)_T?GV_3]9H;[2-^OH]\?M@7238$T"J3_
ME'C_KL0-3)J\"\)6/=5@FCA-EI0X='&25]YE8!]X?)._\&G:OPG3R,Z2"SK_
MLK'_-:(#GTIRXT>H]1]L,134+ASO_-E,8S89#OOY!['E&Q=_ %!+ P04
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M'K@-2'*#6MP()$6$1&.UZ>1@BA@#A^,([A@RM</XE-Q83#1(1.(X=1SFN&<
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M1]>-Q&^7RD8J#6&<$%0ZP0XBZ""ZO5+B8AY=D$/8FY]:U!Y8UHRKH5QB@)^
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M,<[VVDI0<[FP#>/<*AD??T;1<+JG)5Z//]2_N/ FS(XJMA'\=WW0U3K,PN#
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M)A^7U;8!</?&?YG/E,]/G@]!*FL:&/.[WL]9LTQ@T&2&'_*_;@NXNO!\;Q)
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M19G1F^&"NTG<\X>KJYM1<IW7)*,9%P%MO 1U&8GN;%4U) *6^#/+JMX9$-W
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M+JLD!XUT1D""!7TNJFVS0OL.0HYC$E@6M80:TQA$J1,#3(.HN><"MNA[;EX
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M2>: EJLOP#*?CX$#[4C66(G99YKW8MED S:Z3;4CI.,EIF335:L;8CKNE.]
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M6-4N6[&%9.T< -_R9<#KCN(;;)*=T79GS/^H2HGD_G#YAOC53A/*Z),#'B(
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MX4MAR%%$EDKE 3CE'E7*:BK]+$"=,@\))G%B :Y2*Q:13$&2#W:B"UI:Q3>
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M%7-UV'7"^7N2Y"2'H+J@$>+[]&V?GM.I@$*J<?BV4_Y=ID#HN&83GIK4J-!
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M<:FH9J)ZMQ4Z66ATK7SZ4MC3^+UZUC$B.OIH]VC;-83&;Z?:86FOG#6<# M
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M.+#^^./MFY2= *@P\@450ZQ(LV10+7M1XR):X  !A&>@5)":0+HXL7-6_3)
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M(E-W0%-Z0&?98H8K2/HUF<Q 9EFM!%>EK=/.!?\+-YG]G-UIBH?3BVA-G1"
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M^*S$9CL5J91$5#_NMTW3_N'_ E!+ P04    " "2@Z90WKLIVS@"  #;"0
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M36NEF[](/HQ9'NJS[A?X[ M02P$"% ,4    " "2@Z90'R// \     3 @
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M2P$"% ,4    " "2@Z90C75,ACL"  "T!P  &               @ &;$
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ DH.F4*3B7RNI
M P  :1   !@              ( !#!,  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( )*#IE ;?(\9! 0  !<3   8              "
M >L6  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "2@Z90
M3C$O7X$$  !&%@  &               @ $E&P  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ DH.F4$U<\$BU 0  T@,  !@
M     ( !W!\  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M )*#IE!_H4SFM $  -(#   8              "  <<A  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " "2@Z903?G">K,!  #2 P  &
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M970Q,RYX;6Q02P$"% ,4    " "2@Z902Z3]%+0!  #2 P  &0
M    @ %'+0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M )*#IE#OWPG#LP$  -(#   9              "  3(O  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ DH.F4$>5<06T 0  T@,  !D
M             ( !'#$  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " "2@Z90'KO*Y/H!  #+!0  &0              @ $',P  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( )*#IE#!Z[ETMP$
M -(#   9              "  3@U  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ DH.F4/T"FB2R 0  T@,  !D              ( !
M)C<  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "2@Z90
M]W8AUK<!  #2 P  &0              @ $/.0  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( )*#IE"'P&*ZQP$  #<$   9
M      "  ?TZ  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ DH.F4!)$0TNS 0  T@,  !D              ( !^SP  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " "2@Z904F8NX;@!  #2 P
M&0              @ 'E/@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( )*#IE! &@JDN0$  -(#   9              "  =1   !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ DH.F4!95Y"9Q
M!0  @Q\  !D              ( !Q$(  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " "2@Z900C>.B9<"   H"@  &0
M@ %L2   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( )*#
MIE"M5#WC8 (  *L'   9              "  3I+  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ DH.F4-8I[BKD 0  ZP0  !D
M         ( !T4T  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " "2@Z90IVKW E8"   *"   &0              @ 'L3P  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( )*#IE"BJ+"=[@(  $\-
M   9              "  7E2  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ DH.F4/G"1]/8 @  ;@L  !D              ( !GE4
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "2@Z90DV:J
M50X#   ,#   &0              @ &M6   >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( )*#IE# /IE7FP,  ,01   9
M  "  ?);  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
MDH.F4#['JB3< 0  X@0  !D              ( !Q%\  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " "2@Z907(9&+2X"  "2!@  &0
M            @ '780  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( )*#IE >BJ\PX@$  *,$   9              "  3QD  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ DH.F4+80XQB680
M4W(! !0              ( !568  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!
M A0#%     @ DH.F4-Z[*=LX @  VPD   T              ( !'<@  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " "2@Z90"@C&[EH#  !F&   #P
M        @ & R@  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ DH.F4.R6
M15"- 0  D18  !H              ( !!\X  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ DH.F4%P- YJ< 0  "A<  !,
M     ( !S,\  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "T +0 M#
&F=$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634284016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Thyroid Cytopathology Partners<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ServicesAgreementAbstract', window );"><strong>Thyroid Cytopathology Partners</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock', window );">Thyroid Cytopathology Partners</a></td>
<td class="text">Thyroid Cytopathology Partners <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has an agreement with a specialized pathology practice, Thyroid Cytopathology Partners, ("TCP"), to provide testing services to the Company, or TCP Agreement.&#160; The TCP Agreement is effective through October 31, 2022, and thereafter automatically renews every year unless either party provides notice of intent not to renew at least 12 months prior to the end of the then-current term.  Under the TCP Agreement, the Company pays TCP based on a fixed price per test schedule which is reviewed periodically for changes in market pricing, and the TCP Agreement included a clause allowing TCP to sublease a portion of the Company's facility in Austin, Texas. &#160;The Company does not have an ownership interest in or provide any form of financial or other support to TCP. &#160;The Company previously concluded that TCP represented a variable interest entity as a result of the facility arrangement clause, but that the Company was not the primary beneficiary as it did not have the ability to direct the activities that most significantly impacted TCP's economic performance, and therefore did not consolidate TCP.&#160; On February 14, 2019, the TCP Agreement was amended to remove the facility clause.&#160; Accordingly, the Company believes TCP was no longer a variable interest entity as of that date.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div>TCP's portion of rent and related operating expenses reimbursed to the Company for the shared space at the Austin, Texas facility was $11,000 for the three months ended March&#160;31, 2019, and is included in other income, net in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -URI http://asc.fasb.org/topic&amp;trid=2145070<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 35<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197326<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermContractsOrProgramsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ServicesAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ServicesAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780312464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company records its financial assets and liabilities at fair value. The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;I: Inputs which include quoted prices in active markets for identical assets and liabilities;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;II: Inputs other than Level&#160;I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Company&#8217;s financial assets includes money market funds, overnight reverse repurchase agreements and a deposit for the lease of the Company's South San Francisco facility.  Money market funds, included in cash and cash equivalents in the accompanying condensed consolidated balance sheets, were $150.7 million and $57.6 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively, and are Level&#160;I assets as described above.  Overnight reverse repurchase agreements, included in cash and cash equivalents in the accompanying condensed consolidated balance sheets, were zero and $100.0 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively, and are Level II assets as described above.  There were no unrealized gains or losses from overnight reverse repurchase agreements at March&#160;31, 2020 and December&#160;31, 2019. The deposit for the lease, included in restricted cash in the accompanying condensed consolidated balance sheets, was $603,000 as of March&#160;31, 2020 and December&#160;31, 2019, and is a Level I asset as described above. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The contingent consideration in Note 4, Business Combination, associated with the agreement with NanoString on December 3, 2019, is a Level III financial liability. The estimation of the fair value of the contingent consideration is based on the present value of the expected payments calculated by assessing the likelihood of when the related milestones would be achieved, discounted using the Company's estimated borrowing rate. These estimates form the basis for making judgments about the carrying value of the contingent consideration that are not readily apparent from other sources. Changes to the forecasts for the achievement of the milestones and the estimates of the borrowing rate can significantly affect the estimated fair value of the contingent consideration.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6644826896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</a></td>
<td class="text">The following outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive:<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"/><td style="width:72.408%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.539%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.427%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares of common stock subject to outstanding options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,760,128&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,670,819&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,857&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,672&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">936,524&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">538,759&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total common stock equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,716,509&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,235,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787497008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 153,132<span></span>
</td>
<td class="nump">$ 159,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">19,091<span></span>
</td>
<td class="nump">19,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Supplies</a></td>
<td class="nump">6,094<span></span>
</td>
<td class="nump">6,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,045<span></span>
</td>
<td class="nump">2,235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">181,362<span></span>
</td>
<td class="nump">187,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,788<span></span>
</td>
<td class="nump">8,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating lease</a></td>
<td class="nump">8,576<span></span>
</td>
<td class="nump">8,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="nump">63,744<span></span>
</td>
<td class="nump">65,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,725<span></span>
</td>
<td class="nump">2,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">603<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">267,100<span></span>
</td>
<td class="nump">275,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,665<span></span>
</td>
<td class="nump">2,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">10,079<span></span>
</td>
<td class="nump">13,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">1,450<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,194<span></span>
</td>
<td class="nump">17,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">748<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">5,604<span></span>
</td>
<td class="nump">6,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">11,132<span></span>
</td>
<td class="nump">11,506<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">36,678<span></span>
</td>
<td class="nump">35,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2020 and December&#160;31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 125,000,000 shares authorized, 49,999,923 and 49,625,341 shares issued and outstanding as of March 31, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">488,773<span></span>
</td>
<td class="nump">486,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(258,401)<span></span>
</td>
<td class="num">(246,685)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">230,422<span></span>
</td>
<td class="nump">239,455<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 267,100<span></span>
</td>
<td class="nump">$ 275,212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791279856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future minimum lease payments under non-cancelable operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 1,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">2,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">2,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">2,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">2,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">4,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">16,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="nump">3,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future lease payments</a></td>
<td class="nump">12,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: short-term lease liabilities</a></td>
<td class="nump">1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">11,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember', window );">Headquarters and laboratory facilities, South San Francisco, lease signed April 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased', window );">Amount of space leased (in square feet) | ft&#178;</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other assets | Laboratory facilities, Austin, Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of space leased under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vcyt_LaboratoryFacilitiesAustinTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vcyt_LaboratoryFacilitiesAustinTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6643122512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Thyroid Cytopathology Partners (Details) - Thyroid Cytopathology Partners - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Thyroid Cytopathology Partners</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AgreementTermsNonRenewalNoticePeriod', window );">Notice of intent not to renew period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_OtherIncomeRentReimbursement', window );">Reduction to rent expense for TCP's portion of costs for subleased space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_AgreementTermsNonRenewalNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum period required to provide notice of intent not to renew agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_AgreementTermsNonRenewalNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_OtherIncomeRentReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reimbursement from third party for rent and related operating expenses for shared space included in other income in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_OtherIncomeRentReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784329104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (11,716)<span></span>
</td>
<td class="num">$ (1,917)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,905<span></span>
</td>
<td class="nump">1,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_InterestExpenseandPrepaymentPenalty', window );">Interest on end-of-term debt obligation</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_InventoryReserveEffectOnIncomeNet', window );">Write-down of excess supplies</a></td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_NoncashLeaseExpenses', window );">Noncash lease expense</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Revaluation of acquisition-related contingent consideration</a></td>
<td class="num">(484)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">238<span></span>
</td>
<td class="num">(3,447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Supplies</a></td>
<td class="num">(376)<span></span>
</td>
<td class="num">(366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(818)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(331)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">5,450<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent', window );">Accrued liabilities</a></td>
<td class="num">(3,650)<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,301)<span></span>
</td>
<td class="num">(1,011)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(665)<span></span>
</td>
<td class="num">(765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(665)<span></span>
</td>
<td class="num">(749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of taxes on vested restricted stock units</a></td>
<td class="num">(2,304)<span></span>
</td>
<td class="num">(556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of common stock options and employee stock purchases</a></td>
<td class="nump">2,085<span></span>
</td>
<td class="nump">4,737<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(219)<span></span>
</td>
<td class="num">(8,394)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(6,185)<span></span>
</td>
<td class="num">(10,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">159,920<span></span>
</td>
<td class="nump">78,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">153,735<span></span>
</td>
<td class="nump">68,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_CapitalExpendituresIncurredButNotYetPaidNet', window );">Purchases of property and equipment included in accounts payable and accrued liability</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid on debt</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 159,920<span></span>
</td>
<td class="nump">$ 68,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_CapitalExpendituresIncurredButNotYetPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow (inflow) to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_CapitalExpendituresIncurredButNotYetPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of expenses incurred but not yet paid and deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Operating Lease, Right Of Use Asset (Lease Liability)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_InterestExpenseandPrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense and Prepayment Penalty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_InterestExpenseandPrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_InventoryReserveEffectOnIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory Reserve, Effect on Income, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_InventoryReserveEffectOnIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_NoncashLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_NoncashLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6643582288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of the Company's third-party payers as a percentage of total</a></td>
<td class="text">The Company&#8217;s third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"><tr><td style="width:1.0%;"/><td style="width:71.442%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.541%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.909%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Johnson and Johnson Services, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">UnitedHealthcare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">*Less than 10%</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s third-party payers and other customers in excess of 10% of accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows at the following dates:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.684%;"><tr><td style="width:1.0%;"/><td style="width:71.481%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.888%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.540%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.891%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Johnson and Johnson Services, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">*Less than 10%</sup></div></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6639804688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had reserved shares of common stock for issuance as follows:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options and restricted stock units issued and outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,988,461&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,562,484&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options and restricted stock units available for grant under stock option plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,200,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,954,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock available for the Employee Stock Purchase Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">112,226&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173,168&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,300,887&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,690,456&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6639550032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text">Business Combination<div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On December 3, 2019, the Company executed an agreement with NanoString for the exclusive global diagnostics license to the nCounter FLEX Analysis System, and the acquisition of the Prosigna breast cancer prognostic gene signature assay, and the LymphMark lymphoma subtyping assay. The strategic transaction positions the Company to expand its genomic diagnostics business globally, with the ability to deliver its advanced genomic tests to physicians and their patients via hospital and clinical laboratories throughout the European Union and other parts of the world. The Company has accounted for this agreement under Accounting Standards Codification 805, Business Combinations. Pursuant to the terms of the agreement, Veracyte paid NanoString $40.0&#160;million in cash and $10.0&#160;million in Veracyte common stock, and may pay up to an additional $10.0&#160;million in cash, contingent upon the commercial launch of Veracyte diagnostic tests for use on the platform. This contingency was valued at $6.1&#160;million as of the acquisition date and as of December 31, 2019, recorded as a liability, and will be remeasured to fair value at each reporting date until the contingent consideration is settled.  As of March 31, 2020, this contingency was remeasured to $5.6&#160;million with the corresponding change included in general and administrative expense in the Company's condensed consolidated statements of operations and comprehensive loss.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets acquired are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):</span></div><div style="text-indent:36pt;text-align:center;"><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"/><td style="width:84.578%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.422%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prosigna product technology</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prosigna customer relationships</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">nCounter FLEX Dx license</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,880&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LymphMark product technology</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">990&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total identifiable intangible assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,420&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,088&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Identifiable acquisition-related intangibles included in the above table are finite-lived and are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows:</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099%;"><tr><td style="width:1.0%;"/><td style="width:69.535%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:26.465%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Useful life (In Years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prosigna product technology</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prosigna customer relationships</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">nCounter FLEX Dx license</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LymphMark product technology</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. This acquisition includes $1.7&#160;million of goodwill which the Company believes consists principally of the organized workforce that will help the Company execute its strategic plans in relation to the assets acquired. In accordance with ASC 350, goodwill will not be amortized but will be tested for impairment at least annually. As of March 31, 2020, goodwill is not deductible for tax purposes, however, if contingent consideration is paid at a future date, the portions of contingent consideration paid and allocated to the intangible assets for tax purposes will be tax deductible. The accounting for this acquisition is preliminary and will be finalized upon completion of the analysis of certain contracts acquired and executed as part of this acquisition along with the impact on goodwill, should there be any.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787179776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">49,999,923<span></span>
</td>
<td class="nump">49,625,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">49,999,923<span></span>
</td>
<td class="nump">49,625,341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792698096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Nov. 03, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=vcyt_SiliconValleyBankMember', window );">Silicon Valley Bank | Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_LiquidityRequirementMinimum', window );">Liquidity requirement, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Silicon Valley Bank | Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon payment to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Silicon Valley Bank | Line of credit | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Silicon Valley Bank | Line of credit | London Interbank Offered Rate (LIBOR) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Silicon Valley Bank | Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Silicon Valley Bank | Line of credit | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Silicon Valley Bank | Line of credit | London Interbank Offered Rate (LIBOR) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheOneMember', window );">Debt prepayment tranche one | Revolving credit facility | Silicon Valley Bank | Line of credit | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtInstrumentPrepaymentPremium', window );">Prepayment premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheTwoMember', window );">Debt prepayment tranche two | Revolving credit facility | Silicon Valley Bank | Line of credit | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtInstrumentPrepaymentPremium', window );">Prepayment premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheThreeMember', window );">Debt prepayment tranche three | Revolving credit facility | Silicon Valley Bank | Line of credit | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtInstrumentPrepaymentPremium', window );">Prepayment premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtInstrumentPrepaymentPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayment premium waived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtInstrumentPrepaymentPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_LiquidityRequirementMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity Requirement, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_LiquidityRequirementMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=vcyt_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=vcyt_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6601260912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Veracyte, Inc., or Veracyte, or the Company, is a global genomic diagnostics company that improves patient care by providing answers to clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The Company&#8217;s growing menu of genomic tests leverage advances in genomic science and technology to change care for patients, enabling them to avoid risky, costly procedures and quicken time to appropriate treatment. With Veracyte&#8217;s exclusive global access to a best-in-class diagnostics instrument platform, the Company is positioned to deliver its tests to patients worldwide through laboratories and hospitals that can perform the tests locally.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Veracyte was incorporated in the state of Delaware on August&#160;15, 2006 as Calderome,&#160;Inc. Calderome operated as an incubator until early 2008. On March&#160;4, 2008, the Company changed its name to Veracyte,&#160;Inc.  The Company&#8217;s operations are based in South San Francisco, California and Austin, Texas, and it operates in one segment.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company performs its genomic tests for thyroid cancer, lung cancer and idiopathic pulmonary fibrosis, or IPF, in its CLIA-certified laboratory in South San Francisco, California. In December 2019, the Company announced the exclusive global diagnostics license to the NanoString nCounter FLEX Analysis System, and the acquisition of the Prosigna breast cancer prognostic gene signature assay, which is commercially available, and the LymphMark lymphoma subtyping assay, which is in development. Both tests are designed for use on the nCounter system.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company offers genomic tests in four disease areas: thyroid cancer; lung cancer; IPF and breast cancer.</span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Thyroid Cancer - Afirma Genomic Sequencing Classifier and Xpression Atlas.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Company's Afirma offerings comprise the Afirma GSC and Xpression Atlas, which help guide next steps for patients with potentially cancerous thyroid nodules. The offerings are intended to provide physicians with clinically actionable results from a single fine needle aspiration, or FNA biopsy. The Afirma GSC was developed with RNA whole-transcriptome sequencing and machine learning, and is used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery.</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Afirma Xpression Atlas complements the Afirma GSC by providing genomic alteration content from the same FNA samples used in Afirma GSC testing to help physicians decide with greater confidence on the surgical or therapeutic pathway for their patients. The Company commercially launched the Afirma Xpression Atlas in 2018 and in April 2020 introduced an expanded version of the test, which includes significantly more genomic content.</span></div><div style="padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Lung Cancer - Percepta Genomic Sequencing Classifier.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> The Percepta classifier improves lung cancer diagnosis when diagnostic bronchoscopy results are inconclusive. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This second-generation test was developed using the Company's RNA whole-transcriptome sequencing and machine learning platform and was commercially introduced in June 2019. The Percepta classifier identifies patients with lung nodules who are at low risk of cancer and may avoid further, invasive procedures as well as patients at high risk of cancer so they may obtain faster diagnosis and treatment. The test is built upon foundational "field of injury" science - through which genomic changes associated with lung cancer in current and former smokers can be identified with a simple brushing of a person's airway - without the need to sample the often hard-to-reach nodule directly. </span></div><div style="padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">IPF - Envisia Genomic Classifier.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Envisia classifier improves diagnosis of IPF by helping physicians better differentiate IPF from other interstitial lung diseases, or ILDs, without the need for surgery. The test identifies the genomic pattern of usual interstitial pneumonia, or UIP, a hallmark of IPF, with high accuracy on patient samples that are obtained through transbronchial biopsy, a nonsurgical procedure that is commonly used in lung evaluation.</span></div><div style="padding-left:54pt;text-align:justify;"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Breast Cancer - Prosigna Breast Cancer Prognostic Gene Signature Assay.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> The Prosigna test, acquired in December 2019 through the Company's strategic transaction with NanoString, uses advanced genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease. The test uses a set of 50 genes known as the PAM50 gene signature and can provide a breast cancer patient and physician with prognostic score that indicates the probability of cancer recurrence over ten years. Physicians use Prosigna to help guide therapeutic decisions so that patients receive a therapeutic intervention, such as </span></div><div style="padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">chemotherapy, only if clinically warranted. Patient test results outside of the United States include intrinsic breast cancer subtypes to complement the risk-of-recurrence score.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s approach also provides multiple opportunities for partnerships with biopharmaceutical companies. In developing its products, the Company has built or gained access to unique biorepositories, proprietary technology and bioinformatics that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection.</span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company's testing services are performed in its clinical reference laboratories located in South San Francisco, California and Austin, Texas. The Prosigna test kits and associated products are sold to laboratories and hospitals in global markets.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet as of March&#160;31, 2020, the condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2020 and 2019, the condensed consolidated statements of stockholders' equity for the three months ended March&#160;31, 2020 and 2019, and the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2020 and 2019 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results, stockholders' equity  and cash flows for the periods presented. The condensed consolidated balance sheet at December&#160;31, 2019 has been derived from audited financial statements. The results for the three months ended March&#160;31, 2020 are not necessarily indicative of the results expected for the full year or any other period. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying interim period condensed consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Reclassifications</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Certain prior period balances have been reclassified to conform to current period presentation of the Company&#8217;s condensed consolidated financial statements and accompanying notes. Such reclassifications have no effect on previously reported results of operations, retained earnings or consolidated balance sheet totals; however, for the period ended March 31, 2019, the Company reclassified $212,000 of changes in operating assets and liabilities to noncash lease expense in the statement of cash flows.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Use of Estimates</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Items subject to such estimates include: revenue recognition; write-down of supplies; the useful lives of property and equipment; the recoverability of long-lived assets; the incremental borrowing rate for leases; the estimation of the fair value of intangible assets and contingent consideration; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Issuance of Common Stock in a Public Offering</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 7, 2019, the Company issued and sold 6,325,000 shares of common stock in a registered public offering, including 825,000 shares issued and sold upon the underwriters&#8217; exercise in full of their option to purchase additional shares, at a price to the public of&#160;$23.25&#160;per share. The Company's net proceeds from the offering were approximately&#160;$137.8 million, after deducting underwriting discounts and commissions and offering expenses of $9.2 million.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash&#160;and&#160;Cash&#160;Equivalents</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers demand deposits in a bank, money market funds and highly liquid investments with an original maturity of 90 days or less to be cash equivalents.  Cash equivalents include overnight reverse repurchase agreements which are tri-party repurchase agreements and have maturities of&#160;three&#160;months or less at the time of investment and are collateralized by U.S. treasury and agency securities of at&#160;least 102%&#160;of the principal amount. In a tri-party repurchase agreement, a third-party custodian bank functions as an independent intermediary to facilitate transfer of cash and holding the collateral on behalf of the underlying investor for the term of the agreement thereby minimizing risk and exposure to both parties. These overnight reverse repurchase agreements are included within cash equivalents due to their high liquidity and relatively low risk.  There were no overnight reverse repurchase agreements at March 31, 2020.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The worldwide spread of coronavirus, or COVID-19, has created significant uncertainty in the global economy. There have been no comparable recent events that provide guidance as to the effect the spread of COVID-19 as a global pandemic may have, and, as a result, the ultimate impact of COVID-19 and the extent to which COVID-19 impacts the Company&#8217;s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict.  If the financial markets or the overall economy are impacted for an extended period, the Company&#8217;s liquidity, revenues, supplies, goodwill and intangibles may be adversely affected</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The majority of the Company&#8217;s cash and cash equivalents are deposited with one major financial institution in the United States. Deposits in this institution may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Several of the components of the Company&#8217;s sample collection kit and test reagents, and its nCounter FLEX Analysis System and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company&#8217;s requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is also subject to credit risk from its accounts receivable related to its sales. Credit risk for accounts receivable from testing revenue is incorporated in testing revenue accrual rates as the Company assesses historical collection rates and current developments to determine accrual rates and amounts the Company will ultimately collect.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company generally does not perform evaluations of customers&#8217; financial condition for testing revenue and generally does not require collateral.  The Company assesses credit risk and the amount of accounts receivable the Company will ultimately collect for product, biopharmaceutical and collaboration revenue based on collection history, current developments and credit worthiness of the customer.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The estimate of credit losses is not material at March 31, 2020.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Through March&#160;31, 2020, most of the Company&#8217;s revenue has been derived from the sale of Afirma. To date, Afirma has been delivered primarily to physicians in the United States. The Company&#8217;s third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"><tr><td style="width:1.0%;"/><td style="width:71.442%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.541%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.909%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Johnson and Johnson Services, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">UnitedHealthcare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">*Less than 10%</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s third-party payers and other customers in excess of 10% of accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows at the following dates:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.684%;"><tr><td style="width:1.0%;"/><td style="width:71.481%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.888%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.540%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.891%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Johnson and Johnson Services, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">*Less than 10%</sup></div></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Cash</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had deposits of $603,000 included in long-term assets as of March&#160;31, 2020 and December&#160;31, 2019, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the Company&#8217;s South San Francisco facility.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Testing Revenue</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes testing revenue in accordance with the provisions of ASC 606, Revenue from Contracts with Customers, or ASC 606.  Most of the Company&#8217;s revenue is generated from the provision of testing services. These services are completed upon the delivery of test results to the prescribing physician, at which time the Company bills for the services. The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized.  In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2019, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2018 or prior years and recognized additional revenue of $0.6&#160;million, which resulted in a decrease in the Company's loss from operations of $0.6 million and a decrease in loss per share of $0.02 for the three months ended March 31, 2019.  The change in testing revenue estimates for the three months ended March 31, 2020 was not material.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Product Revenue</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company began recognizing product revenue in December 2019, when the Company executed an agreement with NanoString for the exclusive global license to the nCounter platform and acquisition of products for diagnostic use.  More details on this agreement are in Note 4 - Business Combination.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenue from instruments, consumables and in vitro diagnostic kits is recognized generally upon shipment or when the instrument is ready for use by the end customer, which is when title of the product has been transferred to the customer. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a product to the customer, meaning the customer has the ability to use and obtain the benefit of the product. The Company recognizes product revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control.  Shipping and handling costs incurred for product shipments are charged to the Company's customers and included in product revenue. Revenues are presented net of the taxes that are collected from customers and remitted to governmental authorities.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Biopharmaceutical and Collaboration Revenue</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, the Company enters into arrangements for research and development and/or laboratory services. Such arrangements may require the Company to deliver various rights, services and/or samples, including intellectual property rights/licenses, R&amp;D services, and/or laboratory services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments, and/or profit sharing.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods is transferred or services are performed. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, the Company utilizes the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><div><span><br/></span></div><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Collaborative Arrangements</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company enters into collaborative arrangements with partners that fall under the scope of ASC Topic 808, Collaborative Arrangements, or ASC 808. While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects of these arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part of its ongoing major or central operations. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of the Company&#8217;s collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales of licensed products. Each of these payments may result in collaboration revenues or an offset against research and development expense.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net sales of data or other services to our customers are classified under biopharmaceutical revenue, and all other non-customer revenue, such as milestones, are classified under collaboration revenue in our consolidated statements of operations and comprehensive loss.  There was no collaboration revenue in the three months ended March 31, 2020 and 2019.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Up-front Fees: If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Milestone Payments: At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or the collaborative partner&#8217;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the collaborative partner&#8217;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Services Agreement with Loxo Oncology</span></div><div style="padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 9, 2018, the Company entered into an agreement with Loxo Oncology, Inc., or Loxo, whereby the Company agreed to provide certain tissue samples and other services in exchange for agreed-upon fees.  The agreement has a term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTg5ODQ_f0a3db4d-746a-4336-8a43-6dcb1f0c687a">one</span> year with an automatic renewal of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTkwMjE_98287a7d-3a7f-425c-896d-85cf973f3c3e">one</span> year and Loxo may terminate the agreement at any time with at least 90 days' notice.  As of March&#160;31, 2020, the agreement has not been terminated.  The Company evaluated the accounting for this agreement under ASC 606 and concluded the performance obligations thereunder are the delivery of tissue samples and performance of services, both of which are distinct.  For the three months ended March 31, 2019, the Company recognized revenue of $90,000 for the delivery of tissue samples.  There were no deliveries of tissue samples for the three months ended March 31, 2020.  The Company recognized revenue of $250,000 for the performance of services for each of the three months ended March 31, 2020 and 2019, respectively.  The cost of revenue associated with revenue recognized under the agreement with Loxo is not significant.  There was no deferred revenue related to this agreement at either March&#160;31, 2020 or December&#160;31, 2019.</span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Diagnostic Development Agreement with Johnson &amp; Johnson</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 28, 2018, the Company entered into a diagnostics development agreement with Johnson and Johnson Services, Inc., or JJSI, (i) to cooperate on a program to enable the Company to use JJSI samples and clinical data to develop a next generation bronchial genomic classifier diagnostic for lung cancer diagnosis, or Percepta v.2, and a nasal genomic classifier diagnostic for lung cancer and (ii) for JJSI to use Veracyte data generated in two Veracyte development programs for therapeutic purposes and for purposes of developing a companion diagnostic product used in conjunction with a JJSI therapeutic.  The Company granted a license to JJSI with the right to use data and under the Company's intellectual property rights for JJSI's therapeutic purposes, including the development and commercialization of a companion diagnostic for its products, from the Percepta v.2 and Nasal programs.  The license granted to JJSI is not distinct from other performance obligations as JJSI receives benefit only when other performance obligations are met.</span></div><div style="text-indent:36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the agreement, the Company will provide data from its RNA whole-transcriptome sequencing platform to JJSI in exchange for $7.0 million in payments from JJSI.  The Company is also entitled to additional payments from JJSI of up to $13.0 million, conditioned upon the achievement of certain milestones relating to the development and reimbursement of the Percepta v.2 and Nasal tests.  For a period of ten years commencing with the first commercial sale of the Percepta v.2 and Nasal tests, respectively, the Company will make payments to JJSI of one percent of net cash collections for Percepta v.2 and in the low-single digits of net cash collections for the Nasal test, depending on the number and timing of JJSI samples and associated clinical data the Company receives from JJSI.</span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The JJSI agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the JJSI agreement and has analogized to ASC 606 for the delivery of RNA whole-transcriptome sequencing data to JJSI under the collaborative arrangement, which the Company believes is a distinct service for which JJSI meets the definition of a customer. Using the concepts of ASC 606, the Company has identified the delivery of data as its only performance obligation. The Company further determined that the transaction price under the arrangement was the $7.0 million in payments which was allocated to the obligation to deliver data.  The $13.0 million in future potential payments is considered variable consideration because the Company determined that the potential payments are contingent upon </span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">regulatory and commercialization milestones that are uncertain to occur and, as such, were not included in the transaction price, and will be recognized accordingly as each potential payment becomes probable.</span></div><div><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognized revenue of $7.0&#160;million and $4.0&#160;million during 2019 for the provision of data and fulfillment of obligations relating to Percepta v.2 and Nasal program development milestones, respectively.  There was no revenue for the three months ended March 31, 2020.  For the three months ended March 31, 2019, the Company recognized revenue of $3.8&#160;million for the provision of data relating to Percepta v.2, classified under biopharmaceutical revenue in the consolidated statement of operations and comprehensive loss. There was no accounts receivable from JJSI at March 31, 2020 and accounts receivable from JJSI was $2.0&#160;million at December&#160;31, 2019.  There was no deferred revenue related to this agreement at March 31, 2020 and December&#160;31, 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration Agreement with AstraZeneca Group</span></div><div><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 23, 2019, the Company entered into an agreement with Acerta Pharma B.V., or Acerta, a member of AstraZeneca Group whereby the Company agreed to provide genomic information that will support Acerta&#8217;s development of oncology therapeutics.  Acerta will pay the Company for certain development activities and pay milestones to the Company for the achievement of development milestones.  For the three months ended March 31, 2020, the Company recognized $0.1&#160;million of revenue for certain development costs activities and accounts receivable from Acerta was $0.1&#160;million at March 31, 2020.  The agreement will be accounted for in accordance with the policy on collaborative arrangements, as mentioned in this footnote.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Biopharmaceutical Services Agreement</span></div><div><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the quarter ended March 31, 2020, the Company entered into an agreement to provide research and development services of $0.5&#160;million for which the Company recognized $0.3&#160;million of biopharmaceutical revenue for the three months ended March 31, 2020. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Testing Revenue</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of our cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation and amortization, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test. Cost of testing revenue for the three months ended March 31, 2020 included $1.1&#160;million write-down of supplies for the potential expiration of reagents due to an anticipated decline in volumes resulting from the COVID-19 pandemic.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Product Revenue </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of product revenue consists primarily of costs of purchasing instruments and consumables from third-party contract manufacturers, installation, warranty, service and packaging and delivery costs. In addition, cost of product includes royalty costs for licensed technologies included in the Company&#8217;s products and labor expenses. Cost of product revenue for instruments and consumables is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the consolidated statements of operations.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Biopharmaceutical Revenue </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of biopharmaceutical revenue consists of costs of performing activities under arrangements that require the Company to perform research and development services on behalf of a customer pursuant to a biopharmaceutical service agreement. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This ASU requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit </span></div>risks. This guidance became effective for the Company beginning January 1, 2020.  Based on the composition of its trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures.<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (Topic 808). </span>Under&#160;this ASU,&#160;transactions in collaborative arrangements are to be accounted for under ASC 606 if the counterparty is a customer for a good or service (or bundle of goods and services) that is a distinct unit of account. Also, entities are precluded from presenting consideration from transactions with a counterparty that is not a customer together with revenue recognized from ASC 606.  This ASU is effective for all interim and annual reporting periods beginning on or after December 15, 2019, with early adoption permitted.  The Company adopted this ASU in 2019 with no cumulative-effect adjustments or retrospective impact.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>29
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vcyt-20200331.htm": {
   "axisCustom": 1,
   "axisStandard": 24,
   "contextCount": 116,
   "dts": {
    "calculationLink": {
     "local": [
      "vcyt-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vcyt-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "vcyt-20200331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vcyt-20200331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vcyt-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "vcyt-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 348,
   "entityCount": 1,
   "hidden": {
    "http://www.veracyte.com/20200331": 2,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 7
   },
   "keyCustom": 30,
   "keyStandard": 237,
   "memberCustom": 22,
   "memberStandard": 24,
   "nsprefix": "vcyt",
   "nsuri": "http://www.veracyte.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.veracyte.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Business Combination",
     "role": "http://www.veracyte.com/role/BusinessCombination",
     "shortName": "Business Combination",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Fair Value Measurements",
     "role": "http://www.veracyte.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.veracyte.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - Debt",
     "role": "http://www.veracyte.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Stockholders' Equity",
     "role": "http://www.veracyte.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermContractsOrProgramsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Thyroid Cytopathology Partners",
     "role": "http://www.veracyte.com/role/ThyroidCytopathologyPartners",
     "shortName": "Thyroid Cytopathology Partners",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermContractsOrProgramsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130110 - Disclosure - Income Taxes",
     "role": "http://www.veracyte.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Description of Business (Policies)",
     "role": "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies",
     "shortName": "Organization and Description of Business (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Organization and Description of Business (Tables)",
     "role": "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessTables",
     "shortName": "Organization and Description of Business (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307302 - Disclosure - Net Loss Per Common Share (Tables)",
     "role": "http://www.veracyte.com/role/NetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310303 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.veracyte.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313304 - Disclosure - Business Combinations (Tables)",
     "role": "http://www.veracyte.com/role/BusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.veracyte.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322306 - Disclosure - Debt (Tables)",
     "role": "http://www.veracyte.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vcyt:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326307 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.veracyte.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vcyt:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Organization and Description of Business - Narrative (Details)",
     "role": "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails",
     "shortName": "Organization and Description of Business - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i9b93f7856b454811a810d421cd09d494_D20200101-20200331",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Organization and Description of Business - Credit Risk (Details)",
     "role": "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails",
     "shortName": "Organization and Description of Business - Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i9b93f7856b454811a810d421cd09d494_D20200101-20200331",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Net Loss Per Common Share (Details)",
     "role": "http://www.veracyte.com/role/NetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Accrued Liabilities (Details)",
     "role": "http://www.veracyte.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414405 - Disclosure - Business Combinations (Details)",
     "role": "http://www.veracyte.com/role/BusinessCombinationsDetails",
     "shortName": "Business Combinations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i581ad647641b4236a34ecb7f297c1e30_D20191203-20191203",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Business Combination - Acquisition (Details)",
     "role": "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails",
     "shortName": "Business Combination - Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i95a54fa194e14f688292b523de39ca15_D20191203-20191203",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.veracyte.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i4ba4c8f0affe47d8b51e983b2a35f24d_I20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Commitments and Contingencies - Operating Lease (Details)",
     "role": "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails",
     "shortName": "Commitments and Contingencies - Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423409 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.veracyte.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5dc6c074bbd1456a915067e4fec93c91_I20200331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5dc6c074bbd1456a915067e4fec93c91_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - Debt - Debt Obligation for Borrowings (Details)",
     "role": "http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails",
     "shortName": "Debt - Debt Obligation for Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5dc6c074bbd1456a915067e4fec93c91_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vcyt:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427411 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.veracyte.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vcyt:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i4c5d2c55989a46b98b6de9830693a3d5_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vcyt:AgreementTermsNonRenewalNoticePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429412 - Disclosure - Thyroid Cytopathology Partners (Details)",
     "role": "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails",
     "shortName": "Thyroid Cytopathology Partners (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "i4c5d2c55989a46b98b6de9830693a3d5_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vcyt:AgreementTermsNonRenewalNoticePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CostOfRevenue",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if18d64a9919f43c5aceb6119caac7620_D20190101-20190331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "iee6f696c673849f2860c8d67c1f52f19_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "iee6f696c673849f2860c8d67c1f52f19_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Description of Business",
     "role": "http://www.veracyte.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106102 - Disclosure - Net Loss Per Common Share",
     "role": "http://www.veracyte.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Accrued Liabilities",
     "role": "http://www.veracyte.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20200331.htm",
      "contextRef": "if6a89c16b8fa41e78a43a58046145907_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r42",
      "r72"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r104",
      "r147",
      "r152",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r102",
      "r147",
      "r150",
      "r230",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r103",
      "r147",
      "r151",
      "r232",
      "r235",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r17",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts Receivable, after Allowance for Credit Loss"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r17",
      "r105",
      "r106",
      "r148"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.veracyte.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/AccruedLiabilitiesDetails",
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Tax portion of vested restricted stock units"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r64",
      "r202"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r64",
      "r112",
      "r118"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Intangible asset amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total common stock equivalents (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r101",
      "r216",
      "r224"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r41"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r158",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r187",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails",
      "http://www.veracyte.com/role/BusinessCombinationsDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails",
      "http://www.veracyte.com/role/BusinessCombinationsDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails",
      "http://www.veracyte.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r173",
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Equity issued in business acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r63",
      "r180"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Revaluation of acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent consideration, maximum to be paid"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationsDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r172",
      "r175",
      "r178"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Acquisition-related contingent consideration",
        "verboseLabel": "Acquisition related contingent liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationsDetails",
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombination"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r168",
      "r169"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Total identifiable intangible assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r75",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r25",
      "r66"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and and cash equivalents, fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r10",
      "r67",
      "r70",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r60",
      "r66",
      "r69"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r60",
      "r198"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r76",
      "r78",
      "r83",
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r76",
      "r78",
      "r83",
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassificationOfVariableInterestEntityDomain": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categorization of Variable Interest Entities (VIE) for consolidation and (or) disclosure purposes, whether individually or in aggregate, by: (1) VIEs consolidated because the entity is the primary beneficiary, (2) VIEs not consolidated because the entity is not the primary beneficiary, and (3) VIEs or potential VIEs that are not consolidated because necessary information is not available. In general, a VIE is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A VIE often holds financial assets, including loans or receivables, real estate or other property. A VIE may be essentially passive or it may engage in research and development or other activities on behalf of another company.",
        "label": "Variable Interest Entity, Classification [Domain]",
        "terseLabel": "Variable Interest Entity, Classification [Domain]"
       }
      }
     },
     "localname": "ClassificationOfVariableInterestEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r124",
      "r219",
      "r229"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r123",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total number of shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationsDetails",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value; 125,000,000 shares authorized, 49,999,923 and 49,625,341 shares issued and outstanding as of March 31, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r92",
      "r93",
      "r195",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r92",
      "r93",
      "r195",
      "r196",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r92",
      "r93",
      "r195",
      "r196",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r92",
      "r93",
      "r195",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentrations of credit risk (as a percent)",
        "verboseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r90",
      "r92",
      "r93",
      "r94",
      "r195",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r92",
      "r93",
      "r195",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r144",
      "r145",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Contract with customer, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of testing revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Gross receivables concentration risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Revenue concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Prosigna customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r14",
      "r127",
      "r217",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r201",
      "r203"
     ],
     "calculation": {
      "http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Debt principal"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r33",
      "r129",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails",
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "terseLabel": "Balloon payment to be paid"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r34",
      "r74",
      "r135",
      "r138",
      "r139",
      "r140",
      "r200",
      "r201",
      "r203",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails",
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r64",
      "r100"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r64",
      "r120",
      "r122"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "negatedTerseLabel": "Gain on disposal of property and equipment"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per common share, basic and diluted (in usd per share)",
        "verboseLabel": "Net income (loss) per common share, basic and diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.veracyte.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP (in shares)"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]",
        "terseLabel": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r189",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r190",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r190",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level I"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r190",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level II"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance lease liability"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.",
        "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Schedule of identifiable acquisition-related intangibles"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r113",
      "r115",
      "r117",
      "r119",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r113",
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "Finite-lived intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails",
      "http://www.veracyte.com/role/BusinessCombinationsDetails",
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Supplies"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Rollforward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r47",
      "r99",
      "r199",
      "r202",
      "r220"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r59",
      "r61",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid on debt"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r39",
      "r108"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Write-down of supplies"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments under non-cancelable operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r218",
      "r227"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r29",
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails",
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermContractsOrProgramsDisclosureTextBlock": {
     "auth_ref": [
      "r43",
      "r143",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term contracts or programs.",
        "label": "Long-term Contracts or Programs Disclosure [Text Block]",
        "terseLabel": "Thyroid Cytopathology Partners"
       }
      }
     },
     "localname": "LongTermContractsOrProgramsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartners"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r128",
      "r217",
      "r225"
     ],
     "calculation": {
      "http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Net debt obligation"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails",
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r34",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails",
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r60",
      "r62",
      "r65"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r77",
      "r79"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability",
        "totalLabel": "Present value of future lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating Lease, Liability, Current",
        "verboseLabel": "Less: short-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets - operating lease"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future minimum lease payments under non-cancelable operating leases"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r31"
     ],
     "calculation": {
      "http://www.veracyte.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payment of taxes on vested restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r53",
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid in business acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2020 and December\u00a031, 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of a reclassification adjustment made to prior period financial statement amounts.",
        "label": "Prior Period Reclassification Adjustment",
        "terseLabel": "Prior period reclassification adjustment"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from disposal of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r55",
      "r163"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of common stock options and employee stock purchases"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Tissue Samples",
        "verboseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r121",
      "r228"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Payment of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r164",
      "r238"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r6",
      "r13",
      "r66",
      "r69",
      "r236"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r141",
      "r226"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total Revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails",
      "http://www.veracyte.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of debt obligation for borrowings"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of fair value of assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r36",
      "r73",
      "r131",
      "r132",
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r185",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r90",
      "r92",
      "r93",
      "r94",
      "r195",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of the Company's third-party payers as a percentage of total"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Other Services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r160",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options issued and outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r157",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r15",
      "r16",
      "r134",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r134",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares issued and sold (in shares)",
        "verboseLabel": "Sale of common stock in a public offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r15",
      "r16",
      "r134",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (ESPP)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r107"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized Gain (Loss) on Investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r89",
      "r95",
      "r96",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of Variable Interest Entity (VIE).",
        "label": "Variable Interest Entities [Axis]",
        "terseLabel": "Variable Interest Entities [Axis]"
       }
      }
     },
     "localname": "VariableInterestEntitiesByClassificationOfEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "verboseLabel": "Thyroid Cytopathology Partners"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Thyroid Cytopathology Partners"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Shares used to compute net loss per common share, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) resulting from ESPP stock-based compensation expense.",
        "label": "Adjustments To Additional Paid In Capital Share Based Compensation ESPP",
        "terseLabel": "Stock-based compensation expense (ESPP)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) resulting from employee stock-based compensation expense.",
        "label": "Adjustments to Additional Paid in Capital Share Based Compensation Employee",
        "terseLabel": "Stock-based compensation expense (employee)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) resulting from non-employee stock-based compensation expense.",
        "label": "Adjustments to Additional Paid in Capital Share Based Compensation Non Employee",
        "terseLabel": "Stock-based compensation expense (non-employee)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_AgreementTermsNonRenewalNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the minimum period required to provide notice of intent not to renew agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Agreement Terms, Non-Renewal Notice Period",
        "terseLabel": "Notice of intent not to renew period"
       }
      }
     },
     "localname": "AgreementTermsNonRenewalNoticePeriod",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vcyt_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_AutomaticRenewalPeriodContractAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Automatic Renewal Period, Contract Agreement",
        "label": "Automatic Renewal Period, Contract Agreement",
        "terseLabel": "Automatic renewal period of contract agreement"
       }
      }
     },
     "localname": "AutomaticRenewalPeriodContractAgreement",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vcyt_BiopharmaceuticalCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biopharmaceutical Company [Member]",
        "label": "Biopharmaceutical Company [Member]",
        "terseLabel": "Biopharmaceutical Company"
       }
      }
     },
     "localname": "BiopharmaceuticalCompanyMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_BiopharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biopharmaceutical",
        "label": "Biopharmaceutical [Member]",
        "terseLabel": "Biopharmaceutical"
       }
      }
     },
     "localname": "BiopharmaceuticalMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_CapitalExpendituresIncurredButNotYetPaidNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow (inflow) to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid Net",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liability"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaidNet",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_CommonStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "No definition available.",
        "label": "Common Stock [Abstract]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockAbstract",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties.",
        "label": "Concentrations of Credit and Other Risks and Uncertainties [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vcyt_ContractAgreementAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Agreement, Amount",
        "label": "Contract Agreement, Amount",
        "terseLabel": "Contract agreement, amount"
       }
      }
     },
     "localname": "ContractAgreementAmount",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_ContractAgreementConditionalAdditionalReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Agreement, Conditional Additional Receivable",
        "label": "Contract Agreement, Conditional Additional Receivable",
        "terseLabel": "Contractual proceeds"
       }
      }
     },
     "localname": "ContractAgreementConditionalAdditionalReceivable",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_ContractAgreementFeePercentageOfCashCollections": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Agreement, Fee, Percentage Of Cash Collections",
        "label": "Contract Agreement, Fee, Percentage Of Cash Collections",
        "terseLabel": "Percentage of net cash collections, fee"
       }
      }
     },
     "localname": "ContractAgreementFeePercentageOfCashCollections",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vcyt_ContractAgreementReceivableForServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Agreement, Receivable For Services",
        "label": "Contract Agreement, Receivable For Services",
        "terseLabel": "Receivable from agreement"
       }
      }
     },
     "localname": "ContractAgreementReceivableForServices",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DebtInstrumentEndOfTermInterestObligationAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument End Of Term, Interest Obligation Amount",
        "label": "Debt Instrument End Of Term, Interest Obligation Amount",
        "verboseLabel": "End-of-term debt obligation"
       }
      }
     },
     "localname": "DebtInstrumentEndOfTermInterestObligationAmount",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DebtInstrumentPrepaymentPremium": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of prepayment premium waived.",
        "label": "Debt Instrument, Prepayment Premium",
        "terseLabel": "Prepayment premium"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremium",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DebtPaymentTrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Debt Payment Tranche [Axis]",
        "label": "Debt Payment Tranche [Domain]",
        "terseLabel": "Debt Payment Tranche [Domain]"
       }
      }
     },
     "localname": "DebtPaymentTrancheDomain",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_DebtPrepaymentTrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Prepayment Tranche [Axis]",
        "label": "Debt Prepayment Tranche [Axis]",
        "terseLabel": "Debt Prepayment Tranche [Axis]"
       }
      }
     },
     "localname": "DebtPrepaymentTrancheAxis",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vcyt_DebtPrepaymentTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Prepayment Tranche One [Member]",
        "label": "Debt Prepayment Tranche One [Member]",
        "terseLabel": "Debt prepayment tranche one"
       }
      }
     },
     "localname": "DebtPrepaymentTrancheOneMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_DebtPrepaymentTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Prepayment Tranche Three [Member]",
        "label": "Debt Prepayment Tranche Three [Member]",
        "terseLabel": "Debt prepayment tranche three"
       }
      }
     },
     "localname": "DebtPrepaymentTrancheThreeMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_DebtPrepaymentTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Prepayment Tranche Two [Member]",
        "label": "Debt Prepayment Tranche Two [Member]",
        "terseLabel": "Debt prepayment tranche two"
       }
      }
     },
     "localname": "DebtPrepaymentTrancheTwoMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_DevelopedProductTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Developed Product Technology",
        "label": "Developed Product Technology [Member]",
        "terseLabel": "Prosigna product technology"
       }
      }
     },
     "localname": "DevelopedProductTechnologyMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_EmployeeAndNonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee And Non Employee Stock Option [Member]",
        "terseLabel": "Shares of common stock subject to outstanding options"
       }
      }
     },
     "localname": "EmployeeAndNonEmployeeStockOptionMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails",
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the lease for headquarters and laboratory space in South San Francisco, California that expires March 2026.",
        "label": "Headquarters And Laboratory Facilities South San Francisco Lease Two [Member]",
        "terseLabel": "Headquarters and laboratory facilities, South San Francisco, lease signed April 2015"
       }
      }
     },
     "localname": "HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of expenses incurred but not yet paid and deferred rent.",
        "label": "Increase (Decrease) in Accrued Liabilities and Deferred Rent",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) Operating Lease, Right Of Use Asset (Lease Liability)",
        "label": "Increase (Decrease) Operating Lease, Right Of Use Asset (Lease Liability)",
        "negatedTerseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_InterestExpenseandPrepaymentPenalty": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest Expense and Prepayment Penalty",
        "label": "Interest Expense and Prepayment Penalty",
        "terseLabel": "Interest on end-of-term debt obligation"
       }
      }
     },
     "localname": "InterestExpenseandPrepaymentPenalty",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_InventoryReserveEffectOnIncomeNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory Reserve, Effect on Income, Net",
        "label": "Inventory Reserve, Effect on Income, Net",
        "terseLabel": "Write-down of excess supplies"
       }
      }
     },
     "localname": "InventoryReserveEffectOnIncomeNet",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_JohnsonJohnsonServicesInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Johnson &amp; Johnson Services, Inc. [Member]",
        "label": "Johnson &amp; Johnson Services, Inc. [Member]",
        "terseLabel": "Johnson &amp; Johnson"
       }
      }
     },
     "localname": "JohnsonJohnsonServicesInc.Member",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_LaboratoryFacilitiesAustinTexasMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the lease for laboratory facilities in Austin, Texas that expires July 2018.",
        "label": "Laboratory Facilities Austin Texas [Member]",
        "terseLabel": "Laboratory facilities, Austin, Texas"
       }
      }
     },
     "localname": "LaboratoryFacilitiesAustinTexasMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of space leased under the terms of the agreement.",
        "label": "Lessee Leasing Arrangements, Operating Leases, Space Leased",
        "terseLabel": "Amount of space leased (in square feet)"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesSpaceLeased",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "vcyt_LiquidityRequirementMinimum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liquidity Requirement, Minimum",
        "label": "Liquidity Requirement, Minimum",
        "terseLabel": "Liquidity requirement, minimum"
       }
      }
     },
     "localname": "LiquidityRequirementMinimum",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_LymphMarkProductTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "LymphMark Product Technology",
        "label": "LymphMark Product Technology [Member]",
        "terseLabel": "LymphMark product technology"
       }
      }
     },
     "localname": "LymphMarkProductTechnologyMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Medicare, a significant third-party payer.",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_NCounterFLEXDxLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "nCounter FLEX Dx License",
        "label": "nCounter FLEX Dx License [Member]",
        "terseLabel": "nCounter FLEX Dx license"
       }
      }
     },
     "localname": "NCounterFLEXDxLicenseMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_NanoStringMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NanoString",
        "label": "NanoString [Member]",
        "terseLabel": "NanoString"
       }
      }
     },
     "localname": "NanoStringMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails",
      "http://www.veracyte.com/role/BusinessCombinationsDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_NasaRISKMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NasaRISK",
        "label": "NasaRISK [Member]",
        "terseLabel": "NasaRISK"
       }
      }
     },
     "localname": "NasaRISKMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_NoncashLeaseExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash Lease Expenses",
        "label": "Noncash Lease Expenses",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpenses",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_NumberOfDiseaseAreasWithGenomicTesting": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Disease Areas With Genomic Testing",
        "label": "Number of Disease Areas With Genomic Testing",
        "terseLabel": "Number of disease areas with genomic testing"
       }
      }
     },
     "localname": "NumberOfDiseaseAreasWithGenomicTesting",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of major financial institutions, with which cash and cash equivalents are deposited by the entity.",
        "label": "Number of Major Financial Institutions with which Cash and Cash Equivalents Deposited",
        "terseLabel": "Number of major financial institutions with which the company's cash and cash equivalents are deposited (in financial institutions)"
       }
      }
     },
     "localname": "NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vcyt_NumberofTissueSampleDeliveries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Tissue Sample Deliveries",
        "label": "Number of Tissue Sample Deliveries",
        "terseLabel": "Number of tissue sample deliveries (in deliveries)"
       }
      }
     },
     "localname": "NumberofTissueSampleDeliveries",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vcyt_OtherIncomeRentReimbursement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of reimbursement from third party for rent and related operating expenses for shared space included in other income in the income statement.",
        "label": "Other Income Rent Reimbursement",
        "terseLabel": "Reduction to rent expense for TCP's portion of costs for subleased space"
       }
      }
     },
     "localname": "OtherIncomeRentReimbursement",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_OvernightRepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Overnight Repurchase Agreements [Member]",
        "label": "Overnight Repurchase Agreements [Member]",
        "terseLabel": "Overnight repurchase agreements"
       }
      }
     },
     "localname": "OvernightRepurchaseAgreementsMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percent of Principal Amount Needed To Be Collateralized By U.S. Treasury and Agency Securities",
        "label": "Percent of Principal Amount Needed To Be Collateralized By U.S. Treasury and Agency Securities",
        "terseLabel": "Percent of principal amount needed to be collateralized by U.S. treasury and agency securities"
       }
      }
     },
     "localname": "PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vcyt_PerceptaV2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percepta v.2",
        "label": "Percepta v.2 [Member]",
        "terseLabel": "Percepta v.2"
       }
      }
     },
     "localname": "PerceptaV2Member",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_RevenueRecognitionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition",
        "label": "Revenue Recognition [Member]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of number of common shares reserved for future issuance.",
        "label": "Schedule of Common Stock Capital Shares Reserved for Future Issuance [Table Text Block]",
        "terseLabel": "Schedule of reserved shares of common stock for issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vcyt_ServicesAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Thyroid Cytopathology Partners",
        "terseLabel": "Thyroid Cytopathology Partners"
       }
      }
     },
     "localname": "ServicesAgreementAbstract",
     "nsuri": "http://www.veracyte.com/20200331",
     "xbrltype": "stringItemType"
    },
    "vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Exercises in Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Exercises in Period",
        "terseLabel": "Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Value, Options and Non-Option Equity Instruments, Exercises in Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Value, Options and Non-Option Equity Instruments, Exercises in Period",
        "terseLabel": "Issuance of common stock on exercise of stock options and vesting of restricted stock units"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Silicon Valley Bank [Member]",
        "label": "Silicon Valley Bank [Member]",
        "terseLabel": "Silicon Valley Bank"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_TermContractAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term, Contract Agreement",
        "label": "Term, Contract Agreement",
        "terseLabel": "Contract agreement term"
       }
      }
     },
     "localname": "TermContractAgreement",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vcyt_TerminationPeriodContractAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Termination Period, Contract Agreement",
        "label": "Termination Period, Contract Agreement",
        "terseLabel": "Termination period"
       }
      }
     },
     "localname": "TerminationPeriodContractAgreement",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vcyt_TestingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Testing",
        "label": "Testing [Member]",
        "terseLabel": "Testing"
       }
      }
     },
     "localname": "TestingMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_UnitedHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to United Healthcare, a significant third-party payer.",
        "label": "United Healthcare [Member]",
        "terseLabel": "UnitedHealthcare"
       }
      }
     },
     "localname": "UnitedHealthcareMember",
     "nsuri": "http://www.veracyte.com/20200331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "35",
   "Topic": "605",
   "URI": "http://asc.fasb.org/subtopic&trid=2197326"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6228884-111685"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "912",
   "URI": "http://asc.fasb.org/topic&trid=2145070"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r239": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r241": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r242": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r243": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r244": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21843-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01(a)(5))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01.(a)(5))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795129952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Credit Risk (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Revenue concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of credit risk (as a percent)</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Revenue concentration risk | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of credit risk (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Revenue concentration risk | Johnson &amp; Johnson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of credit risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Revenue concentration risk | UnitedHealthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of credit risk (as a percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Gross receivables concentration risk | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of credit risk (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Gross receivables concentration risk | Johnson &amp; Johnson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of credit risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_JohnsonJohnsonServicesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_JohnsonJohnsonServicesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_UnitedHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_UnitedHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780219664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum lease payments under non-cancelable operating leases</a></td>
<td class="text">Future minimum lease payments under non-cancelable operating leases as of March&#160;31, 2020 are as follows (in thousands of dollars):<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.953%;"><tr><td style="width:1.0%;"/><td style="width:85.014%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.986%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Year&#160;Ending&#160;December&#160;31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,760&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,401&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,543&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,614&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total future minimum lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: amount representing interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of future lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,582&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: short-term lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,450&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>vcyt-20200331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vcyt="http://www.veracyte.com/20200331"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vcyt-20200331.xsd" xlink:type="simple"/>
    <context id="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iaaae9dd411cb4154a9358fed9e4e5c6f_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib258dfe7f0534153b328114e89c2109d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e857cb02e9a491ea7ee7312b9dd0c9e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9213dc93b19946a2974d68344371892e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1091751f442346ebbe0c524c9e4668a1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibb46ced0a2aa4ca894e4cd6484a27349_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia5ffa2062f4346428273bee28aee2826_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3b5349320d4849e1a4c2f0d4d126834e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i317fc6085dfa48beab4ffe2a4f5c552d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i981f82a54dc4415d882cff6161e3cb5a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba763e838dce49179b05519385163390_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5becffb3a62e4e55a321ab87745ae9c1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id9509897f2a34febb9f09b1315f20c69_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia694bf82c3654815a3b8657a08ddc3ef_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic90a9436f476424289b0a0487b606770_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id501bb45d2034ad585778730b56f0ce6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia1975f844a2f4c15a1f55afecb1edc91_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i548e8d90f4e34475b13b982b902e4a7d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9da111a620cd40e8a9b6096845bf1ceb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0752101df15545318f42d72d0117da0c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iee6f696c673849f2860c8d67c1f52f19_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic01cb72d9395452cb15cc978c6fadf65_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i826dffa13d5d46d4b8c0b9ad504c14c8_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="idebd9f954da94453a9e58cb23bf8f4e9_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i7b328b3431ee4903a957b091a9b8b09e_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i3840aca904254efdb46618bf70d393a7_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i17fe79e8a15e4bc8a7597e3847bfed46_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i9a4e04bee36940d1a665002bd2ac7bf3_D20190507-20190507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2019-05-07</startDate>
            <endDate>2019-05-07</endDate>
        </period>
    </context>
    <context id="ibd46c80ad5fa42759560c922a438635e_D20190507-20190507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-07</startDate>
            <endDate>2019-05-07</endDate>
        </period>
    </context>
    <context id="ibf1f7f58b4404c6486380201c36cbda8_I20190507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="i54a3ab19387b41df817e1692261c8fdb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i68cca2f7ddd243ba921a37d340208f12_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia991e1722be24c0bb0d615c7c31e199e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i009ef9afb3274f819477849480fd2393_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0ba27eaeae954e789d56c5c4c620cf40_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9b93f7856b454811a810d421cd09d494_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id743ee5e5b8148bf9e58641c5f04b9d3_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id232493caa454088900109db08487758_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i01c7a4983f7b4866abb02d142286638c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i57e55cfffebb431ebba08541e4815fbc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic6c280c6cf154f7ea8dd819b86f85a73_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6c4077b693b4c71a9881ad0c593d17e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id991525e1945478d84f961bb2f9348ac_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">vcyt:RevenueRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0fd47326099244f099c155ab685c07c4_D20180409-20180409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-09</startDate>
            <endDate>2018-04-09</endDate>
        </period>
    </context>
    <context id="if3af9fe09e1e40829129e870dc5bb8e7_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iab389aee6e60456eb379dbae0cc747b5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3d1b5f753a4342188cbb3be12ff68b0d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i280b0e75a2e941528ad5d310116a69ab_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i85aec995c7594a55b57230e1738cb84e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86e73a154d594043a095b33e4c98e484_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0926623973444c5caf73d3278c08787f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9b710a4a5abe4993a9278aad2ed6ed6c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:PerceptaV2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i665bf3400edb456f9bf74af9d39ee05e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:NasaRISKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i68d35cb702de4592a9e6b6b1b313c182_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:PerceptaV2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i01413ef04119474ea6616ffa333f811c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:PerceptaV2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i548a24efc9604bf5b1230a9363724472_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonJohnsonServicesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b8be7bd0c98463195fa2424ea5db120_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8c3fe671598544568e5396dda599a8f9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia18208097ace4d03aa3886966d7c6b01_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8f0a5d6bb3934b7eb407eca1fae3f16a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i275dbe7307a1449492e85c3747f396b1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i70ec834c26f14e2d905193c57ed86a8c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i89b2f2d36fb04fcdb8a12000d2357117_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i661cf60c28f348a588855e09824e1932_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5031ee348bd54e3eb46dbeeabe6bced0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia20f4af3d960436784dac385c143e839_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i581ad647641b4236a34ecb7f297c1e30_D20191203-20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="idcc713d7148f45709edd0e4def2fa275_D20191203-20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="i4d4f80e336944a3588df9f7c63718be8_I20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-03</instant>
        </period>
    </context>
    <context id="i1709eba571e842b192e2031b1c4d9b08_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icd2f25cb091b48ca8213a9a4df7ffbe1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4d9f79d4992742aeaaa9c1d70d147220_I20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-03</instant>
        </period>
    </context>
    <context id="i3b4444e9fe9f4984a86852673528284b_I20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-03</instant>
        </period>
    </context>
    <context id="i366c70e66aab457da18751b8d033eb24_I20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-03</instant>
        </period>
    </context>
    <context id="i414932941beb4ee4b26024d1b7d17b04_I20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:LymphMarkProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-03</instant>
        </period>
    </context>
    <context id="i95a54fa194e14f688292b523de39ca15_D20191203-20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="i4a158a8048db4ff2b300dcd76423ba63_D20191203-20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="id7052d1e1ab243a6bd6b0fe4e6245e27_D20191203-20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="i15687bf922754ae2adfc9ec81a395382_D20191203-20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:LymphMarkProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="i5d59ef541093494588d84ced75c2fef2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i972755a8c17f424e96cf5cd3044f60ec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i884ba2e362494397a39b4b3ac9d4454e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vcyt:OvernightRepurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie698dd87420e44ce95964e6db3c81371_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vcyt:OvernightRepurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia9b90e1ed4f74cacaf0797329a68769b_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vcyt:OvernightRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0a0c568ab03f4e8d8092811c74c0250c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vcyt:OvernightRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4ba4c8f0affe47d8b51e983b2a35f24d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i674973e8b33f469b92b9f3edb0c4eba2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3f2a64c5183543af9a4e1523c2354584_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i40fdccc0cedd4d23b306a72908b22980_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:LaboratoryFacilitiesAustinTexasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6e241de3601549a39ba5ab3def105dc5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:LaboratoryFacilitiesAustinTexasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib4a031c3845c42609372921e497cac2e_I20171103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-03</instant>
        </period>
    </context>
    <context id="i1f90c73b3c3144378fa37effee913e4a_I20171103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-03</instant>
        </period>
    </context>
    <context id="i4e69109f224f45f78b4f86b7853a4f9c_I20171103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-03</instant>
        </period>
    </context>
    <context id="i65e0aac4a63e44328e46b91201a0cd91_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id07f35bf3b6d4efdb97d4f802d200950_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="idc5e731438a1449ba3564ed90fd6f856_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i85b76fac63ed4337ba3f066627f9ee21_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie9151d6a99994c3d8ad8137c5404513a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ife6d0673632e406b88baa85353a6ce0a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vcyt:DebtPrepaymentTrancheAxis">vcyt:DebtPrepaymentTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icb52a798d3dd45b0824f09f89f25bc71_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vcyt:DebtPrepaymentTrancheAxis">vcyt:DebtPrepaymentTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i45329572800d48e7b228e61199a1894c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vcyt:DebtPrepaymentTrancheAxis">vcyt:DebtPrepaymentTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i62c415d1690e4049ba06ee9e1047930c_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="i2f773b17ae664fd1bf7ca8e49fdcbe3a_D20190501-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="ia2da177f87084aacb8ec54951c03d633_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5dc6c074bbd1456a915067e4fec93c91_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i179ded5835fe44c58d0e2db0f9f7bf28_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iec64d800410545c29d93cac8e2c172ed_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i26afcedec6c048e392712b52100ee027_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a47e06c25734fcba6d9adaae38a2200_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i27b942a33cc641c39da58598bca5025d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c5d2c55989a46b98b6de9830693a3d5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i371cedf5a91b4b2abbfb835bb66de072_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>vcyt:segment</measure>
    </unit>
    <unit id="diseaseareas">
        <measure>vcyt:diseaseAreas</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="financial_institution">
        <measure>vcyt:financial_institution</measure>
    </unit>
    <unit id="delivery">
        <measure>vcyt:delivery</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80L2ZyYWc6YzU4MjM2ODE5YTc2NDUzZTkxMmE0NmI5MjE2MTkwODMvdGFibGU6NGM0ZjhiYmFmNjc0NDBiYjk3ZTUwOGQwODdjN2I0OGIvdGFibGVyYW5nZTo0YzRmOGJiYWY2NzQ0MGJiOTdlNTA4ZDA4N2M3YjQ4Yl8zLTEtMS0xLTA_26bd59f7-3b03-4671-b438-a5799fb38181">0001384101</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80L2ZyYWc6YzU4MjM2ODE5YTc2NDUzZTkxMmE0NmI5MjE2MTkwODMvdGFibGU6NGM0ZjhiYmFmNjc0NDBiYjk3ZTUwOGQwODdjN2I0OGIvdGFibGVyYW5nZTo0YzRmOGJiYWY2NzQ0MGJiOTdlNTA4ZDA4N2M3YjQ4Yl82LTEtMS0xLTA_ce99ca91-c3c5-4ec3-91d9-617c95f9c6a5">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80L2ZyYWc6YzU4MjM2ODE5YTc2NDUzZTkxMmE0NmI5MjE2MTkwODMvdGFibGU6NGM0ZjhiYmFmNjc0NDBiYjk3ZTUwOGQwODdjN2I0OGIvdGFibGVyYW5nZTo0YzRmOGJiYWY2NzQ0MGJiOTdlNTA4ZDA4N2M3YjQ4Yl83LTEtMS0xLTA_b6ad5d90-1b7d-41c7-8387-730865614688">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80L2ZyYWc6YzU4MjM2ODE5YTc2NDUzZTkxMmE0NmI5MjE2MTkwODMvdGFibGU6NGM0ZjhiYmFmNjc0NDBiYjk3ZTUwOGQwODdjN2I0OGIvdGFibGVyYW5nZTo0YzRmOGJiYWY2NzQ0MGJiOTdlNTA4ZDA4N2M3YjQ4Yl8xNy0xLTEtMS0w_dc825926-da57-433f-a9f1-8ec2f400bfd1">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80L2ZyYWc6YzU4MjM2ODE5YTc2NDUzZTkxMmE0NmI5MjE2MTkwODMvdGFibGU6NGM0ZjhiYmFmNjc0NDBiYjk3ZTUwOGQwODdjN2I0OGIvdGFibGVyYW5nZTo0YzRmOGJiYWY2NzQ0MGJiOTdlNTA4ZDA4N2M3YjQ4Yl8xOC0xLTEtMS0w_b8229599-78a4-48a5-8057-ff80a9954625">Q1</dei:DocumentFiscalPeriodFocus>
    <vcyt:TermContractAgreement
      contextRef="i0fd47326099244f099c155ab685c07c4_D20180409-20180409"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTg5ODQ_f0a3db4d-746a-4336-8a43-6dcb1f0c687a">P1Y</vcyt:TermContractAgreement>
    <vcyt:AutomaticRenewalPeriodContractAgreement
      contextRef="i0fd47326099244f099c155ab685c07c4_D20180409-20180409"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTkwMjE_98287a7d-3a7f-425c-896d-85cf973f3c3e">P1Y</vcyt:AutomaticRenewalPeriodContractAgreement>
    <dei:DocumentType
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2Njg2_d0de2adc-c0e4-4334-8368-b3409838d940">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6ZTVkZjE4MDg0YzVhNGViYjhlMDQyNjJlOWI5N2Y4ZjcvdGFibGVyYW5nZTplNWRmMTgwODRjNWE0ZWJiOGUwNDI2MmU5Yjk3ZjhmN18wLTAtMS0xLTEyNQ_93969fd6-c8ff-405d-8336-6931a4a55238">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF82NTk3MDY5NzY5MDkz_1af73463-fa37-4198-962c-6fafdefb9ca2">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6ZmU4NGIyNTg0NDUxNGEwMGI1ZjExZWY0Y2Y4Y2U3MmUvdGFibGVyYW5nZTpmZTg0YjI1ODQ0NTE0YTAwYjVmMTFlZjRjZjhjZTcyZV8wLTAtMS0xLTEyOA_7ed4dee1-14f5-4ee4-8f44-7ba426cb4e0c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2NzAw_230d06f0-e72f-477c-93c6-a12d5f34d21e">001-36156</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2NzE3_5f3cbeed-21c3-4524-ac99-8c12ef3c6a12">VERACYTE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6Yzk5MWM5OTZlODBiNDU5NzgyMzlkZDgyNWExMmIwNjUvdGFibGVyYW5nZTpjOTkxYzk5NmU4MGI0NTk3ODIzOWRkODI1YTEyYjA2NV8wLTAtMS0xLTE0MQ_38d43fda-2ca0-4c59-80ab-b35594c32656">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6Yzk5MWM5OTZlODBiNDU5NzgyMzlkZDgyNWExMmIwNjUvdGFibGVyYW5nZTpjOTkxYzk5NmU4MGI0NTk3ODIzOWRkODI1YTEyYjA2NV8wLTItMS0xLTE0OQ_847dd703-e05e-484b-8e73-c08df45bbe56">20-5455398</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2NzQ1_bf7c5376-5a61-44d9-8a38-9f2b7a2cecab">6000 Shoreline Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2NzU5_9419693f-2687-4533-b064-15ddbba51e66">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2Nzgz_b22703b8-fd16-49bc-828d-1319d31cd65f">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2Nzk4_bb9f58f3-9f3d-4d2d-82b3-09ac57760616">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2ODA4_105f6db3-7d3d-4afa-96d8-279e086d0a4d">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2ODEz_922afa8e-daa0-4533-a5b7-caf87d0f6592">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2ODIz_0d86c49a-420c-4ab2-a940-47f1c884d290">243-6300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6ZDNjOWY5ZmJmNWNlNDY2NWJkMzlkMDNiN2E5ZGYyMmYvdGFibGVyYW5nZTpkM2M5ZjlmYmY1Y2U0NjY1YmQzOWQwM2I3YTlkZjIyZl8xLTAtMS0xLTE5MQ_a60ea23d-fd10-4079-85ba-adb138242abd">Common Stock, par value, $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6ZDNjOWY5ZmJmNWNlNDY2NWJkMzlkMDNiN2E5ZGYyMmYvdGFibGVyYW5nZTpkM2M5ZjlmYmY1Y2U0NjY1YmQzOWQwM2I3YTlkZjIyZl8xLTItMS0xLTE5NA_69a20fe2-e213-406c-9a3c-860bcf0ab565">VCYT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6ZDNjOWY5ZmJmNWNlNDY2NWJkMzlkMDNiN2E5ZGYyMmYvdGFibGVyYW5nZTpkM2M5ZjlmYmY1Y2U0NjY1YmQzOWQwM2I3YTlkZjIyZl8xLTQtMS0xLTE5OA_7b916075-f1c4-4628-a3bc-2ceecbf766be">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2ODMx_e7c99186-7714-4a46-a9be-5474ff47b057">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2ODM4_3c5499aa-890a-40cb-b2c8-61ef4a3baaff">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6MGUxYWNlZmQxYzNjNGM3NjkzYWY0OTA1Nzg4NzYzMGIvdGFibGVyYW5nZTowZTFhY2VmZDFjM2M0Yzc2OTNhZjQ5MDU3ODg3NjMwYl8wLTAtMS0xLTIzNzQvdGV4dHJlZ2lvbjo3Y2ZjYjQ3ZWU3OTg0NmRmYjA3Mzg3NzAwYWRkODVkYV83MTQ2ODI1NTgwNjI1_c4680efa-a6dd-4aec-a883-0f78fa7f10bb">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6MGUxYWNlZmQxYzNjNGM3NjkzYWY0OTA1Nzg4NzYzMGIvdGFibGVyYW5nZTowZTFhY2VmZDFjM2M0Yzc2OTNhZjQ5MDU3ODg3NjMwYl8yLTItMS0xLTIyNC90ZXh0cmVnaW9uOmMzM2E2NGQxNmIyYzQ3ZDE5MDI0ZjNkM2QwNTNjZTc0Xzc2OTY1ODEzOTQ0NjU_7df7bf44-db6b-4b84-92c1-c08c8b659308">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGFibGU6MGUxYWNlZmQxYzNjNGM3NjkzYWY0OTA1Nzg4NzYzMGIvdGFibGVyYW5nZTowZTFhY2VmZDFjM2M0Yzc2OTNhZjQ5MDU3ODg3NjMwYl80LTItMS0xLTIzMS90ZXh0cmVnaW9uOjA5ZTIzYWY3NWVmODRiOTViZWY1MzRiOTVlNzk2OWVlXzc2OTY1ODEzOTQ0NjM_7e2e8d32-b3f1-42bc-b874-0b6383aff596">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83Njk2NTgxMzk2ODQz_b18eb525-0b4d-4685-b9fe-25ad5353a862">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iaaae9dd411cb4154a9358fed9e4e5c6f_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xL2ZyYWc6YmVjM2JjNmQ2MmJmNDVkM2E1ZmM2YjNlZDM1MzI0NzgvdGV4dHJlZ2lvbjpiZWMzYmM2ZDYyYmY0NWQzYTVmYzZiM2VkMzUzMjQ3OF83MTQ2ODI1NTgyOTc4_bb88e048-9f34-46af-bc10-9ae53b93be47"
      unitRef="shares">50053437</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNC0xLTEtMS0w_c06575bc-d453-47e7-bbe8-f15e2cdc6e58"
      unitRef="usd">153132000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNC0zLTEtMS0w_8603449d-8b1b-4e32-b62f-207dab9965a8"
      unitRef="usd">159317000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNS0xLTEtMS0w_17bb3144-1e47-4c6e-8481-aa67aed7f4ba"
      unitRef="usd">19091000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNS0zLTEtMS0w_32e91e85-6fe2-4fa6-a8eb-157cd09e2cdc"
      unitRef="usd">19329000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNi0xLTEtMS0w_111a24ca-3616-4eb6-90cc-5a2f8d332312"
      unitRef="usd">6094000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNi0zLTEtMS0w_18d02262-aab6-4370-8bf9-6ab7a5ec3e15"
      unitRef="usd">6806000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNy0xLTEtMS0w_90c711d9-fae1-4dc9-a655-d074cbde5e0a"
      unitRef="usd">3045000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfNy0zLTEtMS0w_2f781c8d-330d-4301-bbbc-f311419c6bb4"
      unitRef="usd">2235000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfOC0xLTEtMS0w_b5114512-23a4-4004-b6fc-5876faefb8d4"
      unitRef="usd">181362000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfOC0zLTEtMS0w_5829d0f9-eb40-4ce6-96d9-6f92fcad1ab6"
      unitRef="usd">187687000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfOS0xLTEtMS0w_be072bd9-7556-4cd7-b493-53b3c9b503f6"
      unitRef="usd">8788000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfOS0zLTEtMS0w_1303fde3-7707-413a-b82a-e7738fc6fd84"
      unitRef="usd">8933000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTEtMS0xLTEtMA_7e761b36-f7cc-4db0-8b01-045f2c013855"
      unitRef="usd">8576000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTEtMy0xLTEtMA_e73a26bd-f110-4624-ae47-6a4f9f81406b"
      unitRef="usd">8808000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTItMS0xLTEtMA_56e13f29-8301-4936-975b-9dc318a88cc6"
      unitRef="usd">63744000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTItMy0xLTEtMA_d2c0f29d-2719-4821-b9b7-53322b07d7fc"
      unitRef="usd">65019000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTMtMS0xLTEtMA_e5a357c4-bf2a-4f0b-8297-09b2991d7a61"
      unitRef="usd">2725000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTMtMy0xLTEtMA_4d2312c1-e2da-4e69-9021-1b20ac5e9ce5"
      unitRef="usd">2725000</us-gaap:Goodwill>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTQtMS0xLTEtMA_35c3b7f0-ac9f-4117-80c3-f066d2a9879d"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTQtMy0xLTEtMA_9f7e815f-d80a-4857-8ff7-824bdcc8b41e"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTUtMS0xLTEtMA_495dbd4f-910c-4afd-acf4-efb31e258a91"
      unitRef="usd">1302000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTUtMy0xLTEtMA_30b8b556-6173-4693-9362-56ff25365e41"
      unitRef="usd">1437000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTYtMS0xLTEtMA_fc451bb4-0504-4666-8ef0-aa99827cc9e0"
      unitRef="usd">267100000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTYtMy0xLTEtMA_097eafe7-322a-4b6e-b4f4-cb2976678f4f"
      unitRef="usd">275212000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTktMS0xLTEtMA_4cb52879-e470-4401-beb2-d5a4d6236455"
      unitRef="usd">7665000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMTktMy0xLTEtMA_0f107639-8c7c-4d3a-a1bf-1cccb0844702"
      unitRef="usd">2328000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjAtMS0xLTEtMA_9694382c-efc6-4f08-aa8d-b08f1c7f6827"
      unitRef="usd">10079000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjAtMy0xLTEtMA_560cc9fe-a0b9-488d-96d7-3e6964308d79"
      unitRef="usd">13734000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjMtMS0xLTEtMA_a86cfd33-bd3d-4f40-ac6e-3cab213199f5"
      unitRef="usd">1450000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjMtMy0xLTEtMA_bfa56782-e3b1-4a3a-9555-21f2ed65d64a"
      unitRef="usd">1407000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjQtMS0xLTEtMA_8ce301e6-c517-41c8-be88-0778b915405b"
      unitRef="usd">19194000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjQtMy0xLTEtMA_74f1b4dc-07c6-42cb-8b12-c65cc509bd45"
      unitRef="usd">17469000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjUtMS0xLTEtMA_435896cf-cef7-4e1c-95dd-e82223e996b5"
      unitRef="usd">748000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjUtMy0xLTEtMA_a1cbe25e-dce4-4685-b3d1-004410dc9867"
      unitRef="usd">694000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjYtMS0xLTEtMA_18306eef-cca1-4b95-8679-eef6b1f44d4e"
      unitRef="usd">5604000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjYtMy0xLTEtMA_ef1997a6-8883-4f9e-a87a-88be17c7ae35"
      unitRef="usd">6088000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjctMS0xLTEtMA_06f4cdce-55cb-446e-8655-bd7bad5026ab"
      unitRef="usd">11132000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjctMy0xLTEtMA_1c5ea472-df72-4ff8-a90a-e64c0cf31056"
      unitRef="usd">11506000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjgtMS0xLTEtMA_6b48235f-b7cd-46a0-ae18-32f88626d5c0"
      unitRef="usd">36678000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjgtMy0xLTEtMA_d135935f-cdb4-4291-a946-2ea30f77d601"
      unitRef="usd">35757000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjktMS0xLTEtMA_cc71c647-6437-48e8-9367-0b3a77c4a2ef"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMjktMy0xLTEtMA_4a20b5bf-b20a-4048-87ea-bf01e3a7b609"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2MTM_7ff85ce5-a0ff-4c70-bf47-812ea73dc390"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2MTM_87460556-d136-45db-bc87-232397bf4649"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2MjQ_2d80b335-4b35-4f53-ab67-d89766515007"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2MjQ_428fcf45-bccf-46ac-b700-473dc35cef5e"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2Mjg_04563424-8699-4e1e-be94-24a77108234c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2Mjg_2c1c0048-dc8c-4488-94a9-cddb2322e7f5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2Mjg_40a0ae85-ec9d-4321-b2c8-e5dd09dc2790"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdhYmQxNzRmNzI4YzRhMGM4ZjRkNWQ1Y2M4NTNhYTBkXzc2OTY1ODEzOTQ2Mjg_dfd9dbb0-41c0-4e6d-808d-f183984a0606"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMS0xLTEtMA_63f918ce-43ac-4876-a10f-1926ae7bf8bf"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzEtMy0xLTEtMA_5b2c7f54-41a1-47c6-8e71-921f0879841f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2MjI_91af66d8-e2b6-45a6-b8c3-5088ebe07bd5"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2MjI_bf735d79-b5c3-4fa4-8039-76320c944ca8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2MzY_4e4ed90c-bfc0-4216-8ff9-44c3329dedf0"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2MzY_7e4a6a7b-c2b5-4b69-aa35-2fd1f63a8401"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2NDg_36045560-ba63-416c-a54a-3eedd403482d"
      unitRef="shares">49999923</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2NDg_c7c44842-10ee-4418-a0e6-330c1f90ff87"
      unitRef="shares">49999923</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2NjA_0c83ecc3-37af-4f30-b952-f3cce3196348"
      unitRef="shares">49625341</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJiNzg4ZDRiM2IyMTRmMDJiODY4YTNhOThiN2E5MWRmXzc2OTY1ODEzOTQ2NjA_52358329-d01d-4641-b90f-237f6de5fc0a"
      unitRef="shares">49625341</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMS0xLTEtMA_c5328c87-dc02-425b-9cec-8c814b825208"
      unitRef="usd">50000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzItMy0xLTEtMA_868e143b-c346-4509-85af-4a3d30887436"
      unitRef="usd">50000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzMtMS0xLTEtMA_e8c1e3c1-f423-44e9-8d61-59a41d91c007"
      unitRef="usd">488773000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzMtMy0xLTEtMA_b5bf34c8-d4b2-455d-8efc-69c578a61f52"
      unitRef="usd">486090000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzQtMS0xLTEtMA_070e7991-51df-4a09-a670-a08baf3d7d40"
      unitRef="usd">-258401000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzQtMy0xLTEtMA_496f3bca-c9db-414b-bf0f-1fb6c6724984"
      unitRef="usd">-246685000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzUtMS0xLTEtMA_2055b009-7adb-4ede-8a3b-eee4497f66dc"
      unitRef="usd">230422000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzUtMy0xLTEtMA_34e2fd0a-ed33-4081-9d56-9d0ae797e6dd"
      unitRef="usd">239455000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzYtMS0xLTEtMA_4dd1625c-64c7-4cc5-9a83-1d4a83d1228d"
      unitRef="usd">267100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xNi9mcmFnOjJkOGYxMDE1NDgzNTQwZDg4OGRlM2UxMWIyMDk2YWMyL3RhYmxlOmUyZTlmOTVmYzk4ZTQwY2FiZDNjZDhmNWU4YTZiYzg3L3RhYmxlcmFuZ2U6ZTJlOWY5NWZjOThlNDBjYWJkM2NkOGY1ZThhNmJjODdfMzYtMy0xLTEtMA_18f192d9-d0c4-4c7f-b91c-6fe2e87c1a54"
      unitRef="usd">275212000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e857cb02e9a491ea7ee7312b9dd0c9e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMy0xLTEtMS0xMTI4_c809cdfd-b701-4578-ad0c-5904b87d718e"
      unitRef="usd">26991000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9213dc93b19946a2974d68344371892e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMy0zLTEtMS0yMzc1_5b0dd957-009c-480a-b076-c40fed31a5e8"
      unitRef="usd">25389000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1091751f442346ebbe0c524c9e4668a1_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNC0xLTEtMS0xMTI4_627a9921-18c7-41a8-bb74-35d15073e468"
      unitRef="usd">3409000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb46ced0a2aa4ca894e4cd6484a27349_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNC0zLTEtMS0yMzc1_e18c0815-43e5-490f-aab4-c619d8bb1882"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5ffa2062f4346428273bee28aee2826_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNS0xLTEtMS0xMTI4_ab8e66b9-8d5a-41f8-8775-a926a220b9d6"
      unitRef="usd">722000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b5349320d4849e1a4c2f0d4d126834e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNS0zLTEtMS0yMzc1_5c9c4517-4ef6-4cfb-9582-0196667fa33f"
      unitRef="usd">4140000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMi0xLTEtMS0w_b0db6563-1402-460e-a1a3-12199fd4e302"
      unitRef="usd">31122000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMi0zLTEtMS0w_86bdc74b-0f2a-49f6-a2b5-d536a46e7fb2"
      unitRef="usd">29529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="i1e857cb02e9a491ea7ee7312b9dd0c9e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNC0xLTEtMS0w_18de23d0-4e87-4a92-8ec2-bca9742b408d"
      unitRef="usd">10568000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i9213dc93b19946a2974d68344371892e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNC0zLTEtMS0w_332646fb-d4aa-467d-80dd-61ecd6aeb109"
      unitRef="usd">8513000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNC0zLTEtMS0w_aab82711-0351-4a39-8e5a-252e41971ed4"
      unitRef="usd">8513000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i1091751f442346ebbe0c524c9e4668a1_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfOS0xLTEtMS0xMTMx_171e4db2-767c-4ce6-a179-2e003c384040"
      unitRef="usd">1559000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ibb46ced0a2aa4ca894e4cd6484a27349_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfOS0zLTEtMS0yMzc3_f98cb6ca-4ca7-4ed0-9b83-97ba15193e59"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ia5ffa2062f4346428273bee28aee2826_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTAtMS0xLTEtMTEzMQ_f5030ec3-56fe-4bc7-a930-a1d4b71feb0e"
      unitRef="usd">116000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i3b5349320d4849e1a4c2f0d4d126834e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTAtMy0xLTEtMjM3Nw_f4d9ba15-ad41-4b83-8989-7403d479ba22"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNS0xLTEtMS0w_b1ad97fc-8855-44be-9900-a7d9a63a50cb"
      unitRef="usd">4407000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNS0zLTEtMS0w_27c3c83a-4f59-44a3-ab68-a5e15031994b"
      unitRef="usd">3435000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNi0xLTEtMS0w_cddff50a-f364-4fed-bbf9-9353c5e2e9a3"
      unitRef="usd">17584000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNi0zLTEtMS0w_77ec5861-b114-4abc-95c8-a4b3239bf5f7"
      unitRef="usd">12477000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNy0xLTEtMS0w_dfcbe66a-206f-4f5a-a522-85925d71ae93"
      unitRef="usd">7813000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfNy0zLTEtMS0w_eabebcf0-8188-4fc5-8852-3b716b3f9a8d"
      unitRef="usd">6904000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfOC0xLTEtMS0w_a0a47042-4acb-4ca7-bf44-60bcfeb22231"
      unitRef="usd">1275000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfOC0zLTEtMS0w_ddce90c5-cf9d-470a-826b-06236f83c795"
      unitRef="usd">267000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfOS0xLTEtMS0w_7ace3ecd-8abe-4ed2-8af2-7f81271ed41e"
      unitRef="usd">43322000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfOS0zLTEtMS0w_01531c31-9487-4bdc-b6e8-999c80c53aa0"
      unitRef="usd">31596000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTAtMS0xLTEtMA_2e74c0c3-30e8-4dd2-ad1d-5c8598813622"
      unitRef="usd">-12200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTAtMy0xLTEtMA_77720ecf-f0fb-48b8-a48a-3d3b2e3d73cd"
      unitRef="usd">-2067000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTEtMS0xLTEtMA_90601392-836b-43e4-9389-466dd52cb007"
      unitRef="usd">55000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTEtMy0xLTEtMA_0abb5e07-a6df-4105-9f2b-a08719b9cfdb"
      unitRef="usd">303000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTItMS0xLTEtMA_010b2798-8293-4d9b-98cb-77f1c29e896c"
      unitRef="usd">539000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTItMy0xLTEtMA_b7ebd370-c77f-4502-9326-97497d177c9b"
      unitRef="usd">453000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTMtMS0xLTEtMA_1388333b-772b-401a-824f-1e02868ea24b"
      unitRef="usd">-11716000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTMtMS0xLTEtMA_ca8254cd-766b-4ad8-9273-caa8eb23e3b0"
      unitRef="usd">-11716000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTMtMy0xLTEtMA_25fd9455-95f9-4845-9dde-d22a7d0d774b"
      unitRef="usd">-1917000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTMtMy0xLTEtMA_87df7ae5-dabe-4b52-8936-c942e9be84ce"
      unitRef="usd">-1917000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTQtMS0xLTEtMA_38e5ddec-ceb7-4d31-abe8-96a8e62275a4"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTQtMy0xLTEtMA_07841c40-b705-412c-9abf-03112e6350e6"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTUtMS0xLTEtMA_db9a145e-1e5f-49da-93c5-02765ccb0c65"
      unitRef="shares">49792631</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yMi9mcmFnOjA1NDYzODhmNmRmMDRiNDZhMTVmZWIzNjE3NmNiOGY5L3RhYmxlOjNiZmRjN2RlMjdlMTQzMTc5NjkxZmI4Yjk5ZDg5ZjgzL3RhYmxlcmFuZ2U6M2JmZGM3ZGUyN2UxNDMxNzk2OTFmYjhiOTlkODlmODNfMTUtMy0xLTEtMA_f1d09511-38cf-4a88-8b93-233e4e670edf"
      unitRef="shares">41168593</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i317fc6085dfa48beab4ffe2a4f5c552d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTMtMS0xLTEtMA_3a5f523b-b2c9-4a3d-b3ef-0fca3103efd0"
      unitRef="shares">49625000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i317fc6085dfa48beab4ffe2a4f5c552d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTMtMy0xLTEtMA_743591a4-0dc6-4385-b038-53d8041401d4"
      unitRef="usd">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i981f82a54dc4415d882cff6161e3cb5a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTMtNS0xLTEtMA_d603d4af-05cb-4715-98e8-b64c30198768"
      unitRef="usd">486090000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iba763e838dce49179b05519385163390_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTMtNy0xLTEtMA_c0a4e9da-c796-46c5-b541-acc63263dfab"
      unitRef="usd">-246685000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTMtOS0xLTEtMA_12ff9e2b-0c0f-4dc9-96cf-7117d44ed8f4"
      unitRef="usd">239455000</us-gaap:StockholdersEquity>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="i5becffb3a62e4e55a321ab87745ae9c1_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTUtMS0xLTEtMA_77915219-daf2-407b-baa9-1de8756a8e18"
      unitRef="shares">314000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="id9509897f2a34febb9f09b1315f20c69_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTUtNS0xLTEtMA_f1e3d4a3-72ca-4b20-bc90-d23e7f7cd3bf"
      unitRef="usd">981000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTUtOS0xLTEtMA_fbfbbc36-fff9-4857-879f-b8395a0b73f4"
      unitRef="usd">981000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i5becffb3a62e4e55a321ab87745ae9c1_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTYtMS0xLTEtMA_e881e39d-8337-4001-8dd0-bed6d85f0ab4"
      unitRef="shares">61000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id9509897f2a34febb9f09b1315f20c69_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTYtNS0xLTEtMA_0e88f9b6-cb41-43a9-a16e-d6fd90c103d3"
      unitRef="usd">1101000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTYtOS0xLTEtMA_d6aee759-e03b-4477-ada6-3e6c798a202e"
      unitRef="usd">1101000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id9509897f2a34febb9f09b1315f20c69_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTctNS0xLTEtMA_30c2d096-f4d8-4b74-a7b3-8e1e65f5bfe4"
      unitRef="usd">2304000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTctOS0xLTEtMA_23623d2a-a117-47ac-b2f0-281f32f86ce4"
      unitRef="usd">2304000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="id9509897f2a34febb9f09b1315f20c69_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTgtNS0xLTEtMA_dee4f6e2-1442-4730-8304-2056fbddcaaa"
      unitRef="usd">2551000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMTgtOS0xLTEtMA_3e7f2695-b140-43f8-aac8-3c32559907e9"
      unitRef="usd">2551000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="id9509897f2a34febb9f09b1315f20c69_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjAtNS0xLTEtMA_8e09721f-d170-4659-b9c3-5b290059b3da"
      unitRef="usd">354000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjAtOS0xLTEtMA_0e0c4a46-e018-44a0-ad8b-82a4cec2cad8"
      unitRef="usd">354000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjEtNy0xLTEtMA_6ab75879-c718-4cf5-a47b-0459da80dc70"
      unitRef="usd">-11716000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia694bf82c3654815a3b8657a08ddc3ef_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjEtNy0xLTEtMA_e851c0f9-1763-4757-8573-9826287c4e98"
      unitRef="usd">-11716000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjEtOS0xLTEtMA_2310e27e-166d-439f-908d-648bc085d79e"
      unitRef="usd">-11716000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjEtOS0xLTEtMA_5cca0510-b4a2-4331-a359-7b07c5cd276a"
      unitRef="usd">-11716000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ic90a9436f476424289b0a0487b606770_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjItMS0xLTEtMA_36d8a6de-a5c8-4010-92f7-2f2fbf90aa7c"
      unitRef="shares">50000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic90a9436f476424289b0a0487b606770_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjItMy0xLTEtMA_265a2813-bf41-4d30-892e-ff180ecf0e6e"
      unitRef="usd">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id501bb45d2034ad585778730b56f0ce6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjItNS0xLTEtMA_4fc2750c-7317-45e8-82b4-ddfbd0d837fc"
      unitRef="usd">488773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1975f844a2f4c15a1f55afecb1edc91_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjItNy0xLTEtMA_22b2f48f-ed61-4393-aa87-d9f58066b8e9"
      unitRef="usd">-258401000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjU1MWYxMWZhYzU4ODQyNzBhMjZiNDU2ODE0MWRhYTAzL3RhYmxlcmFuZ2U6NTUxZjExZmFjNTg4NDI3MGEyNmI0NTY4MTQxZGFhMDNfMjItOS0xLTEtMA_a0ade28e-3204-4ae8-9bb6-021d8a95945b"
      unitRef="usd">230422000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i548e8d90f4e34475b13b982b902e4a7d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTItMS0xLTEtMA_7589a20a-78fb-4706-b147-92a513dae049"
      unitRef="shares">40863000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i548e8d90f4e34475b13b982b902e4a7d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTItMy0xLTEtMA_7b052af7-d1bf-426f-b64f-2fde5f222541"
      unitRef="usd">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9da111a620cd40e8a9b6096845bf1ceb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTItNS0xLTEtMA_9e934d4a-ee14-4b0b-b380-bd917e185459"
      unitRef="usd">313800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0752101df15545318f42d72d0117da0c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTItNy0xLTEtMA_81644d58-f79c-4d7a-8737-d0f857e7f93a"
      unitRef="usd">-234086000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee6f696c673849f2860c8d67c1f52f19_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTItOS0xLTEtMA_2f951efb-981a-43a5-81a8-6b0158fd7c4d"
      unitRef="usd">79755000</us-gaap:StockholdersEquity>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="ic01cb72d9395452cb15cc978c6fadf65_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTQtMS0xLTEtMA_44e8216d-6701-411a-b374-b4e6c0f6b15a"
      unitRef="shares">566000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="ic01cb72d9395452cb15cc978c6fadf65_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTQtMy0xLTEtMA_16e360a4-8da3-4804-8477-fa7c6a34b7f2"
      unitRef="usd">1000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTQtNS0xLTEtMA_968083ab-e2d3-4db0-ae33-b41bd323be5c"
      unitRef="usd">4239000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTQtOS0xLTEtMA_2123e877-0b80-4e3f-92b7-049bf8d87653"
      unitRef="usd">4240000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic01cb72d9395452cb15cc978c6fadf65_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTUtMS0xLTEtMA_3b7db1ce-393f-4b42-b9ed-cad9c0383e3a"
      unitRef="shares">80000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTUtNS0xLTEtMA_3aca55ea-33e0-463e-81f5-18fa3111df7c"
      unitRef="usd">491000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTUtOS0xLTEtMA_f0bef8d7-7ed0-42cc-be81-2e9269ea5c12"
      unitRef="usd">491000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTYtNS0xLTEtMA_dcf25bca-f5d9-4b7c-89b0-3e5be728106f"
      unitRef="usd">556000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTYtOS0xLTEtMA_77530e9d-ac31-48c1-b38f-e0cf6bc98e7f"
      unitRef="usd">556000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTctNS0xLTEtMA_c1b12ee7-8405-4796-a99a-3a296d6f246b"
      unitRef="usd">1598000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTctOS0xLTEtMA_73b419d7-614c-4a73-914f-aa8c8add5a2e"
      unitRef="usd">1598000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee
      contextRef="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTgtNS0xLTEtMA_f6a712a8-4f5b-4bb3-8a8e-2e415bb998b2"
      unitRef="usd">20000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTgtOS0xLTEtMA_0a908e72-5b34-4365-9b90-af979e61ec4b"
      unitRef="usd">20000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="i82ac45a840db408da977df6fa5ce8351_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTktNS0xLTEtMA_923498f2-15d2-40c7-9fba-8a866b92bb47"
      unitRef="usd">141000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMTktOS0xLTEtMA_18b5d86c-9eba-42df-9a39-ae5ecaa58d37"
      unitRef="usd">141000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i826dffa13d5d46d4b8c0b9ad504c14c8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjEtNy0xLTEtMA_230a1667-9b41-4cdc-8098-a15461b32023"
      unitRef="usd">-1917000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjEtNy0xLTEtMA_778028e3-61a6-4745-ac64-9b7c8e3b8331"
      unitRef="usd">-1917000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjEtOS0xLTEtMA_c5ffb074-63a4-44fe-b66c-7f59da2d0b88"
      unitRef="usd">-1917000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjEtOS0xLTEtMA_fa0a5ec2-04c0-4c9b-9109-ebf3bdaa7556"
      unitRef="usd">-1917000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:SharesOutstanding
      contextRef="idebd9f954da94453a9e58cb23bf8f4e9_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjItMS0xLTEtMA_0a0e586e-bf9d-484f-9056-c0ebc7d1b2ea"
      unitRef="shares">41509000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idebd9f954da94453a9e58cb23bf8f4e9_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjItMy0xLTEtMA_469ddff9-455c-4f8a-ae85-7a149b713e73"
      unitRef="usd">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b328b3431ee4903a957b091a9b8b09e_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjItNS0xLTEtMA_8acef1f3-1fd8-4228-b8d3-9409336ef6cd"
      unitRef="usd">319733000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3840aca904254efdb46618bf70d393a7_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjItNy0xLTEtMA_5fd15ac9-3199-4763-8c31-600dbedc71bf"
      unitRef="usd">-236003000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17fe79e8a15e4bc8a7597e3847bfed46_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8yOC9mcmFnOmYwMTMzZmZlYmQ1YTQwMzI5ZWExZWZlMGUyNWRlYWE3L3RhYmxlOjVhNTE5MDBlODNmZDQ0OTRiY2VmMjJhYWU0M2FhNDRkL3RhYmxlcmFuZ2U6NWE1MTkwMGU4M2ZkNDQ5NGJjZWYyMmFhZTQzYWE0NGRfMjItOS0xLTEtMA_4651fd50-fce0-46cf-acb6-227abb5c569d"
      unitRef="usd">83772000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMy0xLTEtMS0w_f6ede3eb-93c5-4a28-a60c-ea133c2ec298"
      unitRef="usd">-11716000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMy0zLTEtMS0w_260044b9-c805-4864-9bcc-929e415c1fbb"
      unitRef="usd">-1917000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfNS0xLTEtMS0w_ced7c693-89d1-4443-8572-04275ab38742"
      unitRef="usd">1972000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfNS0zLTEtMS0w_cf41a831-adfa-4a74-ae69-f471d1375447"
      unitRef="usd">945000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfNi0xLTEtMS0w_1fe828a7-31a5-42cd-85a0-e700092f2db8"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfNi0zLTEtMS0w_0322797f-8710-4a55-8e0b-43d28ddbd716"
      unitRef="usd">16000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:ShareBasedCompensation
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfNy0xLTEtMS0w_26c76012-4a4a-4fbc-a725-fefaac91af59"
      unitRef="usd">2905000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfNy0zLTEtMS0w_bad01743-4603-4247-8582-7b13e388d947"
      unitRef="usd">1759000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfOS0xLTEtMS0w_cc5fb930-0c73-4419-a419-41616ac56e51"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfOS0zLTEtMS0w_c8daa3a6-c41b-4513-8ec6-54755fa1090d"
      unitRef="usd">8000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <vcyt:InterestExpenseandPrepaymentPenalty
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTAtMS0xLTEtMA_adea3219-c1d9-41fc-a6f1-c373724cbd1f"
      unitRef="usd">54000</vcyt:InterestExpenseandPrepaymentPenalty>
    <vcyt:InterestExpenseandPrepaymentPenalty
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTAtMy0xLTEtMA_cbd1aec7-90f5-4338-a783-d609d397d382"
      unitRef="usd">64000</vcyt:InterestExpenseandPrepaymentPenalty>
    <vcyt:InventoryReserveEffectOnIncomeNet
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTEtMS0xLTEtMTc3NA_125c38e2-15b6-4a60-aa78-74e8524edc11"
      unitRef="usd">1088000</vcyt:InventoryReserveEffectOnIncomeNet>
    <vcyt:InventoryReserveEffectOnIncomeNet
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTEtMy0xLTEtMTc3Ng_cdc2464d-6d8f-48bc-9379-0f8b7d95aeca"
      unitRef="usd">0</vcyt:InventoryReserveEffectOnIncomeNet>
    <vcyt:NoncashLeaseExpenses
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTItMS0xLTEtMzc2NA_65abee01-f944-44b3-b1cb-14280f91890c"
      unitRef="usd">232000</vcyt:NoncashLeaseExpenses>
    <vcyt:NoncashLeaseExpenses
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTItMy0xLTEtMzc2NA_f76bce8e-a6f8-424f-bd58-a487d1257e2a"
      unitRef="usd">212000</vcyt:NoncashLeaseExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTEtMS0xLTEtMTAyNg_9f868e31-bfb7-4090-b971-59cca28e1321"
      unitRef="usd">-484000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTEtMy0xLTEtMTAyNg_816ba0e2-f20e-406c-95f1-3be06b3910f6"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTItMS0xLTEtMA_9d00dc94-02ed-4d8d-84f7-462ef1ab4ca2"
      unitRef="usd">-238000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTItMy0xLTEtMA_abf86172-b122-4a9d-8475-4d829736cde9"
      unitRef="usd">3447000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTMtMS0xLTEtMA_fa5679d3-944f-478b-b394-b6a8fe25b22f"
      unitRef="usd">376000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTMtMy0xLTEtMA_9e8d19b8-c872-40a6-854e-79e7b9596b8a"
      unitRef="usd">366000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTQtMS0xLTEtMA_6f2a442d-767f-4b74-a3cf-d8d853645048"
      unitRef="usd">818000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTQtMy0xLTEtMA_e057cc50-3544-4c33-815d-cca428138aa5"
      unitRef="usd">11000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <vcyt:IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTUtMS0xLTEtMA_836bd4d4-b5e0-4d3a-946f-5f5d41af84e1"
      unitRef="usd">331000</vcyt:IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability>
    <vcyt:IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTUtMy0xLTEtMA_e83887ed-d114-4f2b-b01a-2f595a5cf7e7"
      unitRef="usd">292000</vcyt:IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTYtMS0xLTEtMA_972b79f2-fc62-4cc3-a8b3-615cda362a1a"
      unitRef="usd">-135000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTYtMy0xLTEtMA_aff990d2-3e41-4eea-a390-de8b68c4a038"
      unitRef="usd">-37000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTctMS0xLTEtMA_3a2f1fda-64af-430f-8354-f1f5f3c2e879"
      unitRef="usd">5450000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTctMy0xLTEtMA_8efd1395-95fa-4d73-a973-4935fd91702d"
      unitRef="usd">1726000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTgtMS0xLTEtMA_7f417a4b-6eba-4ad4-bb95-edc92f79aa54"
      unitRef="usd">-3650000</vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent>
    <vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTgtMy0xLTEtMA_4e102b87-c73d-436c-ae0a-664c7a198a83"
      unitRef="usd">287000</vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTktMS0xLTEtMA_fbc15bca-bd4f-4011-a779-637dcdf71911"
      unitRef="usd">-5301000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMTktMy0xLTEtMA_21c7ab81-def2-4141-92c2-18a59be92d89"
      unitRef="usd">-1011000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjEtMS0xLTEtMA_a6e5068a-b687-4618-ae5c-745d41d8ee01"
      unitRef="usd">665000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjEtMy0xLTEtMA_392aec7d-947a-45bd-b8b3-b16dcedbc55e"
      unitRef="usd">765000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjItMS0xLTEtMA_db537329-3785-4ed3-954d-b0d37d7f159c"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjItMy0xLTEtMA_a6435313-2e43-43bc-91bb-c8b9f558e686"
      unitRef="usd">16000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjMtMS0xLTEtMA_f27e8b50-4266-4517-b736-459a2d91ebc6"
      unitRef="usd">-665000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjMtMy0xLTEtMA_ec7c92e4-3325-4b09-9f10-1cdf5597147a"
      unitRef="usd">-749000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjYtMS0xLTEtMA_d1525e66-ac99-4a0f-b987-f93ba6dfa0ff"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjYtMy0xLTEtMA_c33477d4-b38f-4a8a-ae3e-73aa15c6f8a8"
      unitRef="usd">12500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjgtMS0xLTEtMA_2275eda7-8af5-4c81-a3c3-4e2adfb238db"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjgtMy0xLTEtMA_64a6cdff-fe58-4052-bd14-917f5ece5a9e"
      unitRef="usd">75000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjktMS0xLTEtMTYzOA_dca01048-9294-4b77-8522-a4d30e166dfb"
      unitRef="usd">2304000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjktMy0xLTEtMTYzOA_b99b01d1-bc51-4c51-84be-c4f267ebe1cd"
      unitRef="usd">556000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjktMS0xLTEtMA_e1fe8a4b-9a90-4387-9d10-283c62140313"
      unitRef="usd">2085000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMjktMy0xLTEtMA_cdd81e83-bace-4aa3-ad44-68d37b57e360"
      unitRef="usd">4737000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzAtMS0xLTEtMA_6bf907c9-fc21-4da6-a047-eb5265b748db"
      unitRef="usd">-219000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzAtMy0xLTEtMA_a590ef45-2190-413a-bb5d-2c1ef79b9de0"
      unitRef="usd">-8394000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzEtMS0xLTEtMA_7e7dc263-f23b-46cd-8863-1ba7a6426cc1"
      unitRef="usd">-6185000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzEtMy0xLTEtMA_896b50e3-6bd5-44e0-88f2-0113110c4cda"
      unitRef="usd">-10154000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzItMS0xLTEtMA_f4b7acd0-febb-4a93-9916-043eff386e80"
      unitRef="usd">159920000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iee6f696c673849f2860c8d67c1f52f19_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzItMy0xLTEtMA_7b87e3ba-23c4-43e0-b65b-de8fc14d4eed"
      unitRef="usd">78598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzMtMS0xLTEtMA_c74d00b4-5786-45dd-a48c-dd5ccb2c1816"
      unitRef="usd">153735000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i17fe79e8a15e4bc8a7597e3847bfed46_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzMtMy0xLTEtMA_8c13331e-d695-417c-97c1-f9e6593aabfc"
      unitRef="usd">68444000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <vcyt:CapitalExpendituresIncurredButNotYetPaidNet
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzYtMS0xLTEtMA_aa3f905f-01a1-4bf3-9677-2407b05bfcfb"
      unitRef="usd">113000</vcyt:CapitalExpendituresIncurredButNotYetPaidNet>
    <vcyt:CapitalExpendituresIncurredButNotYetPaidNet
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzYtMy0xLTEtMA_8f0639ac-8938-4e15-9ffe-31e7c0a47dbd"
      unitRef="usd">95000</vcyt:CapitalExpendituresIncurredButNotYetPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzctMS0xLTEtMA_c43a46c9-190f-4a03-bdb9-71ff4df64a43"
      unitRef="usd">1000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjFjM2EwZGIzODliNzRhY2RhYmFhYjIzOTY2ZDViMDI3L3RhYmxlcmFuZ2U6MWMzYTBkYjM4OWI3NGFjZGFiYWFiMjM5NjZkNWIwMjdfMzctMy0xLTEtMA_266859f9-bcef-4eaa-8d3a-9c2171d6695b"
      unitRef="usd">228000</us-gaap:InterestPaidNet>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjNhOTA1NGZlOWVkMTRiM2ViOTJlODZkZTZhODE3NWFjL3RhYmxlcmFuZ2U6M2E5MDU0ZmU5ZWQxNGIzZWI5MmU4NmRlNmE4MTc1YWNfMS0xLTEtMS0w_c06575bc-d453-47e7-bbe8-f15e2cdc6e58"
      unitRef="usd">153132000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjNhOTA1NGZlOWVkMTRiM2ViOTJlODZkZTZhODE3NWFjL3RhYmxlcmFuZ2U6M2E5MDU0ZmU5ZWQxNGIzZWI5MmU4NmRlNmE4MTc1YWNfMS0zLTEtMS0w_8603449d-8b1b-4e32-b62f-207dab9965a8"
      unitRef="usd">159317000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjNhOTA1NGZlOWVkMTRiM2ViOTJlODZkZTZhODE3NWFjL3RhYmxlcmFuZ2U6M2E5MDU0ZmU5ZWQxNGIzZWI5MmU4NmRlNmE4MTc1YWNfMi0xLTEtMS0w_35c3b7f0-ac9f-4117-80c3-f066d2a9879d"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjNhOTA1NGZlOWVkMTRiM2ViOTJlODZkZTZhODE3NWFjL3RhYmxlcmFuZ2U6M2E5MDU0ZmU5ZWQxNGIzZWI5MmU4NmRlNmE4MTc1YWNfMi0zLTEtMS0w_9f7e815f-d80a-4857-8ff7-824bdcc8b41e"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjNhOTA1NGZlOWVkMTRiM2ViOTJlODZkZTZhODE3NWFjL3RhYmxlcmFuZ2U6M2E5MDU0ZmU5ZWQxNGIzZWI5MmU4NmRlNmE4MTc1YWNfMy0xLTEtMS0w_c59ae5b4-6c1d-402b-a2cd-717e42727a54"
      unitRef="usd">153735000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8zNC9mcmFnOjQ1ZTFiZGU4MzdjNjQxMjJiNjgwM2I1NzIwNWM3NmRiL3RhYmxlOjNhOTA1NGZlOWVkMTRiM2ViOTJlODZkZTZhODE3NWFjL3RhYmxlcmFuZ2U6M2E5MDU0ZmU5ZWQxNGIzZWI5MmU4NmRlNmE4MTc1YWNfMy0zLTEtMS0w_ca0883e5-9467-4940-adcc-05a1412443c4"
      unitRef="usd">159920000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNjI_5df29954-ea2d-48c3-945a-9d903fadacba">Organization and Description of Business&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Veracyte, Inc., or Veracyte, or the Company, is a global genomic diagnostics company that improves patient care by providing answers to clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The Company&#x2019;s growing menu of genomic tests leverage advances in genomic science and technology to change care for patients, enabling them to avoid risky, costly procedures and quicken time to appropriate treatment. With Veracyte&#x2019;s exclusive global access to a best-in-class diagnostics instrument platform, the Company is positioned to deliver its tests to patients worldwide through laboratories and hospitals that can perform the tests locally.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Veracyte was incorporated in the state of Delaware on August&#160;15, 2006 as Calderome,&#160;Inc. Calderome operated as an incubator until early 2008. On March&#160;4, 2008, the Company changed its name to Veracyte,&#160;Inc.  The Company&#x2019;s operations are based in South San Francisco, California and Austin, Texas, and it operates in one segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company performs its genomic tests for thyroid cancer, lung cancer and idiopathic pulmonary fibrosis, or IPF, in its CLIA-certified laboratory in South San Francisco, California. In December 2019, the Company announced the exclusive global diagnostics license to the NanoString nCounter FLEX Analysis System, and the acquisition of the Prosigna breast cancer prognostic gene signature assay, which is commercially available, and the LymphMark lymphoma subtyping assay, which is in development. Both tests are designed for use on the nCounter system.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company offers genomic tests in four disease areas: thyroid cancer; lung cancer; IPF and breast cancer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Thyroid Cancer - Afirma Genomic Sequencing Classifier and Xpression Atlas.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The Company's Afirma offerings comprise the Afirma GSC and Xpression Atlas, which help guide next steps for patients with potentially cancerous thyroid nodules. The offerings are intended to provide physicians with clinically actionable results from a single fine needle aspiration, or FNA biopsy. The Afirma GSC was developed with RNA whole-transcriptome sequencing and machine learning, and is used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Afirma Xpression Atlas complements the Afirma GSC by providing genomic alteration content from the same FNA samples used in Afirma GSC testing to help physicians decide with greater confidence on the surgical or therapeutic pathway for their patients. The Company commercially launched the Afirma Xpression Atlas in 2018 and in April 2020 introduced an expanded version of the test, which includes significantly more genomic content.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;"&gt;Lung Cancer - Percepta Genomic Sequencing Classifier.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; The Percepta classifier improves lung cancer diagnosis when diagnostic bronchoscopy results are inconclusive. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;This second-generation test was developed using the Company's RNA whole-transcriptome sequencing and machine learning platform and was commercially introduced in June 2019. The Percepta classifier identifies patients with lung nodules who are at low risk of cancer and may avoid further, invasive procedures as well as patients at high risk of cancer so they may obtain faster diagnosis and treatment. The test is built upon foundational "field of injury" science - through which genomic changes associated with lung cancer in current and former smokers can be identified with a simple brushing of a person's airway - without the need to sample the often hard-to-reach nodule directly. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;IPF - Envisia Genomic Classifier.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The Envisia classifier improves diagnosis of IPF by helping physicians better differentiate IPF from other interstitial lung diseases, or ILDs, without the need for surgery. The test identifies the genomic pattern of usual interstitial pneumonia, or UIP, a hallmark of IPF, with high accuracy on patient samples that are obtained through transbronchial biopsy, a nonsurgical procedure that is commonly used in lung evaluation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;"&gt;Breast Cancer - Prosigna Breast Cancer Prognostic Gene Signature Assay.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; The Prosigna test, acquired in December 2019 through the Company's strategic transaction with NanoString, uses advanced genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease. The test uses a set of 50 genes known as the PAM50 gene signature and can provide a breast cancer patient and physician with prognostic score that indicates the probability of cancer recurrence over ten years. Physicians use Prosigna to help guide therapeutic decisions so that patients receive a therapeutic intervention, such as &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;chemotherapy, only if clinically warranted. Patient test results outside of the United States include intrinsic breast cancer subtypes to complement the risk-of-recurrence score.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s approach also provides multiple opportunities for partnerships with biopharmaceutical companies. In developing its products, the Company has built or gained access to unique biorepositories, proprietary technology and bioinformatics that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company's testing services are performed in its clinical reference laboratories located in South San Francisco, California and Austin, Texas. The Prosigna test kits and associated products are sold to laboratories and hospitals in global markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet as of March&#160;31, 2020, the condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2020 and 2019, the condensed consolidated statements of stockholders' equity for the three months ended March&#160;31, 2020 and 2019, and the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2020 and 2019 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results, stockholders' equity  and cash flows for the periods presented. The condensed consolidated balance sheet at December&#160;31, 2019 has been derived from audited financial statements. The results for the three months ended March&#160;31, 2020 are not necessarily indicative of the results expected for the full year or any other period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying interim period condensed consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Certain prior period balances have been reclassified to conform to current period presentation of the Company&#x2019;s condensed consolidated financial statements and accompanying notes. Such reclassifications have no effect on previously reported results of operations, retained earnings or consolidated balance sheet totals; however, for the period ended March 31, 2019, the Company reclassified $212,000 of changes in operating assets and liabilities to noncash lease expense in the statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Items subject to such estimates include: revenue recognition; write-down of supplies; the useful lives of property and equipment; the recoverability of long-lived assets; the incremental borrowing rate for leases; the estimation of the fair value of intangible assets and contingent consideration; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Issuance of Common Stock in a Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On May 7, 2019, the Company issued and sold 6,325,000 shares of common stock in a registered public offering, including 825,000 shares issued and sold upon the underwriters&#x2019; exercise in full of their option to purchase additional shares, at a price to the public of&#160;$23.25&#160;per share. The Company's net proceeds from the offering were approximately&#160;$137.8 million, after deducting underwriting discounts and commissions and offering expenses of $9.2 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash&#160;and&#160;Cash&#160;Equivalents&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers demand deposits in a bank, money market funds and highly liquid investments with an original maturity of 90 days or less to be cash equivalents.  Cash equivalents include overnight reverse repurchase agreements which are tri-party repurchase agreements and have maturities of&#160;three&#160;months or less at the time of investment and are collateralized by U.S. treasury and agency securities of at&#160;least 102%&#160;of the principal amount. In a tri-party repurchase agreement, a third-party custodian bank functions as an independent intermediary to facilitate transfer of cash and holding the collateral on behalf of the underlying investor for the term of the agreement thereby minimizing risk and exposure to both parties. These overnight reverse repurchase agreements are included within cash equivalents due to their high liquidity and relatively low risk.  There were no overnight reverse repurchase agreements at March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The worldwide spread of coronavirus, or COVID-19, has created significant uncertainty in the global economy. There have been no comparable recent events that provide guidance as to the effect the spread of COVID-19 as a global pandemic may have, and, as a result, the ultimate impact of COVID-19 and the extent to which COVID-19 impacts the Company&#x2019;s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict.  If the financial markets or the overall economy are impacted for an extended period, the Company&#x2019;s liquidity, revenues, supplies, goodwill and intangibles may be adversely affected&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The majority of the Company&#x2019;s cash and cash equivalents are deposited with one major financial institution in the United States. Deposits in this institution may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Several of the components of the Company&#x2019;s sample collection kit and test reagents, and its nCounter FLEX Analysis System and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company&#x2019;s requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company is also subject to credit risk from its accounts receivable related to its sales. Credit risk for accounts receivable from testing revenue is incorporated in testing revenue accrual rates as the Company assesses historical collection rates and current developments to determine accrual rates and amounts the Company will ultimately collect.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"&gt;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company generally does not perform evaluations of customers&#x2019; financial condition for testing revenue and generally does not require collateral.  The Company assesses credit risk and the amount of accounts receivable the Company will ultimately collect for product, biopharmaceutical and collaboration revenue based on collection history, current developments and credit worthiness of the customer.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"&gt;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The estimate of credit losses is not material at March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Through March&#160;31, 2020, most of the Company&#x2019;s revenue has been derived from the sale of Afirma. To date, Afirma has been delivered primarily to physicians in the United States. The Company&#x2019;s third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.442%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.541%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Johnson and Johnson Services, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;UnitedHealthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;*Less than 10%&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s third-party payers and other customers in excess of 10% of accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows at the following dates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.684%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.481%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.888%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.540%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.891%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Johnson and Johnson Services, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;*Less than 10%&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company had deposits of $603,000 included in long-term assets as of March&#160;31, 2020 and December&#160;31, 2019, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the Company&#x2019;s South San Francisco facility.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Testing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes testing revenue in accordance with the provisions of ASC 606, Revenue from Contracts with Customers, or ASC 606.  Most of the Company&#x2019;s revenue is generated from the provision of testing services. These services are completed upon the delivery of test results to the prescribing physician, at which time the Company bills for the services. The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized.  In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three months ended March 31, 2019, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2018 or prior years and recognized additional revenue of $0.6&#160;million, which resulted in a decrease in the Company's loss from operations of $0.6 million and a decrease in loss per share of $0.02 for the three months ended March 31, 2019.  The change in testing revenue estimates for the three months ended March 31, 2020 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company began recognizing product revenue in December 2019, when the Company executed an agreement with NanoString for the exclusive global license to the nCounter platform and acquisition of products for diagnostic use.  More details on this agreement are in Note 4 - Business Combination.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Product revenue from instruments, consumables and in vitro diagnostic kits is recognized generally upon shipment or when the instrument is ready for use by the end customer, which is when title of the product has been transferred to the customer. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a product to the customer, meaning the customer has the ability to use and obtain the benefit of the product. The Company recognizes product revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control.  Shipping and handling costs incurred for product shipments are charged to the Company's customers and included in product revenue. Revenues are presented net of the taxes that are collected from customers and remitted to governmental authorities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Biopharmaceutical and Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, the Company enters into arrangements for research and development and/or laboratory services. Such arrangements may require the Company to deliver various rights, services and/or samples, including intellectual property rights/licenses, R&amp;amp;D services, and/or laboratory services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments, and/or profit sharing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods is transferred or services are performed. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, the Company utilizes the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company enters into collaborative arrangements with partners that fall under the scope of ASC Topic 808, Collaborative Arrangements, or ASC 808. While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects of these arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part of its ongoing major or central operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The terms of the Company&#x2019;s collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales of licensed products. Each of these payments may result in collaboration revenues or an offset against research and development expense.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net sales of data or other services to our customers are classified under biopharmaceutical revenue, and all other non-customer revenue, such as milestones, are classified under collaboration revenue in our consolidated statements of operations and comprehensive loss.  There was no collaboration revenue in the three months ended March 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Up-front Fees: If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Milestone Payments: At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or the collaborative partner&#x2019;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the collaborative partner&#x2019;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Services Agreement with Loxo Oncology&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 9, 2018, the Company entered into an agreement with Loxo Oncology, Inc., or Loxo, whereby the Company agreed to provide certain tissue samples and other services in exchange for agreed-upon fees.  The agreement has a term of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTg5ODQ_f0a3db4d-746a-4336-8a43-6dcb1f0c687a"&gt;one&lt;/span&gt; year with an automatic renewal of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTkwMjE_98287a7d-3a7f-425c-896d-85cf973f3c3e"&gt;one&lt;/span&gt; year and Loxo may terminate the agreement at any time with at least 90 days' notice.  As of March&#160;31, 2020, the agreement has not been terminated.  The Company evaluated the accounting for this agreement under ASC 606 and concluded the performance obligations thereunder are the delivery of tissue samples and performance of services, both of which are distinct.  For the three months ended March 31, 2019, the Company recognized revenue of $90,000 for the delivery of tissue samples.  There were no deliveries of tissue samples for the three months ended March 31, 2020.  The Company recognized revenue of $250,000 for the performance of services for each of the three months ended March 31, 2020 and 2019, respectively.  The cost of revenue associated with revenue recognized under the agreement with Loxo is not significant.  There was no deferred revenue related to this agreement at either March&#160;31, 2020 or December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Diagnostic Development Agreement with Johnson &amp;amp; Johnson&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 28, 2018, the Company entered into a diagnostics development agreement with Johnson and Johnson Services, Inc., or JJSI, (i) to cooperate on a program to enable the Company to use JJSI samples and clinical data to develop a next generation bronchial genomic classifier diagnostic for lung cancer diagnosis, or Percepta v.2, and a nasal genomic classifier diagnostic for lung cancer and (ii) for JJSI to use Veracyte data generated in two Veracyte development programs for therapeutic purposes and for purposes of developing a companion diagnostic product used in conjunction with a JJSI therapeutic.  The Company granted a license to JJSI with the right to use data and under the Company's intellectual property rights for JJSI's therapeutic purposes, including the development and commercialization of a companion diagnostic for its products, from the Percepta v.2 and Nasal programs.  The license granted to JJSI is not distinct from other performance obligations as JJSI receives benefit only when other performance obligations are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the agreement, the Company will provide data from its RNA whole-transcriptome sequencing platform to JJSI in exchange for $7.0 million in payments from JJSI.  The Company is also entitled to additional payments from JJSI of up to $13.0 million, conditioned upon the achievement of certain milestones relating to the development and reimbursement of the Percepta v.2 and Nasal tests.  For a period of ten years commencing with the first commercial sale of the Percepta v.2 and Nasal tests, respectively, the Company will make payments to JJSI of one percent of net cash collections for Percepta v.2 and in the low-single digits of net cash collections for the Nasal test, depending on the number and timing of JJSI samples and associated clinical data the Company receives from JJSI.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The JJSI agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the JJSI agreement and has analogized to ASC 606 for the delivery of RNA whole-transcriptome sequencing data to JJSI under the collaborative arrangement, which the Company believes is a distinct service for which JJSI meets the definition of a customer. Using the concepts of ASC 606, the Company has identified the delivery of data as its only performance obligation. The Company further determined that the transaction price under the arrangement was the $7.0 million in payments which was allocated to the obligation to deliver data.  The $13.0 million in future potential payments is considered variable consideration because the Company determined that the potential payments are contingent upon &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;regulatory and commercialization milestones that are uncertain to occur and, as such, were not included in the transaction price, and will be recognized accordingly as each potential payment becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognized revenue of $7.0&#160;million and $4.0&#160;million during 2019 for the provision of data and fulfillment of obligations relating to Percepta v.2 and Nasal program development milestones, respectively.  There was no revenue for the three months ended March 31, 2020.  For the three months ended March 31, 2019, the Company recognized revenue of $3.8&#160;million for the provision of data relating to Percepta v.2, classified under biopharmaceutical revenue in the consolidated statement of operations and comprehensive loss. There was no accounts receivable from JJSI at March 31, 2020 and accounts receivable from JJSI was $2.0&#160;million at December&#160;31, 2019.  There was no deferred revenue related to this agreement at March 31, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Collaboration Agreement with AstraZeneca Group&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 23, 2019, the Company entered into an agreement with Acerta Pharma B.V., or Acerta, a member of AstraZeneca Group whereby the Company agreed to provide genomic information that will support Acerta&#x2019;s development of oncology therapeutics.  Acerta will pay the Company for certain development activities and pay milestones to the Company for the achievement of development milestones.  For the three months ended March 31, 2020, the Company recognized $0.1&#160;million of revenue for certain development costs activities and accounts receivable from Acerta was $0.1&#160;million at March 31, 2020.  The agreement will be accounted for in accordance with the policy on collaborative arrangements, as mentioned in this footnote.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Biopharmaceutical Services Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the quarter ended March 31, 2020, the Company entered into an agreement to provide research and development services of $0.5&#160;million for which the Company recognized $0.3&#160;million of biopharmaceutical revenue for the three months ended March 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cost of Testing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of our cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation and amortization, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test. Cost of testing revenue for the three months ended March 31, 2020 included $1.1&#160;million write-down of supplies for the potential expiration of reagents due to an anticipated decline in volumes resulting from the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cost of Product Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cost of product revenue consists primarily of costs of purchasing instruments and consumables from third-party contract manufacturers, installation, warranty, service and packaging and delivery costs. In addition, cost of product includes royalty costs for licensed technologies included in the Company&#x2019;s products and labor expenses. Cost of product revenue for instruments and consumables is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cost of Biopharmaceutical Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cost of biopharmaceutical revenue consists of costs of performing activities under arrangements that require the Company to perform research and development services on behalf of a customer pursuant to a biopharmaceutical service agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. This ASU requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit &lt;/span&gt;&lt;/div&gt;risks. This guidance became effective for the Company beginning January 1, 2020.  Based on the composition of its trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures.&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements (Topic 808). &lt;/span&gt;Under&#160;this ASU,&#160;transactions in collaborative arrangements are to be accounted for under ASC 606 if the counterparty is a customer for a good or service (or bundle of goods and services) that is a distinct unit of account. Also, entities are precluded from presenting consideration from transactions with a counterparty that is not a customer together with revenue recognized from ASC 606.  This ASU is effective for all interim and annual reporting periods beginning on or after December 15, 2019, with early adoption permitted.  The Company adopted this ASU in 2019 with no cumulative-effect adjustments or retrospective impact.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfOTgw_6180214b-7cee-46fc-bdbd-7141b0f8b696"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <vcyt:NumberOfDiseaseAreasWithGenomicTesting
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY4MTY1Mw_7a3e4ef9-35d8-412c-8f82-8d36565cd04f"
      unitRef="diseaseareas">4</vcyt:NumberOfDiseaseAreasWithGenomicTesting>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNjU_b0350904-19dc-4d1a-bf84-e3c392adb982">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet as of March&#160;31, 2020, the condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2020 and 2019, the condensed consolidated statements of stockholders' equity for the three months ended March&#160;31, 2020 and 2019, and the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2020 and 2019 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results, stockholders' equity  and cash flows for the periods presented. The condensed consolidated balance sheet at December&#160;31, 2019 has been derived from audited financial statements. The results for the three months ended March&#160;31, 2020 are not necessarily indicative of the results expected for the full year or any other period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying interim period condensed consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustment
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY4NjI1MA_a3906fd7-adca-4d1e-bb49-710dcd1a0aca"
      unitRef="usd">212000</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:UseOfEstimates
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNDQ_7c48a58c-48c3-42ee-924b-eaa5d1550818">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Items subject to such estimates include: revenue recognition; write-down of supplies; the useful lives of property and equipment; the recoverability of long-lived assets; the incremental borrowing rate for leases; the estimation of the fair value of intangible assets and contingent consideration; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9a4e04bee36940d1a665002bd2ac7bf3_D20190507-20190507"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNjQ2NQ_7ee864b3-2458-4645-81a7-218c35eb149c"
      unitRef="shares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibd46c80ad5fa42759560c922a438635e_D20190507-20190507"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNjUzNA_0d817f12-90ca-4d23-85a4-16513c8edc95"
      unitRef="shares">825000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ibf1f7f58b4404c6486380201c36cbda8_I20190507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNjY3NQ_6cdfa407-fd39-4b18-a403-f70c142d7469"
      unitRef="usdPerShare">23.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9a4e04bee36940d1a665002bd2ac7bf3_D20190507-20190507"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNjc1Mw_774a334b-8bfa-40f2-b4fb-22c7b4f11a68"
      unitRef="usd">137800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i9a4e04bee36940d1a665002bd2ac7bf3_D20190507-20190507"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNjgzNw_df1221da-bdb5-413d-b662-51d66fb7c81b"
      unitRef="usd">9200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNzM_f11c710b-2535-4df4-b98d-93cd90007104">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash&#160;and&#160;Cash&#160;Equivalents&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers demand deposits in a bank, money market funds and highly liquid investments with an original maturity of 90 days or less to be cash equivalents.  Cash equivalents include overnight reverse repurchase agreements which are tri-party repurchase agreements and have maturities of&#160;three&#160;months or less at the time of investment and are collateralized by U.S. treasury and agency securities of at&#160;least 102%&#160;of the principal amount. In a tri-party repurchase agreement, a third-party custodian bank functions as an independent intermediary to facilitate transfer of cash and holding the collateral on behalf of the underlying investor for the term of the agreement thereby minimizing risk and exposure to both parties. These overnight reverse repurchase agreements are included within cash equivalents due to their high liquidity and relatively low risk.  There were no overnight reverse repurchase agreements at March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company had deposits of $603,000 included in long-term assets as of March&#160;31, 2020 and December&#160;31, 2019, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the Company&#x2019;s South San Francisco facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <vcyt:PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzcwMQ_8f007e3f-b90d-4ab6-9f2d-0708163b185a"
      unitRef="number">1.02</vcyt:PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities>
    <vcyt:ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNDY_a2c6965f-2dc2-4986-baea-20baa1d58237">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The worldwide spread of coronavirus, or COVID-19, has created significant uncertainty in the global economy. There have been no comparable recent events that provide guidance as to the effect the spread of COVID-19 as a global pandemic may have, and, as a result, the ultimate impact of COVID-19 and the extent to which COVID-19 impacts the Company&#x2019;s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict.  If the financial markets or the overall economy are impacted for an extended period, the Company&#x2019;s liquidity, revenues, supplies, goodwill and intangibles may be adversely affected&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The majority of the Company&#x2019;s cash and cash equivalents are deposited with one major financial institution in the United States. Deposits in this institution may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Several of the components of the Company&#x2019;s sample collection kit and test reagents, and its nCounter FLEX Analysis System and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company&#x2019;s requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company is also subject to credit risk from its accounts receivable related to its sales. Credit risk for accounts receivable from testing revenue is incorporated in testing revenue accrual rates as the Company assesses historical collection rates and current developments to determine accrual rates and amounts the Company will ultimately collect.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"&gt;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company generally does not perform evaluations of customers&#x2019; financial condition for testing revenue and generally does not require collateral.  The Company assesses credit risk and the amount of accounts receivable the Company will ultimately collect for product, biopharmaceutical and collaboration revenue based on collection history, current developments and credit worthiness of the customer.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"&gt;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The estimate of credit losses is not material at March 31, 2020.&lt;/span&gt;&lt;/div&gt;</vcyt:ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock>
    <vcyt:NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfODI5Mw_b5caa796-c0b9-45cb-9521-b53b370a1ef8"
      unitRef="financial_institution">1</vcyt:NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNTU_181aa203-67e2-4ff6-b461-3e599f2d1f3e">The Company&#x2019;s third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.442%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.541%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Johnson and Johnson Services, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;UnitedHealthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;*Less than 10%&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s third-party payers and other customers in excess of 10% of accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows at the following dates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.684%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.481%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.888%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.540%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.891%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Johnson and Johnson Services, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;*Less than 10%&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i54a3ab19387b41df817e1692261c8fdb_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfMi0xLTEtMS0w_df8bc103-ec48-4ce8-9416-b2a3aad6b798"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i68cca2f7ddd243ba921a37d340208f12_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfMi0zLTEtMS0w_5155f115-e47a-46d4-896a-7d9ac4d7b6e7"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia991e1722be24c0bb0d615c7c31e199e_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfMy0zLTEtMS0w_501c135c-eb4e-49ff-97c0-5c798f322de4"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i009ef9afb3274f819477849480fd2393_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfNC0xLTEtMS0w_9792603d-af5f-4bba-99d2-a48b06b65ec4"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0ba27eaeae954e789d56c5c4c620cf40_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfNC0zLTEtMS0w_6834756e-c870-4902-b57b-45146a2a7af9"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9b93f7856b454811a810d421cd09d494_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfNS0xLTEtMS0w_41b6bead-5c14-44c9-a7f4-e20906b9bccc"
      unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id743ee5e5b8148bf9e58641c5f04b9d3_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmQ2ZGUyZTJlZWU1NDQ5NjlhZmZiNmNjOWJlNWQxOTFhL3RhYmxlcmFuZ2U6ZDZkZTJlMmVlZTU0NDk2OWFmZmI2Y2M5YmU1ZDE5MWFfNS0zLTEtMS0w_9854e977-df34-4379-87e3-ce325dc24124"
      unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id232493caa454088900109db08487758_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmY3YjVlOWVmMTEyMzQyMDU4OGM1ZjcyYjNmMDE4M2JkL3RhYmxlcmFuZ2U6ZjdiNWU5ZWYxMTIzNDIwNTg4YzVmNzJiM2YwMTgzYmRfMS0zLTEtMS0w_d2f56d07-303c-4b00-9a0c-ad673620ad11"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i01c7a4983f7b4866abb02d142286638c_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmY3YjVlOWVmMTEyMzQyMDU4OGM1ZjcyYjNmMDE4M2JkL3RhYmxlcmFuZ2U6ZjdiNWU5ZWYxMTIzNDIwNTg4YzVmNzJiM2YwMTgzYmRfMi0xLTEtMS0w_a763b2fb-0cbd-4238-8ba2-6b9c6e3c4391"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i57e55cfffebb431ebba08541e4815fbc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RhYmxlOmY3YjVlOWVmMTEyMzQyMDU4OGM1ZjcyYjNmMDE4M2JkL3RhYmxlcmFuZ2U6ZjdiNWU5ZWYxMTIzNDIwNTg4YzVmNzJiM2YwMTgzYmRfMi0zLTEtMS0w_ff15be84-0e0c-4b39-b168-55765ee7d8e2"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ic6c280c6cf154f7ea8dd819b86f85a73_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfOTgwNw_6624bacb-b0e6-4164-a34b-d6325a76159e"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="id6c4077b693b4c71a9881ad0c593d17e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfOTgwNw_7db1cb1b-f9c5-4528-b657-244736700390"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNDM_3697d470-4054-4c2e-9a70-abc997f679d0">Revenue Recognition&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Testing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes testing revenue in accordance with the provisions of ASC 606, Revenue from Contracts with Customers, or ASC 606.  Most of the Company&#x2019;s revenue is generated from the provision of testing services. These services are completed upon the delivery of test results to the prescribing physician, at which time the Company bills for the services. The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized.  In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three months ended March 31, 2019, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2018 or prior years and recognized additional revenue of $0.6&#160;million, which resulted in a decrease in the Company's loss from operations of $0.6 million and a decrease in loss per share of $0.02 for the three months ended March 31, 2019.  The change in testing revenue estimates for the three months ended March 31, 2020 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company began recognizing product revenue in December 2019, when the Company executed an agreement with NanoString for the exclusive global license to the nCounter platform and acquisition of products for diagnostic use.  More details on this agreement are in Note 4 - Business Combination.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Product revenue from instruments, consumables and in vitro diagnostic kits is recognized generally upon shipment or when the instrument is ready for use by the end customer, which is when title of the product has been transferred to the customer. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a product to the customer, meaning the customer has the ability to use and obtain the benefit of the product. The Company recognizes product revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control.  Shipping and handling costs incurred for product shipments are charged to the Company's customers and included in product revenue. Revenues are presented net of the taxes that are collected from customers and remitted to governmental authorities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Biopharmaceutical and Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, the Company enters into arrangements for research and development and/or laboratory services. Such arrangements may require the Company to deliver various rights, services and/or samples, including intellectual property rights/licenses, R&amp;amp;D services, and/or laboratory services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments, and/or profit sharing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods is transferred or services are performed. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, the Company utilizes the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company enters into collaborative arrangements with partners that fall under the scope of ASC Topic 808, Collaborative Arrangements, or ASC 808. While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects of these arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part of its ongoing major or central operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The terms of the Company&#x2019;s collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales of licensed products. Each of these payments may result in collaboration revenues or an offset against research and development expense.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net sales of data or other services to our customers are classified under biopharmaceutical revenue, and all other non-customer revenue, such as milestones, are classified under collaboration revenue in our consolidated statements of operations and comprehensive loss.  There was no collaboration revenue in the three months ended March 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Up-front Fees: If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Milestone Payments: At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or the collaborative partner&#x2019;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the collaborative partner&#x2019;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Services Agreement with Loxo Oncology&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 9, 2018, the Company entered into an agreement with Loxo Oncology, Inc., or Loxo, whereby the Company agreed to provide certain tissue samples and other services in exchange for agreed-upon fees.  The agreement has a term of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTg5ODQ_f0a3db4d-746a-4336-8a43-6dcb1f0c687a"&gt;one&lt;/span&gt; year with an automatic renewal of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTkwMjE_98287a7d-3a7f-425c-896d-85cf973f3c3e"&gt;one&lt;/span&gt; year and Loxo may terminate the agreement at any time with at least 90 days' notice.  As of March&#160;31, 2020, the agreement has not been terminated.  The Company evaluated the accounting for this agreement under ASC 606 and concluded the performance obligations thereunder are the delivery of tissue samples and performance of services, both of which are distinct.  For the three months ended March 31, 2019, the Company recognized revenue of $90,000 for the delivery of tissue samples.  There were no deliveries of tissue samples for the three months ended March 31, 2020.  The Company recognized revenue of $250,000 for the performance of services for each of the three months ended March 31, 2020 and 2019, respectively.  The cost of revenue associated with revenue recognized under the agreement with Loxo is not significant.  There was no deferred revenue related to this agreement at either March&#160;31, 2020 or December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Diagnostic Development Agreement with Johnson &amp;amp; Johnson&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 28, 2018, the Company entered into a diagnostics development agreement with Johnson and Johnson Services, Inc., or JJSI, (i) to cooperate on a program to enable the Company to use JJSI samples and clinical data to develop a next generation bronchial genomic classifier diagnostic for lung cancer diagnosis, or Percepta v.2, and a nasal genomic classifier diagnostic for lung cancer and (ii) for JJSI to use Veracyte data generated in two Veracyte development programs for therapeutic purposes and for purposes of developing a companion diagnostic product used in conjunction with a JJSI therapeutic.  The Company granted a license to JJSI with the right to use data and under the Company's intellectual property rights for JJSI's therapeutic purposes, including the development and commercialization of a companion diagnostic for its products, from the Percepta v.2 and Nasal programs.  The license granted to JJSI is not distinct from other performance obligations as JJSI receives benefit only when other performance obligations are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the agreement, the Company will provide data from its RNA whole-transcriptome sequencing platform to JJSI in exchange for $7.0 million in payments from JJSI.  The Company is also entitled to additional payments from JJSI of up to $13.0 million, conditioned upon the achievement of certain milestones relating to the development and reimbursement of the Percepta v.2 and Nasal tests.  For a period of ten years commencing with the first commercial sale of the Percepta v.2 and Nasal tests, respectively, the Company will make payments to JJSI of one percent of net cash collections for Percepta v.2 and in the low-single digits of net cash collections for the Nasal test, depending on the number and timing of JJSI samples and associated clinical data the Company receives from JJSI.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The JJSI agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the JJSI agreement and has analogized to ASC 606 for the delivery of RNA whole-transcriptome sequencing data to JJSI under the collaborative arrangement, which the Company believes is a distinct service for which JJSI meets the definition of a customer. Using the concepts of ASC 606, the Company has identified the delivery of data as its only performance obligation. The Company further determined that the transaction price under the arrangement was the $7.0 million in payments which was allocated to the obligation to deliver data.  The $13.0 million in future potential payments is considered variable consideration because the Company determined that the potential payments are contingent upon &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;regulatory and commercialization milestones that are uncertain to occur and, as such, were not included in the transaction price, and will be recognized accordingly as each potential payment becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognized revenue of $7.0&#160;million and $4.0&#160;million during 2019 for the provision of data and fulfillment of obligations relating to Percepta v.2 and Nasal program development milestones, respectively.  There was no revenue for the three months ended March 31, 2020.  For the three months ended March 31, 2019, the Company recognized revenue of $3.8&#160;million for the provision of data relating to Percepta v.2, classified under biopharmaceutical revenue in the consolidated statement of operations and comprehensive loss. There was no accounts receivable from JJSI at March 31, 2020 and accounts receivable from JJSI was $2.0&#160;million at December&#160;31, 2019.  There was no deferred revenue related to this agreement at March 31, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Collaboration Agreement with AstraZeneca Group&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 23, 2019, the Company entered into an agreement with Acerta Pharma B.V., or Acerta, a member of AstraZeneca Group whereby the Company agreed to provide genomic information that will support Acerta&#x2019;s development of oncology therapeutics.  Acerta will pay the Company for certain development activities and pay milestones to the Company for the achievement of development milestones.  For the three months ended March 31, 2020, the Company recognized $0.1&#160;million of revenue for certain development costs activities and accounts receivable from Acerta was $0.1&#160;million at March 31, 2020.  The agreement will be accounted for in accordance with the policy on collaborative arrangements, as mentioned in this footnote.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Biopharmaceutical Services Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the quarter ended March 31, 2020, the Company entered into an agreement to provide research and development services of $0.5&#160;million for which the Company recognized $0.3&#160;million of biopharmaceutical revenue for the three months ended March 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cost of Testing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of our cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation and amortization, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test. Cost of testing revenue for the three months ended March 31, 2020 included $1.1&#160;million write-down of supplies for the potential expiration of reagents due to an anticipated decline in volumes resulting from the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cost of Product Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cost of product revenue consists primarily of costs of purchasing instruments and consumables from third-party contract manufacturers, installation, warranty, service and packaging and delivery costs. In addition, cost of product includes royalty costs for licensed technologies included in the Company&#x2019;s products and labor expenses. Cost of product revenue for instruments and consumables is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cost of Biopharmaceutical Revenue &lt;/span&gt;&lt;/div&gt;Cost of biopharmaceutical revenue consists of costs of performing activities under arrangements that require the Company to perform research and development services on behalf of a customer pursuant to a biopharmaceutical service agreement.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id991525e1945478d84f961bb2f9348ac_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjQ4MQ_89f3e8b8-3375-449d-a0b1-73c6337be040"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="id991525e1945478d84f961bb2f9348ac_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNDkzODY_ab39bc1e-03d6-489b-b33c-717bec69daf7"
      unitRef="usd">600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id991525e1945478d84f961bb2f9348ac_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNDkzOTM_8fdeb1b4-1ad7-4117-8f5b-0022aff8fcf5"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <vcyt:TerminationPeriodContractAgreement
      contextRef="i0fd47326099244f099c155ab685c07c4_D20180409-20180409"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTkwOTI_ff0914a3-d317-41a2-90a7-6d4e72fcfc44">P90D</vcyt:TerminationPeriodContractAgreement>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i1091751f442346ebbe0c524c9e4668a1_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk0NDg_7734e846-1207-4247-b348-04ed335b8a99"
      unitRef="usd">90000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <vcyt:NumberofTissueSampleDeliveries
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk0OTk_c418bf6a-3239-4ac2-bac0-f58862016747"
      unitRef="delivery">0</vcyt:NumberofTissueSampleDeliveries>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="if3af9fe09e1e40829129e870dc5bb8e7_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk2Mzk_1921cfa4-aa4b-4b22-bc80-8d17b21a2227"
      unitRef="usd">250000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="iab389aee6e60456eb379dbae0cc747b5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk2Mzk_337f1fe7-f97b-42d2-9824-3b2d2fc5c972"
      unitRef="usd">250000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i3d1b5f753a4342188cbb3be12ff68b0d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk2Mzk_b3374183-4517-440f-b707-a36ef67a9f85"
      unitRef="usd">250000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i280b0e75a2e941528ad5d310116a69ab_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk4ODA_afb60b6a-276b-40c7-9bfe-7092991c4af7"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i85aec995c7594a55b57230e1738cb84e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTk4ODA_eebc6e17-feed-4596-9508-53cf51fa634d"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <vcyt:ContractAgreementReceivableForServices
      contextRef="i86e73a154d594043a095b33e4c98e484_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNzcwNDY_32feae21-d9be-462a-b34e-2b8da431129b"
      unitRef="usd">7000000.0</vcyt:ContractAgreementReceivableForServices>
    <vcyt:ContractAgreementConditionalAdditionalReceivable
      contextRef="i86e73a154d594043a095b33e4c98e484_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNzcwNjA_49b170fd-a8dc-4061-86c9-550a3da1e0e1"
      unitRef="usd">13000000.0</vcyt:ContractAgreementConditionalAdditionalReceivable>
    <vcyt:ContractAgreementFeePercentageOfCashCollections
      contextRef="i0926623973444c5caf73d3278c08787f_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNzcwNzU_17008b68-6284-43e4-a96e-b24d4d7e8906"
      unitRef="number">0.01</vcyt:ContractAgreementFeePercentageOfCashCollections>
    <vcyt:ContractAgreementReceivableForServices
      contextRef="i86e73a154d594043a095b33e4c98e484_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNzc3OTU_32feae21-d9be-462a-b34e-2b8da431129b"
      unitRef="usd">7000000.0</vcyt:ContractAgreementReceivableForServices>
    <vcyt:ContractAgreementConditionalAdditionalReceivable
      contextRef="i86e73a154d594043a095b33e4c98e484_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTE1NDQ4NzIxNzc4MTE_49b170fd-a8dc-4061-86c9-550a3da1e0e1"
      unitRef="usd">13000000.0</vcyt:ContractAgreementConditionalAdditionalReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b710a4a5abe4993a9278aad2ed6ed6c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjU1MQ_f703ca01-a91e-41d9-8d0a-e75a11877dd4"
      unitRef="usd">7000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i665bf3400edb456f9bf74af9d39ee05e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjU2NQ_cc62fe52-f87f-48ff-9a4d-81d3bbdfecf6"
      unitRef="usd">4000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68d35cb702de4592a9e6b6b1b313c182_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjU5NQ_e6dacf82-c488-4b58-a528-4bc3d99ee48b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01413ef04119474ea6616ffa333f811c_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjUyMw_09183a76-7b3c-4cc8-a7da-24a3ce983112"
      unitRef="usd">3800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNet
      contextRef="i86e73a154d594043a095b33e4c98e484_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjYwNQ_b65aa3b3-dd44-4818-9e60-56cabcaa20bc"
      unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i548a24efc9604bf5b1230a9363724472_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjUzNw_016b96ec-9bf4-4eca-97a8-d8bdba3a84e5"
      unitRef="usd">2000000.0</us-gaap:AccountsReceivableNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b8be7bd0c98463195fa2424ea5db120_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjQ5NQ_8feff1e6-71c0-4645-b8e3-53c6823a4a02"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNet
      contextRef="i8c3fe671598544568e5396dda599a8f9_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjUwOQ_6117a675-0327-43dc-a867-108141d06e8d"
      unitRef="usd">100000</us-gaap:AccountsReceivableNet>
    <vcyt:ContractAgreementAmount
      contextRef="ia18208097ace4d03aa3886966d7c6b01_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjU3OQ_7f1f3b52-f99c-4ab9-8f56-3cdf6a29728a"
      unitRef="usd">500000</vcyt:ContractAgreementAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f0a5d6bb3934b7eb407eca1fae3f16a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY3NjYxMw_deb59e1c-d9ba-4cbe-bdbb-784e7d5091bb"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryWriteDown
      contextRef="i1e857cb02e9a491ea7ee7312b9dd0c9e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfNzE0NjgyNTY4MzM3Nw_42b63cb2-de57-40a8-9a2f-ad180425448d"
      unitRef="usd">1100000</us-gaap:InventoryWriteDown>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMjcxNTc_eba072ff-8d2b-4262-abfc-96fb3b7631d2">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. This ASU requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit &lt;/span&gt;&lt;/div&gt;risks. This guidance became effective for the Company beginning January 1, 2020.  Based on the composition of its trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures.&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements (Topic 808). &lt;/span&gt;Under&#160;this ASU,&#160;transactions in collaborative arrangements are to be accounted for under ASC 606 if the counterparty is a customer for a good or service (or bundle of goods and services) that is a distinct unit of account. Also, entities are precluded from presenting consideration from transactions with a counterparty that is not a customer together with revenue recognized from ASC 606.  This ASU is effective for all interim and annual reporting periods beginning on or after December 15, 2019, with early adoption permitted.  The Company adopted this ASU in 2019 with no cumulative-effect adjustments or retrospective impact.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RleHRyZWdpb246YzYyZWU5NDQwZjFiNDBkMmI0YzkzYmExNTkwZGUwYmRfNjY5_090f6851-d7a4-4877-ad53-1d02dca4ef1c">Net Loss Per Common Share&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. The following outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.408%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.426%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.539%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.427%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares of common stock subject to outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,760,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,670,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;936,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;538,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,716,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,235,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RleHRyZWdpb246YzYyZWU5NDQwZjFiNDBkMmI0YzkzYmExNTkwZGUwYmRfNjY1_24cdc34c-9e1c-49cd-9ba0-9d94e635d0a6">The following outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive:&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.408%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.426%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.539%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.427%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares of common stock subject to outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,760,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,670,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;936,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;538,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,716,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,235,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i275dbe7307a1449492e85c3747f396b1_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfMi0xLTEtMS0w_aea8027a-32dd-4530-b980-fbd4872f9c7c"
      unitRef="shares">4760128</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i70ec834c26f14e2d905193c57ed86a8c_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfMi0zLTEtMS0w_99ac7b05-c8d5-41e3-8644-974a7b31cfe2"
      unitRef="shares">5670819</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i89b2f2d36fb04fcdb8a12000d2357117_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfMy0xLTEtMS0w_e63243b3-9af2-4ddc-86be-48769ede65ba"
      unitRef="shares">19857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i661cf60c28f348a588855e09824e1932_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfMy0zLTEtMS0w_2a61599d-3acb-4d26-803c-3db79f6b81a3"
      unitRef="shares">25672</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5031ee348bd54e3eb46dbeeabe6bced0_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfNC0xLTEtMS0w_76691314-2b38-4233-bfcd-0960a81e79b5"
      unitRef="shares">936524</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia20f4af3d960436784dac385c143e839_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfNC0zLTEtMS0w_867a94bb-cfe7-49a3-8ca9-2103cc3aea23"
      unitRef="shares">538759</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfNS0xLTEtMS0w_efb0fe08-fce4-436c-8c09-f6e8febe144f"
      unitRef="shares">5716509</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80Ni9mcmFnOmM2MmVlOTQ0MGYxYjQwZDJiNGM5M2JhMTU5MGRlMGJkL3RhYmxlOjBiYjdiMDg1YjZmNDRiM2NhYTJiNmMxMGJkYWY4ZDhhL3RhYmxlcmFuZ2U6MGJiN2IwODViNmY0NGIzY2FhMmI2YzEwYmRhZjhkOGFfNS0zLTEtMS0w_89c947d0-180e-4416-8c09-e30697d0e192"
      unitRef="shares">6235250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RleHRyZWdpb246YTJlODAwYTBkNTYwNDM5NmE3ZjYyYjAzYmIyODBlMTdfMTE0_a5133929-09df-4c3d-b9c3-7d2e22fd415e">Accrued Liabilities&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued liabilities consisted of the following (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RleHRyZWdpb246YTJlODAwYTBkNTYwNDM5NmE3ZjYyYjAzYmIyODBlMTdfMTEw_58a492a1-1c94-4713-98e8-036cb183c988">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued liabilities consisted of the following (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RhYmxlOmI1YzFhN2VmOGM4YjQ0ZDJiY2Y5MTBiMGNiMTExYWIyL3RhYmxlcmFuZ2U6YjVjMWE3ZWY4YzhiNDRkMmJjZjkxMGIwY2IxMTFhYjJfMS0xLTEtMS0w_c89335bb-1cd0-45fe-9449-6e2943a300c5"
      unitRef="usd">7497000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RhYmxlOmI1YzFhN2VmOGM4YjQ0ZDJiY2Y5MTBiMGNiMTExYWIyL3RhYmxlcmFuZ2U6YjVjMWE3ZWY4YzhiNDRkMmJjZjkxMGIwY2IxMTFhYjJfMS0zLTEtMS0w_7baf43c5-1448-457f-b4ee-94e32fe77936"
      unitRef="usd">10100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RhYmxlOmI1YzFhN2VmOGM4YjQ0ZDJiY2Y5MTBiMGNiMTExYWIyL3RhYmxlcmFuZ2U6YjVjMWE3ZWY4YzhiNDRkMmJjZjkxMGIwY2IxMTFhYjJfMi0xLTEtMS0w_92679e30-53b8-47e5-8299-a03d538e6104"
      unitRef="usd">2582000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RhYmxlOmI1YzFhN2VmOGM4YjQ0ZDJiY2Y5MTBiMGNiMTExYWIyL3RhYmxlcmFuZ2U6YjVjMWE3ZWY4YzhiNDRkMmJjZjkxMGIwY2IxMTFhYjJfMi0zLTEtMS0w_2430c1c2-49de-4466-9d87-74fcb231fcef"
      unitRef="usd">3634000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RhYmxlOmI1YzFhN2VmOGM4YjQ0ZDJiY2Y5MTBiMGNiMTExYWIyL3RhYmxlcmFuZ2U6YjVjMWE3ZWY4YzhiNDRkMmJjZjkxMGIwY2IxMTFhYjJfMy0xLTEtMS0w_0da566f2-cf6b-4729-9f53-a854ce7e2505"
      unitRef="usd">10079000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80OS9mcmFnOmEyZTgwMGEwZDU2MDQzOTZhN2Y2MmIwM2JiMjgwZTE3L3RhYmxlOmI1YzFhN2VmOGM4YjQ0ZDJiY2Y5MTBiMGNiMTExYWIyL3RhYmxlcmFuZ2U6YjVjMWE3ZWY4YzhiNDRkMmJjZjkxMGIwY2IxMTFhYjJfMy0zLTEtMS0w_4d98852f-e893-40db-b56a-f0dbfd7fd7b1"
      unitRef="usd">13734000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NDQw_a624d955-e5c1-46ff-b4b8-3032ebd5fb7c">Business Combination&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;On December 3, 2019, the Company executed an agreement with NanoString for the exclusive global diagnostics license to the nCounter FLEX Analysis System, and the acquisition of the Prosigna breast cancer prognostic gene signature assay, and the LymphMark lymphoma subtyping assay. The strategic transaction positions the Company to expand its genomic diagnostics business globally, with the ability to deliver its advanced genomic tests to physicians and their patients via hospital and clinical laboratories throughout the European Union and other parts of the world. The Company has accounted for this agreement under Accounting Standards Codification 805, Business Combinations. Pursuant to the terms of the agreement, Veracyte paid NanoString $40.0&#160;million in cash and $10.0&#160;million in Veracyte common stock, and may pay up to an additional $10.0&#160;million in cash, contingent upon the commercial launch of Veracyte diagnostic tests for use on the platform. This contingency was valued at $6.1&#160;million as of the acquisition date and as of December 31, 2019, recorded as a liability, and will be remeasured to fair value at each reporting date until the contingent consideration is settled.  As of March 31, 2020, this contingency was remeasured to $5.6&#160;million with the corresponding change included in general and administrative expense in the Company's condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets acquired are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.578%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.422%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prosigna product technology&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prosigna customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;nCounter FLEX Dx license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;LymphMark product technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Identifiable acquisition-related intangibles included in the above table are finite-lived and are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.535%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:26.465%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Useful life (In Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prosigna product technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prosigna customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;nCounter FLEX Dx license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;LymphMark product technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. This acquisition includes $1.7&#160;million of goodwill which the Company believes consists principally of the organized workforce that will help the Company execute its strategic plans in relation to the assets acquired. In accordance with ASC 350, goodwill will not be amortized but will be tested for impairment at least annually. As of March 31, 2020, goodwill is not deductible for tax purposes, however, if contingent consideration is paid at a future date, the portions of contingent consideration paid and allocated to the intangible assets for tax purposes will be tax deductible. The accounting for this acquisition is preliminary and will be finalized upon completion of the analysis of certain contracts acquired and executed as part of this acquisition along with the impact on goodwill, should there be any.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i581ad647641b4236a34ecb7f297c1e30_D20191203-20191203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NDU3_d14cb807-7b58-46ae-af8a-e8f1eea238c0"
      unitRef="usd">40000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="idcc713d7148f45709edd0e4def2fa275_D20191203-20191203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NDg2_cf5a150c-a1aa-4839-9ea8-5d18bb15d1a0"
      unitRef="usd">10000000.0</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i4d4f80e336944a3588df9f7c63718be8_I20191203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NDQy_98af0980-cbeb-47d8-8113-5d3cd36651da"
      unitRef="usd">10000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1709eba571e842b192e2031b1c4d9b08_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NDcy_879056f1-1d72-46e3-98df-b5119c18cf9b"
      unitRef="usd">6100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4d4f80e336944a3588df9f7c63718be8_I20191203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NDcy_d66ba2a6-d12f-41b6-9946-8e01ed839801"
      unitRef="usd">6100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icd2f25cb091b48ca8213a9a4df7ffbe1_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTkzNTQ0_a11eef62-6c98-4e5f-be44-797a396805bf"
      unitRef="usd">5600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTkyMjY2_5b95b301-2503-4e46-a6eb-2b56cf35a03e">The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.578%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.422%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prosigna product technology&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prosigna customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;nCounter FLEX Dx license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;LymphMark product technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i4d9f79d4992742aeaaa9c1d70d147220_I20191203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY18wLTEtMS0xLTIyMjg_4255b29f-eb94-4b8c-902c-3deb69d22058"
      unitRef="usd">4120000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i3b4444e9fe9f4984a86852673528284b_I20191203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY18xLTEtMS0xLTIyMzI_230afd59-f474-4f97-b752-7e2e0340aff1"
      unitRef="usd">2430000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i366c70e66aab457da18751b8d033eb24_I20191203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY18yLTEtMS0xLTIyMzI_b6d37d7e-043a-41db-b0cc-3c8b0beae1db"
      unitRef="usd">46880000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i414932941beb4ee4b26024d1b7d17b04_I20191203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY18zLTEtMS0xLTIyMzI_afc561eb-0b34-4960-aad9-3777ffb38f27"
      unitRef="usd">990000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i4d4f80e336944a3588df9f7c63718be8_I20191203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY180LTEtMS0xLTIyMzI_7f7c297e-33d7-4b82-bc24-5c8fccd280b6"
      unitRef="usd">54420000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i4d4f80e336944a3588df9f7c63718be8_I20191203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY181LTEtMS0xLTIyMzI_f637fe0e-6166-4dac-8824-5c5c67ac411d"
      unitRef="usd">1668000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i4d4f80e336944a3588df9f7c63718be8_I20191203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6MmQzMzBmMGRmZjZjNGY4YTkwOTQ4MTIyMzY4M2U4Y2MvdGFibGVyYW5nZToyZDMzMGYwZGZmNmM0ZjhhOTA5NDgxMjIzNjgzZThjY182LTEtMS0xLTIyMzI_235c1ab4-7dba-4ec1-b58a-26c8ff16014a"
      unitRef="usd">56088000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTkyMjY3_9350ee90-fc54-418d-8b83-90962b635834">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Identifiable acquisition-related intangibles included in the above table are finite-lived and are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.535%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:26.465%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Useful life (In Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prosigna product technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prosigna customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;nCounter FLEX Dx license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;LymphMark product technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i95a54fa194e14f688292b523de39ca15_D20191203-20191203"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6YzRjZTk3NmQ4NGEwNDcxZTllZWU3NWUxZjFjMTIxYzMvdGFibGVyYW5nZTpjNGNlOTc2ZDg0YTA0NzFlOWVlZTc1ZTFmMWMxMjFjM18xLTEtMS0xLTIyMzU_74b270ba-e398-4484-86dd-5837ad66a144">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4a158a8048db4ff2b300dcd76423ba63_D20191203-20191203"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6YzRjZTk3NmQ4NGEwNDcxZTllZWU3NWUxZjFjMTIxYzMvdGFibGVyYW5nZTpjNGNlOTc2ZDg0YTA0NzFlOWVlZTc1ZTFmMWMxMjFjM18yLTEtMS0xLTIyMzU_8db119b9-f18c-4e6a-a304-8c27001dea19">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id7052d1e1ab243a6bd6b0fe4e6245e27_D20191203-20191203"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6YzRjZTk3NmQ4NGEwNDcxZTllZWU3NWUxZjFjMTIxYzMvdGFibGVyYW5nZTpjNGNlOTc2ZDg0YTA0NzFlOWVlZTc1ZTFmMWMxMjFjM18zLTEtMS0xLTIyMzU_639b4c2f-183e-4af4-abf4-033ff7e79497">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i15687bf922754ae2adfc9ec81a395382_D20191203-20191203"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGFibGU6YzRjZTk3NmQ4NGEwNDcxZTllZWU3NWUxZjFjMTIxYzMvdGFibGVyYW5nZTpjNGNlOTc2ZDg0YTA0NzFlOWVlZTc1ZTFmMWMxMjFjM180LTEtMS0xLTIyMzU_fc68b8fd-ae44-40b9-8052-6a19cf29c1e5">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:Goodwill
      contextRef="i4d4f80e336944a3588df9f7c63718be8_I20191203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl8xMzEyL2ZyYWc6MzkwNmY2ZGYzMWFjNGQyNmE2YTAzMzcxYWYyZDJhNzEvdGV4dHJlZ2lvbjozOTA2ZjZkZjMxYWM0ZDI2YTZhMDMzNzFhZjJkMmE3MV83MTQ2ODI1NTg3NTAx_564ac6d4-23c2-46ed-b817-e972e916853e"
      unitRef="usd">1700000</us-gaap:Goodwill>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfNzE0NjgyNTU4NTI1Mw_84916405-d377-40f4-88a6-ead0dfe004be">Fair Value Measurements&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company records its financial assets and liabilities at fair value. The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level&#160;I: Inputs which include quoted prices in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level&#160;II: Inputs other than Level&#160;I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level&#160;III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the Company&#x2019;s financial assets includes money market funds, overnight reverse repurchase agreements and a deposit for the lease of the Company's South San Francisco facility.  Money market funds, included in cash and cash equivalents in the accompanying condensed consolidated balance sheets, were $150.7 million and $57.6 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively, and are Level&#160;I assets as described above.  Overnight reverse repurchase agreements, included in cash and cash equivalents in the accompanying condensed consolidated balance sheets, were zero and $100.0 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively, and are Level II assets as described above.  There were no unrealized gains or losses from overnight reverse repurchase agreements at March&#160;31, 2020 and December&#160;31, 2019. The deposit for the lease, included in restricted cash in the accompanying condensed consolidated balance sheets, was $603,000 as of March&#160;31, 2020 and December&#160;31, 2019, and is a Level I asset as described above. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The contingent consideration in Note 4, Business Combination, associated with the agreement with NanoString on December 3, 2019, is a Level III financial liability. The estimation of the fair value of the contingent consideration is based on the present value of the expected payments calculated by assessing the likelihood of when the related milestones would be achieved, discounted using the Company's estimated borrowing rate. These estimates form the basis for making judgments about the carrying value of the contingent consideration that are not readily apparent from other sources. Changes to the forecasts for the achievement of the milestones and the estimates of the borrowing rate can significantly affect the estimated fair value of the contingent consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5d59ef541093494588d84ced75c2fef2_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfMjIwMA_572c43ed-e056-44c1-8194-beaaa7077994"
      unitRef="usd">150700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i972755a8c17f424e96cf5cd3044f60ec_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfMjIwNw_a91ac1df-aed9-4e68-94c9-07dbd81236e7"
      unitRef="usd">57600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i884ba2e362494397a39b4b3ac9d4454e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfMjQxNQ_8c14cac8-57a5-4f50-b53a-c9b75ddbfbc0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie698dd87420e44ce95964e6db3c81371_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfMjQyMg_a9a204df-fc2c-498d-8c14-e4153af1435c"
      unitRef="usd">100000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ia9b90e1ed4f74cacaf0797329a68769b_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfNzE0NjgyNTU4NTI4Mw_20bcb016-6e2e-4989-b860-684a549da393"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i0a0c568ab03f4e8d8092811c74c0250c_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfNzE0NjgyNTU4NTI4Mw_5b5ca42d-dd30-479d-9919-a74fdebcc057"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i4ba4c8f0affe47d8b51e983b2a35f24d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfMjYwNg_acc5e03c-48ba-4421-b939-1519807f0889"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i674973e8b33f469b92b9f3edb0c4eba2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81Mi9mcmFnOjBiM2QxMzAyZWMyMjRjMGE4ZmY4YjcyZDEyMjhkYmFhL3RleHRyZWdpb246MGIzZDEzMDJlYzIyNGMwYThmZjhiNzJkMTIyOGRiYWFfMjYwNg_e51b0ce7-cb0e-464b-b270-f9ef0fd250bf"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMzMwOA_c57bd3af-867b-4794-97f1-afb67133f835">Commitments and Contingencies&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company leases its headquarters and laboratory facilities in South San Francisco, California under a non-cancelable lease agreement for approximately 59,000 square feet. The lease began in June&#160;2015 and ends in March&#160;2026 and contains extension of lease term and expansion options.  The Company had deposits of $603,000 included in long-term assets as of March&#160;31, 2020 and December&#160;31, 2019, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the South San Francisco facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company also leases laboratory and office space in Austin, Texas under a lease that expires in January 2029 and includes options for expansion and early termination in 2025.  The Company provided a cash security deposit for this lease of $139,000, included in other assets in the Company&#x2019;s condensed consolidated balance sheets as of March&#160;31, 2020 and December&#160;31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum lease payments under non-cancelable operating leases as of March&#160;31, 2020 are as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.953%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.014%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.986%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Year&#160;Ending&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: short-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes operating lease expense on a straight-line basis over the non-cancelable lease period.  Operating lease expense was $474,000 and $476,000 for the three months ended March&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its condensed consolidated financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company believes there is no legal proceeding pending that could have, either individually or in the aggregate, a material adverse effect on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <vcyt:LesseeLeasingArrangementsOperatingLeasesSpaceLeased
      contextRef="i3f2a64c5183543af9a4e1523c2354584_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMjEz_788a080e-c325-45f8-863a-c28bb9ad5df3"
      unitRef="sqft">59000</vcyt:LesseeLeasingArrangementsOperatingLeasesSpaceLeased>
    <us-gaap:SecurityDeposit
      contextRef="id6c4077b693b4c71a9881ad0c593d17e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMzcw_27f7bc7a-cf68-4a9d-87c9-e8939ab83cdf"
      unitRef="usd">603000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="ic6c280c6cf154f7ea8dd819b86f85a73_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMzcw_d0b2dec1-c286-4ec6-8bef-542a334b9a40"
      unitRef="usd">603000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="i40fdccc0cedd4d23b306a72908b22980_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfODQ3_5db13825-0a2f-497c-9531-95c7f2c4f3a0"
      unitRef="usd">139000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="i6e241de3601549a39ba5ab3def105dc5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfODQ3_e98079d4-96fb-4d99-bc1a-594e0ad3aa7e"
      unitRef="usd">139000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMzMwNA_643101ed-1399-4275-9372-c2f1f8e76686">Future minimum lease payments under non-cancelable operating leases as of March&#160;31, 2020 are as follows (in thousands of dollars):&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.953%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.014%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.986%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Year&#160;Ending&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: short-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfMS0xLTEtMS0w_b3c6f4d1-6b35-4c3c-943f-dfda423ac459"
      unitRef="usd">1760000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfMi0xLTEtMS0w_20e7c835-93c5-47a6-9944-994881524c24"
      unitRef="usd">2401000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfMy0xLTEtMS0w_8d6d3f5c-8d40-4939-b690-2030ff4f6261"
      unitRef="usd">2472000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfNC0xLTEtMS0w_82dc738f-7789-41b8-b2c4-cb70a803a255"
      unitRef="usd">2543000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfNS0xLTEtMS0w_1f488d77-e7ed-4211-aab9-156513a9e216"
      unitRef="usd">2614000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfNi0xLTEtMS0w_f2cd99a5-bc99-478e-8865-434b851b8c87"
      unitRef="usd">4227000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfNy0xLTEtMS0w_479eccf2-2070-49de-901d-74de4e3e8515"
      unitRef="usd">16017000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfOC0xLTEtMS00OTg_78b50ba5-713e-48f2-8771-e1585569f696"
      unitRef="usd">3435000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfOS0xLTEtMS00OTg_f10d3fd6-fe41-4f2a-b938-480e38aa59df"
      unitRef="usd">12582000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfMTAtMS0xLTEtNDk4_f8c6a99c-a4d9-4e84-91be-8f79bc554bbf"
      unitRef="usd">1450000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RhYmxlOmEyYTg4OWEzOTJhOTQ2MTA4OWZkOGQ4NjQwMTg4M2ZjL3RhYmxlcmFuZ2U6YTJhODg5YTM5MmE5NDYxMDg5ZmQ4ZDg2NDAxODgzZmNfMTEtMS0xLTEtNDk4_7c859d8c-afb0-4659-bfd6-9952376fd812"
      unitRef="usd">11132000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMTgzOA_faba2868-1437-4e19-88f4-9a5f2dbf7ee9"
      unitRef="usd">474000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="if18d64a9919f43c5aceb6119caac7620_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl81OC9mcmFnOjU0MGY3ODRlMGY3OTQ1YTRiMzgzZDczNzFmMjBmZmIwL3RleHRyZWdpb246NTQwZjc4NGUwZjc5NDVhNGIzODNkNzM3MWYyMGZmYjBfMTg0NQ_1a429e41-678c-4ee5-803a-98c85d602be1"
      unitRef="usd">476000</us-gaap:OperatingLeaseExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfNDA1OA_dc11c4a3-2353-4ad0-8271-9db71a998335">Debt&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Loan and Security Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 3, 2017, the Company entered into a loan and security agreement, or Loan and Security Agreement, with Silicon Valley Bank.  The Loan and Security Agreement allows the Company to borrow up to $35.0 million, with a $25.0 million advance term loan, or Term Loan Advance, and a revolving line of credit of up to $10.0 million, or Revolving Line of Credit.  The Term Loan Advance was advanced upon the closing of the Loan and Security Agreement and was used to pay the outstanding balance of the Company&#x2019;s existing long-term debt, which was canceled at that date.  The Company had not drawn on the Revolving Line of Credit as of March&#160;31, 2020.  Borrowings under the Loan and Security Agreement mature on October 1, 2022.  Amounts may be borrowed and repaid under the Revolving Line of Credit up until the earliest of full repayment or maturity of the Loan and Security Agreement, termination of the Loan and Security Agreement, or October 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Term Loan Advance bears interest at a variable rate equal to (i) the thirty-day U.S. London Interbank Offer Rate, or LIBOR, plus (ii) 4.20%, with a minimum rate of 5.43% per annum. Principal amounts outstanding under the Revolving Line of Credit bear interest at a variable rate equal to (i) LIBOR plus (ii) 3.50%, with a minimum rate of 4.70% per annum.  The average Term Loan Advance interest rate for the three months ended March&#160;31, 2020 was 5.8%. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company may prepay the outstanding principal amount under the Term Loan Advance plus accrued and unpaid interest and, if the Term Loan Advance is repaid in full, a prepayment premium. The prepayment premium will be (i) $750,000 if prepayment is made prior to November 3, 2018, (ii) $500,000 if the prepayment is made after November 3, 2018 but on or before November 3, 2019, or (iii) $250,000 if the prepayment is made after November 3, 2019.  In January 2019 and May 2019, the Company prepaid $12.5 million and $12.4 million, respectively, of the principal amount of the Term Loan Advance.  These prepayments did not trigger any prepayment premium because they were partial, not full, repayments of the principal amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, a final payment on the Term Loan Advance in the amount of $1.2 million is due upon the earlier of the maturity date of the Term Loan Advance or its payment in full.  The Loan and Security Agreement contains customary &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;representations, warranties, and events of default such as a material adverse change in the Company's business, operations or financial condition, as well as affirmative and negative covenants. The negative covenants include, among other provisions, covenants that limit or restrict the Company's ability to incur liens, make investments, incur indebtedness, merge with or acquire other entities, dispose of assets, make dividends or other distributions to holders of its equity interests, engage in any new line of business, or enter into certain transactions with affiliates, in each case subject to certain exceptions. The Company&#x2019;s obligations under the Loan and Security Agreement are secured by substantially all of its assets (excluding intellectual property), subject to certain customary exceptions.  The Loan and Security Agreement also requires the Company to achieve certain revenue levels tested quarterly on a trailing twelve-month basis.  However, failure to maintain the revenue levels will not be considered a default if the sum of the Company&#x2019;s unrestricted cash and cash equivalents maintained with Silicon Valley Bank and amount available under the Revolving Line of Credit is at least $40.0 million.  As of March&#160;31, 2020, the Company was in compliance with the loan covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The net debt obligation for borrowings made under the Loan and Security Agreement was as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.848%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.135%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Debt principal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;End-of-term debt obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net debt obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future principal and end-of-term debt obligation payments under the Loan and Security Agreement are $1.3 million and due in 2022. &#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The end-of-term debt obligation accretes over the term of the Loan and Security Agreement until maturity and is included in interest expense in the Company's condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib4a031c3845c42609372921e497cac2e_I20171103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMjUx_f27ed2a6-0331-4e2d-8a2d-b2137f35eb2c"
      unitRef="usd">35000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i1f90c73b3c3144378fa37effee913e4a_I20171103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMjYy_441b25bb-7492-464d-bfa1-3aa936294b2a"
      unitRef="usd">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i4e69109f224f45f78b4f86b7853a4f9c_I20171103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMzUw_65afcf60-1cbc-4af2-8f4c-5d7f888c9e5f"
      unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i65e0aac4a63e44328e46b91201a0cd91_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTEwNQ_87cc19ca-50d5-4487-8523-2f9731e2d040"
      unitRef="number">0.0420</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id07f35bf3b6d4efdb97d4f802d200950_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTEzMg_c92c4fec-f2dc-4b15-ab71-dd845e513b4e"
      unitRef="number">0.0543</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="idc5e731438a1449ba3564ed90fd6f856_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTI3Mw_6c66dc06-5891-43f1-8662-6ebc611875ec"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85b76fac63ed4337ba3f066627f9ee21_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTMwMA_6330af7a-c54f-4f0a-afba-d707875bb7a7"
      unitRef="number">0.0470</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie9151d6a99994c3d8ad8137c5404513a_I20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTM5Mg_24999f96-3a51-422b-b9c6-c2a4d2464ca9"
      unitRef="number">0.058</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <vcyt:DebtInstrumentPrepaymentPremium
      contextRef="ife6d0673632e406b88baa85353a6ce0a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTYyMQ_b16bf6d8-860e-41ad-a2cf-f420e928bf25"
      unitRef="usd">750000</vcyt:DebtInstrumentPrepaymentPremium>
    <vcyt:DebtInstrumentPrepaymentPremium
      contextRef="icb52a798d3dd45b0824f09f89f25bc71_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTY3OA_f1e5edca-ddf3-4359-9b9b-dc6532b6e18a"
      unitRef="usd">500000</vcyt:DebtInstrumentPrepaymentPremium>
    <vcyt:DebtInstrumentPrepaymentPremium
      contextRef="i45329572800d48e7b228e61199a1894c_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTc3NA_52d1a3b5-70ed-43d3-82d6-114fa58b9040"
      unitRef="usd">250000</vcyt:DebtInstrumentPrepaymentPremium>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i62c415d1690e4049ba06ee9e1047930c_D20190101-20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTg3OA_85339157-69c7-493e-b423-70dac29d4d11"
      unitRef="usd">12500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i2f773b17ae664fd1bf7ca8e49fdcbe3a_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMTg4NQ_2e75bae4-bd11-486e-ace2-4d3bbda0e75a"
      unitRef="usd">12400000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="i1f90c73b3c3144378fa37effee913e4a_I20171103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMjE1Ng_fb1d9210-bc67-43c0-86b9-bd1344371080"
      unitRef="usd">1200000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <vcyt:LiquidityRequirementMinimum
      contextRef="ia2da177f87084aacb8ec54951c03d633_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMzUxMQ_5815fad6-e181-4e18-ae4e-85c65b74a9f0"
      unitRef="usd">40000000.0</vcyt:LiquidityRequirementMinimum>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfNDA1OQ_9e98eae7-3ab4-42be-973d-23a0fa884c1a">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The net debt obligation for borrowings made under the Loan and Security Agreement was as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.848%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.135%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Debt principal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;End-of-term debt obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net debt obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5dc6c074bbd1456a915067e4fec93c91_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RhYmxlOjcwNDgxNjQ5M2RjZTRiNTdhYTM4NjBlNjNlYjBmZjcwL3RhYmxlcmFuZ2U6NzA0ODE2NDkzZGNlNGI1N2FhMzg2MGU2M2ViMGZmNzBfMS0xLTEtMS0w_a3ed8e2e-815d-421d-b8bf-8c4edf82842f"
      unitRef="usd">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i179ded5835fe44c58d0e2db0f9f7bf28_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RhYmxlOjcwNDgxNjQ5M2RjZTRiNTdhYTM4NjBlNjNlYjBmZjcwL3RhYmxlcmFuZ2U6NzA0ODE2NDkzZGNlNGI1N2FhMzg2MGU2M2ViMGZmNzBfMS0zLTEtMS0w_54b2c02f-9e6a-439e-a0ad-ce6984686566"
      unitRef="usd">100000</us-gaap:DebtInstrumentFaceAmount>
    <vcyt:DebtInstrumentEndOfTermInterestObligationAmount
      contextRef="i5dc6c074bbd1456a915067e4fec93c91_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RhYmxlOjcwNDgxNjQ5M2RjZTRiNTdhYTM4NjBlNjNlYjBmZjcwL3RhYmxlcmFuZ2U6NzA0ODE2NDkzZGNlNGI1N2FhMzg2MGU2M2ViMGZmNzBfMi0xLTEtMS0w_56e0642a-cd75-4ceb-9a9f-6458a9a8d9c2"
      unitRef="usd">648000</vcyt:DebtInstrumentEndOfTermInterestObligationAmount>
    <vcyt:DebtInstrumentEndOfTermInterestObligationAmount
      contextRef="i179ded5835fe44c58d0e2db0f9f7bf28_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RhYmxlOjcwNDgxNjQ5M2RjZTRiNTdhYTM4NjBlNjNlYjBmZjcwL3RhYmxlcmFuZ2U6NzA0ODE2NDkzZGNlNGI1N2FhMzg2MGU2M2ViMGZmNzBfMi0zLTEtMS0w_987247b7-bb3e-46fa-9803-240839667e97"
      unitRef="usd">594000</vcyt:DebtInstrumentEndOfTermInterestObligationAmount>
    <us-gaap:LongTermDebt
      contextRef="i5dc6c074bbd1456a915067e4fec93c91_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RhYmxlOjcwNDgxNjQ5M2RjZTRiNTdhYTM4NjBlNjNlYjBmZjcwL3RhYmxlcmFuZ2U6NzA0ODE2NDkzZGNlNGI1N2FhMzg2MGU2M2ViMGZmNzBfNC0xLTEtMS0w_925a8d13-446e-4f50-aee5-307718320d5c"
      unitRef="usd">748000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i179ded5835fe44c58d0e2db0f9f7bf28_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RhYmxlOjcwNDgxNjQ5M2RjZTRiNTdhYTM4NjBlNjNlYjBmZjcwL3RhYmxlcmFuZ2U6NzA0ODE2NDkzZGNlNGI1N2FhMzg2MGU2M2ViMGZmNzBfNC0zLTEtMS0w_7ad74d74-533d-4085-87e3-8de0393ed277"
      unitRef="usd">694000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5dc6c074bbd1456a915067e4fec93c91_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82NC9mcmFnOjJiZTZhNTY5Y2YwZDRlM2JiNzNhZDFjNjc1ZDQ3Njg4L3RleHRyZWdpb246MmJlNmE1NjljZjBkNGUzYmI3M2FkMWM2NzVkNDc2ODhfMzgxNQ_7d7fe96c-abc8-4c7d-beec-f59f01392539"
      unitRef="usd">1300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RleHRyZWdpb246ZjhiMzA3ZDAzOTljNDhkMDk5OTI1MjJlM2FjYjY0MDFfMTI2_1061e380-bfa8-4a0e-a908-a8b68b903c1a">Stockholders&#x2019; Equity&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company had reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options and restricted stock units issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,988,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,562,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options and restricted stock units available for grant under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,200,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,954,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock available for the Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;112,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;173,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,300,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,690,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <vcyt:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RleHRyZWdpb246ZjhiMzA3ZDAzOTljNDhkMDk5OTI1MjJlM2FjYjY0MDFfMTIy_dcd2fbc5-3eb2-40f1-b001-c19e2ee8dd09">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company had reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options and restricted stock units issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,988,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,562,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options and restricted stock units available for grant under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,200,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,954,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock available for the Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;112,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;173,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,300,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,690,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vcyt:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfMS0xLTEtMS0w_e93abd66-27f2-4920-947b-74a2788c4725"
      unitRef="shares">5988461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfMS0zLTEtMS0w_b43351fe-30a9-43ed-8e62-10084393a929"
      unitRef="shares">5562484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iec64d800410545c29d93cac8e2c172ed_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfMi0xLTEtMS0w_a56ccbaf-fa39-47d6-b191-87803d4a79f8"
      unitRef="shares">3200200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i26afcedec6c048e392712b52100ee027_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfMi0zLTEtMS0w_41244253-52d0-454f-95ef-f5fd73dd1526"
      unitRef="shares">1954804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i3a47e06c25734fcba6d9adaae38a2200_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfMy0xLTEtMS0w_10ce7037-97fc-4b34-a926-7c8974a53247"
      unitRef="shares">112226</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i27b942a33cc641c39da58598bca5025d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfMy0zLTEtMS0w_32b20ece-8c27-4578-898e-dc4c64bf2633"
      unitRef="shares">173168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i5298bb99d2be4ebebc93cbfb1fcc5135_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfNC0xLTEtMS0w_1001b177-1a3a-4b7f-a6e9-58378dbdcb38"
      unitRef="shares">9300887</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib258dfe7f0534153b328114e89c2109d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl82Ny9mcmFnOmY4YjMwN2QwMzk5YzQ4ZDA5OTkyNTIyZTNhY2I2NDAxL3RhYmxlOjdlZGFjMWJjOTczMzRlZTlhMmIxMDJkMWFhY2I0NDFlL3RhYmxlcmFuZ2U6N2VkYWMxYmM5NzMzNGVlOWEyYjEwMmQxYWFjYjQ0MWVfNC0zLTEtMS0w_60f9c151-aaac-479c-90fe-21d1598d4b34"
      unitRef="shares">7690456</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:LongTermContractsOrProgramsDisclosureTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl83MC9mcmFnOmE2MmVhNDgyOGI2ZTQ0YzA4MjBiNzhmZWQ1OTg4NzczL3RleHRyZWdpb246YTYyZWE0ODI4YjZlNDRjMDgyMGI3OGZlZDU5ODg3NzNfMTY4MQ_8f6414d4-3f1c-4a63-84e0-f5e7bd188b06">Thyroid Cytopathology Partners &lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has an agreement with a specialized pathology practice, Thyroid Cytopathology Partners, ("TCP"), to provide testing services to the Company, or TCP Agreement.&#160; The TCP Agreement is effective through October 31, 2022, and thereafter automatically renews every year unless either party provides notice of intent not to renew at least 12 months prior to the end of the then-current term.  Under the TCP Agreement, the Company pays TCP based on a fixed price per test schedule which is reviewed periodically for changes in market pricing, and the TCP Agreement included a clause allowing TCP to sublease a portion of the Company's facility in Austin, Texas. &#160;The Company does not have an ownership interest in or provide any form of financial or other support to TCP. &#160;The Company previously concluded that TCP represented a variable interest entity as a result of the facility arrangement clause, but that the Company was not the primary beneficiary as it did not have the ability to direct the activities that most significantly impacted TCP's economic performance, and therefore did not consolidate TCP.&#160; On February 14, 2019, the TCP Agreement was amended to remove the facility clause.&#160; Accordingly, the Company believes TCP was no longer a variable interest entity as of that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;TCP's portion of rent and related operating expenses reimbursed to the Company for the shared space at the Austin, Texas facility was $11,000 for the three months ended March&#160;31, 2019, and is included in other income, net in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss.</us-gaap:LongTermContractsOrProgramsDisclosureTextBlock>
    <vcyt:AgreementTermsNonRenewalNoticePeriod
      contextRef="i4c5d2c55989a46b98b6de9830693a3d5_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl83MC9mcmFnOmE2MmVhNDgyOGI2ZTQ0YzA4MjBiNzhmZWQ1OTg4NzczL3RleHRyZWdpb246YTYyZWE0ODI4YjZlNDRjMDgyMGI3OGZlZDU5ODg3NzNfMzkw_4898a8d6-6ae1-4214-9dff-ee1ca43e7492">P12M</vcyt:AgreementTermsNonRenewalNoticePeriod>
    <vcyt:OtherIncomeRentReimbursement
      contextRef="i371cedf5a91b4b2abbfb835bb66de072_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl83MC9mcmFnOmE2MmVhNDgyOGI2ZTQ0YzA4MjBiNzhmZWQ1OTg4NzczL3RleHRyZWdpb246YTYyZWE0ODI4YjZlNDRjMDgyMGI3OGZlZDU5ODg3NzNfMTQ3MQ_88ade00d-adbc-417a-abdc-bfa1a6a7a3d0"
      unitRef="usd">11000</vcyt:OtherIncomeRentReimbursement>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if6a89c16b8fa41e78a43a58046145907_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl83My9mcmFnOmI5NDRkYjFjN2IwMjRkYmI4Yjg2NTU1NzI5ZDYwYWMzL3RleHRyZWdpb246Yjk0NGRiMWM3YjAyNGRiYjhiODY1NTU3MjlkNjBhYzNfMTI1NQ_f0f3e30e-8f1f-4835-8b62-cb82e22cd564">Income Taxes&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company did not record a provision or benefit for income taxes during the three months ended March&#160;31, 2020 and 2019. The Company continues to maintain a full valuation allowance against its net deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The Company does not expect the provisions of the legislation to have a significant impact on the effective tax rate of the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>35
<FILENAME>0001384101-20-000058-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001384101-20-000058-xbrl.zip
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MT@%JA<1 )SV/U>5W!#X?97S5KP!\[J51J]YSF![]*Q?=RQ]/_@M02P,$%
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MEIXCI)1&,G*R<@R^Q!AL]?V/0+H<A4LT"CFV%#&'N(*1C:8P'>3>*X\@%8K
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M2';3:^9?9 PK:8Q2#AM/O?'&*F)-,"A8RQ!AA[LI- 8)02L5YVW6T>W!/U=
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M7?:U7,)2\(3F2]_O.3UH?1\F\F!6F:OW7&BXE=-,@D+2^F@IH@=&I>! (Q@
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M*":&@A@6?1:"H8L.C/(HNC0XQ \.X31S4T[9S)<-N3=E8Y6E# E ?>" VF"
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M2&A)4$Z(HZ[@F;,>9"S>Q(789+)[0^B>B8Q=2:OCN-Y('"8!/4V1S*.LY:?
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MN_I3K#,Q>&+PQ.!/3KHNUI.W;('#X0[L7EB9ZK]1I=T=O%"GY5CUKS<%IBD
MR218R"0P;;>?P1KGSG$$A&:(<ED@L/,4(BJ7A2U\3@N]L8TWF10IYI_DY#.1
MDTD12 R^U@S>Q?+PI @L71%H^P:)IEA:C@I,#:**$R0Q]4@I803P,E.Y2XI
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MZELR:1<Q:;^\&N^?SP>2DDSAHN!(:HH1-=8@D4F!%&:TP)KD64Z6[>M8G#F
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MK]PS8K)>R4*S%,*841L<)JI?S:)V5>\$2%,&_\KP]'0X&H>TAV""UDKM:#P
M6_.X/)W&O\#R.U:C$V6BIA4Z^<2[E"%,N#O+7PF6=$@=.HT>NI 2W$[Z.593
MGQ7<XZBV-.<)N[" _TQ<N-/(16TJ)L]N]NIT8#>.D;&Y1AXC[^6PULI5S!2J
MM=0Q&/#]TGUMRC;!^H>G4X%CZ@2B5JI-8,@![#S\]I$;U]$48/)XVVD<+SS2
M+*T;.!3^PL\?E8WJ&Y81--?H_9RE=%>N[\SMENZ#I@.L-.=>2=7YGVH6;8-?
M^UJ:AI1-]EMM_04VF]$%%!A7G_\+B=<AGWI\SWS9K:OF9^_OLNE5U?*33ED]
MKA!4_^BYO"7].Z38UTENP5/C;BL)7@.J7C*^'KE\JR[4VC$F),8!^[P9]DMS
M7O]]WB5;[S_KC+!,9A1A:0VB%BL$N@M%CA@B<V6U%/GE$JPN5#4MZLJ.3! $
M>[M>KZL3 9]7K=;-*LH"'11 B_@*6H)SP;/E0%.IY7MHVC"R06-L D\S(0"7
M@8I91D]W'<.L,Y-"G'!>/G)!)XT^]3]V=MYL]5ZX48S+S?2,IA@Q](4(WCK3
M'U8Q[#<(']?QR:C/QE^^]@%N6W:X:>L)Y_L""QJ>E..(.)-1-6D4FNCC&M6Y
M2+&'XM&D7Y>+U/AUP\8"_,1[5L?.C8./#,Y+JXQE.@JM5M]N^(W6$\&WVW4J
MP?$8<M?<,7PM>.E@CZ8)ZK%$RKG>"3#*<=6KD\FNN77\E7G>^)W64(U!O!\/
M0Q5/]3^QO^3X_/ZWG:9RW^G6L:.E[P_/[OV<47^8F:^;H"B/9Z:1"N%D&\[W
M25UH%U92UAI2-,>"'AOYKW' QM!Z^PMUN/="55+XB;!3O7GB65BZZGD5<I!:
MTC-&DD/JWHR;I][.S2G=X7Z-L;=Y/1GFX\(N[A)\O1S::GJ_8$+>G6_'LQA
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ME)VY>Z:O._*R(SI2#+]6+75=VW+L]URW%'==OH%WYK#OWT:JS,^%$>#>OIG
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M-V9<+#PG3*A):&1!$TFHE5K&D8@XC1)CE- A>W;HH>]=N-Q%J4?NW_E8E"-
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M-?UM;]-BQOG(EV*5?[E3@]+F_6A<":RV3P@VA+A2%_MOCTY(;(TP<11H+DU
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M2O:\F#U 778N0+Q_PYT%)7!R)[J-D#U*D6218326$8\-T&@D(P76@@S9FMC
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M=^/CT2(?M[ IUH0F2*,T#:@6*F#,\?%$I9E0-(KTUNMH.TU9:P)L(+-^QB;
MOIG<I.C_F)5;KS%<"[;59E/=50&[W7*V O+Q[*9*KJZTG^! MO+V;O(V7@ZY
M)RH2D@:9EB*@1D6!3)@(XA0,)PLB(Z("[*9T.V0_0N#^\&.[>6SP1KS!)63!
M6Z#KW 2]\XA%'.]S8#SF#RR^0?R#H39V]LG,!;+@+RG^%./)@5W!-MJ:COF:
M#G+"21(:P\/ JH0&-&(Z8)*1@(<\C64*_)S0Q1J-9U8.UI0@S;*08.S[\#6<
MM<5<H9]'^QE],V6="M9>>?H,^JY>S!5:P8?2E$50P(BN?'69<(A$.(T IX1E
M9WG1&2%:D < FI69X5C%=N>BEZM>1YR?CT??RT(N5^PO)A,S=G@"_@J'W00'
MT8$,23.$(S-#_%GA=Q[[LD0U\;5=KC87]@_FN8T5O+X8IWCU?,#R.G=_E?N4
M[VQ$&0[;"3F_7QE.RG<2DCQ&&4Z<[M#TMB/?8&C^4*#WQS-T2[)Y;%,W^P$Z
MR+N:<7TNC)WV@7]9T_EE;]@Y,F)<_-KZ?'](D=7CK>;#QPTW;Z&OTVMY(A)J
M1<2IB:A-&8MY+).8:$.X$M%JU+"&L0LS4Z_T='P)QV$9'M_KL._7J[E?W"J
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M.6.0EH&F=\=C5%P<HZL)W=/YIW.AW&5&;XRU^<,ESMF[JY.,,1$R,#,5B9.
M)I:!Y,$H3<RDY$(GVI*MUPE?:6IV"J1!T B-F7A]WI.--*?"V1F_3X?&GU$P
M"Q*?R8UIW/!5PQR%+4]][!!HQCG>@' ,*'+>*O!CNKRS.A7<?W?NZH>]][X^
M)3VA*U>:TS3OXN0".43#+),I)Y*J+!*<L4CH4"6<Z"A;%T"\BQODDU&85W_Y
MUD_QY5+?E;HXB3.;294!N=F4!51P';!,\< P#EJ$9$1I>R<_EDJ!<$/X::.$
MVLP(# M&7++4LD1DY '\6.T&-C90AS+6V"4"ECW%?A%IP*2Q >AU@H!-!(P^
MO(NKJNGLQJ+WP!_[.G!WOZ!@Y3-WQBWZ+_187& V&=S6,WWO!P!C>_BU\J@[
M"]SA$O31\A_#Q4X" E<;C\VWD2J1P&$$S%TT"-CNKA\;G4_\H##=HJ25U=EE
MU^:4W:8V](GH,"]+2P..,JI4M896Y@JYK,62HP*5#Z2T77R[X78';%X@EDH3
M*^4=NFE UN5CK\?]+L#F@G& WGF)A%/F0)9BT-'83#@Z42E<[1$<H=*WAP/!
M ,F"R"P+MS =TH65:K*=#TGEQ8Q^[Q0Z"JU68 DJHS75,9$D3$4&9A^3<<Q9
MV$K5!V/*!V\_DI-$RX@P4.="$=N \DP%/"$1_%!@=RMJB0CO%ATR,8VT(2DH
M<91C5I5(A"3:V"A,M$I:J?JP&V@PB,<U#7AJ94 UYX%4D0@23DTH-!$B0R0D
MLEHK7_I@/H;LG;MU(O7*A.M;Q9#O)8]7!(L>'H/F&4B41W;%>CMYWBBN.JI=
M=GWI[^4FM5;Z*?[8_=V3E!)81Z,#.&T\H'&6!)QD,>B[-K+,9&G*EOR;&24J
ME93'*14TQB"Z2".3IH::*&6A7<(E\,A8(*3SP710RM@Z7.75@@7WS*CVVY6:
MQC5G<=PLU.W\XH[\:%JX>FJX1Z.*.RY^?76]Y_?:Z$D+^G0]Z%.R'O2IQ6]J
M\9N> 0!0B]_TI%_S!ORFE6&_6X3Q5MYWHWA\^H&GLA5<*<K*=(*-Z!Z7[8 I
M>+_N<2S9"2/Z&-WCHG"'L_1ANL?=!^Q\-3$]9+NYU>#GBQ+H\7NY72N"L9F;
M)^QW0WP%__N2'7<+Q/F?L,(_N:_  U##3X'"_\L,1.XL#%!-T%[X\3WLURW=
M9BW4SVA'O[ R3[^S?!)S#"MS'4N0]M)(Q8F25D96J20BR0-X@J_U;/Q9&M4U
MU1_8]SEZ&H]<MX;-:!Y_7U='[VCPO7\P>'=Y='A*#[Z\NSHX_+T']\3=PUWX
M^_CKP8>/=/_LXT47ON_&QV?5/?"LZ7'\.3W"Z]^>)D>'W:0[>)?LOSWZWH6_
MCP<?Z?';TWC_[>YW^/[J>+!O?8\%UVOAXD2"0F>ICH)4DB2@BJB 4V(#;35H
M>$0HFG"P@K>S=-E;^=.:QJ\\7)O'=];U?W\>&M!/65+@,=%:)29^W'6\#2FN
M6<B6\?]SQO]V:I#5'UZ,6FY_%VZ?-[A]')I,,8*.< 7</A-IP#FE^(.Q*(FI
MBBD<LFT:1H_/[1_DP&TJH_HQO/^96SC 6.)'XO;W5#5:_O[H_!V1<%L.?Q<.
M?]G@\$RGFMA$!4S3,*!862Q3'@9Q2$)KJ4WC-'(</HM;?7XC>?I+T^=)J\^_
M9'[_?C1MW3=W8??[;YKL/M8J(\P&6<9X0"/) ADK&BB9A8*%1 "1(+M/*&D5
M^B? _)^_0D];A?Z%,?C\6ZO/WXG!-_WSD:6,Z2P+3&9T0.,H"H20"!>4PEX*
M;N(H10:?8G?"5I_?0);^HO1YA\7H4B!;K?ZE,OU=W/Z6\]^'\S=]]396FG.1
M!+"5H-IGS 2,I4E ,4\U 4U?L6SK-=V.XW5=M5O5?I/DP#]0[5.?,+[IZW@X
MFF"Q[74E$9NA_)?IF?@$6,6.JY+JX.NV$N*'2(A6*-Q%*#3=^S3C1BD;!W&8
MH7M?FX"'D0XRJF%3B0'!D&R]CM+M,/H!4N'!C]VF<K;64GCP)45>\:ILR8I@
MS!X $LOB<JRZ,,6DM2!>E'SX/)R!<+[[KN#274<<K;"X@[ XF 4'PH/#TY.,
MR2248$1D$3$!92 Y6)9%@8D2EB0IMRE/MUZ3;4J2UHAX B+B^1L1?RXB 9?V
M1&M'O!PYL49"M)+@+I+@T[PDL%&HB=5I8 V- FIC@7T'&,B$T! F1,(1KRV*
MMQ.V>9E!K>706@X+ED/1&XTG'F/.BX9&L]C6<G@A$N'-0M>15C#<(EWT<'=2
ME8#MO_U*3RQ3J>!<!8*Z;I>,!CR2)F VXU(E"978LR3:ILD/* %K;8361KA9
M M3PHC>R_A^VCNM5E/*;\E$$OM2C*>))K+84-FNI?V+M]#]=T5:PWE^PKNCH
MU<K6V\C6=_.R-5,,#"NFL E(&- TX8%$(XSS)"99:K&;-,C6:#LB3\GJNLL!
MW#R>MDX,_\O![5R+FO>DH8V> ;9F$_IX;-3H= AW%XN8BJYSV!#1CH<=Q*8;
M"QPCP/'*OES8#]3!IZ[LG0&CY2.-_=37C'O7#ISW@OU\$([^SL_XQ8+R E>_
M.M@]L4**F*4LB.C_S]Z;=[=M9'G#7P7'T_U,_!Y238 KXO?).?*65B:2'%M)
MQODGIP 42-@@P 8(R?2G?^Y252APT6;+IB3,F>Z6):!0RZV[W]_MC\'&<?WN
M9!*#H2.&L1<%\5A*_\E/@_%@>[.,FS8UC]U)-!H([&8;#_KA4(0R&+FN'PH1
MCD=>[XKFTNUY?\EY]TY^^]L5 \]'1^=H#,)W(.6PB]4P77\" CD:]4"A<O&\
M1]O/6V/^+[$8U9G#T<Y*;'\BHYV8R9MMS#>A%*^/@+QG3/FFO:G6VI*UC:GV
M:H6OL9?&$H:DMI#POQT;2=R9BQ4VQTRR\SP]5_T\Y%2DV&L ]$=4[4I'%$G)
MR1KT+NB#288]#L*\*KC-0* :E!XT^A5PSTY9UIT?D41P(I'D;@>2!HPD]J_"
M<>"K@;)*Z*)18RCZ0UZ6"0EM^(&N[")'>%8$^A1A6%3POS ]["6T Q2][FU:
M&F#0 ^<PLUI6TMCU7%?4'A4'YXVAAB-;1G&2&#Z,#_/T4]450M1=5)T9*!&!
ME-C9@6RMR+3;5%DQJM<(3P'(*<!NIJ+,,QAO5<^QN<&!3+&A9XFO%A)GD.4;
MYP<:#L$$\J1"ZH<Z$^= "#(AC'D@\.0\B6 +X4MY8;J53^%4IO#1#JP$/U[0
M9D?<4EURS\_\1L#T6\_@&OC5^WW%=C&1Z_4>'0WN3^_1\9WW'GTI@^7>-1GU
M3HQB\TORU]E?LY.S]S#6^XN_4,'Q?DE./L-S+U]_./D0NG^]_*U_ F-M-!B?
M_Y*>S%^Y)Q_2#W]]>/X1%)S/[^='_6/O]<?C/X^]D\]_?#QY&7HP[_CDY:$+
MBFP4NFXX$/VNUQ_VNP,1];H3;^QV_2C GF?^I+_99%3B_H_"L></X\%(]H)P
M@(68HV$T<8=1;[(.:H\;?HM>HE=_ICFM(/3E4$1P%<;>8#"68M0;N(-QSPV&
M0 G#Z & ">^C;K!3E]NQQ%]SP2V)=)\7YU"WEKS%NA]^^X]3[-%^;C=5'S?U
M*T(5)_4!M!Y0"/3^FM9-IG5G!T7O)?O?X8[N[T"?@*OE_ '26JZ<YR+[J+I$
M7?*N([BIA#TSF \W]G:J!?[C)B9O,!"]OAOV)X,AW/M1#UMM^)XKL8>1"#WJ
MO^B.7;?7MRW=HY/7-\D?A=T^C5]0H[;7JMO:L?B$=2;/=4/R%V(!?[&2A4:/
M3% <?_C]T]^Q-Y:1)T9=%*A@_WI1=R+@OP+/[8_C_E &7OCDI_[P8(OQ"Y<B
MA1\4<8D;48$;^[UPW _Z8=\=#/ICD/K],>J%TG?[<B!:*OAF5/!^]?=@X ;>
M, BZXX'O=0>C 1! +-QN7PB_/_+\0>"))S]YEU$!*O?4.(K#K<!/B"F=X;^(
MNQSRWSO$9H2#'1;3<_*8HBE7]U6$GV[.5 9RY+L]/_:\03P8QN-),(@GHV \
M&?;%(/;#EIR^%3E]_OWB[]%0Q&$\ZG7=, A!]\1D\G@0=H?1.)Y,)JC.8:)(
M[U*F L3SUM#(KXI&>/>5T-J@+7*W*SJ,@(J4@8D& 0ZBS.1+91W\&@>IT/P$
M&ER(%;LMJB4U L5A=(<T-=RZ^2H_)25' DSR001Z,G#)61+.:'2.(Z =OV3#
M&BW<+2V.LQS^5(B+3)O*NS9D=VLH&-40I^XS==4FS 4E4L,W3\-ECNH)#^;!
M8%QJ46K?#VL!RB-1R(5((NLC.Z<+%QQ&25)Z"CM8)K)<<@YWFM(XE+V--#!7
MC<JN<7J=1AO,ZSP/XZ\O\5H:)SPW?.3-Z[9?P  .LS2%60XYLLY%D9!CJP J
M=^1_T-T&5^N'Y*ERG2?%<M6-@*!^/WAW .-E$1S?$8Y![7I/02L 7D#.)%1S
MCYZ?ONTXB[3"1F<PR$XQ =P<3G:]S^50]H0 RW@$:L:@[TWD8!3XL"A7],+(
M=Z^(L)'(V'0['&4EF,1(5,\Q;/AN44@1G69_J*7CY%TC$[K>8Q,*9Z\N3G[[
M>S(.0PQM=8>]:-@=#";C[F3H];M>[(_[+JB>/6PD/3CP-L7"/XV2J<O%B9C@
MCM_L]*,>*K5!W ]&T4#&4>"/(] 4>EX$1^T/=[2IO?+0CQ3!XSE3ZZCHC2RP
M*Y28RD=][)^/IW^'/O:CE6$W]B+0!@)WV!7!V.U&$9B <NCV@X%\\M/P8 OR
MW#\QP@[<&\[RP'E3)%F8+-"/K(20+96O(760.5V?-Q&?N36;B<*A!*(>]"<"
M[!L_$/WA:" COQ='V*9^U+*9NZ W^#UHG^%H%(6]47<X\<&D[<=N=S(:>=V1
M#,*1ZT[&0XDF[<&6+.6OQ68FPV \BD4(,B8:]/MC./ZX-X))C&-?2L]MV<Q7
M/?;CB^/#OT?]?D_$8]$-AX.X.XA[ G/I1#<:]\9PYD$P%@B#<S#><NPVFR$M
M7)S+ C9UBX9C^ =1Q@WC_ZC\WXR2I.\.W0C3[GU_$/:CB8@F;G\,:^P-$-=M
M.R4-KD]'KR@6EYS+EI2(E(8@L;P![';LC[I],00.XGE!-_##43?TQ"""(0>A
M\%%B338IZ9J]KUL#HI&AA];D@LR^#6M[L2;U+4&_>3E)6NNH.QI]548F:2WT
MLZB#(??MKR>EMF&3C$Q1C%XO:G,4?IPGR"-P[IN_!]D!UBM8Q:@^W"@+3(ZB
MWFC<'_4].>B-,-(KQ&38'_;%* 1SY1)Q<:7WZCQ<+=>N_QLS\S<\\7U) OL.
M]_W]ZOBWOP-W%,2C: )Z0D]V!ZZ(NL(+XVX\\'K2]R9![ V?_#0>]K8G@26Q
M30P).D<BI(\$A4.^'N29=%B?O F!A,'0$V-_$O6C:# ,>A,/Y)L?3WR86!".
M+],G6@+Y0@+I8U:H*X<R LLUBN(^J)1#O^L'?M"-PM&P[P4CZ4X$"(3>;@)9
M-CF&)A)"P-R@$">H*#L&Z">0<(!R_0F?/"% 1C>DHP',UA^.O4FO%PTF<AQX
MWD1BOJDOW GH%RT=W1D=A?V3P[^'7N2*?C#LCGL(TMN/^MV)%XVZKCN(Q7 2
M^.0!\2YA-#>A(Q^4V:/,^45D%6;<X6](*!Z+E2(B.Z:[4*+O)O0T LO>'4;N
MR.^!X$(SMS>2TI=N;S#V^[UP/7W974M?'MX@_/)6+[H\C;&N#\4WDMOC#;6<
M39$W@9[0!R-AW!WYX1@;N<AN,/#Z0&*1"#T_&D2NBW@-!YO /77L[H9IZUX\
M'O<#=RSD:#2((S>(QZ&8R($?1V$@P2KA<Q_J<Q^VY_Y5SWUP\MO?G@2C5LA!
M-X #[@XF(]D5H?2Z@Z@?!)'HP9\%G?LFWG<=9+/3T#LZ9+*A<N<[%&8VEDN;
M(Y5.E'#@:EDDTRF9U:MMNG(@0U&5E,.[<BXP W4A"DS)[=#;K'U;P^Z8V_7B
M-5>82 _?V#K"^'R4+.G0!>72IHZ)LF6[[*%L+<MXWS(\UM0-JL9*0@4@BNLI
MGV/V4I[I7^7/Y1L0<H^7=WR YZ9_QX$;^9[;ZP;A"&1&/^R!Z1/XR$KZ>%9N
M;P)ZB'NP66IJ1 9H'E$EZR [1W$+?4]-V#92#M3M%(89XW"YC3K#9O<UDM*0
MU$22E4X(%Q N".@WU\@%-S6Q>4EWX<="I@*YW[.+)%K.X#K!;5$W9^ QQL&3
M[6^*H,S3:BF?J=K6GCW$DUU)CB'E].T[MW!':WMI_?>LJ N+IZ!J%%)\[)+Z
M^:-(+\2J?/*OQN+5R".?=W-CD[YT)^+X-CLQN<Y&T+D!Y\D+HJ ?V?6$C^'<
MQ;V;LS,KD#/_U]5U!>,G/YU16 R#9\C4"4E/7*L6;<](?$<UPA^OWAZ^>'_V
MJN,<G;RX0HFX3^LZR9=<)?7:E,N\,^4R#V>9/U29J$"?D='3;:QJ:]G!]<H(
M]CDC_W*N;;"1:<UEQ[D012$R!+OAI$MYKC7I2,:B2I=.684SS!W;4J,5SJA\
M+FG4:/UW::KU.KJ6'CZ%8KPNS\+Z+:UIEJ#:IRE](HX3U.I V-)D,BP/PW^$
M.4Q+4$$="OW-WV/96UI%F#DZSS&-CPK/%D5^GI2\T/I1RJ9+DWE"N6/H\B^2
M<+FV!%U7![>$*NK@!8G#S,5'JF:$M^BZ=-2?4?4/@-1XV7-9P+Y0F!@^(<+_
M5 DFR]&DL*B0]SM*2E 5B(%B)>-2#T_5<C*+:,_X)7@49AE4O)4PJ5F> L^F
M@T+E2,(78+8ZA@$CR6PJ^&S0N,J ?G0.K74Z!=</</5 * M4E\ H PIC5:Y4
MH6XXES2!TZ?E@AH'%!$BA$%9!1^P2L]Z6WX*Y8+>;902FM3'/(#[HDCB>JF&
M K:.RAEDY 0K_"8&?M ,3%=8>*#W@/?0^0%F *2@P;_3%"98<<$B$.-R];2S
M;=JUBF@OX!IU#V4.)$3GNU'^ -N$U9/F&P5>K@IQ(<"4AJ?AH&!)_ZG I@7Q
MNV* "<272*F:$F[%N>Q2O)B!)F ^_\XOX.6BX\3P%"9@PF?F,#8?W$RN?X.B
M36@K!Y(J)8&NJ#;4W&[E+BS!VMZ1JUIE^HI@M:4H9[07] .N^QQL)$[VY%G
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M7S^?I"<_'[DGWNO9\>>I=_SS[]ZQ]T>"((\GGY_'Q^^LEIBB+Z.)]&0748;
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MQ5QTG#=@+J$YWG%>91A<QU\5.4;0X:=?5_/%[!BD,QLC_Y/E%Z@VOI3X]]I
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M*E+F"VS@^[LJ5J^UA$.3I[$?R[T.@QT>]#>YJWO0,[P5KV5+L_>;9HE>217
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MM$,&[D.=IC7H]W2JVU6:=S*LBO4VC-QS4>>'U;!]3;"_]R*E0EQTU1O XQK
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M&-XBD89($2K"J-)3=CB533X.LPH@+DW5M:)LT+M1Z5?#"<H&<?(TZH#91H@
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M1OM,2L5CV/D2R#7.]X_A@0O<&E@5AOC@H_@Q$XT!7CE0#@S%;5H6\?U9!)Q
M:;H3[=V"'CM7, =D74&Q7!9)4"UUCU/2#_*BR"\2[(O& =U(!LLZEJK<X&*!
MI 'ZG#!N6-7*9ZN#7*6VZY1N;.X*HV[K2K;?F_A +NLIZ:E'J!>"0G\BVZC=
MOJV03RA1)Y3)Y8Z\I1*+L3C//<,+R6_4D25V;M'O*&6)_$P(_3^3G,%CG@I
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M40$_AR_3ID2P%EQY'N/<!H<TD<_P\> F*H-YD<RB LY%S_;'H]ZQ_CSO >X
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MX<GI^6/[]^^P@]VCO&ZZ2+W0\$+CH;;M/#SIWW]VEY<97F9XF;&O,F,0'CX
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MNQ;!Y02$"DWHV2>0+K\!#P9G^!H^7F=1#;M!_B+D"O8<913#H,-@,0HL"^P
M/^#= NY/:Y1."4KDI S^&^P?V%Y@ZX]JGA>P;1D*M5G0/SSX;SJ^65Z@0(2_
MS@1*;)C7U6U3?A[JY?)&P%1!8K TUILVRHMY3A:3\1U%99DC9!G,\":IID0R
MP,(W\%<1\,,:!+$J@73^#BH46&0D$6=@MT5IF0<U6*U$AK!-T8CH!"W6)+MF
MO8[TPY2FB(:?'@V/J5*C:0:R8)+PR=/1E/@V7#EQ/<(C0Q*]R>L4]GH: 6U:
M[= ERE[P9HRS CTTR/(J(%Z$"?'"*V6X#GXFM]WJ@4(Y,*0>QS).0,4=L7C
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MO&@T)2./-.>E_5RM&A*)-:0'ZD!XG/09U-54; Z/G!2TTC1:H$2 +6(J*T?
M+D1>8&"BX,E0@<LSDB\TH;56#^STI(AFK,"MM'L2W!NZQ7D'88\FN;L]*,KX
MUBZMUJWU.Y?G6NM "XD5_HB\I1F*HJPQ;>$8HXK#SU=-7CMD65BQEY4X">12
M#JIQ@"%HQ9HSZE9FT17:#EM&60:#WK?[,CIVO:Z-P:QQQWY@*^&]V 2XHU<L
MS3ZA-/M^^[BK/B&)?F04<SP+)>9WHXQM JP'BF\<G(9'@Q.*@I33"&UH\FPX
M%P?(K@C8>I*4&$V(C0$G1^,:D>?-D=J?JN<Y7SSD);V!.P_N^O_U_YP/^F<O
MP4A'2<HI'^,:C$LV/Q.\H;4A!BH(&,9E0Y#QMT+T T5R_>D(KYXH>[%^'!SU
M!H+?-<>D&'R1=8?5CE^]0M@UE)US>.)/L&9!>5K(B/VCL]ZYXUI%[1GD!HH0
M?,\LDPSLI*2L%ZTXSF8)I<CPO\VWC*\"G7,7O8%QM#Y@@-8+H34QH?4JY3>=
M!EQYDR2C%-33Y>S/#LJ0WT"WG0V!MH](D)R%1E\D7Y_PVR8-G&[?3Z#*PD49
M_#,"\V,1_!)E7R3W8:/YD,(]6\+UB7S-3@R0)/B/'X].>H>6_>2&_W'@_#1@
MYRX,3RJ%R:V0.,A:%S;^33[2/W0_(JKY1_/>6WGO2ES?93W\@X,A,B/)L]!2
M:?V;D771!)BKA[\[/_D)_P.ZUB1!74Y2Y]#T&*GD&O4[V4*;-H()(A&GCC@R
M=Y3FI=RDMQQ6+_BE'="Z[7A!*M;DQPW>CZH<*65P"!*D/;,A1G1L6)I$]G54
M)!Q-$%\@R'38JF?)<PE]):#:'\1PB_W>^]2#<;(85D2Y1$,@(%81@H_P,AW.
MVS>_O/\8!O,4Z.59 H,<]X",#7&@#WU6S_ACL!4GO>.CGS" #RO+ZAG,^$,K
MPP<MB*JL(E:7[7:L.T=:Y/9KI/DZTSWJG6R8[G'O[+ YW7^QLB\N"&MQS=%E
MG=%CJ.US%'*!V9B!$,3:!7"0#R_R.V8FW99&T8PFZ42FG^ K]R5.^X/NR]-_
M*?$)8_X9*QH.@2TEF%F*6]Y^(AL0"856L^IL'B6Q0WT96'7)>,WK"8H1>8%T
MKI!4*)T7AW^=)41EGQL)<_H7' 1@<@9:%J7H[.204_D2G3)GWDO0O(^) M$A
MK<9H>K4NE_.0&>''D\-;QV&%JST *U29>-79D]YZAM/QX#MFUH/;9[WR:YB?
MW; ](PI<I-9OE*W;??Z%S2/\L6_5/?PHAF2,^ :ADB8<-F=W3\4R.!;)L/H;
M:"6#!#,KX6/F*6_(3KR1]2?QM^1%KIQ2,^^0K^$8OH/>"O%]9HM5M ;" J:E
M'[7,LW)C>97L6W(3/4>4PUZ.IJ"CIYP#(M,VCY#Z;PZ9-@?HYY.:5_HG<+%]
M9V5\1ZW/VS0[C*M'"5A (U@/?*] S]\</4A9I5VR-^04XY@<#D,^2XETC2/T
MN&N_>H1, 3-%&F0OLHZB2BV#]A>'CL^7_$PFE(W>Y40^3/0&X@U''H\3"D]?
M*YI#IB91V^=+(G+Y%SHD'B)?H/9%?G"*!Y;\'?LH.1[)FR_^0_(MKPX0@"S
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M](1E$^!E5%A47M+"''!5;@]I6H/=H3THDX-T%+;GX+-EMI7K+BSQ^4;9?GZ
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MU4@22<:Z)"C<U @R&DW);M.?)T<_,(!+SX31H8.M3\I)WS%FN&L%XB^*&X(
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MV^IXZS\QW41;%SM>8XXCQ, _MPS2#5?[72]!&VP<.X'O<(5*>J<;"^_)%-0
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ME P"BG:WG=,X)@[0!E#%=5(5#N:1+M'#(ZSP%M8^C#(:*^RZHM'7$Y"GUQ(
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MV?][6Y7!/L$"_/SV;*Y5];H"Q'E=9U&I /@H5AX1(&7(@H4[C>A"HKJ-1XI
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M\DUG1=:5R\N^I<,<^:_[5P@&'[9P1.LE9*7QO$KTT!QE3F@5V#0+/U2?@=2
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MYB!!UC<&_M6UA-]LI.$8G2JB'51 \%N^>#P[8W&3;963YHHDR+.%OXU?)G:
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M)76@8'V\4ZA.PX0:^D#4T//[BQIZ4#8.->WR:$/>KD%IQW)3&I%0\!&ZS=+
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M)2@6]2P&CU2?J'4JN#T ^RXY#R>HA;!%5V%1@1?9+S7(P!@<-/4P\Q9GU2K
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M+W/''6#K7!D(CV<D*N<-W=?.>\(+_[6GT$(]^6+.G;JKD26 O?;#Z^_FO;5
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MR4S-AKH1KOLQDD<\[$/JS6#=2 O2"EHD(-9I'<M06,&>(,Q.0 2AM@V_7.Q
MV$2K Z%=['.#4#>M+GA088$QT9=RNJUC\U9"UYXZY<PA<_O1'AJI]O*:742G
M['ZL]L-[T3<LY:F5ZW KU^G]I?*=LK'W*QN;==YYJPDV U>+R-IA]H1@"30,
M\.?FZ&LESVS=U<SKNK0T\#@R1<)E/NNVT/@Y?L([6=5$8S<4'>W4Q@[#Y@WK
MVH%T?(*%3>LS69_*&\(4M>5.5YWHB'B/$BLP..0J(K300YP.4?()5QW1JF1%
M@5.U%#@0M7 C%'0NL-.@C6\WN_:!'Z7YB-^%REC3HIP6I2Q*K!J(L/NEU5M"
M39+OUN5(&A+0>\/Z ]>/K-JAR9UK1)13&EX;4!:LHZ$YF<O<K6?NO5MVPD
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M,"83&BC::'$PP D+*WLV2W*Q_2#X@JI^E;[34!][TQ5]F8<+Y\LK4$L#!!0
M   ( )*#IE",0>G$"PT  %=]   1    =F-Y="TR,#(P,#,S,2YX<V3M76US
M(C<2_KZ_8HXOEZL*A@'LM5WK3>&WQ'>VH8#-YN[+EIAI0/$@L9+&-OGUU](,
M!CR@F<$02'!54H9!W>KN1_VBE]%^^NEY&#B/("3E[*S@'I0+#C"/^Y3USPI?
M.M?%X\)/GS]\^/2/8O&W\]:M<\F]< A,.1<"B +?>:)JX'SU03XX/<&'SE<N
M'N@C*18_&Z(+/AH+VA\HIU*NE%__*D[+Y?)AM]JM%5V_ZA=KW?)1\?C8<XO@
M]XY[1Q7B'E7*/_9/JY7N\5&MYA8/:T?E8JU7.2D>'Y9)D1P?'AZ>^+U>%0X-
MTV=Y*KT!#(F#BC%Y^BS/"@.E1J>ETM/3T\%3]8"+?JE2+KNEW^YNVZ9I(6X;
M4/8PU_JY*X))^VI)_]PE$B;-'[VQFFN.9B3X# X\/BQI=<O5JCMIK7E1"W?*
MI"+,>^'..&/A<#&!KT1)C4=0PD9%; 6">K/]^%.Y9CLY+$4_OG21SG_"FR@E
M:#=4<,W%\!)Z) RPCY!]#TE >Q1\'#8!Z($QUV#F9T5$']0]&8(<$0\R&.[S
M!\?1>-+AB OEL 1IC\BND5<*A63N2;'L%K7%HQ%PRSVBS+">M46"J 2!DOI;
M<<KBX%GZA5)V 4)9[!,RRB_$+&$D2/PDOS SP]L].3DI/>OQNE2,Y  T[8OZ
M8]&MY.MVV4C.WC=^*T[HUB'#U%?SR3"A>Z,,BQTTBRBSE/<1H9;E1,OB'KU-
MEM7D6%6(Q9$G(QP3 MWM89X.)7@'??Y8\H&F>J-<1J0_+'5 PAA7AHM^$C\;
MC2CK\>@!/M+#Z'0REEK0F\3F1(99X+#FSRD1GN!!BG>71H*/0"@*<C8[&08#
M ;VS@LY1Q4E$_>:1X  EF31)=##O$/KG$I)X86#4O9WJ,^&@1\A902(D 406
MVF7U?>CE51])**-_"^T#TLVK/9) \)=7?"0@K^)((K&66678:_H._NY0_ZQP
MP;&T*3CZV9?6S?*:QW0:-9YPF_";CL#/6"N[^)]3G%;A1<=0?2J];ON*2RC!
M;[#/YO-KY6+BN(F%\%4LR$PW[T0+R>*'$^-93<I\8$B,'R0/J*]G(><DT)5#
M>P"@9'9[IW*R@.$:,"J(0!M-"2]HQ#R=6:9.S-6)V+ZC-6/C)A&HW@ 418'7
M!]T\6SN.VN]7P='Y8:Z7?^T[KB\&E+S7P AM9)2$8:,AJCM  OH(MUR^S45S
M=&/'O5HNU[+A/NW2X3UGVJF#O3ISW3JZW_>!,$6HK;CW,."!#T)>?0^I&J\-
M_ 6L[8#7<#*Q"N"S'?W3B;IZQW@*Q 61@^N /ZW/KZ<<[8@>ELM'JR"J^3NF
M@SW"L2'ZA-$_C!08N"Y!>H*.]#?>.P\E99 ],F?B9<&NXI9=-ZIEJ?0"+D,!
M^&66K0FN,XPU;A/6[ZC-6;J)P]S#^= ZT7OA:4,1)UF5U5'$ BKN9)]JIRS&
M[Y!NL%XX8XXV,*LX77X+F%$7[U#.&_Z>"%TM/L(E*$*#M8*:X&V#MU:NU=X
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M%E(KQE;N9K.=+/M)F&UG\S?@ML;<+S"83A8_(>4GA+*YA?COZZ%<Z7;[P7V
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M8FMPNG./T?WB\JJ$\\!/KFK7<&9X+!T4 Y4"!VT<<> UB29)P/][%IO$/&^
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M?44,Y&RIDT%9Y[,CPK)()*.XU.62*1C!<[1ZA-'0@@WK !V+'5A%X"UJ4Z_
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M]L#KGN[!XHSGN1325AEWZX3FN[ )03F30%&;7;?\@Q4//T#"XLX:O'5ZM:O
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M#R-,2>B&'DU41HS!(8:FX*718:/W+F)/Z0F^*DT-][2TD=?<&9\ SZFWR$=
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M5TGHG(:,.-R'44@Q1!Z/(45^ C'C##M>[ 7,,>G>-)&>1F0X0_<G51BNJ0L
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M)$*QRX43"*/,S,/'+^UCUP6+C4S$?(:=WD;#>$0F_KCH@S&R MJ4)V#/)+Q
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M'M6*;UPK*).1TUS[3CL>4R^,.^WK_*]]_=4OE.Y7@#[5/X#&BK9=U#0M@R\
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MP@CAQ&4^]1$SVIX]%K$TEJP5@UQJIA8-Y>;Q<6W<>/<$D'H>U&7P3,R(6^7
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MC!E5I1\2N#0.J#VN>IDLW6?:'3^0W4&NX5[#$-Z:&PT649QZEZ%5%51Y%Y\
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M1]D#V>Y<1(?GC9B0Z*[E<5:BQ_T] ]^JC*%/Y>=R]:PY4<XHH4QDVEA%O(
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M/RI-7*OG!)M;NR7N569LX-5K/UF]YL>]YDYH+(-6Y DFW+CU>D)C>E;-)_@
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M #)EO*>" <8+"'B2:]]):O,K<RJ9Z"7%U CIVX,L)342NEE5?E-@9UH-#NS
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M @'K7]8J5X& SW)=F0_ZC^7%K3/W*,'7^"Y9>-/3_88,S>3]2WY_.OC&:!!
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M'@IG!KNH<DCR.1Y@5-ZXJ-OI*W_Y(M^*[NO-)]5D)LTRPA4L) 60L1Q 4E!
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M-]P)$^?W^IKB(5_JLS%&?:.O:7CZ.E^]SK->X<4S_ L5AV:"*%5D2()4I1#
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M+&D03G2&@_OOW@D+NG4L'"'/)O#P#@/^*9JSA>"_H/SA]>1J/)]>OYXD&&"
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MY7UO 3;JX&HVB"IHZS00< YC9*<L<<GA]B8$#8Q%%)7L !A/T; ;0)H_N^Q
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MG=!(>@+BC);$T0Q"TN@X[R(Q;RL!NQ4B-GSBV8UH.\/'/_W\2)#O\0>'MQA
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MC%ID;@R1RN"BD>!)2$D0[A.-/C&0=D.]8@>.T"9J^NG75\,!.EK6#0!F2?^
MJF1QBZ5$F7*XF;T@%D 1I5WF3'-EZB!D^?I^.O)5N^[:2YH-Q.+OASX,1\/Y
M$&9H"Q>)S.>3$0I]5FSB_/I&-. UIR*'I0\F8T [J'(F7+@,CN/FRS;D?QZ/
MDET)[#=&KW[M7D5/#=B@.WP]/!]+'"@S:$.YCAFMJ1;$*PO$:J:2U,QKNZ'9
M0J>(:^IJO@X$MN/L&'TT@*SUA=XG?UUN\]9GI0ZRSXYQXJ/41/J2?V<EBBF
M\R$IZNF&RKGN[E+OD],,HHY2]I:KU",DWP9^IE?XUD<R&J#SC\1BX)F==>CK
MX5=.@"-,*LHXBX:F*EOA5HKZW?OJH:@#^3< I/N'I6M^UETN!DPDR5UTQ/"
MW%!;^A;X0" P:J7D$&25;>YILOH]JJX$J0XUT0"N-JP,$83,BBH43FF1$HPF
M'F@FEDNAHK8NLBJ;VX$FJ=KY="7\'"GQ%L*]R?C;5YA>O($POW-P 0%=QFB
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M0E)67>Z&AUUQ;GA*)^?XSU'7T>G])W^]N"W%^&3Q1C^ZTP?%Y1"B3$2+,H\
MOR66JDQ$B$XHP-"$5LEY>X*FKNJZ5Z]8O^&>G-\,9W$TF5W=O<NRSN842^=@
M+R+ZT[CL@N$H&4,I#4G)4*??R8'T]FOGNL+4MH+PFLI[.<;J\*R,K<^J9+@J
MYF,\!37T$8-/-A"A,/*5.F@2,HTD&ZDLBS'F5&7-5C1?=[SHS5*^!3T%R\M
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MDVGY_/5;'U>K[\OD:G[^Q8_?3CU:]UF<O,?E"%__F*SC>\@8QCM*6,+ JY2
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MVQRET"Z"#;+80?;\P!=.K!0GA\6BL8PZ4+)/%G*_A 2 2#I,8!U&KT*-9JO
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M2P$"% ,4    " "2@Z90SH/:"2@)  "]40  %P              @ $
M=F-Y="TP,S,Q,C R,'AE>#,Q,2YH=&U02P$"% ,4    " "2@Z90M4=-HS8)
M  !74@  %P              @ %="0  =F-Y="TP,S,Q,C R,'AE>#,Q,BYH
M=&U02P$"% ,4    " "2@Z909!E+L)8%   !*P  %P              @ '(
M$@  =F-Y="TP,S,Q,C R,'AE>#,R,2YH=&U02P$"% ,4    " "2@Z90>LL$
M@)(%   9*P  %P              @ &3&   =F-Y="TP,S,Q,C R,'AE>#,R
M,BYH=&U02P$"% ,4    " "2@Z90/VT_ R58 @ O;A< $0
M@ %:'@  =F-Y="TR,#(P,#,S,2YH=&U02P$"% ,4    " "2@Z90C$'IQ L-
M  !7?0  $0              @ &N=@( =F-Y="TR,#(P,#,S,2YX<V102P$"
M% ,4    " "2@Z90,7RY*,08  #S]@  %0              @ 'H@P( =F-Y
M="TR,#(P,#,S,5]C86PN>&UL4$L! A0#%     @ DH.F4&U((U*(00  (*4"
M !4              ( !WYP" '9C>70M,C R,# S,S%?9&5F+GAM;%!+ 0(4
M Q0    ( )*#IE!/[,Q-"J,  )6 !@ 5              "  9K> @!V8WET
M+3(P,C P,S,Q7VQA8BYX;6Q02P$"% ,4    " "2@Z90N,C<$+==  #V P0
M%0              @ '7@0, =F-Y="TR,#(P,#,S,5]P<F4N>&UL4$L%!@
0   *  H G@(  ,'? P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780292224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consisted of the following (in thousands of dollars):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,497&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,582&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,634&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,079&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787303792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VERACYTE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5455398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6000 Shoreline Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-6300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value, $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VCYT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,053,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001384101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6764865920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 03, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember', window );">NanoString</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration, maximum to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember', window );">Headquarters and laboratory facilities, South San Francisco, lease signed April 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level I | Headquarters and laboratory facilities, South San Francisco, lease signed April 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level I | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">150,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=vcyt_OvernightRepurchaseAgreementsMember', window );">Overnight repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=vcyt_OvernightRepurchaseAgreementsMember', window );">Overnight repurchase agreements | Level II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and and cash equivalents, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=vcyt_OvernightRepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=vcyt_OvernightRepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6638258688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_CommonStockAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options issued and outstanding (in shares)</a></td>
<td class="nump">5,988,461<span></span>
</td>
<td class="nump">5,562,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total number of shares reserved for issuance (in shares)</a></td>
<td class="nump">9,300,887<span></span>
</td>
<td class="nump">7,690,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember', window );">Shares of common stock subject to outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_CommonStockAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">3,200,200<span></span>
</td>
<td class="nump">1,954,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_CommonStockAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">112,226<span></span>
</td>
<td class="nump">173,168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_CommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_CommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787286448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 79,755<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 313,800<span></span>
</td>
<td class="num">$ (234,086)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units</a></td>
<td class="nump">4,240<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan (ESPP)</a></td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax portion of vested restricted stock units</a></td>
<td class="num">(556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee', window );">Stock-based compensation expense (employee)</a></td>
<td class="nump">1,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee', window );">Stock-based compensation expense (non-employee)</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP', window );">Stock-based compensation expense (ESPP)</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">(1,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(1,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,917)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">83,772<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">319,733<span></span>
</td>
<td class="num">(236,003)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">239,455<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">486,090<span></span>
</td>
<td class="num">(246,685)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units</a></td>
<td class="nump">981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan (ESPP)</a></td>
<td class="nump">1,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax portion of vested restricted stock units</a></td>
<td class="num">(2,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee', window );">Stock-based compensation expense (employee)</a></td>
<td class="nump">2,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP', window );">Stock-based compensation expense (ESPP)</a></td>
<td class="nump">354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">(11,716)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(11,716)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,716)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 230,422<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 488,773<span></span>
</td>
<td class="num">$ (258,401)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) resulting from ESPP stock-based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) resulting from employee stock-based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) resulting from non-employee stock-based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Exercises in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Value, Options and Non-Option Equity Instruments, Exercises in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6643653744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not record a provision or benefit for income taxes during the three months ended March&#160;31, 2020 and 2019. The Company continues to maintain a full valuation allowance against its net deferred tax assets.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The Company does not expect the provisions of the legislation to have a significant impact on the effective tax rate of the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6638532960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Leases</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company leases its headquarters and laboratory facilities in South San Francisco, California under a non-cancelable lease agreement for approximately 59,000 square feet. The lease began in June&#160;2015 and ends in March&#160;2026 and contains extension of lease term and expansion options.  The Company had deposits of $603,000 included in long-term assets as of March&#160;31, 2020 and December&#160;31, 2019, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the South San Francisco facility.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also leases laboratory and office space in Austin, Texas under a lease that expires in January 2029 and includes options for expansion and early termination in 2025.  The Company provided a cash security deposit for this lease of $139,000, included in other assets in the Company&#8217;s condensed consolidated balance sheets as of March&#160;31, 2020 and December&#160;31, 2019. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum lease payments under non-cancelable operating leases as of March&#160;31, 2020 are as follows (in thousands of dollars):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.953%;"><tr><td style="width:1.0%;"/><td style="width:85.014%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.986%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Year&#160;Ending&#160;December&#160;31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,760&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,401&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,543&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,614&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total future minimum lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: amount representing interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of future lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,582&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: short-term lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,450&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes operating lease expense on a straight-line basis over the non-cancelable lease period.  Operating lease expense was $474,000 and $476,000 for the three months ended March&#160;31, 2020 and 2019, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingencies</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its condensed consolidated financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company believes there is no legal proceeding pending that could have, either individually or in the aggregate, a material adverse effect on the Company&#8217;s condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>116</ContextCount>
  <ElementCount>267</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2106102 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Thyroid Cytopathology Partners</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/ThyroidCytopathologyPartners</Role>
      <ShortName>Thyroid Cytopathology Partners</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Description of Business (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/OrganizationandDescriptionofBusinessPolicies</Role>
      <ShortName>Organization and Description of Business (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Organization and Description of Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/OrganizationandDescriptionofBusinessTables</Role>
      <ShortName>Organization and Description of Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/NetLossPerCommonShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2310303 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/AccruedLiabilities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2313304 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/BusinessCombination</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/CommitmentsandContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2322306 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/Debt</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2326307 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/StockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Organization and Description of Business - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/OrganizationandDescriptionofBusinessNarrativeDetails</Role>
      <ShortName>Organization and Description of Business - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Organization and Description of Business - Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/OrganizationandDescriptionofBusinessCreditRiskDetails</Role>
      <ShortName>Organization and Description of Business - Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/NetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Business Combinations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BusinessCombinationsDetails</Role>
      <ShortName>Business Combinations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/BusinessCombinationsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Business Combination - Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BusinessCombinationAcquisitionDetails</Role>
      <ShortName>Business Combination - Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Commitments and Contingencies - Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CommitmentsandContingenciesOperatingLeaseDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423409 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - Debt - Debt Obligation for Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/DebtDebtObligationforBorrowingsDetails</Role>
      <ShortName>Debt - Debt Obligation for Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2427411 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/StockholdersEquityTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="vcyt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2429412 - Disclosure - Thyroid Cytopathology Partners (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails</Role>
      <ShortName>Thyroid Cytopathology Partners (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/ThyroidCytopathologyPartners</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="vcyt-20200331.htm">vcyt-20200331.htm</File>
    <File>vcyt-03312020xex311.htm</File>
    <File>vcyt-03312020xex312.htm</File>
    <File>vcyt-03312020xex321.htm</File>
    <File>vcyt-03312020xex322.htm</File>
    <File>vcyt-20200331.xsd</File>
    <File>vcyt-20200331_cal.xml</File>
    <File>vcyt-20200331_def.xml</File>
    <File>vcyt-20200331_lab.xml</File>
    <File>vcyt-20200331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636679968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of reserved shares of common stock for issuance</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had reserved shares of common stock for issuance as follows:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options and restricted stock units issued and outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,988,461&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,562,484&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options and restricted stock units available for grant under stock option plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,200,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,954,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock available for the Employee Stock Purchase Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">112,226&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173,168&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,300,887&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,690,456&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636414816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consisted of the following (in thousands of dollars):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,497&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,582&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,634&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,079&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784292528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation expenses</a></td>
<td class="nump">$ 7,497<span></span>
</td>
<td class="nump">$ 10,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">2,582<span></span>
</td>
<td class="nump">3,634<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 10,079<span></span>
</td>
<td class="nump">$ 13,734<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787366464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 03, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition related contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,604<span></span>
</td>
<td class="nump">$ 6,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,725<span></span>
</td>
<td class="nump">2,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember', window );">NanoString</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid in business acquisition</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration, maximum to be paid</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition related contingent liability</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember', window );">NanoString | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity issued in business acquisition</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794114544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Narrative (Details)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 07, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 09, 2018</div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>delivery </div>
<div>financial_institution </div>
<div>diseaseAreas </div>
<div>segment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_NumberOfDiseaseAreasWithGenomicTesting', window );">Number of disease areas with genomic testing | diseaseAreas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustment', window );">Prior period reclassification adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued and sold (in shares) | shares</a></td>
<td class="nump">6,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 23.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 137,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities', window );">Percent of principal amount needed to be collateralized by U.S. treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited', window );">Number of major financial institutions with which the company's cash and cash equivalents are deposited (in financial institutions) | financial_institution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 603,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,067,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net income (loss) per common share, basic and diluted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_NumberofTissueSampleDeliveries', window );">Number of tissue sample deliveries (in deliveries) | delivery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,576,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,808,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,582,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember', window );">Headquarters and laboratory facilities, South San Francisco, lease signed April 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vcyt_BiopharmaceuticalCompanyMember', window );">Biopharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Tissue Samples</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_TermContractAgreement', window );">Contract agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AutomaticRenewalPeriodContractAgreement', window );">Automatic renewal period of contract agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_TerminationPeriodContractAgreement', window );">Termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Other Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_TestingMember', window );">Testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,991,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-down of supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_TestingMember', window );">Testing | Revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net income (loss) per common share, basic and diluted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalMember', window );">Biopharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vcyt_JohnsonJohnsonServicesInc.Member', window );">Johnson &amp; Johnson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ContractAgreementReceivableForServices', window );">Receivable from agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ContractAgreementConditionalAdditionalReceivable', window );">Contractual proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ContractAgreementFeePercentageOfCashCollections', window );">Percentage of net cash collections, fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vcyt_JohnsonJohnsonServicesInc.Member', window );">Johnson &amp; Johnson | Percepta v.2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vcyt_JohnsonJohnsonServicesInc.Member', window );">Johnson &amp; Johnson | NasaRISK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vcyt_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vcyt_BiopharmaceuticalCompanyMember', window );">Biopharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ContractAgreementAmount', window );">Contract agreement, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vcyt_BiopharmaceuticalCompanyMember', window );">Biopharmaceutical Company | Biopharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued and sold (in shares) | shares</a></td>
<td class="nump">825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a reclassification adjustment made to prior period financial statement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_AutomaticRenewalPeriodContractAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Automatic Renewal Period, Contract Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_AutomaticRenewalPeriodContractAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ContractAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Agreement, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ContractAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ContractAgreementConditionalAdditionalReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Agreement, Conditional Additional Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ContractAgreementConditionalAdditionalReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ContractAgreementFeePercentageOfCashCollections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Agreement, Fee, Percentage Of Cash Collections</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ContractAgreementFeePercentageOfCashCollections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ContractAgreementReceivableForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Agreement, Receivable For Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ContractAgreementReceivableForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_NumberOfDiseaseAreasWithGenomicTesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Disease Areas With Genomic Testing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_NumberOfDiseaseAreasWithGenomicTesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major financial institutions, with which cash and cash equivalents are deposited by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_NumberofTissueSampleDeliveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Tissue Sample Deliveries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_NumberofTissueSampleDeliveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of Principal Amount Needed To Be Collateralized By U.S. Treasury and Agency Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_TermContractAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term, Contract Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_TermContractAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_TerminationPeriodContractAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Termination Period, Contract Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_TerminationPeriodContractAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vcyt_BiopharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vcyt_BiopharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_TestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_TestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=vcyt_RevenueRecognitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=vcyt_RevenueRecognitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_JohnsonJohnsonServicesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_JohnsonJohnsonServicesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_PerceptaV2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_PerceptaV2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_NasaRISKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_NasaRISKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_BiopharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_BiopharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6776377328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of fair value of assets acquired and liabilities assumed</a></td>
<td class="text">The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"/><td style="width:84.578%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.422%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prosigna product technology</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prosigna customer relationships</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">nCounter FLEX Dx license</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,880&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LymphMark product technology</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">990&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total identifiable intangible assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,420&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,088&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock', window );">Schedule of identifiable acquisition-related intangibles</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Identifiable acquisition-related intangibles included in the above table are finite-lived and are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows:</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099%;"><tr><td style="width:1.0%;"/><td style="width:69.535%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:26.465%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Useful life (In Years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prosigna product technology</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prosigna customer relationships</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">nCounter FLEX Dx license</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LymphMark product technology</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787574352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Acquisition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 03, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,725<span></span>
</td>
<td class="nump">$ 2,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember', window );">Prosigna product technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Prosigna customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterFLEXDxLicenseMember', window );">nCounter FLEX Dx license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_LymphMarkProductTechnologyMember', window );">LymphMark product technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember', window );">NanoString</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="nump">$ 54,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">56,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember', window );">NanoString | Prosigna product technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="nump">4,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember', window );">NanoString | Prosigna customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="nump">2,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember', window );">NanoString | nCounter FLEX Dx license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="nump">46,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember', window );">NanoString | LymphMark product technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="nump">$ 990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterFLEXDxLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterFLEXDxLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_LymphMarkProductTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_LymphMarkProductTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775233536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Debt Obligation for Borrowings (Details) - Line of credit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtInstrumentEndOfTermInterestObligationAmount', window );">End-of-term debt obligation</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net debt obligation</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="nump">$ 694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtInstrumentEndOfTermInterestObligationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument End Of Term, Interest Obligation Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtInstrumentEndOfTermInterestObligationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787212656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">$ 31,122<span></span>
</td>
<td class="nump">$ 29,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of testing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,407<span></span>
</td>
<td class="nump">3,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">17,584<span></span>
</td>
<td class="nump">12,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,813<span></span>
</td>
<td class="nump">6,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible asset amortization</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">43,322<span></span>
</td>
<td class="nump">31,596<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,200)<span></span>
</td>
<td class="num">(2,067)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss and comprehensive loss</a></td>
<td class="num">(11,716)<span></span>
</td>
<td class="num">(1,917)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (11,716)<span></span>
</td>
<td class="num">$ (1,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted (in usd per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used to compute net loss per common share, basic and diluted (in shares)</a></td>
<td class="nump">49,792,631<span></span>
</td>
<td class="nump">41,168,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_TestingMember', window );">Testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">$ 26,991<span></span>
</td>
<td class="nump">$ 25,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of testing revenue</a></td>
<td class="nump">10,568<span></span>
</td>
<td class="nump">8,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">3,409<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of testing revenue</a></td>
<td class="nump">1,559<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalMember', window );">Biopharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">722<span></span>
</td>
<td class="nump">4,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of testing revenue</a></td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_TestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_TestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6639900336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text">Net Loss Per Common Share<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. The following outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"/><td style="width:72.408%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.539%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.427%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares of common stock subject to outstanding options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,760,128&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,670,819&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,857&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,672&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">936,524&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">538,759&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total common stock equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,716,509&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,235,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779000384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet as of March&#160;31, 2020, the condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2020 and 2019, the condensed consolidated statements of stockholders' equity for the three months ended March&#160;31, 2020 and 2019, and the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2020 and 2019 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results, stockholders' equity  and cash flows for the periods presented. The condensed consolidated balance sheet at December&#160;31, 2019 has been derived from audited financial statements. The results for the three months ended March&#160;31, 2020 are not necessarily indicative of the results expected for the full year or any other period. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying interim period condensed consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Use of Estimates</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Items subject to such estimates include: revenue recognition; write-down of supplies; the useful lives of property and equipment; the recoverability of long-lived assets; the incremental borrowing rate for leases; the estimation of the fair value of intangible assets and contingent consideration; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock', window );">Concentrations of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The worldwide spread of coronavirus, or COVID-19, has created significant uncertainty in the global economy. There have been no comparable recent events that provide guidance as to the effect the spread of COVID-19 as a global pandemic may have, and, as a result, the ultimate impact of COVID-19 and the extent to which COVID-19 impacts the Company&#8217;s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict.  If the financial markets or the overall economy are impacted for an extended period, the Company&#8217;s liquidity, revenues, supplies, goodwill and intangibles may be adversely affected</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The majority of the Company&#8217;s cash and cash equivalents are deposited with one major financial institution in the United States. Deposits in this institution may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Several of the components of the Company&#8217;s sample collection kit and test reagents, and its nCounter FLEX Analysis System and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company&#8217;s requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is also subject to credit risk from its accounts receivable related to its sales. Credit risk for accounts receivable from testing revenue is incorporated in testing revenue accrual rates as the Company assesses historical collection rates and current developments to determine accrual rates and amounts the Company will ultimately collect.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company generally does not perform evaluations of customers&#8217; financial condition for testing revenue and generally does not require collateral.  The Company assesses credit risk and the amount of accounts receivable the Company will ultimately collect for product, biopharmaceutical and collaboration revenue based on collection history, current developments and credit worthiness of the customer.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The estimate of credit losses is not material at March 31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash&#160;and&#160;Cash&#160;Equivalents</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers demand deposits in a bank, money market funds and highly liquid investments with an original maturity of 90 days or less to be cash equivalents.  Cash equivalents include overnight reverse repurchase agreements which are tri-party repurchase agreements and have maturities of&#160;three&#160;months or less at the time of investment and are collateralized by U.S. treasury and agency securities of at&#160;least 102%&#160;of the principal amount. In a tri-party repurchase agreement, a third-party custodian bank functions as an independent intermediary to facilitate transfer of cash and holding the collateral on behalf of the underlying investor for the term of the agreement thereby minimizing risk and exposure to both parties. These overnight reverse repurchase agreements are included within cash equivalents due to their high liquidity and relatively low risk.  There were no overnight reverse repurchase agreements at March 31, 2020.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Cash</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had deposits of $603,000 included in long-term assets as of March&#160;31, 2020 and December&#160;31, 2019, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the Company&#8217;s South San Francisco facility.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Testing Revenue</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes testing revenue in accordance with the provisions of ASC 606, Revenue from Contracts with Customers, or ASC 606.  Most of the Company&#8217;s revenue is generated from the provision of testing services. These services are completed upon the delivery of test results to the prescribing physician, at which time the Company bills for the services. The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized.  In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2019, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2018 or prior years and recognized additional revenue of $0.6&#160;million, which resulted in a decrease in the Company's loss from operations of $0.6 million and a decrease in loss per share of $0.02 for the three months ended March 31, 2019.  The change in testing revenue estimates for the three months ended March 31, 2020 was not material.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Product Revenue</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company began recognizing product revenue in December 2019, when the Company executed an agreement with NanoString for the exclusive global license to the nCounter platform and acquisition of products for diagnostic use.  More details on this agreement are in Note 4 - Business Combination.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenue from instruments, consumables and in vitro diagnostic kits is recognized generally upon shipment or when the instrument is ready for use by the end customer, which is when title of the product has been transferred to the customer. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a product to the customer, meaning the customer has the ability to use and obtain the benefit of the product. The Company recognizes product revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control.  Shipping and handling costs incurred for product shipments are charged to the Company's customers and included in product revenue. Revenues are presented net of the taxes that are collected from customers and remitted to governmental authorities.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Biopharmaceutical and Collaboration Revenue</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, the Company enters into arrangements for research and development and/or laboratory services. Such arrangements may require the Company to deliver various rights, services and/or samples, including intellectual property rights/licenses, R&amp;D services, and/or laboratory services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments, and/or profit sharing.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods is transferred or services are performed. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, the Company utilizes the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><div><span><br/></span></div><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Collaborative Arrangements</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company enters into collaborative arrangements with partners that fall under the scope of ASC Topic 808, Collaborative Arrangements, or ASC 808. While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects of these arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part of its ongoing major or central operations. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of the Company&#8217;s collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales of licensed products. Each of these payments may result in collaboration revenues or an offset against research and development expense.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net sales of data or other services to our customers are classified under biopharmaceutical revenue, and all other non-customer revenue, such as milestones, are classified under collaboration revenue in our consolidated statements of operations and comprehensive loss.  There was no collaboration revenue in the three months ended March 31, 2020 and 2019.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Up-front Fees: If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Milestone Payments: At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or the collaborative partner&#8217;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the collaborative partner&#8217;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Services Agreement with Loxo Oncology</span></div><div style="padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 9, 2018, the Company entered into an agreement with Loxo Oncology, Inc., or Loxo, whereby the Company agreed to provide certain tissue samples and other services in exchange for agreed-upon fees.  The agreement has a term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTg5ODQ_f0a3db4d-746a-4336-8a43-6dcb1f0c687a">one</span> year with an automatic renewal of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRlMTI2ZGRjNGZlMzRiODhiOTIwNGQwNTEyMzk5Y2FmL3NlYzpkZTEyNmRkYzRmZTM0Yjg4YjkyMDRkMDUxMjM5OWNhZl80MC9mcmFnOjQ3OGU0NDRhYTk1NzQzM2VhYzU1MzJmNTRhZDg0YzlmL3RleHRyZWdpb246NDc4ZTQ0NGFhOTU3NDMzZWFjNTUzMmY1NGFkODRjOWZfMTkwMjE_98287a7d-3a7f-425c-896d-85cf973f3c3e">one</span> year and Loxo may terminate the agreement at any time with at least 90 days' notice.  As of March&#160;31, 2020, the agreement has not been terminated.  The Company evaluated the accounting for this agreement under ASC 606 and concluded the performance obligations thereunder are the delivery of tissue samples and performance of services, both of which are distinct.  For the three months ended March 31, 2019, the Company recognized revenue of $90,000 for the delivery of tissue samples.  There were no deliveries of tissue samples for the three months ended March 31, 2020.  The Company recognized revenue of $250,000 for the performance of services for each of the three months ended March 31, 2020 and 2019, respectively.  The cost of revenue associated with revenue recognized under the agreement with Loxo is not significant.  There was no deferred revenue related to this agreement at either March&#160;31, 2020 or December&#160;31, 2019.</span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Diagnostic Development Agreement with Johnson &amp; Johnson</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 28, 2018, the Company entered into a diagnostics development agreement with Johnson and Johnson Services, Inc., or JJSI, (i) to cooperate on a program to enable the Company to use JJSI samples and clinical data to develop a next generation bronchial genomic classifier diagnostic for lung cancer diagnosis, or Percepta v.2, and a nasal genomic classifier diagnostic for lung cancer and (ii) for JJSI to use Veracyte data generated in two Veracyte development programs for therapeutic purposes and for purposes of developing a companion diagnostic product used in conjunction with a JJSI therapeutic.  The Company granted a license to JJSI with the right to use data and under the Company's intellectual property rights for JJSI's therapeutic purposes, including the development and commercialization of a companion diagnostic for its products, from the Percepta v.2 and Nasal programs.  The license granted to JJSI is not distinct from other performance obligations as JJSI receives benefit only when other performance obligations are met.</span></div><div style="text-indent:36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the agreement, the Company will provide data from its RNA whole-transcriptome sequencing platform to JJSI in exchange for $7.0 million in payments from JJSI.  The Company is also entitled to additional payments from JJSI of up to $13.0 million, conditioned upon the achievement of certain milestones relating to the development and reimbursement of the Percepta v.2 and Nasal tests.  For a period of ten years commencing with the first commercial sale of the Percepta v.2 and Nasal tests, respectively, the Company will make payments to JJSI of one percent of net cash collections for Percepta v.2 and in the low-single digits of net cash collections for the Nasal test, depending on the number and timing of JJSI samples and associated clinical data the Company receives from JJSI.</span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The JJSI agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the JJSI agreement and has analogized to ASC 606 for the delivery of RNA whole-transcriptome sequencing data to JJSI under the collaborative arrangement, which the Company believes is a distinct service for which JJSI meets the definition of a customer. Using the concepts of ASC 606, the Company has identified the delivery of data as its only performance obligation. The Company further determined that the transaction price under the arrangement was the $7.0 million in payments which was allocated to the obligation to deliver data.  The $13.0 million in future potential payments is considered variable consideration because the Company determined that the potential payments are contingent upon </span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">regulatory and commercialization milestones that are uncertain to occur and, as such, were not included in the transaction price, and will be recognized accordingly as each potential payment becomes probable.</span></div><div><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognized revenue of $7.0&#160;million and $4.0&#160;million during 2019 for the provision of data and fulfillment of obligations relating to Percepta v.2 and Nasal program development milestones, respectively.  There was no revenue for the three months ended March 31, 2020.  For the three months ended March 31, 2019, the Company recognized revenue of $3.8&#160;million for the provision of data relating to Percepta v.2, classified under biopharmaceutical revenue in the consolidated statement of operations and comprehensive loss. There was no accounts receivable from JJSI at March 31, 2020 and accounts receivable from JJSI was $2.0&#160;million at December&#160;31, 2019.  There was no deferred revenue related to this agreement at March 31, 2020 and December&#160;31, 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration Agreement with AstraZeneca Group</span></div><div><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 23, 2019, the Company entered into an agreement with Acerta Pharma B.V., or Acerta, a member of AstraZeneca Group whereby the Company agreed to provide genomic information that will support Acerta&#8217;s development of oncology therapeutics.  Acerta will pay the Company for certain development activities and pay milestones to the Company for the achievement of development milestones.  For the three months ended March 31, 2020, the Company recognized $0.1&#160;million of revenue for certain development costs activities and accounts receivable from Acerta was $0.1&#160;million at March 31, 2020.  The agreement will be accounted for in accordance with the policy on collaborative arrangements, as mentioned in this footnote.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Biopharmaceutical Services Agreement</span></div><div><span><br/></span></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the quarter ended March 31, 2020, the Company entered into an agreement to provide research and development services of $0.5&#160;million for which the Company recognized $0.3&#160;million of biopharmaceutical revenue for the three months ended March 31, 2020. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Testing Revenue</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of our cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation and amortization, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test. Cost of testing revenue for the three months ended March 31, 2020 included $1.1&#160;million write-down of supplies for the potential expiration of reagents due to an anticipated decline in volumes resulting from the COVID-19 pandemic.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Product Revenue </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of product revenue consists primarily of costs of purchasing instruments and consumables from third-party contract manufacturers, installation, warranty, service and packaging and delivery costs. In addition, cost of product includes royalty costs for licensed technologies included in the Company&#8217;s products and labor expenses. Cost of product revenue for instruments and consumables is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the consolidated statements of operations.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Biopharmaceutical Revenue </span></div>Cost of biopharmaceutical revenue consists of costs of performing activities under arrangements that require the Company to perform research and development services on behalf of a customer pursuant to a biopharmaceutical service agreement.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This ASU requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit </span></div>risks. This guidance became effective for the Company beginning January 1, 2020.  Based on the composition of its trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures.<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (Topic 808). </span>Under&#160;this ASU,&#160;transactions in collaborative arrangements are to be accounted for under ASC 606 if the counterparty is a customer for a good or service (or bundle of goods and services) that is a distinct unit of account. Also, entities are precluded from presenting consideration from transactions with a counterparty that is not a customer together with revenue recognized from ASC 606.  This ASU is effective for all interim and annual reporting periods beginning on or after December 15, 2019, with early adoption permitted.  The Company adopted this ASU in 2019 with no cumulative-effect adjustments or retrospective impact.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780307648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Loan and Security Agreement</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 3, 2017, the Company entered into a loan and security agreement, or Loan and Security Agreement, with Silicon Valley Bank.  The Loan and Security Agreement allows the Company to borrow up to $35.0 million, with a $25.0 million advance term loan, or Term Loan Advance, and a revolving line of credit of up to $10.0 million, or Revolving Line of Credit.  The Term Loan Advance was advanced upon the closing of the Loan and Security Agreement and was used to pay the outstanding balance of the Company&#8217;s existing long-term debt, which was canceled at that date.  The Company had not drawn on the Revolving Line of Credit as of March&#160;31, 2020.  Borrowings under the Loan and Security Agreement mature on October 1, 2022.  Amounts may be borrowed and repaid under the Revolving Line of Credit up until the earliest of full repayment or maturity of the Loan and Security Agreement, termination of the Loan and Security Agreement, or October 1, 2022.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Term Loan Advance bears interest at a variable rate equal to (i) the thirty-day U.S. London Interbank Offer Rate, or LIBOR, plus (ii) 4.20%, with a minimum rate of 5.43% per annum. Principal amounts outstanding under the Revolving Line of Credit bear interest at a variable rate equal to (i) LIBOR plus (ii) 3.50%, with a minimum rate of 4.70% per annum.  The average Term Loan Advance interest rate for the three months ended March&#160;31, 2020 was 5.8%. </span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company may prepay the outstanding principal amount under the Term Loan Advance plus accrued and unpaid interest and, if the Term Loan Advance is repaid in full, a prepayment premium. The prepayment premium will be (i) $750,000 if prepayment is made prior to November 3, 2018, (ii) $500,000 if the prepayment is made after November 3, 2018 but on or before November 3, 2019, or (iii) $250,000 if the prepayment is made after November 3, 2019.  In January 2019 and May 2019, the Company prepaid $12.5 million and $12.4 million, respectively, of the principal amount of the Term Loan Advance.  These prepayments did not trigger any prepayment premium because they were partial, not full, repayments of the principal amount.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, a final payment on the Term Loan Advance in the amount of $1.2 million is due upon the earlier of the maturity date of the Term Loan Advance or its payment in full.  The Loan and Security Agreement contains customary </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">representations, warranties, and events of default such as a material adverse change in the Company's business, operations or financial condition, as well as affirmative and negative covenants. The negative covenants include, among other provisions, covenants that limit or restrict the Company's ability to incur liens, make investments, incur indebtedness, merge with or acquire other entities, dispose of assets, make dividends or other distributions to holders of its equity interests, engage in any new line of business, or enter into certain transactions with affiliates, in each case subject to certain exceptions. The Company&#8217;s obligations under the Loan and Security Agreement are secured by substantially all of its assets (excluding intellectual property), subject to certain customary exceptions.  The Loan and Security Agreement also requires the Company to achieve certain revenue levels tested quarterly on a trailing twelve-month basis.  However, failure to maintain the revenue levels will not be considered a default if the sum of the Company&#8217;s unrestricted cash and cash equivalents maintained with Silicon Valley Bank and amount available under the Revolving Line of Credit is at least $40.0 million.  As of March&#160;31, 2020, the Company was in compliance with the loan covenants.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The net debt obligation for borrowings made under the Loan and Security Agreement was as follows (in thousands of dollars):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"><tr><td style="width:1.0%;"/><td style="width:70.848%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.135%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.909%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt principal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">End-of-term debt obligation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">648&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net debt obligation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">694&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future principal and end-of-term debt obligation payments under the Loan and Security Agreement are $1.3 million and due in 2022. &#160;</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The end-of-term debt obligation accretes over the term of the Loan and Security Agreement until maturity and is included in interest expense in the Company's condensed consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
